

FOURDS

FACILITY
ONCOLOGY
REGISTRY
DATA
STANDARDS



Commission
on Cancer

FORDS

Facility Oncology Registry Data Standards Revised for 2010

(Incorporates all updates since originally published in July 2002)

Includes updates to May 1, 2010

See Appendix C for a summary of changes.



**© 2002 AMERICAN COLLEGE OF SURGEONS
All Rights Reserved**

Table of Contents

Preface 2010.....	xi
SECTION ONE: Case Eligibility and Overview of Coding Principles.....	1–32
Case Eligibility	3
Tumors Required by the CoC to be Accessioned, Abstracted, and Followed.....	3
Reportable-by-Agreement Cases	3
Ambiguous Terms at Diagnosis.....	3
Class of Case.....	5
Date of First Contact.....	5
Overview of Coding Principles	7
Unique Patient Identifier Codes.....	7
National Provider Identifier	7
Coding Dates.....	7
Cancer Identification.....	8
Patient Address and Residency Rules.....	14
<i>In Utero</i> Diagnosis and Treatment.....	14
Comorbidities and Complications	15
Stage of Disease at Initial Diagnosis	15
AJCC TNM Staging.....	16
Collaborative Staging	17
First Course of Treatment	20
Treatment, Palliative, and Prophylactic Care	28
Embolization.....	29
Outcomes	29
Case Administration	30
SECTION TWO: Coding Instructions	33–356
Patient Identification	35-94
Accession Number	37
Sequence Number	38
Medical Record Number.....	40
Social Security Number	41
Military Medical Record Number Suffix.....	42
Last Name	43
First Name.....	44
Middle Name (Middle Initial).....	45
Patient Address (Number and Street) at Diagnosis	46
Patient Address at Diagnosis–Supplemental	47
City/Town at Diagnosis (City or Town).....	48
State at Diagnosis (State).....	49
Postal Code at Diagnosis (ZIP Code)	51
County at Diagnosis.....	52

Patient Identification (continued)

Patient Address (Number and Street)–Current	53
Patient Address–Current–Supplemental	54
City/Town–Current	55
State–Current	56
Postal Code–Current (ZIP Code)	58
Telephone.....	59
Place of Birth	60
Date of Birth	61
Date of Birth Flag	62
Age at Diagnosis.....	63
Race 1.....	64
Race 2.....	66
Race 3.....	67
Race 4.....	68
Race 5.....	69
Spanish Origin–All Sources (Spanish/Hispanic Origin)	70
Sex.....	71
Primary Payer at Diagnosis.....	72
Comorbidities and Complications #1	74
Comorbidities and Complications #2	76
Comorbidities and Complications #3	77
Comorbidities and Complications #4	78
Comorbidities and Complications #5	79
Comorbidities and Complications #6	80
Comorbidities and Complications #7	81
Comorbidities and Complications #8	82
Comorbidities and Complications #9	83
Comorbidities and Complications #10	84
NPI–Managing Physician	85
Following Physician (Follow-Up Physician).....	86
NPI–Following Physician	87
Primary Surgeon	88
NPI–Primary Surgeon.....	89
Physician #3 (Other Physician).....	90
NPI–Physician #3 (Radiation Oncologist–CoC Preferred)	91
Physician #4 (Other Physician).....	92
NPI–Physician #4 (Medical Oncologist–CoC Preferred)	93
Cancer Identification	95-132
Class of Case.....	97
Facility Referred From.....	99
NPI–Institution Referred From.....	100
Facility Referred To.....	101

Cancer Identification (continued)	
NPI–Institution Referred To	102
Date of First Contact.....	103
Date of First Contact Flag.....	104
Date of Initial Diagnosis	105
Date of Diagnosis Flag	106
Primary Site	107
Laterality.....	108
Histology.....	109
Behavior Code	110
Grade/Differentiation.....	112
Grade Path System.....	114
Grade Path Value	115
Lymph-Vascular Invasion.....	116
Diagnostic Confirmation.....	117
Ambiguous Terminology Diagnosis	120
Date of Conclusive Diagnosis.....	121
Date of Conclusive DX Flag.....	122
Date of Multiple Tumors	124
Date of Mult Tumors Flag	125
Type of Multiple Tumors Reported as One Primary	127
Multiplicity Counter	128
Regional Lymph Nodes Examined	129
Regional Lymph Nodes Positive	130
Stage of Disease at Diagnosis	131-208
Date of Surgical Diagnostic and Staging Procedure.....	133
RX Date–DX/Stg Proc Flag.....	134
Surgical Diagnostic and Staging Procedure.....	136
Surgical Diagnostic and Staging Procedure at This Facility	138
Clinical T	139
Clinical N.....	140
Clinical M	141
Clinical Stage Group.....	142
Clinical Stage (Prefix/Suffix) Descriptor	143
Staged By (Clinical Stage).....	144
Pathologic T	145
Pathologic N	146
Pathologic M.....	147
Pathologic Stage Group	148
Pathologic Stage (Prefix/Suffix) Descriptor	149
Staged By (Pathologic Stage)	150
CS Tumor Size	151
CS Extension.....	152

Stage of Disease at Diagnosis (continued)

CS Tumor Size/Ext Eval.....	153
CS Lymph Nodes.....	154
CS Reg Nodes Eval.....	155
CS Mets at DX.....	156
CS Mets at DX–Bone.....	157
CS Mets at DX–Brain.....	158
CS Mets at DX–Liver.....	159
CS Mets at DX–Lung.....	160
CS Mets Eval.....	161
CS Site-Specific Factor 1.....	162
CS Site-Specific Factor 2.....	165
CS Site-Specific Factor 3.....	167
CS Site-Specific Factor 4.....	169
CS Site-Specific Factor 5.....	171
CS Site-Specific Factor 6.....	172
CS Site-Specific Factor 7.....	174
CS Site-Specific Factor 8.....	175
CS Site-Specific Factor 9.....	176
CS Site-Specific Factor 10.....	177
CS Site-Specific Factor 11.....	178
CS Site-Specific Factor 12.....	179
CS Site-Specific Factor 13.....	180
CS Site-Specific Factor 14.....	181
CS Site-Specific Factor 15.....	182
CS Site-Specific Factor 16.....	183
CS Site-Specific Factor 17.....	184
CS Site-Specific Factor 18.....	185
CS Site-Specific Factor 19.....	186
CS Site-Specific Factor 20.....	187
CS Site-Specific Factor 21.....	188
CS Site-Specific Factor 22.....	189
CS Site-Specific Factor 23.....	190
CS Site-Specific Factor 24.....	191
CS Site-Specific Factor 25.....	192
Derived AJCC-6 T.....	193
Derived AJCC-6 T Descript.....	194
Derived AJCC-6 N.....	195
Derived AJCC-6 N Descript.....	196
Derived AJCC-6 M.....	197
Derived AJCC-6 M Descript.....	198
Derived AJCC-6 Stage Group.....	199
Derived AJCC-7 T.....	200

Stage of Disease at Diagnosis (continued)	
Derived AJCC-7 T Descript	201
Derived AJCC-7 N.....	202
Derived AJCC-7 N Descript	203
Derived AJCC-7 M.....	204
Derived AJCC-7 M Descript	205
Derived AJCC-6 Stage Group	206
Derived SS1977	207
Derived SS2000	208
First Course of Treatment	209-294
Date of First Course of Treatment	211
Date of 1 st Crs RX Flag.....	212
RX Summ–Treatment Status	214
Date of First Surgical Procedure.....	215
RX Date–Surgery Flag.....	216
Date of Most Definitive Surgical Resection of the Primary Site.....	218
RX Date Mst Defn Srg Flag.....	219
Surgical Procedure of Primary Site	221
Surgical Procedure of Primary Site at This Facility	222
Approach – Surgery of the Primary Site at This Facility	223
Surgical Margins of the Primary Site	224
Scope of Regional Lymph Node Surgery	225
Scope of Regional Lymph Node Surgery at This Facility	227
Surgical Procedure/Other Site	229
Surgical Procedure/Other Site at This Facility	231
Date of Surgical Discharge	232
RX Date Surg Disch Flag	233
Readmission to the Same Hospital within 30 Days of Surgical Discharge	235
Reason for No Surgery of Primary Site	236
Date Radiation Started	237
RX Date–Radiation Flag.....	238
Location of Radiation Treatment.....	240
Radiation Treatment Volume.....	241
Regional Treatment Modality	245
Regional Dose: cGy	248
Boost Treatment Modality	249
Boost Dose: cGy	252
Number of Treatments to This Volume	253
Radiation/Surgery Sequence.....	254
Date Radiation Ended	256
RX Date Rad Ended Flag.....	257
Reason for No Radiation.....	259
Date Systemic Therapy Started.....	260

First Course of Treatment (continued)	
RX Date Systemic Flag.....	261
Date Chemotherapy Started	263
RX Date–Chemo Flag.....	264
Chemotherapy	266
Chemotherapy at This Facility.....	267
Date Hormone Therapy Started	270
RX Date–Hormone Flag	271
Hormone Therapy (Hormone/Steroid Therapy)	273
Hormone Therapy at This Facility (Hormone/Steroid Therapy)	275
Date Immunotherapy Started	277
RX Date–BRM Flag	278
Immunotherapy	280
Immunotherapy at This Facility.....	282
Hematologic Transplant and Endocrine Procedures.....	283
Systemic/Surgery Sequence.....	284
Date Other Treatment Started	287
RX Date–Other Flag	288
Other Treatment	290
Other Treatment at This Facility.....	291
Palliative Care.....	292
Palliative Care at This Facility.....	294
Outcomes	295-310
Date of First Recurrence	297
Recurrence Date–1 st Flag.....	298
Type of First Recurrence	300
Date of Last Contact or Death	303
Date of Last Contact Flag	304
Vital Status.....	305
Cancer Status	306
Following Registry	307
NPI–Following Registry	308
Follow-Up Source.....	309
Next Follow-Up Source (Next Follow-Up Method).....	310
Case Administration	311-353
Abstracted By	313
Facility Identification Number (FIN)	314
NPI–Reporting Facility.....	315
Archive FIN	316
NPI–Archive FIN.....	317
Date Case Completed–CoC	318
Override ACSN/CLASS/SEQ	319
Override HOSPSEQ/DXCONF.....	320

Case Administration (continued)	
Override CoC–SITE/TYPE	321
Override HOSPSEQ/SITE	322
Override SITE/TNM-STAGE GROUP	323
Override AGE/SITE/MORPH	324
Override SURG/DXCONF	325
Override SITE/TYPE.....	326
Override HISTOLOGY	327
Override LEUK, LYMPHOMA	329
Override SITE/BEHAVIOR	330
Override SITE/LAT/MORPH.....	331
CoC Coding System–Current	332
CoC Coding System–Original	334
Race Coding System–Current.....	336
Race Coding System–Original.....	337
Site Coding System–Current	338
Site Coding System–Original	339
Morphology Coding System–Current.....	340
Morphology Coding System–Original.....	341
ICD-O-2 Conversion Flag	342
ICD-O-3 Conversion Flag	343
TNM Edition Number.....	344
ICD Revision Comorbidities and Complications	345
RX Coding System–Current	346
Derived AJCC–Flag.....	347
Derived SS1977–Flag	348
Derived SS2000–Flag	349
CS Version Input Original	350
CS Version Input Current	351
CS Version Derived	352

APPENDIX A: Definitions of Single and Subsequent Primaries for Hematologic Malignancies (only for use prior to January 1, 2010, diagnoses)

APPENDIX B: Site-Specific Surgery Codes

APPENDIX C: FORDS Page Revisions

APPENDIX D: FORDS Items Required to Be Complete to Enter *Date Case Completed* – CoC for Cases Diagnosed in 2010

Preface 2010

The *Facility Oncology Registry Data Standards (FORDS)* manual provides definitions and detailed instructions for coding patient diagnosis, treatment, and outcomes. The manual also describes the types of cases that must be abstracted and followed and explains the relationships among data items. Registry data maintained with standardized quality control mechanisms support meaningful evaluation and analysis.

FORDS: Revised for 2010

Following the initial release of *FORDS* in July 2002, the manual has undergone a series of modifications and revisions. In order to avoid the need to implement major changes in data annually, the registry community has agreed to the adoption of major changes once every three or four years. *FORDS: Revised for 2010* is to be supplemented by the *AJCC Cancer Staging Manual (7th Edition)*, the *Collaborative Stage (CS) Data Collection System (Version 2)*, and the *Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual* that will be implemented in 2010. *The 2007 Multiple Primary and Histology Coding Rules* will also be required. Implementation of *FORDS: Revised for 2010* is required of all Commission on Cancer (CoC)-approved cancer programs starting with cases diagnosed on January 1, 2010.

In 2010, the format used to transmit dates from hospitals to central registries or NCDB has been modified for interoperability with nonregistry data systems. *FORDS: Revised for 2010* describes the changes. Depending on registry software, these changes may be transparent to registrars. New date flags have been introduced for use when a valid, known date is not entered; those flags are described in this manual.

Some additional new items are incorporated in *FORDS: Revised for 2010*.

- *Date Case Completed – CoC* is inserted automatically by the registry software when data that should be available to the registry following the patient's main contact with the facility has been successfully abstracted, based on *Class of Case*. All items in *FORDS: Revised for 2010* are required; it is understood that some information may become available after this date.
- *RX Summ–Treatment Status* provides a simple, summary indicator of whether the patient received any treatment from any facility, is managed by active surveillance (watchful waiting), or is untreated.
- *RX Hosp–Surg App 2010* indicates whether the patient's principle surgery at the facility was open, closed, robotic assisted, or converted from closed or robotic assisted to open.
- *Grade Path System* and *Grade Path Value* were added to *FORDS: Revised for 2010* at the request of AJCC to record the original pathologist's designation of a 2, 3 or 4-grade system and its value. They supplement, and do not replace, the item *Grade/Differentiation*.
- *Lymph-vascular Invasion* was also added at the request of AJCC. It records pathologic evidence of the presence or absence of cancer cells in the lymphatic ducts or blood vessels of the primary tumor.
- Some new CS items have been added. *CS Mets at DX–Bone*, *CS Mets at DX–Brain*, *CS Mets at DX–*

Liver, and *CS Mets at DX–Lung* record metastases to those sites evident at initial diagnosis. The possible number of site-specific factors (SSF) for CS schema has been increased from six to 25. Not all are used by CS, and not all are required to be coded by CoC. The software-assigned codes for tracking CS version also have been modified and one additional item has been added.

Some modified codes are also introduced in *FORDS: Revised for 2010*.

- *Clinical Stage (Prefix/Suffix) Descriptor* was clarified in the February 2010 update. In the past, its codes indicated that code 4 (corresponding to “y”) is not applicable for clinical stage. Code 4 now no longer is included in the definitions for clinical stage.
- *Class of Case* has been rewritten in response to requests from registrars. The new two-digit codes offer more flexibility for recording diagnosis and treatment by the facility as distinct from diagnosis and treatment performed by a staff physician, and for distinguishing between all or part of first course treatment at the facility. It also has more specificity for recording non-analytic cases, and will handle some situations that previously were not well-handled by any *Class of Case* code. *Class of Case* should be converted automatically to the new codes when registry software for 2010 is implemented.
- *Method of Diagnostic Confirmation* was modified to reflect differences in diagnostic methods used for hematopoietic and lymphoid tumors as compared to solid tumors, and a new code 3 was added.
- *Laterality* now has a specific code (5) for use when the tumor arises from the midline of a paired site. The rules now permit coding non-paired sites to right or left when applicable.
- *Race* codes 1-6 were modified. Code 09 (Asian Indian or Pakistani) has been converted to 15, to avoid accidental use of the code 09 for “unknown”. New codes 16 and 17 are now available to differentiate between Asian Indian and Pakistani. The new codes may be used for pre-2010 cases.
- *Surgical Procedure of the Primary Site* for brain was modified to add more specificity for resection of brain tumors. The new codes may be used for pre-2010 cases.
- The radiation item, *Number of Treatments to This Volume*, has been extended from two to three digits, to handle some of the high numbers of treatments given in split fractions.
- Pathologic and clinical AJCC T, N, M and stage group codes have been expanded from two to four digits, so that it is possible to code the longer codes as defined in the *AJCC Manual for Staging*. These items are entered as left-justified, always capitalizing the alphabetic components. The new, longer codes may be used for pre-2010 cases where applicable.
- CS expanded the storage codes for *CS Extension* and *CS Lymph Nodes* from two to three digits to avoid changing the meaning of the original codes. These storage codes are generally invisible to registrars.

Treatment dates for chemotherapy, hormone therapy and immunotherapy are re-introduced for use in 2010. They were discontinued in 2003, but are necessary to evaluate adherence to recommended treatment practices. Many registries continued to collect them after 2003. For registries that did not collect them, those dates may be blank for cases diagnosed from 2003 through 2009.

Some modifications in coding instructions were also made.

- *Section I* instructions for assigning *Date of First Contact* now clarify that the first contact date for analytic cases is the date the case become analytic. For nonanalytic cases, it is the date the case becomes assignable to the respective *Class of Case*. Additional clarification has been added for determining when *Date of First Contact* should be changed if *Class of Case* changes.
- *Section I* has new language distinguishing among treatment, palliative and prophylactic care.
- If the *Date of Initial Diagnosis* is entirely unknown, the rules now require that the year portion be estimated. Because of this rule change, *Date of Diagnosis Flag* was removed from the CoC required items in the February 2010 update.
- The instructions for *Surgical Procedure of the Primary Site* for bladder were modified to clarify the coding of surgical procedures used for men and women with bladder cancer.
- The definitions of codes 0 and 9 for *Radiation/Surgery Sequence* and *Systemic/Surgery Sequence* have been changed for consistency with SEER. For cases diagnosed in 2010 or later, use code 0 (not 9) if it is unknown whether the patient was treated with either surgery or systemic therapy. This change in coding instructions applies only to cases diagnosed in 2010 or later.
- New codes were added to five administrative items to reflect changes in coding versions. *Morphology Coding System—Original* and *Morphology Coding System—Current* have new codes 8 because, beginning with 2010 diagnoses, some new hematopoietic histology codes will be used. TNM Edition Number has a new code 07 to represent use of the *AJCC Cancer Staging Manual*, 7th edition. *Race Coding System—Original* and *Race Coding System—Current* have a code 7 added to reflect the changes in race codes.

The February 2010 updates include changes in histologic specifications for all site-specific primary site surgery codes and for several other items for consistency with the new hematopoietic and lymphoid coding rules. See Appendix C for the changes.

Additional Coding References

The following references are required to code some items. Coding instructions for items from these sources are not reproduced in *FORDS: Revised for 2010* in order to avoid redundancy and possible conflict when the primary manuals are updated. For each, use the most current version applicable for the diagnosis year.

Fritz A, Percy C, Jack A, et al (eds). *ICD-O: International Classification of Diseases for Oncology*, 3rd ed. Geneva, World Health Organization: 2000.

Edge S, Byrd D, Compton C, et al (eds): *AJCC Cancer Staging Manual*, 7th ed. American Joint Committee on Cancer, Chicago IL. Springer: 2009.

Collaborative Stage Data Collection System, Version 2. Available at <http://cancerstaging.org/cstage/manuals.html>.

Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual and the Hematopoietic and Lymphoid Neoplasms Database (Hematopoietic DB). Available at

<http://seer.cancer.gov/registrars/> (Note: these coding procedures require use of a small number of histology codes not published in *ICD-O-3* above).

Johnson CH, Peace S, Adamo P, et al. *The 2007 Multiple Primary and Histology Coding Rules*. National Cancer Institute, Surveillance, Epidemiology and End Results Program. Bethesda, MD: 2007. Available for download at <http://seer.cancer.gov/registrars/>.

*SEER*Rx – Interactive Drug Database*. National Cancer Institute, Surveillance, Epidemiology and End Results Program, Bethesda MD. Available for download at <http://seer.cancer.gov/registrars/>.

The following references may also be useful.

NAACCR Inc. 2010 Implementation Guidelines and Recommendations. North American Association of Central Cancer Registries. Available at

http://www.naacr.org/index.asp?Col_SectionKey=7&Col_ContentID=431

Thornton M, O’Conner L (eds). *Standards for Cancer Registries, Volume II: Data Standards and Data Dictionary*, 14th ed. North American Association of Central Cancer Registries, Springfieldfield IL: 2009. Available at http://www.naacr.org/index.asp?Col_SectionKey=7&Col_ContentID=133.

SEER Program Coding and Staging Manual (<http://seer.cancer.gov/tools/codingmanuals/index.html>).

An interactive tool that incorporates many of the references above is provided free by Registry Plus. The *Registry Plus Online Help* application has full copies of the *FORDS*, *Collaborative Stage*, and *Multiple Primary and Histology Coding* manuals as well as the *NAACCR Data Dictionary*, the *SEER Coding Manual*, and the introduction and histology sections of *ICD-O-3*. It also describes all standard edits with links to the item definitions they use and explanations for interpreting them. *Registry Plus Online Help* is available at <http://www.cdc.gov/cancer/npcr>. Select “Registry Plus” under Tools; select “Online Help” under Registry Plus Components; then select “Technical Information and Installation.” Follow the instructions to download and install. Because of the many coding changes planned for implementation in 2010, the version with 2010 documentation may not be available until mid-year in 2010.

SECTION ONE:

Case Eligibility and Overview of Coding Principles

CASE ELIGIBILITY

The American College of Surgeons Commission on Cancer (CoC) requires registries in accredited programs to accession, abstract, and conduct follow-up activities for required tumors diagnosed and/or initially treated at the abstracting facility. The tumors must meet the criteria for analytic cases (*Class of Case* 00-22), and pathologically and clinically diagnosed inpatients and outpatients must be included.

TUMORS REQUIRED BY THE CoC TO BE ACCESSIONED, ABSTRACTED, AND FOLLOWED

Malignancies with an ICD-O-3* behavior code of 2 or 3 are required for all sites.

EXCEPTION 1: Juvenile astrocytoma, listed as 9421/1 in ICD-O-3, *is required* and should be recorded as 9421/3 in the registry.

EXCEPTION 2: Malignant primary skin cancers (C44. _) with histology codes 8000–8110 *are not required* by the CoC. Skin primaries with those histologies diagnosed prior to January 1, 2003, were required to be accessioned and followed if the AJCC stage group at diagnosis was II, III, or IV. Those cases should remain in the registry data and continue to be followed.

EXCEPTION 3: Carcinoma in situ of the cervix (CIS) and intraepithelial neoplasia grade III (8077/2) of the cervix (CIN III), prostate (PIN III), vulva (VIN III), vagina (VAIN III), and anus (AIN III) *are not required* by CoC.

Nonmalignant primary intracranial and central nervous system tumors diagnosed on or after January 1, 2004, with an ICD-O-3* behavior code of 0 or 1 are required for the following sites: meninges (C70. _), brain (C71. _), spinal cord, cranial nerves, and other parts of central nervous system (C72. _), pituitary gland (C75.1), craniopharyngeal duct (C75.2) and pineal gland (C75.3).

REPORTABLE-BY-AGREEMENT CASES

Registries may be requested to collect information about tumors that are not required to be abstracted by the CoC for accredited programs. Ordinarily, such requests will come from the facility's cancer committee or the central registry. The CoC does not require that reportable-by-agreement cases be accessioned, abstracted, followed, or submitted, but the requestor may identify the extent of information needed.

Examples of Reportable-by-Agreement Cases:

- The cancer committee requests abstracting and follow-up of *Class of Case* 30 cases.
- The state central registry requests abstracting and reporting of pathology-only cases.

AMBIGUOUS TERMS AT DIAGNOSIS

As part of the registry case-finding activities, all pathology reports should be reviewed to confirm whether a case is required. If the terminology is ambiguous, use the following guidelines to determine whether a particular case should be included.

Ambiguous Terms that Constitute a Diagnosis

Apparent(ly)	Presumed
Appears	Probable
Comparable with	Suspect(ed)
Compatible with	Suspicious (for)
Consistent with	Tumor* (beginning with 2004 diagnoses and only for C70.0–C72.9, C75.1–75.3)
Favors	Typical of
Malignant appearing	
Most likely	
Neoplasm** (beginning with 2004 diagnoses and only for C70.0–C72.9, C75.1–75.3)	

*additional terms for nonmalignant primary intracranial and central nervous system tumors only

EXCEPTION: If a cytology is reported as *suspicious*, do not interpret it as a diagnosis of cancer. Abstract the case only if a positive biopsy or a physician’s clinical impression of cancer supports the cytology findings.

Examples of Diagnostic Terms:

- The inpatient discharge summary documents a chest X ray *consistent with carcinoma* of the right upper lobe. The patient refused further work-up or treatment. *Consistent with carcinoma* is indicative of cancer.
- The mammogram report states *suspicious for malignancy*. *Suspicious for malignancy* is indicative of cancer.

Ambiguous Terms That Do Not Constitute a Diagnosis without additional information

Cannot be ruled out	Questionable
Equivocal	Rule out
Possible	Suggests
Potentially malignant	Worrisome

Examples of Nondiagnostic Terms:

- The inpatient discharge summary documents a chest x-ray *consistent with neoplasm* of the right upper lobe. The patient refused further work-up or treatment. *Consistent with neoplasm* is not indicative of cancer. While “consistent with” can indicate involvement, “neoplasm” without specification of malignancy is not considered diagnostic except for non-malignant primary intracranial and central nervous system tumors.
- Final diagnosis is reported as *possible carcinoma* of the breast. *Possible* is not a diagnostic term for cancer.

Genetic findings in the absence of pathologic or clinical evidence of reportable disease are indicative of risk only and do not constitute a diagnosis.

CLASS OF CASE

All accessioned cases are assigned a *Class of Case* (NAACCR Item #610) based on the nature of involvement of the facility in the care of the patient.

Analytic Cases

Cases diagnosed and/or administered any of the first course of treatment at the accessioning facility after the registry's reference date are analytic (*Class of Case* 00-22). A network clinic or outpatient center belonging to the facility is considered part of the facility.

Analytic cases *Class of Case* 10-22 are included in treatment and survival analysis.

Analytic cases *Class of Case* 00, diagnosed on or after January 1, 2006, are not required to be staged or followed. *Class of Case* 00 is reserved for patients who were originally diagnosed by the reporting facility and received all of their treatment elsewhere or a decision not to treat was made elsewhere. If the patient received no treatment, either because the patient refused recommended treatment or a decision was made not to treat, the *Class of Case* is 14. If there is no information about whether or where the patient was treated, the *Class of Case* is 10.

Nonanalytic Cases

Nonanalytic cases (*Class of Case* 30-99) are not usually included in routine treatment or survival statistics. The CoC does not require registries in accredited programs to accession, abstract, or follow these cases.

Modifications to Class of Case in 2010

Class of Case was redefined for use beginning in 2010. The codes in this manual allow differentiation between analytic and nonanalytic cases and make additional distinctions. For analytic cases, the codes distinguish cases diagnosed in a staff physician's office from those diagnosed initially by the facility and patients fully treated at the facility from those partially treated by the reporting facility. Nonanalytic cases are distinguished by whether the patient received care at the facility or did not personally appear there. Patients who received care from the facility are distinguished by the reasons a case may not be analytic: diagnosed prior to the patient's reference date, type of cancer that is not required by CoC to be abstracted, consultation, in-transit care, and care for recurrent or persistent disease. Patients who did not receive care from the reporting facility are distinguished by care given in one or more staff physician offices, care given through an agency whose cancer cases are abstracted by the reporting facility but are not part of it, pathology only cases, and death certificate only cases.

DATE OF FIRST CONTACT

The *Date of First Contact* (NAACCR Item #580) is the date of the facility's first inpatient or outpatient contact with the patient for diagnosis or treatment of the cancer. For analytic cases, the *Date of First Contact* is the date the patient qualifies as an analytic case *Class of Case* 00-22. Usually, the *Date of First Contact* is the date of admission for diagnosis or for treatment. If the patient was admitted for noncancer-related reasons, the *Date of First Contact* is the date the cancer was first suspected during the hospitalization. If the patient's diagnosis or treatment is as an outpatient of the facility, the *Date of First Contact* is the date the patient first appeared at the facility for that purpose.

If the patient was initially diagnosed at the facility and went elsewhere for treatment (*Class of Case* 00), but then returned for treatment that was initially expected to occur elsewhere, the *Class of Case* is updated to 13 or 14 but the *Date of First Contact* is not changed because it still represents the date the patient became analytic. If the *Class of Case* changes from nonanalytic (for example, consult only, *Class of Case* 30) to analytic (for example, part of first course treatment administered at the facility, *Class of Case* 21), the *Date of First Contact* is updated to the date the case became analytic (the date the patient was admitted for treatment).

When a pathology specimen is collected off site and submitted to the facility to be read (and the specimen is positive for cancer), the case is not required by the Commission on Cancer to be abstracted unless the patient receives first course treatment from the facility.

- If the patient subsequently receives first course treatment at the facility, the case is analytic and must be abstracted and followed. The *Date of First Contact* is the date the patient reported to the facility for the treatment; and the *Class of Case* (NAACCR Item #610) is 11 or 12 if the diagnosing physician is a staff physician at the reporting facility or 20 or 21 for any other physician. A staff physician is one who is employed by the facility, is under contract with it, or has routine admitting privileges there.

When a staff physician performs a biopsy off site and the specimen is not submitted to the facility to be read, the case is not required to be abstracted unless the patient receives some first course care at the facility.

- If the patient subsequently receives first course treatment at the facility, the case is analytic and must be abstracted and followed. The *Date of First Contact* is the date the patient reported to the facility for the treatment and the *Class of Case* is 11 or 12.

For nonanalytic cases, the *Date of First Contact* is the date the patient's nonanalytic status begins with respect to the cancer. For example, for a patient diagnosed and treated entirely in a staff physician's office (*Class of Case* 40), the date the physician initially diagnosed the cancer is the *Date of First Contact*. For autopsy only cases, the *Date of First Contact* is the date of death.

If the state or regional registry requires pathology-only cases to be abstracted and reported, the *Date of First Contact* is the date the specimen was collected and the *Class of Case* is 43. If a patient whose tumor was originally abstracted as a *Class of Case* 43 receives first course treatment subsequently as an inpatient or outpatient at the facility, update both *Class of Case* and *Date of First Contact* to reflect the patient's first in-person contact with the facility.

OVERVIEW OF CODING PRINCIPLES

UNIQUE PATIENT IDENTIFIER CODES

Accession Number (NAACCR Item #550) and *Sequence Number* (NAACCR Item #560) uniquely identify the patient and the tumor. Each cancer patient in a registry is assigned a unique accession number, and each primary diagnosed for that patient is assigned a sequence number. The accession number *never* changes.

- Accession numbers are never reassigned, even if a patient is removed from the registry.
- The sequence number is the sequence of all tumors over the lifetime of a patient and is counted throughout the patient's lifetime.
- Only tumors that would have been reportable at the time of diagnosis for CoC or by agreement with a central registry or the program's cancer committee are required to be counted when assigning sequence numbers. A registry may contain a single abstract for a patient with a sequence number of 02, because the first tumor was not cared for by the program or was not otherwise required to be accessioned. Because of differences in requirements, it is possible for two registries with dissimilar eligibility requirements (for example, a facility registry and a state central registry) to assign different sequence numbers to the same tumor, even though the sequence number codes and instructions applied are the same.

NATIONAL PROVIDER IDENTIFIER

The National Provider Identifier (NPI) is a unique identification number for health care providers that was implemented in 2007 and 2008 by the Centers for Medicare and Medicaid Services (CMS) as part of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). For billing purposes, large practices and large group providers were required to use NPI codes by May 2007; small health plans were required to use NPI codes by May 2008. Individual item descriptions in Section Two of this volume should be consulted for specific coding instructions.

The NPI data items are:

<i>NPI–Archive FIN</i>	<i>(NAACCR Item #3105)</i>
<i>NPI–Following Physician</i>	<i>(NAACCR Item #2475)</i>
<i>NPI–Following Registry</i>	<i>(NAACCR Item #2445)</i>
<i>NPI–Institution Referred From</i>	<i>(NAACCR Item #2415)</i>
<i>NPI–Institution Referred To</i>	<i>(NAACCR Item #2425)</i>
<i>NPI–Managing Physician</i>	<i>(NAACCR Item #2465)</i>
<i>NPI–Physician #3</i>	<i>(NAACCR Item #2495)</i>
<i>NPI–Physician #4</i>	<i>(NAACCR Item #2505)</i>
<i>NPI–Primary Surgeon</i>	<i>(NAACCR Item #2485)</i>
<i>NPI–Reporting Facility</i>	<i>(NAACCR Item #545)</i>

CODING DATES

Beginning in 2010, the way dates are transmitted between facility registries and central registries or the National Cancer Data Base (NCDB) was changed to improve the interoperability or communication of cancer registry data with other electronic record systems. Registry software may display dates in the traditional manner or in the interoperable format. Traditional dates are displayed in MMDDCCYY form, with 99 representing unknown day or month portions, and 99999999 representing a completely unknown date. In the traditional form, some dates also permit 88888888 or 00000000 for special meaning. Interoperable dates are displayed in CCYYMMDD form, with the unknown portions of the date filled with blank spaces. If a date is entirely blank, an associated date flag is used to explain the missing date. The following table illustrates the relationship among these items for *Date of Most Definitive Surgical Resection of the Primary Site*, where *each lower case 'b' represents a blank space*. Flags are not used for software-generated dates.

Description	Traditional Date of Most Definitive Surgical Resection of the Primary Site	Interoperable Date of Most Definitive Surgical Resection of the Primary Site	Rx Date Mst Defn Srg Flag
	Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999	Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable.	
Full date known	MMDDCCYY (example: 02182007)	CCYYMMDD (example: 20070218)	bb
Month and year known	MM99CCYY (example: 02992007)	CCYYMMbb (example: 200702bb)	bb
Year only known	9999CCYY (example: 99992007)	CCYYbbbb (example: 2007bbbb)	bb
Unknown if any surgery performed	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	10
No surgery performed	00000000 (example: 00000000)	bbbbbbbb (example: bbbbbbbb)	11
Date is unknown, surgery performed	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	12

CANCER IDENTIFICATION

Follow the instructions in the **ICD-O-3** section “Coding Guidelines for Topography and Morphology” (ICD-O-3 pp. 19–42) to code *Primary Site* (NAACCR Item #400), *Histology* (NAACCR Item #522), *Behavior Code* (NAACCR Item #523), and *Grade/Differentiation* (NAACCR Item #440).

Primary Site

The instructions for coding primary site are found in the “Topography” section of the **ICD-O-3** “Coding Guidelines for Topography and Morphology” (ICD-O-3 pp. 23–26). The following guidelines should be followed for consistent analysis of primary sites for particular histologies.

Hematopoietic and Lymphoid Cancers

Beginning with cases diagnosed in 2010, the **Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual** is to be used for coding primary site, histology, and grade of hematopoietic and lymphoid tumors (M-9590-9992) and to determine whether multiple conditions represent one or more tumors to be abstracted. For tumors diagnosed prior to January 1, 2010, use the rules applicable when the cancer was diagnosed (See Appendix A).

Kaposi Sarcoma

- Code Kaposi sarcoma to the site in which it arises.
- Code to Skin (C44.9) if Kaposi sarcoma arises simultaneously in the skin and another site or the primary site is not identified.

Melanoma

- Code to Skin, NOS (C44.9) if a patient is diagnosed with metastatic melanoma and the primary site is not identified.

Specific Tissues with Ill-Defined Sites

- If any of the following histologies appears only with an ill-defined site description (eg, “abdominal” or “arm”), code it to the tissue in which such tumors arise rather than the ill-defined region (C76._) of the body, which contains multiple tissues. Use the alphabetic index in **ICD-O-3** to assign the most specific site if only a general location is specified in the record.

Histology	Description	Code to This Site
8720–8790	Melanoma	C44._, Skin
8800–8811, 8813–8830, 8840–8921, 9040–9044	Sarcoma except periosteal fibrosarcoma and dermatofibrosarcoma	C49._, Connective, Subcutaneous and Other Soft Tissues
8990–8991	Mesenchymoma	C49._, Connective, Subcutaneous and Other Soft Tissues
9120–9170	Blood vessel tumors, lymphatic vessel tumors	C49._, Connective, Subcutaneous and Other Soft Tissues
9580–9582	Granular cell tumor and alveolar soft part sarcoma	C49._, Connective, Subcutaneous and Other Soft Tissues
9240–9252	Mesenchymal chondrosarcoma and giant cell tumors	C40._, C41._ for Bone and Cartilage C49._, Connective, Subcutaneous and Other Soft Tissues
8940–8941	Mixed tumor, salivary gland type	C07._ for Parotid Gland C08._ for Other and Unspecified Major Salivary Glands

Laterality

Laterality (NAACCR Item #410) must be recorded for the following paired organs as 1-5 or 9. Organs that are not paired, for which you have not recorded right or left laterality, are coded 0. Midline origins are coded 5. This code is new for 2010, and it may be used retrospectively for cases diagnosed prior to 2010.

Paired Organ Sites

ICD-O-3	Site
C07.9	Parotid gland
C08.0	Submandibular gland
C08.1	Sublingual gland
C09.0	Tonsillar fossa
C09.1	Tonsillar pillar
C09.8	Overlapping lesion of tonsil
C09.9	Tonsil, NOS
C30.0	Nasal cavity (excluding nasal cartilage and nasal septum)
C30.1	Middle ear
C31.0	Maxillary sinus
C31.2	Frontal sinus
C34.0	Main bronchus (excluding carina)
C34.1–C34.9	Lung
C38.4	Pleura

C40.0	Long bones of upper limb and scapula
C40.1	Short bones of upper limb
C40.2	Long bones of lower limb
C40.3	Short bones of lower limb
C41.3	Rib and clavicle (excluding sternum)
C41.4	Pelvic bones (excluding sacrum, coccyx, and symphysis pubis)
C44.1	Skin of eyelid
C44.2	Skin of external ear
C44.3	Skin of other and unspecified parts of face
C44.5	Skin of trunk
C44.6	Skin of upper limb and shoulder
C44.7	Skin of lower limb and hip
C47.1	Peripheral nerves and autonomic nervous system of upper limb and shoulder
C47.2	Peripheral nerves and autonomic nervous system of lower limb and hip
C49.1	Connective, subcutaneous, and other soft tissues of upper limb and shoulder
C49.2	Connective, subcutaneous, and other soft tissues of lower limb and hip
C50.0–C50.9	Breast
C56.9	Ovary
C57.0	Fallopian tube
C62.0–C62.9	Testis
C63.0	Epididymis
C63.1	Spermatic cord
C64.9	Kidney, NOS
C65.9	Renal pelvis
C66.9	Ureter
C69.0–C69.9	Eye and lacrimal gland
C70.0	Cerebral meninges, NOS (excluding diagnoses prior to 2004)
C71.0	Cerebrum (excluding diagnoses prior to 2004)
C71.1	Frontal lobe (excluding diagnoses prior to 2004)
C71.2	Temporal lobe (excluding diagnoses prior to 2004)
C71.3	Parietal lobe (excluding diagnoses prior to 2004)
C71.4	Occipital lobe (excluding diagnoses prior to 2004)
C72.2	Olfactory nerve (excluding diagnoses prior to 2004)
C72.3	Optic nerve (excluding diagnoses prior to 2004)
C72.4	Acoustic nerve (excluding diagnoses prior to 2004)
C72.5	Cranial nerve, NOS (excluding diagnoses prior to 2004)
C74.0–C74.9	Adrenal gland
C75.4	Carotid body

Morphology: Histology Code

The instructions for coding histology and behavior of solid tumors are found in the “Morphology” section of the **ICD-O-3** “Coding Guidelines for Topography and Morphology” (ICD-O-3 pp. 27-30)

To code multiple or mixed histologies present in one primary, the most recent **SEER 2007 Multiple Primary and Histology Coding Rules** replaces all previous multiple histology rules. These rules are effective for cases diagnosed January 1, 2007 and after; do not use them to abstract cases diagnosed before January 1, 2007.

Morphology: Grade/Differentiation

The instructions for coding grade and differentiation are found in the “Morphology” section of the **ICD-O-3** “Coding Guidelines for Topography and Morphology” (ICD-O-3 pp. 30–34).

For sites other than breast, prostate and kidney, code the tumor grade using the following priority order: (1) terminology, (2) histologic grade, (3) nuclear grade.

The grade of a tumor, including brain, can be established through magnetic resonance imaging (MRI) or positron emission tomography (PET) when there is no tissue diagnosis.

For primary tumors of the brain and spinal cord (C71.0–C72.9) do not record the WHO grade as the tumor *Grade/Differentiation* (NAACCR Item #440); record the WHO grade in the data item *CS Site-Specific Factor 1* (NAACCR Item #2880). Grade astrocytomas (M-9383, 9484, 9400, 9401, 9410-9412, 9420, 9421) according to ICD-O-3 rules: I (well differentiated), Code 1; II (intermediate differentiation), Code 2; III (poorly differentiated), Code 3; IV (anaplastic), Code 4. Do not automatically code glioblastoma multiforme as Grade IV if no grade is given, code 9 (Unknown).

Some primary sites are routinely assigned a grade other than *Grade/Differentiation* (NAACCR Item #440) that is defined by **ICD-O-3**. For the *Grade/Differentiation* item, it is necessary to convert from these systems to *Grade/Differentiation* as described in the following sections.

Coding Two-Grade Systems

Two-grade systems apply to colon, rectosigmoid junction, rectum (C18.0–C20.9), and heart (C38.0). Code these sites using a two-grade system; Low Grade (2) or High Grade (4). If the grade is listed as 1/2 or as Low Grade, then code 2. If the grade is listed as 2/2 or as High Grade, then code 4.

Code	Terminology	Histologic Grade
2	Low grade	1/2
4	High grade	2/2

Coding Three-Grade Systems

Three grade-systems apply to peritoneum (C48.1, C48.2), endometrium (C54.1), fallopian tube (C57.0), and brain and spinal cord (C71.0–C72.9). For sites other than breast, prostate and kidney, code the tumor grade using the following priority order: (1) Terminology, (2) Histologic Grade, and (3) Nuclear Grade as shown in the following table.

Code	Terminology	Histologic Grade	Nuclear Grade
2	Low grade, well to moderately differentiated	I/III or 1/3	1/3, 1/2
3	Medium grade, moderately undifferentiated, relatively undifferentiated	II/III or 2/3	2/3
4	High grade, poorly differentiated to undifferentiated	III/III or 3/3	2/2, 3/3

Breast (C50.0-C50.9)

For breast cancers, code the tumor grade using the following priority order: (1) Bloom-Richardson (Nottingham) Scores, (2) Bloom-Richardson Grade, (3) Nuclear Grade (4) Terminology, and (5) Histologic Grade as shown in the table below.

Code	Bloom-Richardson (Nottingham) Scores	Bloom-Richardson Grade	Nuclear Grade	Terminology	Histologic Grade
1	3–5 points	Low grade	1/3, 1/2	Well differentiated	I/III or 1/3
2	6, 7 points	Intermediate grade	2/3	Moderately differentiated	II/III or 2/3
3	8, 9 points	High grade	2/2, 3/3	Poorly differentiated	III/III or 3/3

Kidney (C64.9)

For kidney cancers, code the tumor grade using the following priority rules: (1) Fuhrman Grade, (2) Nuclear Grade, (3) Terminology (well differentiated, moderately differentiated), (4) Histologic Grade. These prioritization rules do not apply to Wilms tumor (M-8960).

Prostate (C61.9)

For prostate cancers, code the tumor grade using the table below following priority order: (1) Gleason Score (this is the sum of the patterns, for example, if the pattern is 2+4 the score is 6), (2) Terminology, (3) Histologic Grade, and (4) Nuclear Grade.

Code	Gleason's Score (sum of primary and secondary patterns)	Terminology	Histologic Grade
1	2, 3, 4	Well differentiated	I
2	5, 6	Moderately differentiated	II
3	7, 8, 9, 10	Poorly differentiated	III

Path Grade System and Path Grade Value

Two items introduced in 2010 describe the grade system and value as assigned by the pathologist, prior to any conversion for *Grade/Differentiation*. *Grade Path Value* (NAACCR Item #441) refers to the numeric value of the grade as reported by the pathologist using a 2, 3 or 4-grade system. *Grade Path System* (NAACCR Item #449) identifies whether the pathologist was using a 2, 3 or 4-grade system. When there

is no information available on grade, the pathologist used a verbal description of grade, or a specialized grade is described (for example, Bloom-Richardson), these two items are to be left blank.

Tumor Grade and AJCC Staging

The **AJCC Cancer Staging Manual** may state that specific histologies are to be considered a specific grade. Follow AJCC instructions when assigning stage only. Follow ICD-O-3 rules and rules in this section for assigning a grade to tumors recorded in your abstract. The specialized grades described in the *AJCC Cancer Staging Manual* are recorded directly as Collaborative Staging items.

Multiple Primaries

The most recent **SEER Multiple Primary and Histology Coding Rules** contain site-specific rules for lung, breast, colon, melanoma of the skin, head and neck, kidney, renal pelvis/ureter/bladder, and malignant and nonmalignant brain primaries. A separate set of rules addresses the specific and general rules for all other sites. The multiple primary rules guide and standardize the process of determining the number of primaries. The histology rules contain detailed histology coding instructions.

The **SEER Multiple Primary and Histology Coding Rules** do not apply to hematopoietic and lymphoid tumors. Use the **Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual** and the **Hematopoietic and Lymphoid Neoplasms Database** to code hematopoietic primaries (lymphoma and leukemia M9590-9989) diagnosed on January 1, 2010, or later. Use the tables in Appendix A of *FORDS Revised for 2010* only for hematopoietic and lymphoid cases diagnosed prior to 2010. Primary site and timing are not applicable for determining whether these malignancies represent one or more primaries.

Paired Organ Sites

A list of paired organ sites can be found earlier in this section. Refer to the **SEER Multiple Primary and Histology Coding Rules** to determine whether involvement of paired sites should be coded as one or two primaries.

Revising the Original Diagnosis

Data are gathered from multiple sources using the most recent and complete information available. Over time, the patient's records may contain new information such as tests, scans, and consults. Change the primary site, laterality, histology, and stage as the information becomes more complete. If the primary site or histology is changed, it may also be necessary to revise site-specific staging and treatment codes. There is no time limit for making revisions that give better information about the original diagnosis or stage. However, if staging information is updated, it is important to adhere to the timing requirements for the respective staging system. Most cases that require revision are unknown primaries.

Example

The institution clinically diagnoses a patient with carcinomatosis. The registry enters the case as an unknown primary (C80.9), carcinoma, NOS (8010/3), stage of disease unknown. Nine months later, a paracentesis shows serous cystadenocarcinoma. The physician says that the patient has an ovarian primary. Change the primary site to ovary (C56.9), histology to serous cystadenocarcinoma (8441/3), and diagnostic confirmation to positive cytologic study, no positive histology (code 2). If enough information is available that meets the AJCC timing requirements for staging, change the stage from not applicable (88) to the appropriate staging basis, TNM elements, and stage group, or to unknown. Update the Collaborative Staging input items and rerun the derivation program.

Example

A physician may decide that a previously clinically diagnosed malignancy is a benign lesion. The patient is referred from a nursing home to the facility. The chest X ray shows a cavitory lesion in the right lung. The family requests that the patient undergo no additional workup or treatment. Discharge

diagnosis is “probable carcinoma of right lung.” The registry abstracts a lung primary (C34.9). Two years later a chest X ray shows an unchanged lesion. The physician documents “lung cancer ruled out.” Delete the case from the database. Adjust the sequence number(s) of any other primaries the patient may have. If the deleted case is the patient’s only primary, do not reuse the accession number.

PATIENT ADDRESS AND RESIDENCY RULES

The patient’s address at diagnosis is the patient’s place of residence at the time of original diagnosis. It does not change if the patient moves. If the patient has more than one primary tumor, the address at diagnosis may be different for each primary.

The current address initially is the patient’s residence at the time the patient was first seen at the accessioning facility for this primary. The current address is updated if the patient moves. If the patient has more than one primary tumor, the current address should be the same for each primary.

Normally a residence is the home named by the patient. Legal status and citizenship are not factors in residency decisions. Rules of residency are identical to or comparable with the rules of the Census Bureau whenever possible. The registry can resolve residency questions by using the Census Bureau’s definition, “the place where he or she lives and sleeps most of the time or the place the person considers to be his or her usual home.” State Vital Statistics rules may differ from Census rules. Do not record residence from the death certificate. Review each case carefully.

Rules for Persons with Ambiguous Residences

Persons with More than One Residence (summer and winter homes): Use the address the patient specifies if a usual residence is not apparent.

Persons with No Usual Residence (transients, homeless): Use the address of the place the patient was staying when the cancer was diagnosed. This location may be a shelter or the diagnosing facility.

Persons Away at School: College students are residents of the school area. Boarding school students below the college level are residents of their parents’ homes.

Persons in Institutions: The Census Bureau states, “Persons under formally authorized, supervised care or custody” are residents of the institution. This classification includes the following:

- Incarcerated persons
- Persons in nursing, convalescent, and rest homes
- Persons in homes, schools, hospitals, or wards for the physically disabled, mentally retarded, or mentally ill.
- Long-term residents of other hospitals, such as Veterans Affairs (VA) hospitals.

Persons in the Armed Forces and on Maritime Ships: Members of the armed forces are residents of the installation area. Use the stated address for military personnel and their families. Military personnel may use the installation address or the surrounding community’s address. The Census Bureau has detailed residency rules for Navy personnel, Coast Guard, and maritime ships. Refer to Census Bureau publications for the detailed rules.

IN UTERO DIAGNOSIS AND TREATMENT

Beginning in 2009, diagnosis and treatment dates for a fetus prior to birth are to be assigned the actual date of the event. In the past, those dates were set by rule to the date the baby was born. The exact date may be used for cases diagnosed prior to 2009.

COMORBIDITIES AND COMPLICATIONS

The CoC requires that the registry record include up to 10 comorbid conditions, factors influencing the health status of the patient, and treatment complications, to be copied from the patient record. All are considered secondary diagnoses. The information is recorded in the **International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)** code form, typically on the patient's discharge abstract or face sheet of the billing record.

The items describing patient comorbid conditions and complications are:

- Comorbidities and Complications #1 (NAACCR Item #3110)*
- Comorbidities and Complications #2 (NAACCR Item #3120)*
- Comorbidities and Complications #3 (NAACCR Item #3130)*
- Comorbidities and Complications #4 (NAACCR Item #3140)*
- Comorbidities and Complications #5 (NAACCR Item #3150)*
- Comorbidities and Complications #6 (NAACCR Item #3160)*
- Comorbidities and Complications #7 (NAACCR Item #3161)*
- Comorbidities and Complications #8 (NAACCR Item #3162)*
- Comorbidities and Complications #9 (NAACCR Item #3163)*
- Comorbidities and Complications #10 (NAACCR Item #3164)*

Comorbidities are preexisting medical conditions or conditions that were present at the time the patient was diagnosed with this cancer (for example, chronic conditions such as COPD, diabetes, and hypertension). Comorbid conditions are identified by ICD-9-CM codes 001–139.8 and 240–999.9. Comorbid conditions are coded without the decimal point and adding trailing 0s to the code value. Thus, 496 (COPD) is coded as 49600.

Complications are conditions that occur during the hospital stay, while the patient is being treated for the cancer (for example, postoperative urinary tract infection or pneumonia). Complications may also occur following the completion of therapy and be a cause for readmission to the hospital. Complications are identified by the ICD-9-CM “E” codes which classify environmental events, circumstances, and conditions as the cause of injury, poisoning, and other adverse effects. Only “E” codes that describe adverse effects occurring during medical care are collected in this data item. They are represented by ICD-9-CM codes E870–E879.9 (misadventures to patients during surgical and medical care) and E930–E949.9 (drugs and medicinal and biologic substances causing adverse effects in therapeutic use). Complications are coded with the leading character “E,” without the decimal point, and retaining trailing zeroes. Thus, E930.0 is coded as E9300.

Factors influencing the health status of patients are circumstances or problems that are not themselves a current illness or injury and are identified by the ICD-9-CM “V” codes (for example, women receiving postmenopausal hormone replacement therapy, or a history of malignant neoplasm). Only specific “V” codes which describe health characteristics are collected in this data item. They are represented by ICD-9-CM codes V07.2–V07.39 (prophylactic measures), V10–V15.9 (personal health history), V22.2–V23.1 (pregnancy), V25.4 (contraception), V44–V45.89 (artificial opening and other post surgical states), V50.41–V50.49 (prophylactic organ removal). Factors influencing the health status of patients are coded with the leading character “V,” without the decimal point, and trailing zeros. Thus, V23.1 is coded as V2310.

STAGE OF DISEASE AT INITIAL DIAGNOSIS

Surgical Diagnostic and Staging Procedures

Surgical Diagnostic and Staging Procedure (NAACCR Item #1350) and *Surgical Diagnostic and Staging Procedure at This Facility* (NAACCR Item #740) refer solely to surgical procedures performed specifically for diagnosis or staging of the tumor and do not apply to surgical treatment. *Date of Surgical Diagnostic and Staging Procedure* (NAACCR Item #1280) refers to the date on which the surgical diagnostic and/or staging procedure was performed at any facility.

EXCEPTION: Do not code surgical procedures that aspirate, biopsy, or remove regional lymph nodes in an effort to diagnose and/or stage disease in the data item *Surgical Diagnostic and Staging Procedure* (NAACCR Item #1350). Use the data item *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292) to code these procedures. Additionally, do not record the date of surgical procedures that aspirate, biopsy, or remove regional lymph nodes in the data item *Date of Surgical Diagnostic and Staging Procedure* (NAACCR Item #1280). Record the date of this surgical procedure in the data item *Date of First Course of Treatment* (NAACCR Item #1270) and/or *Date of First Surgical Procedure* (NAACCR Item #1200), as appropriate.

AJCC TNM STAGING

AJCC TNM Stage is based on the clinical, operative, and pathologic assessment of the anatomic extent of disease and is used to make appropriate treatment decisions, determine prognosis, and measure end results. The following general rules apply to AJCC staging of all sites.

- *Clinical staging* includes any information obtained about the extent of cancer before initiation of definitive treatment (surgery, systemic or radiation therapy, active surveillance, or palliative care) or within four months after the date of diagnosis, whichever is *shorter*, as long as the cancer has not clearly progressed during that time frame.
- *Pathologic staging* includes any information obtained about the extent of cancer through completion of definitive surgery as part of first course treatment or identified within 4 months after the date of diagnosis, whichever is *longer*, as long as there is no systemic or radiation therapy initiated or the cancer has not clearly progressed during that time frame.

The CoC requires the use of AJCC staging to allow physicians to determine appropriate treatment, and a goal of cancer registry staging is to provide high-quality information about cancer stage before and after treatment. Systematic use of this established staging schema enables the reliable evaluation of treatment results and outcomes reported from various institutions on a local, regional and national basis. If the treating physician(s) has not recorded this information, registrars *will* code these items based on the best available information.

- The CoC *requires* registries in accredited cancer programs to record the **clinical** (pretreatment) classifications of T, N, M, and stage group for *Class of Case* 10–22 cases diagnosed on or after January 1, 2008.
- The CoC *recommends* that registries in accredited cancer programs record the clinical classifications of T, N, M, and stage group for *Class of Case* 00 cases diagnosed on or after January 1, 2008.
- The CoC *recommends* that registries in accredited cancer programs record the pathologic classifications (for surgical cases) of T, N, M, and stage group for cases diagnosed on or after January 1, 2008.
- CoC does not require that registrars use information not available in the facility's records to assign staging information. However, if that information is obtained along with other material from another source, it may be used.

The AJCC items that must be coded for Class of Case 10–22 are:

Clinical T (NAACCR Item #940)

Clinical N (NAACCR Item #950)

Clinical M (NAACCR Item #960)

Clinical Stage Group (NAACCR Item #970)

Clinical Stage (Prefix/Suffix) Descriptor (NAACCR Item #980)

Staged By (Clinical Stage) (NAACCR Item #990)

The AJCC items that are recommended to be coded are:

- Pathologic T (NAACCR Item #880)*
- Pathologic N (NAACCR Item #890)*
- Pathologic M (NAACCR Item #900)*
- Pathologic Stage Group (NAACCR Item #910)*
- Pathologic Stage (Prefix/Suffix) Descriptor (NAACCR Item #920)*
- Staged By (Pathologic Stage) (NAACCR Item #930)*

- If a patient has multiple primaries, stage each primary independently.
- If the stage group cannot be determined from the recorded components, then record it as unknown.
- When a patient with multiple primaries develops metastases, a biopsy may distinguish the source of distant disease. Stage both primaries as having metastatic disease if the physician is unable to conclude which primary has metastasized. If, at a later time, the physician identifies which primary has metastasized, update the stage(s) as appropriate.
- If pediatric staging is used and AJCC staging is not applied, code 88 for clinical and pathologic T, N, and M as well as stage group. If either clinical or pathologic staging was applied for a pediatric tumor, enter the appropriate codes for both and do not code 88.

Ambiguous Terminology

If the wording in the patient record is ambiguous with respect to tumor spread, use the following guidelines:

Ambiguous Terms Describing Tumor Spread

Terms that Constitute Tumor Involvement or Extension		Terms that Do Not Constitute Tumor Involvement or Extension
Adherent	Into	Approaching
Apparent	Onto	Equivocal
Compatible with	Out onto	Possible
Consistent with	Probable	Questionable
Encroaching upon	Suspect	Suggests
Fixation, fixed	Suspicious	Very close to
Induration	To	

COLLABORATIVE STAGING

Collaborative Staging (CS) is to be used for cases diagnosed on or after January 1, 2004. It is not to be used for cases diagnosed prior to that date.

How Collaborative Staging Works

Collaborative Staging was designed for registrar use. It relieves registrars from the necessity of staging a single case according to more than one staging system. It avoids most problems that can occur when it is necessary to consider multiple pieces of information simultaneously to assign a single code. For Collaborative Staging, registrars code discrete pieces of information once and the CS computer algorithm derives the values for the 6th and 7th editions of the **AJCC Cancer Staging Manual** T, N, M, Stage Group, and descriptors, as well as Summary Stage 1977 and Summary Stage 2000. The derived stage codes are ideally suited for data analysis because of the consistency that can be obtained with objectively recorded, identically processed data items.

The timing rule for CS coding was designed to make use of the most complete information possible to yield the “best stage” information for the tumor at the time of diagnosis– “use all information gathered through completion of surgery(ies) in first course of treatment or all information available within four months of the date of diagnosis in the absence of disease progression, whichever is longer.” Disease progression is defined as further direct extension or distant metastasis known to have developed after the diagnosis was established. Information about tumor extension, lymph node involvement, or distant metastasis obtained after disease progression is documented should be excluded from the CS coding.

The following CS data items are coded by the registrar. Items with an asterisk (*) have site-specific variations for some codes.

- CS Tumor Size* (NAACCR Item #2800) *
- CS Extension* (NAACCR Item #2810) *
- CS Tumor Size/Ext Eval* (NAACCR Item #2820)
- CS Lymph Nodes* (NAACCR Item #2830) *
- CS Reg Lymph Nodes Eval* (NAACCR Item #2840)
- Regional Lymph Nodes Examined* (NAACCR Item #830)
- Regional Lymph Nodes Positive* (NAACCR Item #820)
- CS Mets at DX* (NAACCR Item #2850) *
- CS Mets at DX – Bone* (NAACCR Item #2851)
- CS Mets at DX – Brain* (NAACCR Item #2852)
- CS Mets at DX – Liver* (NAACCR Item #2853)
- CS Mets at DX – Lung* (NAACCR Item #2854)
- CS Mets Eval* (NAACCR Item #2860)
- CS Site-Specific Factors 1-25* (Schema-specific)

The CS algorithm produces the output items listed below. The derived AJCC items are separate from the physician-coded items; and the derived Summary Stage items are separate from the manually coded items collected by the CoC in the past. The derived items must never be manually altered.

- Derived AJCC-6 T* (NAACCR Item #2940)
- Derived AJCC-6 T Descript* (NAACCR Item #2950)
- Derived AJCC-6 N* (NAACCR Item #2960)
- Derived AJCC-6 N Descript* (NAACCR Item #2970)
- Derived AJCC-6 M* (NAACCR Item #2980)
- Derived AJCC-6 M Descript* (NAACCR Item #2990)
- Derived AJCC-6 Stage Group* (NAACCR Item #3000)
- Derived AJCC-7 T* (NAACCR Item #3400)
- Derived AJCC-7 T Descript* (NAACCR Item #3402)
- Derived AJCC-7 N* (NAACCR Item #3410)
- Derived AJCC-7 N Descript* (NAACCR Item #3412)
- Derived AJCC-7 M* (NAACCR Item #3420)
- Derived AJCC-7 M Descript* (NAACCR Item #3422)
- Derived AJCC-7 Stage Group* (NAACCR Item #3430)
- Derived SS1977* (NAACCR Item #3010)
- Derived SS2000* (NAACCR Item #3020)

Finally, the registry software that runs the CS algorithm produces the following flags that describe how the derived items were computed.

- Derived AJCC-Flag* (NAACCR Item #3030)
- Derived SS1997-Flag* (NAACCR Item #3040)
- Derived SS2000-Flag* (NAACCR Item #3050)
- CS Version Original* (NAACCR Item #2935)
- CS Version Derived* (NAACCR Item #2936)
- CS Version Input Current* (NAACCR Item #297)

All derived items are assigned a “storage value,” which is stored in the computer and used for data transmission and analysis, and an associated “display value,” which is displayed on the computer screen or in printed reports. The display values (for example, “N3c”) were designed to be familiar and readily interpretable to registrars and physicians.

Like the AJCC and Summary Stage codes that are derived from it, CS is a site-specific staging system. The CS algorithm uses tumor site and histology to determine which CS schema to apply. Collaborative Staging codes are defined for every site and histology combination. The *AJCC Cancer Staging Manual* does not cover all sites, and some histologies are excluded from sites with an AJCC coding scheme. When the CS algorithm processes a site-histology combination that does not have an applicable AJCC code, it assigns the display string “NA” for “Not applicable.” A blank display string for a derived item means the CS algorithm was not run for the case.

Coding CS Items

The complete instructions and site-histology defined codes are available in the current version of **Collaborative Stage Data Collection System**.

See the definitions for the Site Specific Factors in this manual for the requirements for staging for cases diagnosed in 2010. This list is likely to change in future years.

Using CS Derived Values

Some differences in the ways that the CS algorithm operates and how the AJCC stage assignment rules are made can result in differences between the derived values for some patients and the direct-coded stages. The differences of most interest to registrars are those that might explain discrepancies between the derived AJCC T, N, M, and Stage Group values and the values recorded for the same cases by physicians.

As a “best stage” system, CS makes use of the most complete information available to stage the tumor. The *AJCC Cancer Staging Manual* distinguishes between clinical staging, based on information available prior to primary treatment, and pathologic staging, based on information gathered as a product of the treatment process (particularly surgery). It also has specific rules governing how the components gathered at different times in the process may be combined. The CS algorithm derives a clinical (c) or pathologic (p) descriptor for each of the T, N, and M stage components based on the source of information used to validate the most extensive spread of the tumor, and uses the components to derive a stage group without reference to the value of the descriptors. Some derived stage groups may involve combinations that are neither clinical nor pathologic according to AJCC rules, so a case that is unstageable for a physician applying AJCC rules may be assigned a Derived AJCC Stage Group value by the CS algorithm. Other cases may involve combinations that do not match either the physician-assigned clinical stage or the pathologic stage.

FIRST COURSE OF TREATMENT

The first course of treatment includes all methods of treatment recorded in the treatment plan and administered to the patient before disease progression or recurrence. “Active surveillance” is a form of planned treatment for some patients; its use is coded in the new *RX Summ–Treatment Status* item. “No therapy” is a treatment option that occurs if the patient refuses treatment, the family or guardian refuses treatment, the patient dies before treatment starts, or the physician recommends no treatment be given. If the patient refuses all treatment, code “patient refused” (code 7 or 87) for all treatment modalities.

Treatment Plan

A treatment plan describes the type(s) of therapies intended to modify, control, remove, or destroy proliferating cancer cells. The documentation confirming a treatment plan may be found in several different sources; for example, medical or clinic records, consultation reports, and outpatient records.

- All therapies specified in the physician(s) treatment plan are a part of the first course of treatment if they are actually administered to the patient.
- A discharge plan must be part of the patient's record in a JCAHO-accredited hospital and may contain part or all of the treatment plan.
- An established protocol or accepted management guidelines for the disease can be considered a treatment plan in the absence of other written documentation.
- If there is no treatment plan, established protocol, or management guidelines, and consultation with a physician advisor is not possible, use the principle: "initial treatment must begin within four months of the date of initial diagnosis."

Time Periods for First Course of Treatment

If first course treatment was provided, the *Date of First Course of Treatment* (NAACCR Item #1270) is the earliest of *Date of First Surgical Procedure* (NAACCR Item #1200), *Date Radiation Started* (NAACCR Item #1210), *Date Systemic Therapy Started* (NAACCR Item #3230), or *Date Other Treatment Started* (NAACCR Item #1250).

- If no treatment is given, record the date of the decision not to treat, the date of patient refusal, or the date the patient expired.
- If active surveillance ("watchful waiting") was selected, record the date of that decision.
- Additional data items further define the parameters for specific treatments and treatment modalities, as described in the following sections.

A new item, *RX Summ–Treatment Status* (NAACCR Item #1285), implemented in 2010, summarizes whether the patient received any first course treatment, no treatment, or is being managed by active surveillance.

All Malignancies except Leukemias

The first course of treatment includes all therapy planned and administered by the physician(s) during the first diagnosis of cancer. Planned treatment may include multiple modes of therapy and may encompass intervals of a year or more. Any therapy administered after the discontinuation of first course treatment is subsequent treatment.

Leukemias

The first course of treatment includes all therapies planned and administered by the physician(s) during the first diagnosis of leukemia. Record all remission-inducing or remission-maintaining therapy as the first course of treatment. Treatment regimens may include multiple modes of therapy. The administration of these therapies can span a year or more. A patient may relapse after achieving a first remission. All therapy administered after the relapse is secondary or subsequent treatment.

Surgery

First course surgery items describe the most definitive type of surgical treatment the patient received from any facility, when it was performed, and its efficacy. When no surgical treatment is given, the reason is recorded. Major aspects of surgical care provided by the individual facility are also recorded so that hospital cancer programs can evaluate local patient care.

Individual item descriptions in Section Two of this manual should be consulted for specific coding instructions. The paragraphs below describe how the surgery items fit together.

The following summary items apply to all surgical procedures performed at this facility and at other facilities:

Surgical Procedure of Primary Site (NAACCR Item #1290)
Radiation/Surgery Sequence (NAACCR Item #1380)
Scope of Regional Lymph Node Surgery (NAACCR Item #1292)
Surgical Procedure/Other Site (NAACCR Item #1294)
Surgical Margins of the Primary Site (NAACCR Item #1320)
Reason for No Surgery of Primary Site (NAACCR Item #1340)
Date of First Surgical Procedure (NAACCR Item #1200)
RX Date–Surgery Flag (NAACCR Item #1201)
Date of Most Definitive Surgical Resection of the Primary Site (NAACCR Item #3170)
RX Date Mst Defn Srg Flag (NAACCR Item #3171)
Date of Surgical Discharge (NAACCR Item #3180)
RX Date Surg Disch Flag (NAACCR Item #3181)
Readmission to the Same Hospital Within 30 Days of Surgical Discharge (NAACCR Item #3190)

The following items apply to surgical procedures performed at this facility:

Surgical Procedure of Primary Site at This Facility (NAACCR Item #670)
RX Hosp–Surg App 2010 (NAACCR Item #668)
Scope of Regional Lymph Node Surgery at This Facility (NAACCR Item #672)
Surgical Procedure/Other Site at This Facility (NAACCR Item #674)

Relationships among Surgical Items

Date of First Surgical Procedure is the date that the first *Surgical Procedure of Primary Site*, *Scope of Regional Lymph Node Surgery*, or *Surgical Procedure/Other Site* is performed as part of first course treatment.

- If surgery was the only type of first course treatment performed or was the first of multiple treatment modalities, *Date of First Surgical Procedure* is the same as *Date of First Course of Treatment*. Both dates can be used to describe lag time between diagnosis and initialization of specific aspects of treatment.

Surgical Procedure of Primary Site, *Scope of Regional Lymph Node Surgery*, and *Surgical Procedure/Other Site* record three distinct aspects of first course therapeutic surgical procedures that may be performed during one or multiple surgical events. If multiple primaries are treated by a single surgical event, code the appropriate surgical items separately for each primary.

- *Surgical Procedure of Primary Site* is a site-specific item that describes the most invasive extent of local tumor destruction or surgical resection of the primary site and of surrounding tissues or organs that are removed in continuity with the primary site.
- *Scope of Regional Lymph Node Surgery* describes the removal, biopsy, or aspiration of sentinel nodes and other regional lymph nodes that drain the primary site and may include surgical procedures that aspirate, biopsy, or remove regional lymph nodes in an effort to diagnose and/or stage disease as well as removal of nodes for treatment of the disease.

Surgical Procedure/Other Site describes first course resection of distant lymph node(s) and/or regional or distant tissue or organs beyond the *Surgical Procedure of the Primary Site* code.

If surgery of the respective type was performed, the code that best describes the surgical procedure is recorded whether or not any cancer was found in the resected portion. Incidental removal of tissue or organs, when it is not performed as part of cancer treatment (for example, incidental removal of an appendix), does not alter code assignment.

The code ranges and corresponding descriptions for site-specific *Surgical Procedure of Primary Site* code are grouped according to the general nature of the procedure:

- Codes 10 through 18 are site-specific descriptions of tumor-destruction procedures that do not produce a pathologic specimen.
- Codes 20 through 80 are site-specific descriptions of resection procedures.
- The special code 98 applies to specific tumors that cannot be clearly defined in terms of primary nonprimary site. *Surgical Procedure of Primary Site* should be coded 98 for any tumor characterized by the specific sites and/or morphologies identified in the site-specific code instructions for *Unknown and Ill-Defined Primary Sites* and *Hematopoietic/Reticuloendothelial/Immunoproliferating/Myeloproliferative Disease*. The item *Surgical Procedure/Other Site* is used to indicate whether surgery was performed for these tumors.

When multiple first course primary site surgical procedures are performed for a single tumor, the most extensive or definitive is the last performed, and the code represents the cumulative effect of the separate procedures.

Response categories are defined in logical sequence. Within groups of codes, procedures are defined with increasing degrees of descriptive precision. Succeeding groups of codes define progressively more extensive forms of resection.

For codes 00 through 79, the descriptions of the surgical procedures are hierarchical. Last-listed responses take precedence over earlier-listed responses (regardless of the code or numeric value).

To the extent possible, codes and their definitions are the same as those previously assigned in *ROADS* to accommodate analysis in registries that maintain unconverted data. As a result of added and modified codes, however, the numeric code sequence may deviate from the order in which the descriptions of the surgical procedures are listed.

Example: A rectosigmoid primary surgically treated by polypectomy with electrocautery, which is listed *after* polypectomy alone, is coded 22.

20	Local tumor excision, NOS
26	Polypectomy
27	Excisional biopsy
Combination of 20 or 26–27 WITH	
21	Photodynamic therapy (PDT)
22	Electrocautery
23	Cryosurgery
24	Laser ablation
25	Laser excision

Scope of Regional Lymph Node Surgery distinguishes between sentinel lymph node biopsy and removal of other regional lymph nodes and distinguishes removal of regional lymph nodes during the same surgical procedure as a sentinel node biopsy from subsequent removal.

- One important use of registry data is the tracking of treatment patterns over time. In order to compare contemporary treatment to previously published treatment based on the former codes, or to data still unmodified from pre-1998 definitions, the ability to differentiate surgeries in which four or more regional lymph nodes are removed is desirable. The compromise incorporated in the *Scope of Regional Lymph Node Surgery* codes separates removal of one to three nodes (code 4) from removal of four or more nodes in the response categories (code 5). It is **very important** to note that this distinction is made to permit comparison of current surgical procedures with procedures coded in the past when the removal of fewer than four nodes was not reflected in surgery codes. The distinction between fewer than four nodes and four or more nodes removed is not intended to reflect clinical significance when applied to a particular surgical procedure.

Surgical Procedure/Other Site describes surgery performed on tissue or organs other than the primary site or regional lymph nodes. It is also used to describe whether surgery was performed for tumors having unknown or ill-defined primary sites or hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease morphologies. If any surgical treatment was performed on these cancers, *Surgical Procedure/Other Site* is coded 1.

Surgical Procedure of Primary Site at This Facility, *Scope of Regional Lymph Node Surgery at This Facility*, and *Surgical Procedure/Other Site at This Facility* are identical to *Surgical Procedure of Primary Site*, *Scope of Regional Lymph Node Surgery*, and *Surgical Procedure/Other Site*, respectively, except they each refer solely to surgery provided by the respective facility.

Six surgery items augment the information recorded in *Surgical Procedure of Primary Site*. The items *Date of Most Definitive Surgical Resection of the Primary Site*, *Surgical Margins of the Primary Site*, *Date of Surgical Discharge*, and *Readmission to the Same Hospital Within 30 Days of Surgical Discharge* apply to the most definitive (most invasive) first course primary site surgery performed, that is, to the event recorded under *Surgical Procedure of Primary Site*. When no surgical procedure of the primary site is performed, the reason is recorded in the item *Reason for No Surgery of Primary Site*.

- *Date of Most Definitive Surgical Resection* is the date on which the specific procedure recorded in *Surgical Procedure of Primary Site* was performed. If only one first course surgical procedure was performed, then the date will be the same as that for *Date of First Surgical Procedure*.
- *Surgical Margins of the Primary Site* records the pathologist's determination of the presence of microscopic or macroscopic involvement of cancer at the margins of resection following the surgical resection described by *Surgical Procedure of Primary Site*.
- *RX Hosp–Surg App 2010* distinguishes among open surgery, laparoscopic surgery, and robotic assisted surgery when it is performed by the reporting facility. If more than one surgical procedure is performed by the facility, this item refers to the most definitive (most invasive) first course primary site surgery performed.
- *Date of Surgical Discharge* is the date the patient was discharged following the procedure recorded in *Surgical Procedure of Primary Site*. It is on or after the *Date of Most Definitive Surgical Resection*.
- *Readmission to the Same Hospital Within 30 Days of Surgical Discharge* distinguishes a planned from an unplanned hospital admission and is used as a quality of care indicator.
- *Reason for No Surgery* identifies why surgical therapy was not provided to the patient and distinguishes a physician's not recommending surgical therapy due to contraindicating conditions from a patient's refusal of a recommended treatment plan.

Radiation

The radiation items in *FORDS* are clinically relevant and reflect contemporary practice. These items record regional and boost treatment information.

The following summary items apply to all radiation therapy administered at this facility and at other facilities:

- Date Radiation Started* (NAACCR Item #1210)
- RX Date–Radiation Flag* (NAACCR Item #1211)
- Location of Radiation Treatment* (NAACCR Item #1550)
- Radiation Treatment Volume* (NAACCR Item #1540)
- Regional Treatment Modality* (NAACCR Item #1570)
- Regional Dose (cGy)* (NAACCR Item #1510)
- Boost Treatment Modality* (NAACCR Item #3200)
- Boost Dose (cGy)* (NAACCR Item #3210)
- Number of Treatments to This Volume* (NAACCR Item #1520)
- Radiation/Surgery Sequence* (NAACCR Item #1380)
- Date Radiation Ended* (NAACCR Item #3220)
- RX Date Rad Ended Flag* (NAACCR Item #3221)
- Reason for No Radiation* (NAACCR Item #1430)

Relationships among Radiation Items

Date Radiation Started is the date that the first radiation therapy was delivered to the patient as part of all of the first course of therapy. This item in combination with *Date Radiation Ended* allows the duration of treatment to be calculated.

- If radiation was the only type of first course treatment performed or was the first of multiple treatment modalities, *Date Radiation Started* is the same as *Date of First Course of Treatment*. Both dates can be used to describe lag time between diagnosis and initialization of specific aspects of treatment.

Location of Radiation Treatment can be used to assess where therapy was provided. This item allows for the distinction between summary treatment and treatment given at the accessioning facility. Codes are provided that allow the description of where regional and boost dose therapy were provided, whether all the therapy was provided at the accessioning facility or if all or some of the radiation therapy was referred out to another treatment location.

The targeted anatomic region is described by *Radiation Treatment Volume*. The treatment volume may be the same as the primary site of disease; however, the available code values provide descriptions of anatomic regions that may extend beyond the primary site of disease and may be used to describe the treatment of metastatic disease.

The type of regional dose therapy and its concomitant dose are captured by the items *Regional Treatment Modality* and *Regional Dose (cGy)*. These two items describe the type of radiation delivered to the patient and the most significant therapeutic dose delivered.

- Codes 20 through 32 of *Regional Treatment Modality* apply to the delivery of beam radiation. If the patient record does not specify the specific modality employed, then code the most general description of the modality, code 20.
- Codes 40 through 43 describe proton radiation (code 40) and specific type of stereotactic radiotherapy (codes 41–43). If stereotactic radiotherapy is delivered to a patient but the exact modality is not recorded, use code 41 (Stereotactic radiosurgery, NOS).

- Codes 50 through 55 are used to record different types of brachytherapy administration, also known as radioactive seed implants. Code 50 should be used to record the application of radioactive materials not otherwise specified.
- Codes 60 through 62 provide codes to describe the administration of specific radioisotopes. Code 60 (Radioisotopes, NOS) should be used when specific details of the radioisotope administration is not available.
- Code 98 is reserved for cases where it is known that radiation therapy was delivered but the modality is not recorded in the patient record.
- The unit of measure for radiologic dosing is the centigray (cGy), which has replaced the use of “rads” to describe radiation dose.
- If only one radiation treatment modality is delivered to a patient and it is not specified as either regional or boost treatment, assume it’s regional treatment and code the items *Regional Treatment Modality* (NAACCR Item #1570) and *Regional Dose (cGy)* (NAACCR Item #1510) accordingly.

A boost treatment is provided to a smaller volume within the same volume as regional radiation in order to enhance the effect of the regional treatment.

- The boost dose may or may not employ the same treatment modality. For example, external beam radiation may be used for regional treatment and be followed by brachytherapy to provide the boost dose.
- Not all patients who receive radiation therapy receive a boost dose radiation. For these cases, boost modality and dose should be coded as 00 and 00000, respectively.

In addition to knowing the duration of treatment and the modalities and doses involved, it is critical to know the number of treatments to be able to gauge the intensity of the dose delivered to the patient. The data item *Number of Treatments to This Volume* describes the total number of therapeutic treatments (regional and boost combined) delivered to the anatomic volume coded in *Radiation Treatment Volume*.

Two items augment the information recorded in the radiation modality, dose, volume, and number of treatment items.

- *Radiation/Surgery Sequence* identifies those instances where radiation therapy and the surgical management of the patient are not discrete and overlap with respect to time. Radiation therapy can precede the surgical resection of a tumor and then be continued after the patient’s surgery, or radiation can be administered intraoperatively.
- *Reason for No Radiation* identifies why radiation therapy was not provided to the patient and distinguishes a physician’s not recommending this therapy due to contraindicating conditions from a patient’s refusal of a recommended treatment plan.

Systemic Therapy

Systemic therapy encompasses the treatment modalities captured by the items chemotherapy, hormone therapy, and immunotherapy. The systemic therapy items in *FORDS* separate the administration of systemic agents or drugs from medical procedures which affect the hormonal or immunologic balance of the patient.

The following summary items apply to all systemic therapy administered at this facility and at other facilities:

Date Systemic Therapy Started (NAACCR Item #3230)
RX Date Systemic Flag (NAACCR Item #3231)
Date Chemotherapy Started (NAACCR Item #1220)
RX Date-Chemo Flag (NAACCR Item #1221)
Date Hormone Therapy Started (NAACCR Item #1230)
RX Date-Hormone Flag (NAACCR Item #1231)
Date Immunotherapy Started (NAACCR Item #1240)
RX Date BRM Flag (NAACCR Item #1241)
Systemic/Surgery Sequence (NAACCR Item #1639)
Chemotherapy (NAACCR Item #1390)
Hormone Therapy (NAACCR Item #1400)
Immunotherapy (NAACCR Item #1410)
Hematologic Transplant and Endocrine Procedures (NAACCR Item #3250)

The following items describe systemic therapy performed at this facility:

Chemotherapy at This Facility (NAACCR Item #700)
Hormone Therapy at This Facility (NAACCR Item #710)
Immunotherapy at This Facility (NAACCR Item #720)

Clarification of Systemic Therapy Terms	
Term	Definition
Chemotherapy	Cancer therapy that achieves its antitumor effect through the use of antineoplastic drugs that inhibit the reproduction of cancer cells by interfering with DNA synthesis and mitosis.
Hormone therapy	Cancer therapy that achieves its antitumor effect through changes in hormonal balance. This type of therapy includes the administration of hormones, agents acting via hormonal mechanisms, antihormones, and steroids.
Immunotherapy	Cancer therapy that achieves its antitumor effect by altering the immune system or changing the host's response to the tumor cells.
Endocrine therapy	Cancer therapy that achieves its antitumor effect through the use of radiation or surgical procedures that suppress the naturally occurring hormonal activity of the patient (when the cancer occurs at another site) and, therefore, alter or affect the long-term control of the cancer's growth.
Hematologic transplants	Bone marrow or stem cell transplants performed to protect patients from myelosuppression or bone marrow ablation associated with the administration of high-dose chemotherapy or radiation therapy.

Chemotherapy agents are administered in treatment cycles, either singly or in a combination regimen of two or more chemotherapy drugs. If a patient has an adverse reaction, the managing physician may change one of the agents in a combination regimen. If the replacement agent belongs to the same group (chemotherapeutic agents are grouped as alkylating agents, antimetabolites, natural products, or other miscellaneous) as the original agent, there is no change in the regimen. However, if the replacement agent is of a different group than the original agent, the new regimen represents the start of subsequent therapy, *only the original agent or regimen is recorded as first course therapy*. Refer to the *SEER*Rx Interactive Drug Database* (<http://seer.cancer.gov/>) for a list of chemotherapeutic agents.

Systemic agents may be administered by intravenous infusion or given orally. Other methods of administration include the following:

Method	Administration
Intrathecal	Administered directly into the cerebrospinal fluid through a lumbar puncture needle into an implanted access device (for example, Ommaya reservoir).
Pleural/pericardial	Injected directly into pleural or pericardial space to control malignant effusions.
Intraperitoneal	Injected into the peritoneal cavity.
Hepatic artery	Injected into a catheter inserted into the artery that supplies blood to the liver.

Relationships among Systemic Therapy Items

The data item *Date Systemic Therapy Started* describes the first date on which any first course systemic treatment was administered to the patient. Nine out of 10 patients treated with systemic therapy receive only a single class of drugs (chemotherapy, hormone therapy, or immunotherapy). Of the remaining patients who receive a combined regimen of systemic therapies, two-thirds begin these combined regimens simultaneously. For the purposes of clinical surveillance, the collection of multiple dates to describe the sequence of systemic therapy administration is not necessary.

The data items *Chemotherapy*, *Hormone Therapy*, and *Immunotherapy* describe whether or not each respective class of agent(s) or drug(s) were administered to the patient as part of first course therapy, based on *SEER*Rx*. In the case of chemotherapy, additional distinction is allowed for instances where single or multiagent regimens were administered. Each of these three items includes code values that describe the reason a particular class of drugs is not administered to the patient and distinguishes a physician's not recommending systemic therapy due to contraindicating conditions from a patient's refusal of a recommended treatment plan. The associated date items were previously defined by CoC, though discontinued in *FORDS* from 2003 through 2009 and the same fields may be used to collect them now, if allowed by the registry software.

Hematologic Transplant and Endocrine Procedures captures those infrequent instances in which a medical, surgical, or radiation procedure is performed on a patient that has an effect on the hormonal or immunologic balance of the patient. Hematologic procedures, such as bone marrow transplants or stem cell harvests, are typically employed in conjunction with administration of systemic agent(s), usually chemotherapy.

- Endocrine procedures, either radiologic or surgical, may be administered in combination with systemic agent(s), typically hormonal therapeutic agents.
- As first course therapy, hematologic procedures will rarely be administered in conjunction with endocrine radiation or surgery. The use of code 40 in response to this data item should be reviewed and confirmed with the managing physician(s).

Other Treatment

Other Treatment encompasses first course treatment that cannot be described as surgery, radiation, or systemic therapy according to the defined data items found in this manual.

This item is also used for supportive care treatment for reportable hematopoietic diseases that do not meet the usual definition in which treatment “modifies, controls, removes, or destroys proliferating cancer tissue.” Treatments such as phlebotomy, transfusions, and aspirin are recorded in *Other Treatment* data item for certain hematopoietic diseases, and should be coded 1.

The following items apply to all Other Treatment provided at this facility and at other facilities:

Date Other Treatment Started (NAACCR Item #1250)

RX Date–Other Flag (NAACCR Item #1251)

Other Treatment (NAACCR Item #1420)

Other Treatment at This Facility (NAACCR Item #730)

Palliative Care

Palliative care is provided to prolong the patient's life by controlling symptoms, to alleviate persistent pain, or to make the patient comfortable. Palliative care provided to relieve symptoms may include surgery, radiation therapy, systemic therapy (chemotherapy, hormone therapy, or other systemic drugs), and/or other pain management therapy. Palliative care is not used to diagnose or stage the primary tumor.

The following items apply to all palliative care provided at this facility and at other facilities:

Palliative Care (NAACCR #3270)

Palliative Care at This Facility (NAACCR Item #3280)

Any surgical procedure, radiation therapy, and/or systemic therapy that is provided to modify, control, remove, or destroy primary or metastatic cancer tissue, is coded in the respective first course of treatment fields and also identified in the *Palliative Care* items. Refer to the preceding discussion of the surgery, radiation and systemic therapy data items for specific coding guidelines. Because these treatments are less aggressive when given for palliation than for treatment, the treatment plan or treatment notes will indicate when they are performed for palliative purposes.

- Record as palliative care any of the treatment recorded in the first course therapy items that was provided to prolong the patient's life by managing the patient's symptoms, alleviating pain, or making the patient more comfortable.
- Palliative care can involve pain management that may not include surgery, radiation or systemic treatment.
- It is possible for a patient to receive one or a combination of treatment modalities in conjunction with palliative care intended to reduce the burden of pain. For example, a patient with metastatic prostate cancer may receive an orchiectomy and systemic hormone therapy in combination with palliative radiation for bone metastasis.

TREATMENT, PALLIATIVE, AND PROPHYLACTIC CARE

Any first course radiation or systemic treatment that acts to kill cancer cells is to be reported as treatment. For example, when total body irradiation (TBI) is given to prepare the patient for a bone marrow transplant (BMT), the TBI acts in two ways. First, it suppresses the immune system to reduce the body's ability to reject the BMT. Second, it contributes to the patient's treatment by destroying cancer cells in the bone marrow, though its use alone would generally not be sufficient to produce a cure. Both the TBI and the BMT should be coded as treatment. The situation is analogous to the use of breast-conserving surgery and adjuvant radiation when the surgery or radiation alone may not be sufficient to produce a cure, though together they are more effective.

When first course surgery, systemic treatment, or radiation is undertaken to reduce the patient's symptoms, that treatment should be coded as palliative care. An example is radiation to bone metastases for prostate cancer to reduce bone pain, which is palliative when there is no expectation that the radiation will effectively reduce the cancer burden. Palliative care involving surgery, systemic treatment, or radiation is also coded as treatment. This treatment qualifies the patient as analytic.

The term "prophylactic" is used in medical practice in a variety of ways. An action taken to prevent

cancer from developing (such as a double mastectomy for a healthy woman who has several relatives diagnosed with breast cancer when they were young) is not reportable; there is no cancer to report. Actions taken as part of planned first course treatment to prevent spread or recurrence of the cancer are sometimes characterized as “prophylactic” (for example, performing an oophorectomy or providing Tamoxifen to a breast cancer mastectomy patient). These treatments are to be coded as treatment.

EMBOLIZATION

The term *embolization* refers to the intentional blocking of an artery or vein. The mechanism and the reason for embolization determine how and whether it is to be recorded.

Chemoembolization is a procedure in which the blood supply to the tumor is blocked surgically or mechanically and anticancer drugs are administered directly into the tumor. This procedure permits a higher concentration of drug to be in contact with the tumor for a longer period of time. Code chemoembolization as *Chemotherapy* when the embolizing agent(s) is a chemotherapeutic drug(s) or when the term *chemoembolization* is used with no reference to the agent. Use *SEER*Rx Interactive Drug Database* (<http://seer.cancer.gov/registrars/>) to determine whether the drugs used are classified as chemotherapeutic agents. Also code as *Chemotherapy* when the patient has primary or metastatic cancer in the liver and the only information about embolization is a statement that the patient had chemoembolization, tumor embolization or embolization of the tumor in the liver. However, if alcohol is specified as the embolizing agent, even in the liver, code the treatment as *Other Therapy*.

Radioembolization is embolization combined with injection of small radioactive beads or coils into an organ or tumor. Code *Radiation Modality* as brachytherapy when tumor embolization is performed using a radioactive agent or radioactive seeds.

Embolization is coded as *Other Therapy* (code 1) if the embolizing agent is alcohol, or if the embolized site is other than the liver and the only information in the record is that the patient was given “embolization” with no reference to the agent.

Do not code presurgical embolization of hypervascular tumors with particles, coils or alcohol. These presurgical embolizations are typically performed to make the resection of the primary tumor easier. Examples where presurgical embolization is used include meningiomas, hemangioblastomas, paragangliomas, and renal cell metastases in the brain.

OUTCOMES

The outcomes data items describe the known clinical and vital status of the patient. Follow-up information is obtained at least annually for all living Class of Case 10-22 patients included in a cancer registry’s database. Recorded follow-up data should reflect the most recent information available to the registry that originates from reported patient hospitalizations, known patient readmissions, contact with the patient’s physician, and/or direct contact with the patient.

Individual item descriptions in Section Two of this manual should be consulted for specific coding instructions. The paragraphs below describe the range of follow-up information that should be obtained.

Follow-up items that are required to be in the facility’s database:

There may be times when first course treatment information is incomplete. Therefore, it is important to continue follow-up efforts to be certain the necessary treatment information is collected. This includes:

- Complete first course of treatment information when *Surgical Procedure of Primary Site* (NAACCR Item #1290) is delayed six months or more following the *Date of First Contact* (NAACCR Item #580).
- *Readmission to the Same Hospital Within 30 Days of Surgical Discharge* (NAACCR Item #3190) following the most definitive surgery.

- Radiation, chemotherapy, hormone therapy, immunotherapy, hematologic transplant and endocrine procedures, or other treatment that had been indicated as being planned as part of first course of treatment, but not been started or completed as of the most recent follow-up date. Use “reason for no” treatment codes of 88 or 8 as ticklers to identify incomplete treatment information.
- When all planned first course treatment has been recorded, first course treatment items no longer need to be followed.
- The CoC does not require Class 00 cases diagnosed on or after January 1, 2006 to be followed.
- Follow-up for disease recurrence should be conducted until (a) evidence of disease recurrence is reported, or (b) the patient dies. If the *Type of First Recurrence* (NAACCR Item #1880) is coded 70 (never cancer free), when the patient was last seen, but treatment was still underway, then check at follow-up to see whether the patient subsequently became cancer-free. Occasionally, if first course treatment ends due to disease progression, it may be the second course or subsequent treatment that results in a cancer-free status. If the *Type of First Recurrence* is coded 00 (became cancer-free and has had no recurrence), then continue to follow for recurrence and record the type and date when it occurs. Reappearance of a tumor of the same histology in the same primary site during the time period defined by the SEER Multiple Primary and Histology Coding Rules does not constitute a recurrence.

Once the first recurrence has been recorded, do not update recurrence items further.

While the patient is alive, be sure that contact information is kept current. Contact information includes:

Patient Address–Current (NAACCR Item #2350)

City/Town–Current (NAACCR Item #1810)

State–Current (NAACCR Item #1820)

Postal Code–Current (NAACCR Item #1830)

Telephone (NAACCR Item #2360)

Date of Last Contact (NAACCR Item #1750)

Follow-Up Source, (NAACCR Item #1790)

Next Follow-Up Source (NAACCR Item #1800).

Following Registry (NAACCR Item #2440)

Follow-up for *Vital Status* (NAACCR Item #1760) and *Cancer Status* (NAACCR Item #1770) should be conducted annually for all analytic cases in the cancer program’s registry. *Class of Case* 00 patients that are not followed will have the most recent information as of the *Date of Last Contact*.

Once the patient’s death has been recorded and all care given prior to death is recorded, no further follow-up is performed.

CASE ADMINISTRATION

Correct and timely management of case records in a registry data set are necessary to describe the nature of the data in the cancer record and to facilitate meaningful analysis of data, and it is necessary to understand each item’s respective purpose to ensure their accuracy and how to use them in facility analysis.

Administrative Tracking

The following administrative tracking items are required to be in the facility's database:

Abstracted By (NAACCR Item #570)
Facility Identification Number (FIN) (NAACCR Item #540)
NPI-Reporting Facility (NAACCR Item #545)
Archive FIN (NAACCR Item #3100)
NPI-Archive FIN (NAACCR Item #3105)

Abstracted By, *Facility Identification Number (FIN)*, and *NPI-Reporting Facility* identify the individual and facility responsible for compiling the record. *Archive FIN* and *NPI-Archive FIN* store the identification numbers assigned to the original abstracting facility and are used to convey the original identity assigned to a facility that has since merged with another. In a registry with more than one abstractor or serving more than one facility, it will ordinarily be necessary to enter these three numbers only when they change. All of these items should be autocoded by the registry software.

Note: A complete list of FINs is available on the American College of Surgeons Web site at <http://www.facs.org/cancer/coc/fin.html>. NPI numbers are available through the facility's billing or accounting department or at <https://nppes.cms.hhs.gov/NPPES/Welcome.do>.

EDITS Overrides

Some of the CoC edits identify rare, but possible, code combinations. For these edits, an override flag can be set if, upon review, the unusual combination is verified as being correct. Once set, the error message will not be repeated on subsequent EDITS passes.

- When no error message is generated by an edit that uses an override item, no action by the registrar is needed.
- If an error message is generated, the problem can often be resolved by checking the accuracy of the entry for each item that contributes to the edit and correcting any problems identified. If correction of data entry errors resolves the problem, do not make an override entry. If the codes reflect the information in the patient record, check for physician notes indicating the unusual combination of circumstances (for example, a colon adenocarcinoma in a child) has been confirmed.
- Enter the override code according to the instructions for the data item. If no comment regarding the unusual circumstances can be found in the record, it may be necessary to check with the managing physician or pathologist to determine whether it is appropriate to override the edit.

The following override items are required to be in the facility's database:

Override Acsn/Class/Seq (NAACCR Item #1985)
Override Age/Site/Morph (NAACCR Item #1990)
Override CoC– Site/Type (NAACCR Item #1987)
Override Site/Type (NAACCR Item #2030)
Override Histology (NAACCR Item #2040)
Override Leuk/Lymphoma (NAACCR Item #2070)
Override Site/Behavior (NAACCR Item #2071)
Override Site/Lat/Morph (NAACCR Item #2074)
Override HospSeq/DxConf (NAACCR Item #1986)
Override HospSeq/Site (NAACCR Item #1988)
Override Site/TNM-StgGrp (NAACCR Item #1989)
Override Surg/DxConf (NAACCR Item #2020)

Code Versions Used

Twelve items describe the version of codes applied to record information in the registry record. Because registries cover many years of cases, registry data will be recorded according to many different coding systems. These items are necessary for the analysis of registry data and for further conversions, so it is important that they be maintained accurately.

The following code version items are required to be in the facility's database:

CoC Coding System–Current (NAACCR Item #2140)
CoC Coding System–Original (NAACCR Item #2150)
Race Coding System–Current (NAACCR Item #170)
Race Coding System–Original (NAACCR Item #180)
Site Coding System–Current (NAACCR Item #450)
Site Coding System–Original (NAACCR Item #460)
Morphology Coding System–Current (NAACCR Item #470)
Morphology Coding System–Original (NAACCR Item #480)
ICD-O-2 Conversion Flag (NAACCR Item #1980)
ICD-O-3 Conversion Flag (NAACCR Item #2116)
TNM Edition Number (NAACCR Item #1060)
RX Coding System–Current (NAACCR Item #1460)

All of these items are capable of being autocoded. Registry software operations differ, but typically the registrar will need to update the version of CoC codes, race coding system, site coding system, and morphology coding system whenever it changes.

For newly abstracted cases, code version information will be applied both as the current and original code versions. When registry data are converted to an updated version for a coding system, the code for the current version should be updated automatically by the conversion.

It is not possible to convert from one version of AJCC TNM to another. The registrar should ascertain that the correct version number is recorded for autocoding.

RX Coding System–Current identifies whether the treatment information was recorded using CoC rules or SEER rules and the version of each applied. The CoC requires that the *FORDS* manual be followed for all cases diagnosed January 1, 2003, or later (*RX Coding System–Current* = 06).

The *ICD-O-3 Conversion Flag* identifies how conversion from ICD-O-2 to ICD-O-3 was accomplished, and the *ICD-O-2 Conversion Flag* identifies how conversion from ICD-O-1 to ICD-O-2 was accomplished. Both should be autocoded at the time of conversion. If the results of either conversion were verified by review for some cases, the conversion flag will need to be updated to indicate that the case was reviewed.

SECTION TWO:
Instructions for Coding

Patient Identification

ACCESSION NUMBER

Item Length: 9
 NAACCR Item #550
 Revised 01/04, 01/10

Description

Provides a unique identifier for the patient consisting of the year in which the patient was first seen at the reporting facility and the consecutive order in which the patient was abstracted.

Rationale

This data item protects the identity of the patient and allows cases to be identified on a local, state, and national level.

Instructions for Coding

- When a patient is deleted from the database, **do not** reuse the accession number for another patient.
- The first four numbers specify the year and the last five numbers are the numeric order in which the patient was entered into the registry database.
- Numeric gaps are allowed in accession numbers.
- A patient's accession number is never reassigned.
- If a patient is first accessioned into the registry, then the registry later changes its reference date and the patient is subsequently accessioned into the registry with a new primary, use the original accession number associated with the patient and code the data item *Sequence Number* (NAACCR Item #560) appropriately.

Code	Definition
(fill spaces)	Nine-digit number used to identify the year in which the patient was first seen at the reporting facility for the diagnosis and/or treatment of cancer.

Examples

Code	Reason
200300033	Patient enters the hospital in 2003, and is diagnosed with breast cancer. The patient is the thirty-third patient accessioned in 2003.
200300033	A patient with the accession number 200300033 for a breast primary returns to the hospital with a subsequent colon primary in 2004. The accession number will remain the same. <i>Sequence Number</i> (NAACCR Item #560) will distinguish this primary.
200300010	Patient diagnosed in November 2002 at another facility enters the reporting facility in January 2003, and is the tenth case accessioned in 2003.
200300012	Patient diagnosed in staff physician office in December 2002 enters the reporting facility in January 2003, and is the twelfth case accessioned in 2003.
199100067	Patient enters the hospital in 1991 and is diagnosed with prostate cancer. The registry later sets a new reference date of January 1, 1997. The same patient presents with a diagnosis of lymphoma in 2005. <i>Sequence Number</i> (NAACCR Item #560) will distinguish this primary.
200300001	First patient diagnosed and/or treated and entered into the registry database for 2003.
200300999	Nine hundred ninety-ninth patient diagnosed and/or treated and entered into the registry database for 2003.
200401504	One thousand five hundred fourth patient diagnosed and/or treated and entered into the registry database for 2004.

SEQUENCE NUMBER

Item Length: 2
 Allowable Values: 00–88, 99
 NAACCR Item #560
 Revised 06/05, 04/07, 01/10

Description

Indicates the sequence of malignant and nonmalignant neoplasms over the lifetime of the patient.

Rationale

This data item is used to distinguish among cases having the same accession numbers, to select patients with only one malignant primary tumor for certain follow-up studies, and to analyze factors involved in the development of multiple tumors.

Instructions for Coding

- Codes 00–59 and 99 indicate neoplasms of *in situ* or malignant behavior (*Behavior* equals 2 or 3). Codes 60–88 indicate neoplasms of non-malignant behavior (*Behavior* equals 0 or 1).
- Code 00 only if the patient has a single malignant primary. If the patient develops a subsequent malignant or *in situ* primary tumor, change the code for the first tumor from 00 to 01, and number subsequent tumors sequentially.
- Code 60 only if the patient has a single nonmalignant primary. If the patient develops a subsequent non-malignant primary, change the code for the first tumor from 60 to 61, and assign codes to subsequent nonmalignant primaries sequentially.
- If two or more malignant or *in situ* neoplasms are diagnosed at the same time, assign the lowest sequence number to the diagnosis with the worst prognosis. If no difference in prognosis is evident, the decision is arbitrary.
- Any tumor in the patient's past which is reportable or reportable-by-agreement at the time the current tumor is diagnosed must be taken into account when sequencing subsequently accessioned tumors. However, do not reassign sequence numbers if one of those tumors becomes nonreportable later.
- Sequence numbers should be reassigned if the facility learns later of an unaccessioned tumor that affects the sequence.

Malignant or In Situ Primaries

Code	Definition
00	One malignant or <i>in situ</i> primary only in the patient's lifetime
01	First of two or more independent malignant or <i>in situ</i> primaries
02	Second of two or more independent or <i>in situ</i> primaries
...	
...	(Actual sequence of this malignant or <i>in situ</i> primary)
...	
59	Fifty-ninth of 59 or more independent malignant or <i>in situ</i> primaries
99	Unknown number of malignant or <i>in situ</i> primaries

Non-Malignant Primaries

Code	Definition
60	One nonmalignant primary only in the patient's lifetime
61	First of two or more independent nonmalignant primaries
62	Second of two or more independent nonmalignant primaries
...	
...	(Actual sequence of this nonmalignant primary)
...	
87	Twenty-seventh of 27 or more independent nonmalignant primaries
88	Unspecified number of independent nonmalignant primaries

Examples

Code	Reason
00	Patient with no previous history of cancer diagnosed with <i>in situ</i> breast carcinoma on June 13, 2003
01	The sequence number is changed when the patient with an <i>in situ</i> breast carcinoma diagnosed June 13, 2003, is diagnosed with a subsequent melanoma on August 30, 2003
02	Sequence number assigned to the melanoma diagnosed on August 30, 2003, following a breast cancer <i>in situ</i> diagnosis on June 13, 2003
04	A nursing home patient is admitted to the hospital for first course surgery for a colon adenocarcinoma. The patient has a prior history of three malignant cancers of the type the registry is required to accession, though the patient was not seen for these cancers at the hospital. No sequence numbers 01, 02 or 03 are accessioned for this patient.
60	The sequence number assigned to a benign brain tumor diagnosed on November 1, 2005, following a breast carcinoma diagnosed on June 13, 2003, and a melanoma on August 30, 2003.
63	Myeloproliferative disease (9975/1) is diagnosed by the facility in 2003 and accessioned as Sequence 60. A benign brain tumor was diagnosed and treated elsewhere in 2002; the patient comes to the facility with a second independent benign brain tumor in 2004. Unaccessioned earlier brain tumor is counted as Sequence 61, myeloproliferative disease is resequenced to 62, and second benign brain tumor is Sequence 63.

MEDICAL RECORD NUMBER

Item Length: 11
 Right Justified, Leading Blanks
 NAACCR Item #2300

Description

Records the medical record number usually assigned by the reporting facility's health information management (HIM) department.

Rationale

This number identifies the patient within a reporting facility. It can be used to reference a patient record and it helps to identify multiple reports on the same patient.

Instructions for Coding

- Record the medical record number.
- When a patient enters a military hospital as a family member of a military sponsor, do not code the patient's relationship to the military sponsor in this field. See data item *Military Medical Record Number Suffix* (NAACCR Item #2310).

Examples

Code	Reason
—NNNN	If the medical record number is fewer than 11 characters, right justify the characters and allow leading blanks.
—NNNNRT (Radiology) —NNSU (One-day surgery clinic)	Record standard abbreviations for departments that do not use HIM medical record numbers.
—UNK	Unknown

SOCIAL SECURITY NUMBERItem Length: 9
NAACCR Item #2320**Description**

Records the patient's Social Security number.

Rationale

This data item can be used to identify patients with similar names.

Instructions for Coding

- Code the patient's Social Security number.
- A patient's Medicare claim number may not always be identical to the person's Social Security number.
- Code Social Security numbers that end with "B" or "D" as 999999999. The patient receives benefits under the spouse's number and this is the spouse's Social Security number.

Code	Definition
(fill spaces)	Record the patient's Social Security number without dashes
999999999	Patient does not have a Social Security number; SSN is not available.

MILITARY MEDICAL RECORD NUMBER SUFFIX Item Length: 2
 Allowable Values: 01–20, 30–69, 98, 99
 NAACCR Item #2310

Description

Records the patient identifier used by military hospitals to record the relationship of the patient to the sponsor.

Rationale

This data item supplements the medical record number in a military medical facility by describing the patient's relationship to the military sponsor.

Instructions for Coding

- Record the Family Member Prefix (FMP) codes assigned by individual military medical facilities.
- Leave blank for non-military facilities.

Code	Definition
01-19	Child
20	Sponsor
30-39	Spouse
40-44	Mother
45-49	Father
50-54	Mother-in-law
55-59	Father-in-law
60-69	Other eligible dependents
98	Civilian emergency (AF/Navy)
99	Not classified elsewhere; stillborn
(leave blank)	Not a military facility

LAST NAME

Item Length: 40
Mixed Case, Left Justified
NAACCR Item #2230
Revised 01/04, 01/10

Description

Identifies the last name of the patient.

Rationale

This data item is used by hospitals as a patient identifier.

Instructions for Coding

- Truncate name if more than 40 letters long. Blanks, spaces, hyphens, and apostrophes are allowed. Do not use other punctuation.
- Do not leave blank; code as UNKNOWN if the patient's last name is unknown.
- This field may be updated if the last name changes.

Examples

Code	Reason
Mc Donald	Recorded with space as Mc Donald
O'Hara	Recorded with apostrophe as O'Hara
Smith-Jones	Janet Smith marries Fred Jones and changes her last name to Smith-Jones
UNKNOWN	Patient's last name is not known, use UNKNOWN

FIRST NAME

Item Length: 40
Mixed Case, Left Justified
NAACCR Item #2240
Revised 01/10

Description

Identifies the first name of the patient.

Rationale

This data item is used by hospitals to differentiate between patients with the same last names.

Instructions for Coding

Truncate name if more than 40 letters long. Do not use punctuation.

Examples

Code	Reason
Michael	Patient's name is Michael David Hogan
(leave blank)	If patient's first name is not known, do not fill in the space.

**MIDDLE NAME
(MIDDLE INITIAL)**

Item Length: 40
Mixed Case, Left Justified
NAACCR Item #2250
Revised 01/10

Description

Identifies the middle name or middle initial of the patient.

Rationale

This data item helps distinguish between patients with identical first and last names.

Instructions for Coding

Truncate the name if more than 40 letters long. Record the middle initial if the complete name is not provided. Do not use punctuation.

Examples

Code	Reason
David	Patient's name is Michael David Hogan
D	Patient's name is Michael D. Hogan
(leave blank)	If patient's middle name is not known or there is none, do not fill in the space.

**PATIENT ADDRESS (NUMBER AND STREET)
AT DIAGNOSIS**

Item Length: 60
Uppercase, Left Justified
NAACCR Item #2330
Revised 01/10

Description

Identifies the patient's address (number and street) at the time of diagnosis.

Rationale

The address is part of the patient's demographic data and has multiple uses. It indicates referral patterns and allows for the analysis of cancer clusters or environmental studies.

Instructions for Coding

- Record the number and street address or the rural mailing address of the patient's usual residence when the tumor was diagnosed.
- The address should be fully spelled out with standardized use of abbreviations and punctuation per U.S. Postal Service postal addressing standards. The USPS Postal Addressing Standards, Pub 28, November 2000 can be found on the Internet at <http://pe.usps.gov/cpim/ftp/pubs/pub28/pub28.pdf>.
- Abbreviations should be limited to those recognized by the Postal Service standard abbreviations. They include, but are not limited to: AVE (avenue), BLVD (boulevard), CIR (circle), CT (court), DR (drive), PLZ (plaza), PARK (park), PKWY (parkway), RD (road), SQ (square), ST (street), APT (apartment), BLDG (building), FL (floor), STE (suite), UNIT (unit), RM (room), DEPT (department), N (north), NE (northeast), NW (northwest), S (south), SE (southeast), SW (southwest), E (east), W (west). A complete list of recognized street abbreviations is provided in Appendix C of USPS Pub 28.
- Punctuation is normally limited to periods (for example, 39.2 RD), slashes for fractional addresses (101 1/2 MAIN ST), and hyphens when a hyphen carries meaning (289-01 MONTGOMERY AVE). Use of the pound sign (#) to designate address units should be avoided whenever possible. The preferred notation is as follows: 102 MAIN ST APT 101. If a pound sign is used, there must be a space between the pound sign and the secondary number (425 FLOWER BLVD #72).
- If the patient has multiple tumors, the address may be different for subsequent primaries.
- Do not update this data item if the patient's address changes.
- See "Residency Rules" in Section One for further instructions.

Code	Definition
103 FIRST AVE SW APT 102	The use of capital letters is preferred by the USPS; use recognized USPS standardized abbreviations; do not use punctuation unless absolutely necessary to clarify an address; leave blanks between numbers and words.
UNKNOWN	If the patient's address is unknown, enter UNKNOWN.

**PATIENT ADDRESS AT DIAGNOSIS
–SUPPLEMENTAL**

Item Length: 60
 Uppercase, Left Justified
 NAACCR Item #2335
 Revised 09/06, 01/10

Description

Provides the ability to store additional address information such as the name of a place or facility (for example, a nursing home or name of an apartment complex) at the time of diagnosis.

Rationale

A registry may receive the name of a facility instead of a proper street address containing the street number, name, direction, and other elements necessary to locate an address on a street file for the purpose of geocoding.

Instructions for Coding

- Record the place or facility (for example, a nursing home or name of an apartment complex) of the patient's usual residence when the tumor was diagnosed.
- If the patient has multiple tumors, the address may be different for subsequent primaries.
- Do not use this data item to record the number and street address of the patient.
- Do not update this data item if the patient's address changes.
- See "Residency Rules" in Section One for further instructions.

Code	Definition
VALLEYVIEW NURSING HOME	The use of capital letters is preferred by the USPS; use recognized USPS standardized abbreviations; do not use punctuation unless absolutely necessary to clarify an address; leave blanks between numbers and words.
(leave blank)	If this address space is not needed, then leave blank.

**CITY/TOWN AT DIAGNOSIS
(CITY OR TOWN)**

Item Length: 50
 Uppercase, Left Justified
 NAACCR Item #70
 Revised 01/10

Description

Identifies the name of the city or town in which the patient resides at the time the tumor is diagnosed and treated.

Rationale

The city or town is part of the patient's demographic data and has multiple uses. It indicates referral patterns and allows for the analysis of cancer clusters or environmental studies.

Instructions for Coding

- If the patient resides in a rural area, record the name of the city or town used in his or her mailing address.
- If the patient has multiple malignancies, the city or town may be different for subsequent primaries.
- Do not update this data item if the patient's city or town of residence changes.
- See "Residency Rules" in Section One for further instructions.

Code	Definition
CITY NAME	Do not use punctuation, special characters, or numbers. The use of capital letters is preferred by the USPS; it also guarantees consistent results in queries and reporting. Abbreviate where necessary.
UNKNOWN	If the patient's city or town is unknown.

**STATE AT DIAGNOSIS
(STATE)**

Item Length: 2
Uppercase
NAACCR Item #80
Revised 09/06, 01/10

Description

Identifies the patient's state of residence at the time of diagnosis.

Rationale

The state of residence is part of the patient's demographic data and has multiple uses. It indicates referral patterns and allows for the analysis of cancer clusters or environmental studies.

Instructions for Coding

- Use U.S. Postal Service abbreviation for the state, territory, commonwealth, U.S. possession, or Canadian province or territory in which the patient resides at the time the tumor is diagnosed and treated.
- If the patient has multiple tumors, the state of residence may be different for subsequent primaries.
- If the patient is a foreign resident, then code either XX or YY depending on the circumstance.
- Do not update this data item if the patient's state of residence changes.

Code Definition

IL	If the state in which the patient resides at the time of diagnosis and treatment is Illinois, then use the USPS code for the state of Illinois.
XX	Resident of a country other than the U.S. (including its territories, commonwealths, or possessions) or Canada and the country is <i>known</i> .
YY	Resident of a country other than the U.S. (including its territories, commonwealths, or possessions) or Canada and the country is <i>unknown</i> .
US	Resident of the U.S. (including its territories, commonwealths, or possessions) and the state is <i>unknown</i> .
CN	Resident of Canada and the province is <i>unknown</i> .
ZZ	Residence unknown.

Common U.S. Abbreviations (refer to the ZIP Code directory for further listings):

State		State		State	
Alabama	AL	Massachusetts	MA	Tennessee	TN
Alaska	AK	Michigan	MI	Texas	TX
Arizona	AZ	Minnesota	MN	Utah	UT
Arkansas	AR	Mississippi	MS	Vermont	VT
California	CA	Missouri	MO	Virginia	VA
Colorado	CO	Montana	MT	Washington	WA
Connecticut	CT	Nebraska	NE	West Virginia	WV
Delaware	DE	Nevada	NV	Wisconsin	WI
District of Columbia	DC	New Hampshire	NH	Wyoming	WY
Florida	FL	New Jersey	NJ	United States, state unknown	US
Georgia	GA	New Mexico	NM	American Samoa	AS
Hawaii	HI	New York	NY	Guam	GU
Idaho	ID	North Carolina	NC	Puerto Rico	PR
Illinois	IL	North Dakota	ND	Virgin Islands	VI
Indiana	IN	Ohio	OH	Palau	PW
Iowa	IA	Oklahoma	OK	Micronesia	FM
Kansas	KS	Oregon	OR	Marshall Islands	MH
Kentucky	KY	Pennsylvania	PA	Outlying Islands	UM
Louisiana	LA	Rhode Island	RI	APO/FPO Armed Services America	AA
Maine	ME	South Carolina	SC	APO/FPO Armed Services Europe	AE
Maryland	MD	South Dakota	SD	APO/FPO Armed Services Pacific	AP

Canadian Provinces and Territory Abbreviations

Province/Territory		Province/Territory	
Alberta	AB	Nunavut	NU
British Columbia	BC	Ontario	ON
Manitoba	MB	Prince Edward Island	PE
New Brunswick	NB	Quebec	QC
Newfoundland and Labrador	NL	Saskatchewan	SK
Northwest Territories	NT	Yukon	YT
Nova Scotia	NS	Canada, province unknown	CD

**POSTAL CODE AT DIAGNOSIS
(ZIP CODE)**

Item Length: 9
 Left Justified
 NAACCR Item #100
 Revised 01/04

Description

Identifies the postal code of the patient's address at diagnosis.

Rationale

The postal code is part of the patient's demographic data and has multiple uses. It will provide a referral pattern report and allow analysis of cancer clusters or environmental studies.

Instructions for Coding

- For U.S. residents, record the patient's nine-digit extended postal code at the time of diagnosis and treatment.
- For Canadian residents, record the six-character postal code.
- When available, record the postal code for other countries.
- If the patient has multiple malignancies, the postal code may be different for subsequent primaries.
- Do not update this data item if the patient's postal code changes.
- See "Residency Rules" in Section One for further instructions.

Code	Definition
(fill spaces)	The patient's nine-digit U.S. extended postal code. Do not record hyphens.
60611_ _ _ _	When the nine-digit extended U.S. ZIP Code is not available, record the five-digit postal code, left justified, followed by four blanks.
M6G2S8_ _ _	The patient's six-character Canadian postal code left justified, followed by three blanks.
88888_ _ _ _ or 888888888	Permanent address in a country other than Canada, United States, or U.S. possessions and postal code is unknown.
99999_ _ _ _ or 999999999	Permanent address in Canada, United States, or U.S. possession and postal code is unknown.

COUNTY AT DIAGNOSIS

Item Length: 3
 Allowable Values: 001–997, 998, 999
 NAACCR Item #90
 Revised 09/06, 01/10

Description

Identifies the county of the patient's residence at the time the reportable tumor is diagnosed.

Rationale

This data item may be used for epidemiological purposes. For example, to measure the cancer incidence in a particular geographic area.

Instructions for Coding

- For U.S. residents, use codes issued by the Federal Information Processing Standards (FIPS) publication *Counties and Equivalent Entities of the United States, Its Possessions, and Associated areas*. This publication is available in a reference library or can be accessed on the Internet through the U.S. EPA's Envirofacts Data Warehouse and Applications Web site at <http://www.epa.gov/>.
- If the patient has multiple tumors, the county codes may be different for each tumor.
- If the patient is a non-U.S. resident and is coded XX in *State at Diagnosis* (NAACCR Item #80), then code the patient's country of residence in this space.
- For country codes, see the current version of *Standards for Cancer Registries Volume II: Data Standards and Data Dictionary*.
- Do not update this data item if the patient's county of residence changes.

Code	Label	Definition
001–997	County at diagnosis	Valid FIPS code.
998	Outside state/county code unknown	Known town, city, state, or country of residence, but county code not known and a resident outside of the state of the reporting institution (must meet all criteria).
999	County unknown	The county of the patient is unknown. It is not documented in the patient's medical record.

**PATIENT ADDRESS (NUMBER AND STREET)
CURRENT**

Item Length: 60
 Uppercase, Left Justified
 NAACCR Item #2350
 Revised 09/04, 01/10

Description

Identifies the patient's current address (number and street).

Rationale

This data item provides a current address used for follow-up purposes. It is different from *Patient Address at Diagnosis* (NAACCR #2330).

Instructions for Coding

- Record the number and street address or the rural mailing address of the patient's current usual residence.
- The address should be fully spelled out with standardized use of abbreviations and punctuation per U.S. Postal Service postal addressing standards. The USPS Postal Addressing Standards, Pub 28, November 2000 can be found on the Internet at <http://pe.usps.gov/cpim/ftp/pubs/pub28/pub28.pdf>.
- Abbreviations should be limited to those recognized by the Postal Service standard abbreviations. They include, but are not limited to: AVE (avenue), BLVD (boulevard), CIR (circle), CT (court), DR (drive), PLZ (plaza), PARK (park), PKWY (parkway), RD (road), SQ (square), ST (street), APT (apartment), BLDG (building), FL (floor), STE (suite), UNIT (unit), RM (room), DEPT (department), N (north), NE (northeast), NW (northwest), S (south), SE (southeast), SW (southwest), E (east), W (west). A complete list of recognized street abbreviations is provided in Appendix C of USPS Pub 28.
- Punctuation is normally limited to periods (for example, 39.2 RD), slashes for fractional addresses (101 1/2 MAIN ST), and hyphens when a hyphen carries meaning (289-01 MONTGOMERY AVE). Use of the pound sign (#) to designate address units should be avoided whenever possible. The preferred notation is as follows: 102 MAIN ST APT 101. If a pound sign is used, there must be a space between the pound sign and the secondary number (425 FLOWER BLVD #72).
- Update this data item if the patient's address changes.
- Do not change this item when the patient dies.
- See "Residency Rules" in Section One for further instructions.

Code	Definition
103 FIRST AVE SW APT 102	The use of capital letters is preferred by the USPS; use recognized USPS standardized abbreviations; do not use punctuation unless absolutely necessary to clarify an address; leave blanks between numbers and words.
UNKNOWN	The patient's street address is unknown.

**PATIENT ADDRESS CURRENT
–SUPPLEMENTAL**

Item Length: 60
 Uppercase, Left Justified
 NAACCR Item #2355
 Revised 09/06, 01/10

Description

Provides the ability to store additional address information such as the name of a place or facility (for example, a nursing home or name of an apartment complex).

Rationale

A registry may receive the name of a facility instead of a proper street address containing the street number, name, direction, and other elements necessary to locate an address on a street file for the purpose of geocoding.

Instructions for Coding

- Record the place or facility (for example, a nursing home or name of an apartment complex) of the patient's current usual residence.
- If the patient has multiple tumors, the address may be different for subsequent primaries.
- Update this data item if a patient's address changes.
- Do not use this data item to record the number and street address of the patient.
- Do not change this item when the patient dies.
- See "Residency Rules" in Section One for further instructions.

Code	Definition
VALLEYVIEW NURSING HOME	The use of capital letters is preferred by the USPS; use recognized USPS standardized abbreviations; do not use punctuation unless absolutely necessary to clarify an address; leave blanks between numbers and words.
(leave blank)	If this address space is not needed, then leave blank.

CITY/TOWN–CURRENT

Item Length: 50

Uppercase, Left Justified

NAACCR Item #1810

Revised 09/04

Description

Identifies the name of the city or town of the patient's current usual residence.

Rationale

This data item provides a current city or town used for follow-up purposes. It is different from *City/Town at Diagnosis* (NAACCR Item #70).

Instructions for Coding

- If the patient resides in a rural area, record the name of the city or town used in his or her mailing address.
- If the patient has multiple malignancies, the current city or town should be the same for all tumors.
- Update this data item if the patient's city or town of residence changes.
- Do not change this item when the patient dies.
- See "Residency Rules" in Section One for further instructions.

Code	Definition
CITY NAME	Do not use punctuation, special characters, or numbers. The use of capital letters is preferred by the USPS; it also guarantees consistent results in queries and reporting. Abbreviate where necessary.
UNKNOWN	The city in which the patient resides is unknown.

STATE–CURRENT

Item Length: 2
 Uppercase
 NAACCR Item #1820
 Revised 09/06

Description

Identifies the patient's current state of residence.

Rationale

This item provides a current state of residence used for follow-up purposes. It is different from *State at Diagnosis* (NAACCR Item #80).

Instructions for Coding

- Use U.S. Postal Service abbreviation for the state, territory, commonwealth, U.S. possession, or Canadian province or territory of the patient's current usual residence.
- If the patient has multiple tumors, the current state of residence should be the same for all tumors.
- If the patient is a foreign resident, then code either XX or YY depending on the circumstance.
- Update this data item if the patient's state of residence changes.
- Do not change this item when the patient dies.

Code	Definition
IL	If the state in which the patient resides at the time of diagnosis and treatment is Illinois, then use the USPS code for the state of Illinois.
XX	Resident of a country other than the U.S. (including its territories, commonwealths, or possessions) or Canada and the country <i>is known</i> .
YY	Resident of a country other than the U.S. (including its territories, commonwealths, or possessions) or Canada and the country <i>is unknown</i> .
US	Resident of the U.S. (including its territories, commonwealths, or possessions) and the state <i>is unknown</i> .
CN	Resident of Canada and the province <i>is unknown</i> .
ZZ	Residence unknown.

Common U.S. abbreviations (refer to the ZIP Code directory for further listings):

State		State		State	
Alabama	AL	Massachusetts	MA	Tennessee	TN
Alaska	AK	Michigan	MI	Texas	TX
Arizona	AZ	Minnesota	MN	Utah	UT
Arkansas	AR	Mississippi	MS	Vermont	VT
California	CA	Missouri	MO	Virginia	VA
Colorado	CO	Montana	MT	Washington	WA
Connecticut	CT	Nebraska	NE	West Virginia	WV
Delaware	DE	Nevada	NV	Wisconsin	WI
District of Columbia	DC	New Hampshire	NH	Wyoming	WY
Florida	FL	New Jersey	NJ	United States, state unknown	US
Georgia	GA	New Mexico	NM	American Samoa	AS
Hawaii	HI	New York	NY	Guam	GU
Idaho	ID	North Carolina	NC	Puerto Rico	PR
Illinois	IL	North Dakota	ND	Virgin Islands	VI
Indiana	IN	Ohio	OH	Palau	PW
Iowa	IA	Oklahoma	OK	Micronesia	FM
Kansas	KS	Oregon	OR	Marshall Islands	MH
Kentucky	KY	Pennsylvania	PA	Outlying Islands	UM
Louisiana	LA	Rhode Island	RI	APO/FPO Armed Services America	AA
Maine	ME	South Carolina	SC	APO/FPO Armed Services Europe	AE
Maryland	MD	South Dakota	SD	APO/FPO Armed Services Pacific	AP

Canadian Provinces or Territory abbreviations:

Province/Territory		Province/Territory	
Alberta	AB	Nunavut	NU
British Columbia	BC	Ontario	ON
Manitoba	MB	Prince Edward Island	PE
New Brunswick	NB	Quebec	QC
Newfoundland and Labrador	NL	Saskatchewan	SK
Northwest Territories	NT	Yukon	YT
Nova Scotia	NS	Canada, province unknown	CD

**POSTAL CODE–CURRENT
(ZIP CODE)**

Item Length: 9
 Left Justified
 NAACCR Item #1830
 Revised 01/04

Description

Identifies the postal code of the patient's current address.

Rationale

This data item provides a current postal code for follow-up purposes and should be updated. It is different from *Postal Code at Diagnosis* (NAACCR Item #100).

Instructions for Coding

- For U.S. residents, record the nine-digit extended postal code for the patient's current usual residence.
- For Canadian residents, record the six-character postal code.
- When available, record the postal code for other countries.
- If the patient has multiple tumors, the postal code should be the same.
- Update this data item if the patient's postal code changes.

Code	Definition
(fill spaces)	The patient's nine-digit U.S. extended postal code. Do not record hyphens.
60611_ _ _ _	When the nine-digit extended U.S. ZIP Code is not available, record the five-digit postal code, left justified, followed by four blanks.
M6G2S8_ _ _	The patient's six-character Canadian postal code left justified, followed by three blanks.
88888_ _ _ _ or 888888888	Permanent address in a country other than Canada, United States, or U.S. possessions and postal code is unknown.
99999_ _ _ _ or 999999999	Permanent address in Canada, United States, or U.S. possession and postal code is unknown.

TELEPHONEItem Length: 10
NAACCR Item #2360

Description

Records the current telephone number with area code for the patient.

Rationale

This data item may be used by the hospital registry to contact the patient for follow-up.

Instructions for Coding

- The telephone number should be the current number with area code of the patient.
- Update this data item if the patient's telephone number changes.

Code	Definition
(fill spaces)	Number is entered without dashes.
0000000000	Patient does not have a telephone.
9999999999	Telephone number is unavailable or unknown.

PLACE OF BIRTH

Item Length: 3
 Allowable Values: 000–750, 998, 999
 NAACCR Item #250
 Revised 09/06

Description

Records the patient's place of birth.

Rationale

This data item is used to evaluate medical care delivery to special populations and to identify populations at special risk for certain cancers.

Instructions for Coding

- Use the most specific code.
- Use the SEER Geocodes for "Place of Birth." These codes include states of the United States as well as foreign countries.
- For SEER Geocodes, see the most recent *Standards for Cancer Registries Volume II: Data Standards and Data Dictionary*.

Code	Definition
000–750	SEER Geocode
998	Place of birth outside of the United States, no other detail known.
999	Place of birth unknown.

DATE OF BIRTH

Item Length: 8
NAACCR Item #240
Revised 1/10

Description

Identifies the date of birth of the patient.

Rationale

This data item is useful for patient identification. It is also useful when analyzing tumors according to age cohort.

Instructions for Coding

- Record the patient's date of birth as indicated in the patient record. For single-digit day or month, record with a lead 0 (for example, September is 09). Use the full four-digit year for year.
- For *in utero* diagnosis and treatment, record the actual date of birth. It will follow one or both dates for those events.
- If only the patient age is available, calculate the year of birth from age and the year of diagnosis and leave day and month of birth unknown (for example, a 60 year old patient diagnosed in 2010 is calculated to have been born in 1950).
- If month is unknown, the day is coded unknown. If the year can not be determined, the day and month are both coded unknown.
- If the date of birth can not be determined at all, record the reason in *Date of Birth Flag* (NAACCR Item #241)
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about date entry in their own systems. The traditional format for *Date of Birth* is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date of Birth* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date. The *Date of Birth Flag* (NAACCR Item #241) is used to explain why *Date of Birth* is not a known date. See *Date of Birth Flag* for an illustration of the relationships among these items.

DATE OF BIRTH FLAG

Item Length: 2
 NAACCR Item #241
 Valid Codes: 12, Blank
 New Item: 1/1/2010

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date of Birth* (NAACCR Item #240).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate nondate information that had previously been transmitted in date fields.

Instructions for Coding

- Leave this item blank if *Date of Birth* (NAACCR Item #240) has a full or partial date recorded.
- Code 12 if the *Date of Birth* can not be determined at all.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software

Code	Definition
12	A proper value is applicable but not known (for example, birth date is unknown)
(Blank)	A valid date value is provided in item <i>Date of Birth</i> (NAACCR Item #240)

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date of Birth* (NAACCR Item #240) and *Date of Birth Flag* (NAACCR Item #241). ***In the table below, the lowercase letter “b” is used to represent each blank space.***

Description	Traditional Birth Date	Interoperable Birth Date	Date of Birth Flag
	Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999	Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown.	
Full date known	MMDDCCYY (example: 02181942)	CCYYMMDD (example: 19420218)	bb
Month and year known	MM99CCYY (example: 02991942)	CCYYMMbb (example: 194202bb)	bb
Year only known	9999CCYY (example: 99991942)	CCYYbbbb (example: 1942bbbb)	bb
Unknown date	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	12

AGE AT DIAGNOSIS

Item Length: 3
Allowable Values: 000–120, 999
Right Justified, Zero-filled
NAACCR Item #230
Revised 09/01/08

Description

Records the age of the patient at his or her last birthday before diagnosis.

Rationale

This data item is useful for patient identification. It may also be useful when analyzing tumors according to specific patient age.

Instructions for Coding

If the patient has multiple primaries, then the age at diagnosis may be different for subsequent primaries.

Code	Definition
000	Less than one year old; diagnosed <i>in utero</i>
001	One year old but less than two years old
002	Two years old
...	Actual age in years
120	One hundred twenty years old
999	Unknown age

RACE 1

Item length: 2

Allowable Values: 01–08, 10–17, 20–22, 25–28, 30–32, 96–99

NAACCR Item #160

Revised 01/04, 09/08, 01/10

Description

Identifies the primary race of the person.

Rationale

Racial origin captures information used in research and cancer control activities comparing stage at diagnosis and/or treatment by race. The full coding system should be used to allow for an accurate national comparison.

Instructions for Coding

- Additional races reported by the person should be coded in *Race 2*, *Race 3*, *Race 4*, and *Race 5*.
- *Race 1* is the field used to compare with race data on cases diagnosed prior to January 1, 2000.
- “Race” is analyzed with *Spanish/Hispanic Origin* (NAACCR Item #190). Both items must be recorded. All tumors for the same patient should have the same race code.
- If the patient is multiracial, then code all races using *Race 2* (NAACCR Item #161) through *Race 5* (NAACCR Item #164), and code all remaining *Race* items 88.
- If the person is multiracial and one of the races is white, code the other race(s) first with white in the next race field.
- If the person is multiracial and one of the races is Hawaiian, code Hawaiian as *Race 1*, followed by the other race(s).
- A known race code (other than blank or 99) must not occur more than once. For example, do not code “Black” in *Race 1* for one parent and “Black” in *Race 2* for the other parent.
- If *Race 1* is coded 99, then *Race 2* through *Race 5* must all be coded 99.
- Codes 08–13 became effective with diagnoses on or after January 1, 1988.
- Code 14 became effective with diagnoses on or after January 1, 1994.
- In 2010, code 09 was converted to the new code 15, and codes 16 and 17 were added.
- Codes 20–97 became effective with diagnoses on or after January 1, 1991. SEER participants in San Francisco, San Jose–Monterey, and Los Angeles are permitted to use codes 14 and 20–97 for cases diagnosed after January 1, 1987.
- If *Race Coding System–Current* (NAACCR Item #170) is less than six (6) for cases diagnosed prior to January 1, 2000, then *Race 2* through *Race 5* must be blank.
- If a patient diagnosed prior to January 1, 2000, develops a subsequent primary after that date, then *Race Coding System–Current* must be six (6), and data items *Race 2* through *Race 5* that do not have specific race recorded must be coded 88.

Code	Label	Code	Label
01	White	20	Micronesian, NOS
02	Black	21	Chamorroan
03	American Indian, Aleutian, or Eskimo (includes all indigenous populations of the Western hemisphere)	22	Guamanian, NOS
04	Chinese	25	Polynesian, NOS
05	Japanese	26	Tahitian
06	Filipino	27	Samoan
07	Hawaiian	28	Tongan
08	Korean	30	Melanesian, NOS
10	Vietnamese	31	Fiji Islander
11	Laotian	32	New Guinean
12	Hmong	96	Other Asian, including Asian, NOS and Oriental, NOS
13	Kampuchean (Cambodian)	97	Pacific Islander, NOS
14	Thai	98	Other
15	Asian Indian or Pakistani, NOS (formerly code 09)	99	Unknown
16	Asian Indian		
17	Pakistani		

Examples

Code	Reason
01	A patient was born in Mexico of Mexican parentage. Code also <i>Spanish/Hispanic Origin</i> (NAACCR Item #190).
02	A black female patient.
05	A patient has a Japanese father and a Caucasian mother. (Caucasian will be coded in <i>Race 2</i>).

RACE 2

Item Length: 2

Allowable Values: 01–08, 10–17, 20–22, 25–28, 30–32, 88, 96–99

NAACCR Item #161

Revised 01/04, 09/08, 01/10

Description

Identifies the patient's race.

Rationale

Racial origin captures information used in research and cancer control activities comparing stage at diagnosis and/or treatment by race. The full coding system should be used to allow for an accurate national comparison.

Instructions for Coding

- “Race” is analyzed with *Spanish/Hispanic Origin* (NAACCR Item #190). Both items must be recorded. All tumors for the same patient should have the same race code.
- If *Race 1* (NAACCR Item #160) is coded 99, then *Race 2* must be coded 99.
- Codes 08–13 became effective with diagnoses on or after January 1, 1988.
- Code 14 became effective with diagnoses on or after January 1, 1994.
- In 2010, code 09 was converted to the new code 15, and codes 16 and 17 were added.
- Codes 20–97 became effective with diagnoses on or after January 1, 1991. SEER participants in San Francisco, San Jose–Monterey, and Los Angeles are permitted to use codes 14 and 20–97 for cases diagnosed after January 1, 1987.
- See the instructions for *Race 1* (NAACCR Item #160) for coding sequences for entering multiple races.

Code	Label	Code	Label
01	White	20	Micronesian, NOS
02	Black	21	Chamorroan
03	American Indian, Aleutian, or Eskimo (includes all indigenous populations of the Western hemisphere)	22	Guamanian, NOS
04	Chinese	25	Polynesian, NOS
05	Japanese	26	Tahitian
06	Filipino	27	Samoan
07	Hawaiian	28	Tongan
08	Korean	30	Melanesian, NOS
10	Vietnamese	31	Fiji Islander
11	Laotian	32	New Guinean
12	Hmong	88	No additional races
13	Kampuchean (Cambodian)	96	Other Asian, including Asian, NOS and Oriental, NOS
14	Thai	97	Pacific Islander, NOS
15	Asian Indian or Pakistani, NOS (formerly code 09)	98	Other
16	Asian Indian	99	Unknown
17	Pakistani		

RACE 3

Item Length: 2

Allowable Values: 01–08, 10–17,
20–22, 25–28, 30–32, 88, 96–99

NAACCR Item #162

Revised 01/04, 09/08, 01/10

Description

Identifies the patient's race.

Rationale

Racial origin captures information used in research and cancer control activities comparing stage at diagnosis and/or treatment by race. The full coding system should be used to allow for an accurate national comparison.

Instructions for Coding

- “Race” is analyzed with *Spanish/Hispanic Origin* (NAACCR Item #190). Both items must be recorded. All tumors for the same patient should have the same race code.
- If *Race 2* (NAACCR Item #161) is coded 88 or 99, then *Race 3* must be coded with the same value.
- Codes 08–13 became effective with diagnoses on or after January 1, 1988.
- Code 14 became effective with diagnoses on or after January 1, 1994.
- In 2010, code 09 was converted to the new code 15, and codes 16 and 17 were added.
- Codes 20–97 became effective with diagnoses on or after January 1, 1991. SEER participants in San Francisco, San Jose–Monterey, and Los Angeles are permitted to use codes 14 and 20–97 for cases diagnosed after January 1, 1987.
- See the instructions for Race 1 (NAACCR Item #160) for coding sequences for entering multiple races.

Code	Label	Code	Label
01	White	20	Micronesian, NOS
02	Black	21	Chamorroan
03	American Indian, Aleutian, or Eskimo (includes all indigenous populations of the Western hemisphere)	22	Guamanian, NOS
04	Chinese	25	Polynesian, NOS
05	Japanese	26	Tahitian
06	Filipino	27	Samoan
07	Hawaiian	28	Tongan
08	Korean	30	Melanesian, NOS
10	Vietnamese	31	Fiji Islander
11	Laotian	32	New Guinean
12	Hmong	88	No additional races
13	Kampuchean (Cambodian)	96	Other Asian, including Asian, NOS and Oriental, NOS
14	Thai	97	Pacific Islander, NOS
15	Asian Indian or Pakistani, NOS (formerly code 09)	98	Other
16	Asian Indian	99	Unknown
17	Pakistani		

RACE 4

Item Length: 2

Allowable Values: 01–08, 10–17, 20–22, 25–28, 30–32, 88, 96–99

NAACCR Item #163

Revised 01/04, 09/08, 01/10

Description

Identifies the patient's race.

Rationale

Racial origin captures information used in research and cancer control activities comparing stage at diagnosis and/or treatment by race. The full coding system should be used to allow for an accurate national comparison.

Instructions for Coding

- “Race” is analyzed with *Spanish/Hispanic Origin* (NAACCR Item #190). Both items must be recorded. All tumors for the same patient should have the same race code.
- If *Race 3* (NAACCR Item #162) is coded 88 or 99, then *Race 4* must be coded with the same value.
- Codes 08–13 became effective with diagnoses on or after January 1, 1988.
- Code 14 became effective with diagnoses on or after January 1, 1994.
- In 2010, code 09 was converted to the new code 15, and codes 16 and 17 were added.
- Codes 20–97 became effective with diagnoses on or after January 1, 1991. SEER participants in San Francisco, San Jose–Monterey, and Los Angeles are permitted to use codes 14 and 20–97 for cases diagnosed after January 1, 1987.
- See the instructions for *Race 1* (NAACCR Item #160) for coding sequences for entering multiple races.

Code	Label	Code	Label
01	White	20	Micronesian, NOS
02	Black	21	Chamorroan
03	American Indian, Aleutian, or Eskimo (includes all indigenous populations of the Western hemisphere)	22	Guamanian, NOS
04	Chinese	25	Polynesian, NOS
05	Japanese	26	Tahitian
06	Filipino	27	Samoan
07	Hawaiian	28	Tongan
08	Korean	30	Melanesian, NOS
10	Vietnamese	31	Fiji Islander
11	Laotian	32	New Guinean
12	Hmong	88	No additional races
13	Kampuchean (Cambodian)	96	Other Asian, including Asian, NOS and Oriental, NOS
14	Thai	97	Pacific Islander, NOS
15	Asian Indian or Pakistani, NOS (formerly code 09)	98	Other
16	Asian Indian	99	Unknown
17	Pakistani		

RACE 5

Item Length: 2
 Allowable Values: 01–08, 10–17,
 20–22, 25–28, 30–32, 88, 96–99
 NAACCR Item #164
 Revised 01/04, 09/08, 01/10

Description

Identifies the patient's race.

Rationale

Racial origin captures information used in research and cancer control activities comparing stage at diagnosis and/or treatment by race. The full coding system should be used to allow for an accurate national comparison.

Instructions for Coding

- “Race” is analyzed with *Spanish/Hispanic Origin* (NAACCR Item #190). Both items must be recorded. All tumors for the same patient should have the same race code.
- If *Race 4* (NAACCR Item #163) is coded 88 or 99, then *Race 5* must be coded with the same value.
- Codes 08–13 became effective with diagnoses on or after January 1, 1988.
- Code 14 became effective with diagnoses on or after January 1, 1994.
- In 2010, code 09 was converted to the new code 15, and codes 16 and 17 were added.
- Codes 20–97 became effective with diagnoses on or after January 1, 1991. SEER participants in San Francisco, San Jose–Monterey, and Los Angeles are permitted to use codes 14 and 20–97 for cases diagnosed after January 1, 1987.
- See the instructions for *Race 1* (NAACCR Item #160) for coding sequences for entering multiple races.

Code	Label	Code	Label
01	White	20	Micronesian, NOS
02	Black	21	Chamorroan
03	American Indian, Aleutian, or Eskimo (includes all indigenous populations of the Western hemisphere)	22	Guamanian, NOS
04	Chinese	25	Polynesian, NOS
05	Japanese	26	Tahitian
06	Filipino	27	Samoan
07	Hawaiian	28	Tongan
08	Korean	30	Melanesian, NOS
10	Vietnamese	31	Fiji Islander
11	Laotian	32	New Guinean
12	Hmong	88	No additional races
13	Kampuchean (Cambodian)	96	Other Asian, including Asian, NOS and Oriental, NOS
14	Thai	97	Pacific Islander, NOS
15	Asian Indian or Pakistani, NOS (formerly code 09)	98	Other
16	Asian Indian	99	Unknown
17	Pakistani		

**SPANISH ORIGIN–ALL SOURCES
(SPANISH/HISPANIC ORIGIN)**

Item Length: 1
 Allowable Values: 0–7, 9
 NAACCR Item #190
 Revised 09/04

Description

Identifies persons of Spanish or Hispanic origin.

Rationale

This code is used by hospital and central registries to identify whether or not the person should be classified as “Hispanic” for purposes of calculating cancer rates. Hispanic populations have different patterns of occurrence of cancer from other populations that may be included in the 01 (White category) of *Race 1* through *Race 5* (NAACCR Item #s 160–164).

Instructions for Coding

- Persons of Spanish or Hispanic origin may be of any race, but these categories are generally not used for Native Americans, Filipinos, or others who may have Spanish names.
- Code 0 (Non-Spanish; non-Hispanic) for Portuguese and Brazilian persons.
- If the patient has multiple tumors, all records should have the same code.

Code	Label
0	Non-Spanish; non-Hispanic
1	Mexican (includes Chicano)
2	Puerto Rican
3	Cuban
4	South or Central America (except Brazil)
5	Other specified Spanish/Hispanic origin (includes European; excludes Dominican Republic)
6	Spanish, NOS; Hispanic, NOS; Latino, NOS (There is evidence other than surname or maiden name that the person is Hispanic, but he/she cannot be assigned to any category of 1–5)
7	Spanish surname only (The only evidence of the person’s Hispanic origin is surname or maiden name, and there is no contrary evidence that the person is not Hispanic)
8	Dominican Republic (for use with patients who were diagnosed with cancer on January 1, 2005, or later)
9	Unknown whether Spanish or not; not stated in patient record

SEX

Item Length: 1
Allowable Values: 1–4, 9
NAACCR Item #220

Description

Identifies the sex of the patient.

Rationale

This data item is used to compare cancer rates and outcomes by site. The same sex code should appear in each medical record for a patient with multiple tumors.

Instructions for Coding

Record the patient's sex as indicated in the medical record.

Code	Label
1	Male
2	Female
3	Other (hermaphrodite)
4	Transsexual
9	Not stated in patient record

PRIMARY PAYER AT DIAGNOSIS

Item Length: 2
 Allowable Values: 01, 02, 10,
 20, 21, 31, 35, 60–68, 99
 NAACCR Item #630
 Revised 06/05, 01/10

Description

Identifies the patient's primary payer/insurance carrier at the time of initial diagnosis and/or treatment.

Rationale

This item is used in financial analysis and as an indicator for quality and outcome analyses. Joint Commission on Accreditation of Healthcare Organizations (JCAHO) requires the patient admission page to document the type of insurance or payment structure that will cover the patient while being cared for at the hospital.

Instructions for Coding

- If the patient is diagnosed at the reporting facility, record the payer at the time of diagnosis.
- If the patient is diagnosed elsewhere or the payer at the time of diagnosis is not known record the payer when the patient is initially admitted for treatment.
- Record the type of insurance reported on the patient's admission page.
- Codes 21 and 65–68 are to be used for patients diagnosed on or after January 1, 2006.
- If more than one payer or insurance carrier is listed on the patient's admission page record the first.
- If the patient's payer or insurance carrier changes, do not change the initially recorded code.

Code	Label	Definition
01	Not insured	Patient has no insurance and is declared a charity write-off.
02	Not insured, self-pay	Patient has no insurance and is declared responsible for charges.
10	Insurance, NOS	Type of insurance unknown or other than the types listed in codes 20, 21, 31, 35, 60–68.
20	Private insurance: Managed Care, HMO, or PPO	An organized system of prepaid care for a group of enrollees usually within a defined geographic area. Generally formed as one of four types: a group model, an independent physician association (IPA), a network, or a staff model. "Gate-keeper model" is another term for describing this type of insurance.
21	Private insurance: Fee-for-Service	An insurance plan that does not have a negotiated fee structure with the participating hospital. Type of insurance plan not coded as 20.
31	Medicaid	State government administered insurance for persons who are uninsured, below the poverty level, or covered under entitlement programs. Medicaid other than described in code 35.
35	Medicaid administered through a Managed Care plan	Patient is enrolled in Medicaid through a Managed Care program (for example, HMO or PPO). The Managed Care plan pays for all incurred costs.
60	Medicare without supplement, Medicare, NOS	Federal government funded insurance for persons who are 62 years of age or older, or are chronically disabled (Social Security insurance eligible). Not described in codes 61, 62, or 63.
61	Medicare with supplement, NOS	Patient has Medicare and another type of unspecified insurance to pay costs not covered by Medicare.
62	Medicare administered through a Managed Care plan	Patient is enrolled in Medicare through a Managed Care plan (for example, HMO or PPO). The Managed Care plan pays for all incurred costs.

Code	Label	Definition
63	Medicare with private supplement	Patient has Medicare and private insurance to pay costs not covered by Medicare.
64	Medicare with Medicaid eligibility	Federal government Medicare insurance with State Medicaid administered supplement.
65	TRICARE	Department of Defense program providing supplementary civilian-sector hospital and medical services beyond a military treatment facility to military dependents, retirees, and their dependents. Formally CHAMPUS (Civilian Health and Medical Program of the Uniformed Services).
66	Military	Military personnel or their dependents who are treated at a military facility.
67	Veterans Affairs	Veterans who are treated in Veterans Affairs facilities.
68	Indian/Public Health Service	Patient who receives care at an Indian Health Service facility or at another facility, and the medical costs are reimbursed by the Indian Health Service. Patient receives care at a Public Health Service facility or at another facility, and medical costs are reimbursed by the Public Health Service.
99	Insurance status unknown	It is unknown from the patient's medical record whether or not the patient is insured.

Examples

Code	Reason
01	An indigent patient is admitted with no insurance coverage.
20	A patient is admitted for treatment and the patient admission page states the primary insurance carrier is an HMO.
62	A 65-year-old male patient is admitted for treatment and the patient admission page states the patient is covered by Medicare with additional insurance coverage from a PPO.

COMORBIDITIES AND COMPLICATIONS #1
(Secondary Diagnoses)

Item Length: 5
Allowable Values: 00000, 00100–13980,
24000–99990, E8700–E8799, E9300–
E9499, V0720–V0739, V1000–
V1590, V2220–V2310, V2540, 4400–
V4589, V5041–V5049
Left Justified, Zero-filled
NAACCR Item #3110
Revised 06/05

Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-9-CM codes. All are considered secondary diagnoses.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- Secondary diagnoses must be reported for patients who have inpatient hospitalizations at your facility.
- Secondary diagnoses should be reported for patients receiving outpatient care or treated in oncology clinics at your facility when available.
- Consult the patient record for the discharge abstract. Secondary diagnoses are found on the discharge abstract. Information from the billing department at your facility may be consulted when a discharge abstract is not available.
- Code the secondary diagnoses in the sequence in which they appear on the discharge abstract or are recorded by the billing department at your facility.
- Report the secondary diagnoses for this cancer using the following priority rules:
 - Surgically treated patients:
 - a) following the most definitive surgery of the primary site
 - b) following other non-primary site surgeries
 - Non-surgically treated patients:
 - following the first treatment encounter/episode
 - In cases of non-treatment:
 - following the last diagnostic/evaluative encounter
- If the data item *Readmission To The Same Hospital Within 30 Days Of Surgical Discharge* (NAACCR Item #3190) is coded 1, 2, or 3, then use available *Comorbidities and Complications* data items to record E codes appearing on the "readmission" discharge abstract.
- **Do not** record any neoplasms (ICD-9-CM codes 140–239.9) listed as secondary diagnoses for this data item.
- **Do not** record causes of injury and poisoning unrelated to the patient's medical care (ICD-9-CM codes E800–E869.9, E880–E929.9, or E950–E999).
- **Do not** record the following factors influencing health status and contact with health services (ICD-9-CM codes V01–V07.1, V07.4–V09.91, V16–V21.9, V23.2–V25.3, V25.5–V43.89, V46–V50.4, or V50.8–V83.89).
- If no secondary diagnoses were documented, then code 00000 in this data item, and leave the remaining "Comorbidities and Complications" data items blank.
- If fewer than 10 secondary diagnoses are listed, then code the diagnoses listed, and leave the remaining "Comorbidities and Complications" data items blank.

Code	Definition
(fill spaces)	Report the ICD-9-CM codes for up to 10 comorbid conditions or complications. <i>Note:</i> For comorbid conditions (ICD-9-CM codes 001–139.8 and 240–999.9) there is an assumed decimal point between the third and fourth characters. <i>Note:</i> For complications (ICD-9-CM “E” codes) and factors influencing health status (ICD-9-CM “V” codes) there is an assumed decimal point between the fourth and fifth characters.
00000	No comorbid conditions or complications documented.

Examples

Code	Reason
49600	COPD (ICD-9-CM code 496)
25001	Type 1 diabetes mellitus (ICD-9-CM code 250.01)
40100	Hypertension (ICD-9-CM code 401)
E8732	The patient was inadvertently exposed to an overdose of external beam radiation (ICD-9-CM code E873.2)
E8782	The patient with colon cancer underwent surgical resection and subsequently experienced an anastomotic leak (ICD-9-CM code E878.2)
E9300	During hospitalization the patient has an adverse reaction to Ampicillin, a semisynthetic form of penicillin (ICD-9-CM code E930.0)
V1030	The patient has a personal history of breast cancer (ICD-9-CM code V10.3)

COMORBIDITIES AND COMPLICATIONS #2
(Secondary Diagnoses)

Item Length: 5
Allowable Values:00100–13980,
24000,99990, E8700–E8799, E9300–
E9499,V0720–V0739,V1000–V1590, V2220–
V2310, V2540, V4400–V4589, V5041–V5049
Left Justified, Zero-filled
NAACCR Item #3120
Revised 06/05

Description

Records the patient’s preexisting medical conditions, factors influencing health status, and/or complications during the patient’s hospital stay for the treatment of this cancer. Both are considered secondary diagnoses.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- If only one comorbid condition or complication is listed, then leave this data item blank.
- If only two comorbid conditions or complications are listed, then code the diagnoses listed and leave the remaining “Comorbidities and Complications” items blank.
- For further Instructions for Coding, see *Comorbidities and Complications #1* (NAACCR Item #3110).

Code	Definition
(fill spaces)	Report the ICD-9-CM codes for up to 10 comorbid conditions or complications. <i>Note:</i> For comorbid conditions (ICD-9-CM codes 001–139.8 and 240–999.9) there is an assumed decimal point between the third and fourth characters. <i>Note:</i> For complications (ICD-9-CM “E” codes) and factors influencing health status (ICD-9-CM “V” codes) there is an assumed decimal point between the fourth and fifth characters.
(leave blank)	Fewer than two comorbid conditions or complications documented.

COMORBIDITIES AND COMPLICATIONS #3
(Secondary Diagnoses)

Item Length: 5
Allowable Values: 00100–13980,
24000–99990, E8700–E8799,
E9300–E9499, V0720–V0739,
V1000–V1590, V2220–V2310,
V2540, V4400–V4589, V5041–V5049
Left Justified, Zero-filled
NAACCR Item #3130
Revised 06/05

Description

Records the patient’s preexisting medical conditions, factors influencing health status, and/or complications during the patient’s hospital stay for the treatment of this cancer. Both are considered secondary diagnoses.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- If fewer than three comorbid conditions or complications are listed, then leave this data item blank.
- If only three comorbid conditions or complications are listed, then code the diagnoses listed and leave the remaining “Comorbidities and Complications” items blank.
- For further Instructions for Coding, see *Comorbidities and Complications #1* (NAACCR Item #3110).

Code	Definition
(fill spaces)	Report the ICD-9-CM codes for up to 10 comorbid conditions or complications. <i>Note:</i> For comorbid conditions (ICD-9-CM codes 001–139.8 and 240–999.9) there is an assumed decimal point between the third and fourth characters. <i>Note:</i> For complications (ICD-9-CM “E” codes) and factors influencing health status (ICD-9-CM “V” codes) there is an assumed decimal point between the fourth and fifth characters.
(leave blank)	Fewer than three comorbid conditions or complications documented.

COMORBIDITIES AND COMPLICATIONS #4
(Secondary Diagnoses)

Item Length: 5
 Allowable Values: 00100–13980,
 24000–99990, E8700–E8799, E9300–
 E9499, E9300–E9499, V0720–V0739,
 V1000–V1590, V2220–V2310, V2540,
 V4400–V4589, V5041–V5049
 Left Justified, Zero-filled
 NAACCR Item #3140
 Revised 06/05

Description

Records the patient’s preexisting medical conditions, factors influencing health status, and/or complications during the patient’s hospital stay for the treatment of this cancer. Both are considered secondary diagnoses.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- If fewer than four comorbid conditions or complications are listed, then leave this data item blank.
- If only four comorbid conditions or complications are listed, then code the diagnoses listed and leave the remaining “Comorbidities and Complications” items blank.
- For further Instructions for Coding, see *Comorbidities and Complications #1* (NAACCR Item #3110).

Code	Definition
(fill spaces)	Report the ICD-9-CM codes for up to 10 comorbid conditions or complications. <i>Note:</i> For comorbid conditions (ICD-9-CM codes 001–139.8 and 240–999.9) there is an assumed decimal point between the third and fourth characters. <i>Note:</i> For complications (ICD-9-CM “E” codes) and factors influencing health status (ICD-9-CM “V” codes) there is an assumed decimal point between the fourth and fifth characters.
(leave blank)	Fewer than four comorbid conditions or complications documented.

COMORBIDITIES AND COMPLICATIONS #5
(Secondary Diagnoses)

Item Length: 5

Allowable Values:00100–13980, 24000–99990, E8700–E8799, E9300–E9499, E9300–E9499, V0720–V0739, V1000–V1590, V2220–V2310, V2540,V4400–V4589, V5041–V5049
 Left Justified, Zero-filled
 NAACCR Item #3150
 Revised 06/05

Description

Records the patient’s preexisting medical conditions, factors influencing health status, and/or complications during the patient’s hospital stay for the treatment of this cancer. Both are considered secondary diagnoses.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to risk adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- If fewer than five comorbid conditions or complications are listed, then leave this data item blank.
- If only five comorbid conditions or complications are listed, then code the diagnoses listed and leave the remaining “Comorbidities and Complications” items blank.
- For further Instructions for Coding, see *Comorbidities and Complications #1* (NAACCR Item #3110).

Code	Definition
(fill spaces)	Report the ICD-9-CM codes for up to 10 comorbid conditions or complications. <i>Note:</i> For comorbid conditions (ICD-9-CM codes 001–139.8 and 240–999.9) there is an assumed decimal point between the third and fourth characters. <i>Note:</i> For complications (ICD-9-CM “E” codes) and factors influencing health status (ICD-9-CM “V” codes) there is an assumed decimal point between the fourth and fifth characters.
(leave blank)	Fewer than five comorbid conditions or complications documented.

COMORBIDITIES AND COMPLICATIONS #6
(Secondary Diagnoses)

Item Length: 5
Allowable Values: 00100–13980,
24000–99990, E8700–E8799,
E9300–E9499, E9300–E9499,
V0720–V0739, V1000–V1590,
V2220–V2310, V2540,
V4400–V4589, V5041–V5049
Left Justified, Zero-filled
NAACCR Item #3160
Revised 06/05

Description

Records the patient’s preexisting medical conditions, factors influencing health status, and/or complications during the patient’s hospital stay for the treatment of this cancer. Both are considered secondary diagnoses.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- If fewer than six comorbid conditions or complications are listed, then leave this data item blank.
- If only six comorbid conditions or complications are listed, then code the diagnoses listed and leave the remaining “Comorbidities and Complications” items blank.
- For further Instructions for Coding, see *Comorbidities and Complications #1* (NAACCR Item #3110).

Code	Definition
(fill spaces)	Report the ICD-9-CM codes for up to 10 comorbid conditions or complications. <i>Note:</i> For comorbid conditions (ICD-9-CM codes 001–139.8 and 240–999.9) there is an assumed decimal point between the third and fourth characters. <i>Note:</i> For complications (ICD-9-CM “E” codes) and factors influencing health status (ICD-9-CM “V” codes) there is an assumed decimal point between the fourth and fifth characters.
(leave blank)	Fewer than six comorbid conditions and complications documented.

COMORBIDITIES AND COMPLICATIONS #7
(Secondary Diagnoses)

Item Length: 5
 Allowable Values: 00100–13980,
 24000–99990, E8700–E8799,
 E9300–E9499, E9300–E9499,
 V0720–V0739, V1000–V1590,
 V2220–V2310, V2540,
 V4400–V4589, V5041–V5049
 Left Justified, Zero-filled
 NAACCR Item #3161
 Added 06/05

Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer. Both are considered secondary diagnoses.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- *Comorbidities and Complications #8* is to be used for patients diagnosed on or after January 1, 2006.
- If fewer than eight comorbid conditions or complications are listed, then leave this data item blank.
- If only eight comorbid conditions or complications are listed, then code the diagnoses listed and leave the remaining "Comorbidities and Complications" items blank.

For further Instructions for Coding, see *Comorbidities and Complications #1* (NAACCR Item #3110).

Code	Definition
(fill spaces)	Report the ICD-9-CM codes for up to 10 comorbid conditions or complications. <i>Note:</i> For comorbid conditions (ICD-9-CM codes 001–139.8 and 240–999.9) there is an assumed decimal point between the third and fourth characters. <i>Note:</i> For complications (ICD-9-CM "E" codes) and factors influencing health status (ICD-9-CM "V" codes) there is an assumed decimal point between the fourth and fifth characters.
(leave blank)	Fewer than seven comorbid conditions and complications documented.

COMORBIDITIES AND COMPLICATIONS #8
(Secondary Diagnoses)

Item Length: 5
Allowable Values: 00100–13980,
24000–99990, E8700–E8799,
E9300–E9499, E9300–E9499,
V0720–V0739, V1000–V1590,
V2220–V2310, V2540,
V4400–V4589, V5041–V5049
Left Justified, Zero-filled
NAACCR Item #3162
Added 06/05

Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer. Both are considered secondary diagnoses.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- *Comorbidities and Complications #8* is to be used for patients diagnosed on or after January 1, 2006.
- If fewer than eight comorbid conditions or complications are listed, then leave this data item blank.
- If only eight comorbid conditions or complications are listed, then code the diagnoses listed and leave the remaining "Comorbidities and Complications" items blank.
- For further Instructions for Coding, see *Comorbidities and Complications #1* (NAACCR Item #3110).

Code	Definition
(fill spaces)	Report the ICD-9-CM codes for up to 10 comorbid conditions or complications. <i>Note:</i> For comorbid conditions (ICD-9-CM codes 001–139.8 and 240–999.9) there is an assumed decimal point between the 3rd and 4th characters. <i>Note:</i> For complications (ICD-9-CM "E" codes) and factors influencing health status (ICD-9-CM "V" codes) there is an assumed decimal point between the 4th and 5th characters.
(leave blank)	Fewer than eight comorbid conditions and complications documented.

COMORBIDITIES AND COMPLICATIONS #9
(Secondary Diagnoses)

Item Length: 5
 Allowable Values: 00100–13980,
 24000–99990, E8700–E8799,
 E9300–E9499, E9300–E9499,
 V0720–V0739, V1000–V1590,
 V2220–V2310, V2540,
 V4400–V4589, V5041–V5049
 Left Justified, Zero-filled
 NAACCR Item #3163
 Added 06/05

Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer. Both are considered secondary diagnoses.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- *Comorbidities and Complications #9* is to be used for patients diagnosed on or after January 1, 2006.
- If fewer than nine comorbid conditions or complications are listed, then leave this data item blank.
- If only nine comorbid conditions or complications are listed, then code the diagnoses listed and leave the remaining "Comorbidities and Complications" items blank.
- For further Instructions for Coding, see *Comorbidities and Complications #1* (NAACCR Item #3110).

Code	Definition
(fill spaces)	Report the ICD-9-CM codes for up to 10 comorbid conditions or complications. <i>Note:</i> For comorbid conditions (ICD-9-CM codes 001–139.8 and 240–999.9) there is an assumed decimal point between the third and fourth characters. <i>Note:</i> For complications (ICD-9-CM "E" codes) and factors influencing health status (ICD-9-CM "V" codes) there is an assumed decimal point between the fourth and fifth characters.
(leave blank)	Fewer than nine comorbid conditions and complications documented.

COMORBIDITIES AND COMPLICATIONS #10
(Secondary Diagnoses)

Item Length: 5
Allowable Values: 00100–13980,
24000–99990, E8700–E8799,
E9300–E9499, E9300–E9499,
V0720–V0739, V1000–V1590,
V2220–V2310, V2540,
V4400–V4589, V5041–V5049
Left Justified, Zero-filled
NAACCR Item #3164
Added 06/05

Description

Records the patient’s preexisting medical conditions, factors influencing health status, and/or complications during the patient’s hospital stay for the treatment of this cancer. Both are considered secondary diagnoses.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- *Comorbidities and Complications #10* is to be used for patients diagnosed on or after January 1, 2006.
- If fewer than 10 comorbid conditions or complications are listed, then leave this data item blank.
- For further Instructions for Coding, see *Comorbidities and Complications #1* (NAACCR Item #3110).

Code	Definition
(fill spaces)	Report the ICD-9-CM codes for up to 10 comorbid conditions or complications. <i>Note:</i> For comorbid conditions (ICD-9-CM codes 001–139.8 and 240–999.9) there is an assumed decimal point between the third and fourth characters. <i>Note:</i> For complications (ICD-9-CM “E” codes) and factors influencing health status (ICD-9-CM “V” codes) there is an assumed decimal point between the fourth and fifth characters.
(leave blank)	Fewer than 10 comorbid conditions and complications documented.

NPI–MANAGING PHYSICIAN

Item Length: 10
 Allowable Value: 10 digits
 NAACCR Item #2465
 Revised 04/07, 09/08

Description

Identifies the physician who is responsible for the overall management of the patient during diagnosis and/or treatment of this cancer.

Rationale

The managing physician is responsible for the patient's work-up, plans the treatment, and directs the delivery of patient care in accordance with CoC Standards. In most cases, the managing physician is responsible for AJCC staging.

Instructions for Coding

- Record the 10-digit NPI for the physician responsible for managing the patient's care.
- Check with the billing or health information departments to determine the physician's NPI or search at <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.
- Do not update this item. Once the registry has designated a managing physician for the patient, this item should not be changed even if a different managing physician is assigned.

Code	Definition
(fill spaces)	10-digit NPI number for the managing physician.
(leave blank)	NPI for the managing physician is unknown or not available.

**FOLLOWING PHYSICIAN
(FOLLOW-UP PHYSICIAN)**

Item Length: 8
Left Justified
NAACCR Item #2470

Description

Records the identification number of the person currently responsible for the patient's medical care.

Rationale

The following physician is the first contact for obtaining information on a patient's status and subsequent treatment. This information may be used for outcomes studies.

Instructions for Coding

- The registry assigns a unique number to the following physician. Many registries use the physician's state medical license number.
- Change this data item when patient follow-up becomes the responsibility of another physician.

Code	Definition
(fill spaces)	The identification number may include numbers and letters.
99999999	The following physician is unknown or an identification number is not assigned.

NPI-FOLLOWING PHYSICIAN

Item Length: 10
 Allowable Value: 10 digits
 NAACCR Item #2475
 Revised 04/07, 09/08

Description

Records the NPI for the physician currently responsible for the patient's medical care.

Rationale

The following physician is the first contact for obtaining information on a patient's status and subsequent treatment. This information may be used for outcomes studies.

NPI-Following Physician is the NPI equivalent of *Following Physician* (NAACCR Item #2470). Both are required during a period of transition.

Instructions for Coding

- Record the 10-digit NPI for the physician currently responsible for the patient's medical care.
- Check with the billing or health information departments to determine the physician's NPI or search at <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>.
- Change this data item when patient follow-up becomes the responsibility of another physician.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.

Code	Definition
(fill spaces)	10-digit NPI number for the following physician.
(leave blank)	NPI for the following physician is unknown or not available.

PRIMARY SURGEON

Item Length: 8
 Left Justified
 NAACCR Item #2480

Description

Records the identification number of the physician who performed the most definitive surgical procedure.

Rationale

Administrative, physician, and service referral reports are based on this data item.

Instructions for Coding

- The registry assigns a unique number to the primary surgeon. Many registries use the physician's state medical license number.
- Once the registry has designated a primary surgeon for the patient, the information should not be changed or updated even if the patient receives care from another surgeon.
- Do not update this data item.

Code	Definition
(fill spaces)	The identification number may include numbers and letters. <i>Note:</i> If the patient did not have surgery, use the code for the surgeon who performed any surgery or did a surgical consultation.
00000000	If the patient had no surgery and no surgical consultation.
88888888	If the physician who performed a surgical procedure was not a surgeon, for example, radiation oncologist, diagnostic radiologist, or general practitioner.
99999999	The primary surgeon is unknown or an identification number is not assigned.

NPI-PRIMARY SURGEON

Item Length: 10
 Allowable Value: 10 digits
 NAACCR Item #2485
 Revised 04/07, 09/08

Description

Identifies the physician who performed the most definitive surgical procedure.

Rationale

Administrative, physician, and service referral reports are based on this item.

NPI-Primary Surgeon is the NPI equivalent of *Primary Surgeon* (NAACCR Item #2480). Both are required during a period of transition.

Instructions for Coding

- Record the 10-digit NPI for the physician who performed the most definitive surgical procedure.
- Check with the billing or health information departments to determine the physician's NPI or search at <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.
- Do not update this item. Once the registry has designated a primary surgeon for the patient, the information should not be changed or updated even if the patient receives care from another surgeon.

Code	Definitions
(fill spaces)	10-digit NPI number for the primary surgeon.
(leave blank)	The patient did not have surgery. NPI for the primary surgeon is unknown or not Available. The physician who performed the surgical procedure was not a surgeon (for example, general practitioner).

**PHYSICIAN #3
(OTHER PHYSICIAN)**

Item Length: 8
 Left Justified
 NAACCR Item #2490
 Revised 01/04, 01/10

Description

Records the identification number of another physician involved in the care of the patient. The Commission on Cancer recommends that this data item identify the physician who performed the most definitive radiation therapy.

Rationale

Administrative, physician, and service referral reports are based on this data item. It also can be used for follow-up purposes.

Instructions for Coding

- The registry assigns a unique number to this data item. Many registries use the physician's state medical license number.
- If the registry has designated a primary radiation oncologist for the patient, the information in this data item should not be changed or updated even if the patient receives care from another radiation oncologist.
- Do not update this data item.

Code	Definition
(fill spaces)	The identification number may include numbers and letters.
00000000	None; no additional physician.
99999999	Physician is unknown or an identification number is not assigned.

NPI–PHYSICIAN #3
(Radiation Oncologist–CoC Preferred Use)

Item Length: 10
 Allowable Value: 10 digits
 Revised 04/07, 09/08, 01/10

Description

Records the NPI for a physician involved in the care of the patient. The Commission on Cancer recommends that this item identify the physician who performed the most definitive radiation therapy.

Rationale

Administrative, physician, and service referral reports are based on this data item. It also can be used for follow-up purposes.

NPI–Physician #3 is the NPI equivalent of *Physician #3* (NAACCR Item #2490). Both are required during a period of transition.

Instructions for Coding

- Record the 10-digit NPI for the physician.
- Check with the billing or health information departments to determine the physician’s NPI or search at <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>.
- Do not update this item. If the registry has designated a primary radiation oncologist for the patient, the information in this data item should not be changed or updated even if the patient receives care from another radiation oncologist.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.

Code	Definition
(fill spaces)	10-digit NPI number for the primary radiation oncologist.
(leave blank)	NPI for the primary radiation oncologist is unknown or not available.

**PHYSICIAN #4
(OTHER PHYSICIAN)**

Item Length: 8
 Left Justified
 NAACCR Item #2500
 Revised 01/04, 01/10

Description

Records the identification number of another physician involved in the care of the patient. The Commission on Cancer recommends that this data item identify the physician who gives the most definitive systemic therapy.

Rationale

Administrative, physician, and service referral reports are based on this data item. It also can be used for follow-up purposes.

Instructions for Coding

- The registry assigns a unique number to this data item. Many registries use the physician's state medical license number.
- If the registry has designated a primary medical oncologist for the patient, the information in this data item should not be changed or updated even if the patient receives care from another medical oncologist.
- Do not update this data item.

Code	Definition
(fill spaces)	The identification number may include numbers and letters.
00000000	None; no additional physician.
99999999	Physician is unknown or an identification number is not assigned.

NPI–PHYSICIAN #4
(Medical Oncologist–CoC Preferred Use)

Item Length: 10
 Allowable Value: Ten digits
 NAACCR Item #2505
 Revised 04/07, 09/08, 01/10

Description

Records the NPI for a physician involved in the care of the patient. The Commission on Cancer recommends that this data item identify the physician who gives the most definitive systemic therapy.

Rationale

Administrative, physician, and service referral reports are based on this data item. It also can be used for follow-up purposes.

NPI–Physician #4 is the NPI equivalent of *Physician #4* (NAACCR Item #2500). Both are required during a period of transition.

Instructions for Coding

- Record the 10-digit NPI for the physician.
- Check with the billing or health information departments to determine the physician's NPI or search at <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>.
- Do not update this item. If the registry has designated a primary medical oncologist for the patient, the information in this data item should not be changed or updated even if the patient receives care from another radiation oncologist.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.

Code	Definition
(fill spaces)	10-digit NPI number for the primary medical oncologist.
(leave blank)	NPI for the primary medical oncologist is unknown or not available.

Cancer Identification

CLASS OF CASE

Item Length: 2
 Allowable Values: 00, 10-14,
 20-22, 30-38, 40-43, 49, 99
 NAACCR Item #610
 Revised 09/08; 01/10; 05/10

Description

Class of Case divides cases into two groups. Analytic cases (codes 00–22) are those that are required by CoC to be abstracted because of the program’s primary responsibility in managing the cancer. Analytic cases are grouped according to the location of diagnosis and first course of treatment. Nonanalytic cases (codes 30–49 and 99) may be abstracted by the facility to meet central registry requirements or in response to a request by the facility’s cancer program. Nonanalytic cases are grouped according to the reason a patient who received care at the facility is nonanalytic, or the reason a patient who never received care at the facility may have been abstracted.

Rationale

Class of Case reflects the facility’s role in managing the cancer, whether the cancer is required to be reported by CoC, and whether the case was diagnosed after the program’s Reference Date.

Instructions for Coding

- The code structure for this item was revised in 2010. See *NAACCR Inc. 2010 Implementation Guidelines and Recommendations* for conversion instructions between code structures.
- Code the *Class of Case* that most precisely describes the patient’s relationship to the facility.
- Code 00 applies only when it is known the patient went elsewhere for treatment. If that information is not available, code *Class of Case* 10.
- It is possible that information for coding *Class of Case* will change during the patient’s first course of care. If that occurs, change the code accordingly.
- Document *Facility Referred To* and NPI–Facility Referred To (NAACCR Item #s 2420 and 2425) or the applicable physician NPI (NAACCR #s 2585, 2495, 2505) for patients coded 00 to establish that the patient went elsewhere for treatment
- Code 34 or 36 if the diagnosis benign or borderline (*Behavior* 0 or 1) for any site diagnosed before 2004 or for any site other than meninges (C70._), brain (C71._), spinal cord, cranial nerves, and other parts of central nervous system (C72._), pituitary gland (C75.1), craniopharyngeal duct (C75.2) and pineal gland (C75.3) that were diagnosed in 2004 or later.
- Code 34 or 36 for carcinoma in situ of the cervix (CIS) and intraepithelial neoplasia grade III (8077/2 or 8148/2) of the cervix (CIN III), prostate (PIN III), vulva (VIN III), vagina (VAIN III), and anus (AIN III).
- A staff physician (codes 10-12, 41) is a physician who is employed by the reporting facility, under contract with it, or a physician who has routine practice privileges there.

Codes

Analytic Classes of Case (Required by CoC to be abstracted by accredited programs)	
	<i>Initial diagnosis at reporting facility</i>
00	Initial diagnosis at the reporting facility AND all treatment or a decision not to treat was done elsewhere
10	Initial diagnosis at the reporting facility or in a staff physician’s office AND part or all of first course treatment or a decision not to treat was at the reporting facility, NOS
11	Initial diagnosis in staff physician’s office AND part of first course treatment was done at the reporting facility
12	Initial diagnosis in staff physician’s office AND all first course treatment or a decision not to treat was done at the reporting facility
13	Initial diagnosis at the reporting facility AND part of first course treatment was done at the reporting facility

14		Initial diagnosis at the reporting facility AND all first course treatment or a decision not to treat was done at the reporting facility
		<i>Initial diagnosis elsewhere</i>
20		Initial diagnosis elsewhere AND all or part of first course treatment was done at the reporting facility, NOS
21		Initial diagnosis elsewhere AND part of first course treatment was done at the reporting facility
22		Initial diagnosis elsewhere AND all first course treatment or a decision not to treat was done at the reporting facility
Classes of Case not required by CoC to be abstracted (May be required by Cancer Committee, state or regional registry, or other entity)		
		<i>Patient appears in person at reporting facility</i>
30		Initial diagnosis and all first course treatment elsewhere AND reporting facility participated in diagnostic workup (for example, consult only, staging workup after initial diagnosis elsewhere)
31		Initial diagnosis and all first course treatment elsewhere AND reporting facility provided in-transit care
32		Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility with disease recurrence or persistence
33		Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility with disease history only
34		Type of case not required by CoC to be accessioned (for example, a benign colon tumor) AND initial diagnosis AND part or all of first course treatment by reporting facility
35		Case diagnosed before program's Reference Date AND initial diagnosis AND all or part of first course treatment by reporting facility
36		Type of case not required by CoC to be accessioned (for example, a benign colon tumor) AND initial diagnosis elsewhere AND all or part of first course treatment by reporting facility
37		Case diagnosed before program's Reference Date AND initial diagnosis elsewhere AND all or part of first course treatment by facility
38		Initial diagnosis established by autopsy at the reporting facility, cancer not suspected prior to death
		<i>Patient does not appear in person at reporting facility</i>
40		Diagnosis AND all first course treatment given at the same staff physician's office
41		Diagnosis and all first course treatment given in two or more different staff physician offices
42		Nonstaff physician or non-CoC accredited clinic or other facility, not part of reporting facility, accessioned by reporting facility for diagnosis and/or treatment by that entity (for example, hospital abstracts cases from an independent radiation facility)
43		Pathology or other lab specimens only
49		Death certificate only
99		Nonanalytic case of unknown relationship to facility (not for use by CoC accredited cancer programs for analytic cases).

Examples

Code	Reason
32	After treatment failure, the patient was admitted to the facility for supportive care
11	Patient was diagnosed by a staff physician, received radiation at another facility, then underwent surgical resection at the reporting facility
42	Patients from an unaffiliated, free-standing clinic across the street that hospital abstracts with its cases because many physicians work both at the clinic and the hospital.

FACILITY REFERRED FROM

Item Length: 10
 Right Justified, Zero-filled
 NAACCR Item #2410
 Revised 09/08

Description

Identifies the facility that referred the patient to the reporting facility.

Rationale

Each facility's identification number (FIN) is unique. This number is used to document and monitor referral patterns.

Instructions for Coding

- For facilities with seven-digit FINs in the range of 6020009–6953290 that were assigned by the CoC before January 1, 2001, the coded FIN will consist of three leading zeros followed by the full seven-digit number.
- For facilities with eight-digit FINs greater than or equal to 10000000 that were assigned by the CoC after January 1, 2001, the coded FIN will consist of two leading zeros followed by the full eight-digit number.

Code	Definition
(fill spaces)	Seven or eight-digit FIN.
000000000	If the patient was not referred to the reporting facility from another facility.
009999999	If the patient was referred, but the referring facility's ID number is unknown.

Examples

Code	Reason
0006439999	6439999, General Hospital, Anytown, Illinois
0010000099	10000099, Anytown Medical Center, Anytown, Illinois

Note: A complete list of FINs is available on the American College of Surgeons Web site at <http://www.facs.org/cancer/coc/fin.html>.

NPI–INSTITUTION REFERRED FROM

Item Length: 10
 Allowable Value: Ten digits
 NAACCR Item #2415
 Revised 04/07, 09/08

Description

Identifies the facility that referred the patient to the reporting facility.

Rationale

Each facility's NPI is unique. This number is used to document and monitor referral patterns.

NPI–Institution Referred From is the NPI equivalent of *Facility Referred From* (NAACCR Item #2410). Both are required during a period of transition.

Instructions for Coding

- Record the 10-digit NPI for the referring facility.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.
- Check with the registry, billing, or health information departments of the facility to determine its NPI, or search on <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>.

Code	Definition
(fill spaces)	10-digit NPI number for the facility.
(leave blank)	NPI for the referring facility is unknown or not available.
(leave blank)	If the patient was not referred to the reporting facility from another facility.

FACILITY REFERRED TO

Item Length: 10
 Right Justified, Zero-filled
 NAACCR Item #2420
 Revised 09/08

Description

Identifies the facility to which the patient was referred for further care after discharge from the reporting facility.

Rationale

Each facility's identification number (FIN) is unique. This number is used to document and monitor referral patterns.

Instructions for Coding

- For facilities with seven-digit FINs in the range of 6020009–6953290 that were assigned by the CoC before January 1, 2001, the coded FIN will consist of three leading zeros followed by the full seven-digit number.
- For facilities with eight-digit FINs greater than or equal to 10000000 that were assigned by the CoC after January 1, 2001, the coded FIN will consist of two leading zeros followed by the full eight-digit number.

Code	Definition
(fill spaces)	Eight-digit facility ID number.
000000000	If the patient was not referred to another facility.
009999999	If the patient was referred, but the facility's ID number is unknown.

Examples

Code	Reason
0006439999	6439999, General Hospital, Anytown, Illinois
0010000099	10000099, Anytown Medical Center, Anytown, Illinois

Note: A complete list of FINs is available on the American College of Surgeons Web site at <http://www.facs.org/cancer/coc/fin.html>.

NPI–INSTITUTION REFERRED TO

Item Length: 10

Allowable Value: 10 digits

NAACCR Item #2425

Revised 04/07, 09/08

Description

Identifies the facility to which the patient was referred for further care after discharge from the reporting facility.

Rationale

Each facility's NPI is unique. This number is used to document and monitor referral patterns.

NPI–Institution Referred To is the NPI equivalent of *Facility Referred To* (NAACCR Item #2420). Both are required during a period of transition.

Instructions for Coding

- Record the 10-digit NPI for the facility to which the patient was referred.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.
- Check with the registry, billing, or health information departments of the facility to determine its NPI or search on <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>.

Code	Definition
(fill spaces)	10-digit NPI number for the facility.
(leave blank)	NPI for the facility referred to is unknown or not available.
(leave blank)	If the patient was not referred to another facility.

DATE OF FIRST CONTACT

Item Length: 8
 NAACCR Item #580
 Revised 09/06, 01/04, 01/10

Description

Date of first contact with the reporting facility for diagnosis and/or treatment of this cancer.

Rationale

This data item can be used to measure the time between first contact and the date that the case was abstracted. It can also be used to measure the length of time between the first contact and treatment for quality of care reports.

Instructions for Coding

- Record the date the patient first had contact with the facility as either an inpatient or outpatient for diagnosis and/or treatment of a reportable tumor. The date may be the date of an outpatient visit for a biopsy, X ray, or laboratory test, or the date a pathology specimen was collected at the hospital.
- If this is an autopsy-only or death certificate-only case, then use the date of death.
- When a patient is diagnosed in a staff physician's office, the date of first contact is the date the patient was physically first seen at the reporting facility.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date of First Contact* is MMDDCCYY, with 99 indentifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date of First Contact* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date. The *Date of First Contact Flag* (NAACCR Item #581) is used to explain why *Date of First Contact* is not a known date. See *Date of First Contact Flag* for an illustration of the relationships among these items.

Examples

A patient has an outpatient mammography that is suspicious for malignancy on February 12, 2008, and subsequently undergoes an excisional biopsy or radical surgical procedure on February 14, 2008.	February 12, 2008
Patient undergoes a biopsy in a physician's office on September 8, 2009. The pathology specimen was sent to the reporting facility and was read as malignant melanoma. The patient enters that same reporting facility on September 14, 2009 for wide reexcision.	September 14, 2009
Patient has an MRI of the brain on December 7, 2010, for symptoms including severe headache and disorientation. The MRI findings are suspicious for astrocytoma. Surgery on December 19 removes all gross tumor.	December 7, 2010
Information is limited to the description "Spring," 2003.	April 2003
Information is limited to the description "The middle of the year," 2003.	July 2003
Information is limited to the description "Fall," 2003.	October 2003
If information is limited to the description "Winter," try to determine if this means the beginning or the end of the year.	December or January

DATE OF FIRST CONTACT FLAG

Item Length: 2
 NAACCR Item #581
 Valid codes: 12, Blank
 New Item: 1/1/2010

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date of First Contact* (NAACCR Item #580).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate nondate information that had previously been transmitted in date fields.

Instructions for Coding

- Leave this item blank if *Date of First Contact* (NAACCR Item #580) has a full or partial date recorded.
- Code 12 if the *Date of First Contact* can not be determined at all.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software

Code	Definition
12	A proper value is applicable but not known (that is, the date of first contact is unknown)
(blank)	A valid date value is provided in item <i>Date of First Contact</i> (NAACCR Item #580)

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date of First Contact* (NAACCR Item #580) and *Date of First Contact Flag* (NAACCR Item #581). *In the table below, the lowercase letter “b” is used to represent each blank space.*

Description	Traditional Date of First Contact	Interoperable Date of First Contact	Date of First Contact Flag
	Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999	Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown.	
Full date known	MMDDCCYY (example: 02182010)	CCYYMMDD (example: 20100218)	bb
Month and year known	MM99CCYY (example: 02992010)	CCYYMMbb (example: 201002bb)	bb
Year only known	9999CCYY (example: 99992010)	CCYYbbbb (example: 2010bbbb)	bb
Unknown date	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	12

DATE OF INITIAL DIAGNOSIS

Item Length: 8
NAACCR Item #390
Revised 09/04, 09/08, 1/10

Description

Records the date of initial diagnosis by a physician for the tumor being reported.

Rationale

The timing for staging and treatment of cancer begins with the date of initial diagnosis for cancer.

Instructions for Coding

- Use the first date of diagnosis whether clinically or histologically established.
- If the physician states that in retrospect the patient had cancer at an earlier date, use the earlier date as the date of diagnosis.
- Use the date treatment was started as the date of diagnosis if the patient receives a first course of treatment before a definitive diagnosis.
- Refer to the list of “Ambiguous Terms” in Section One for language that represents a diagnosis of cancer.
- The date of death is the date of diagnosis for a *Class of Case* (NAACCR Item #610) 38 (diagnosed at autopsy) or 49 (death certificate only).
- Use the actual date of diagnosis for an *in utero* diagnosis, for cases diagnosed on January 1, 2009, or later..
- If the year diagnosis can not be identified, it must be approximated. In that instance, the month and day are unknown.

Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date of Initial Diagnosis* MMDDCCYY, with 99 indentifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date of Initial Diagnosis* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date.

DATE OF DIAGNOSIS FLAG

Item Length: 2
NAACCR Item #391
Valid codes: 12, Blank
New Item: 1/1/2010, deleted 02/10

This item has been removed from *FORDS: Revised for 2010*.

PRIMARY SITE

Item Length: 4
 NAACCR Item #400
 Revised 01/04, 09/08, 01/10

Description

Identifies the primary site.

Rationale

Primary site is a basis for staging and the determination of treatment options. It also affects the prognosis and course of the disease.

Instructions for Coding

- Record the ICD-O-3 topography code for the site of origin.
- Consult the physician advisor to identify the primary site or the most definitive site code if the medical record does not contain that information.
- Topography codes are indicated by a “C” preceding the three-digit code number. Do not record the decimal point.
- Follow the Instructions for Coding in ICD-O-3, pages 20–40 and in the current *SEER Multiple Primary and Histology Coding Rules* to assign site for solid tumors.
- Follow the instructions in *Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual* and the Hematopoietic and Lymphoid Neoplasms Database (Hematopoietic DB) for assigning site for lymphomas, leukemia and other hematopoietic neoplasms.
- Use subcategory 8 for single tumors that overlap the boundaries of two or more sub-sites and the point of origin is not known.
- Use subcategory 9 for multiple tumors that originate in different subsites of one organ.

Examples

Code	Reason
C108	Overlapping lesion of oropharynx. Code overlapping lesion when a large tumor involves both the lateral wall of the oropharynx (C10.2) and the posterior wall of the oropharynx (C10.3) and the point of origin is not stated.
C678	Overlapping lesion of bladder. Code overlapping lesion of the bladder when a single lesion involves the dome (C67.1) and the lateral wall (C67.2) and the point of origin is not stated.
C189	Colon, NOS. Familial polyposis with carcinoma and carcinoma in situ throughout the transverse (C18.4) and descending colon (C18.6) would be one primary and coded to colon, NOS (C18.9). For a full explanation see the <i>SEER 2007 Multiple Primary and Histology Coding Rules</i> .
C16–	Stomach (sub-site as identified). An extranodal lymphoma of the stomach is coded to C16.– (sub-site as identified).

LATERALITY

Item Length: 1
 Allowable Values: 0–4, 9
 NAACCR Item #410
 Revised 01/10, 05/10

Description

Identifies the side of a paired organ or the side of the body on which the reportable tumor originated. This applies to the primary site only.

Rationale

Laterality supplements staging and extent of disease information and defines the number of primaries involved.

Instructions for Coding

- Code laterality for all paired sites. (See Section One for additional information.)
- Do not code metastatic sites as bilateral involvement.
- Where the right and left sides of paired sites are contiguous (come into contact) and the lesion is at the point of contact of the right and left sides, use code 5, midline. Note that “midline of the right breast” is coded 1, right; midline in this usage indicates the primary site is C50.8 (overlapping sites).
- Non-paired sites may be coded right or left, if appropriate. Otherwise, code non-paired sites 0.

Code	Definition
0	Organ is not a paired site.
1	Origin of primary is right.
2	Origin of primary is left.
3	Only one side involved, right or left origin not specified.
4	Bilateral involvement at time of diagnosis, lateral origin unknown for a single primary; or both ovaries involved simultaneously, single histology; bilateral retinoblastomas; bilateral Wilms tumors
5	Paired site: midline tumor
9	Paired site, but no information concerning laterality

HISTOLOGY

Item Length: 4
 NAACCR Item #522
 Revised 09/06, 01/10, 03/10

Description

Identifies the microscopic anatomy of cells.

Rationale

Histology is a basis for staging and the determination of treatment options. It also affects the prognosis and course of the disease.

Instructions for Coding

- ICD-O-3 identifies the morphology codes with an “M” preceding the code number. Do not record the “M.”
- Record histology using the ICD-O-3 codes in the Numeric Lists/Morphology section (ICD-O-3, pp. 69–104) and in the Alphabetic Index (ICD-O-3, pp. 105–218).
- Follow the coding rules outlined on pages 20 through 40 of ICD-O-3.
- Use the current *Multiple Primary and Histology Coding Rules* when coding the histology for all reportable solid tumors. These rules are effective for cases diagnosed January 1, 2007, or later. Do not use these rules to abstract cases diagnosed prior to January 1, 2007.
- Review all pathology reports.
- Code the **final** pathologic diagnosis for solid tumors.
- For lymphomas, leukemias and other hematopoietic tumors, follow the instructions in *Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual* and the Hematopoietic and Lymphoid Neoplasms Database (Hematopoietic DB)
- The codes for cancer, NOS (8000) and carcinoma, NOS (8010) are **not** interchangeable. If the physician says that the patient has carcinoma, then code carcinoma, NOS (8010).

Examples

Code	Label	Definition
8140	Adenocarcinoma	Final pathologic diagnosis is carcinoma, NOS (8010) of the prostate. Microscopic diagnosis specifies adenocarcinoma (8140) of the prostate.
9680	Diffuse large B-cell lymphoma	Diffuse large B-cell lymphoma, per the WHO Classification of Hematopoietic and Lymphoid Neoplasms.

BEHAVIOR CODE

Item Length: 1
 Allowable Values: 0–3
 NAACCR Item #523
 Revised 04/04, 01/10

Description

Records the behavior of the tumor being reported. The fifth digit of the morphology code is the behavior code.

Rationale

The behavior code is used by pathologists to describe whether tissue samples are benign (0), borderline (1), in situ (2), or invasive (3).

Instructions for Coding

- Code 3 if any invasion is present, no matter how limited.
- If the specimen is from a metastatic site, code the histology of the metastatic site and code 3 for behavior.

Note: The ICD-O-3 behavior code for juvenile astrocytoma (9421/1) is coded as 3 by agreement of North American registry standard-setters. Refer to “Case Eligibility” in Section One for information.

Code	Label	Definition
0	Benign	Benign
1	Borderline	Uncertain whether benign or malignant.
		Borderline malignancy.
		Low malignant potential.
		Uncertain malignant potential.
2	In situ and/or carcinoma in situ	Adenocarcinoma in an adenomatous polyp with no invasion of stalk.
		Clark level 1 for melanoma (limited to epithelium).
		Comedocarcinoma, noninfiltrating (C50.-).
2	Synonymous with in situ	Confined to epithelium.
		Hutchinson melanotic freckle, NOS (C44.-).
		Intracystic, noninfiltrating.
		Intraductal.
		Intraepidermal, NOS.
		Intraepithelial, NOS.
		Involvement up to, but not including the basement membrane.
		Lentigo maligna (C44.-).
		Lobular neoplasia (C50.-).
		Lobular, noninfiltrating (C50.-).
		Noninfiltrating.
		No stromal involvement.

Code	Label	Definition
2		Papillary, noninfiltrating or intraductal.
		Precancerous melanosis (C44.-).
		Queyrat erythroplasia (C60.-).
3	Invasive	Invasive or microinvasive.

Example

Code	Reason
3	Intraductal carcinoma (8500/2) with focal areas of invasion.

GRADE/DIFFERENTIATION

Item Length: 1
Allowable Values: 1–9
NAACCR Item #440
Revised 01/04, 09/08, 01/10

Description

Describes the tumor's resemblance to normal tissue. Well differentiated (Grade 1) is the most like normal tissue, and undifferentiated (Grade 4) is the least like normal tissue. Grades 5–8 define particular cell lines for lymphomas and leukemias.

Rationale

This data item is useful for prognosis.

Instructions for Coding

- Code grade according to ICD-O-3 (pp. 30–31 and 67).
- Code the grade or differentiation as stated in the **final** pathologic diagnosis. If grade is not stated in the final pathologic diagnosis, use the information from the microscopic description or comments.
- When the pathology report(s) lists more than one grade of tumor, code to the highest grade, even if the highest grade is only a focus (Rule G, ICD-O-3, p. 21).
- Code the grade or differentiation from the pathologic examination of the primary tumor, not from metastatic sites.
- When there is no tissue diagnosis, it may be possible to establish grade through magnetic resonance imaging (MRI) or positron emission tomography (PET). When available, code grade based on the recorded findings from these imaging reports.
- If the primary site is unknown, code *Grade/Differentiation* as 9 (Unknown).
- Code the grade for in situ lesions if the information is available. If the lesion is both invasive and in situ, code only the invasive portion. If the invasive component grade is unknown, then code 9.
- **Do not** use “high grade,” “low grade,” or “intermediate grade” descriptions for lymphomas as a basis for differentiation. These terms are categories in the Working Formulation of Lymphoma Diagnoses and do not relate to *Grade/Differentiation*.
- Codes 5–8 define T-cell or B-cell origin for leukemias and lymphomas. T-cell, B-cell, or null cell classifications have precedence over grading or differentiation.
- Do not use the WHO grade to code this data item.
- If no grade is given for astrocytomas, code 9 (Unknown).
- If no grade is given for glioblastoma multiforme, code 9 (Unknown).
- See Section I to convert other solid tumor grade systems to *Grade/Differentiation*.
- If *Grade Path System* (NAACCR Item #449) and *Grade Path Value* (NAACCR Item #441) are coded, *Grade/Differentiation* (NAACCR Item #440) must not be 9.

Code	Grade/Cell	Label
1	Grade I,1,i	Well differentiated; differentiated, NOS
2	Grade II,2,ii I/III or 1/3	Moderately differentiated; moderately well differentiated; intermediate differentiation
3	Grade III,3,iii II/III or 2/3	Poorly differentiated; dedifferentiated
4	Grade IV,4,iv III/III or 3/3	Undifferentiated; anaplastic
For Lymphomas and Leukemias		
5		T cell; T-precursor
6		B cell; pre-B; B-precursor
7		Null cell; non T-non B
8		NK (natural killer) cell (effective with diagnosis 1/1/95 and after)
For Use in All Histologies		
9		Cell type not determined, not stated or not applicable; unknown primary; high grade dysplasia (adenocarcinoma in situ)

GRADE PATH SYSTEM

Item Length: 1
 Allowable Values: 2–4, blank
 NAACCR Item #449
 New Item: 1/1/2010

Description

Indicates whether a two, three or four grade system was used in the pathology report.

Rationale

This item is used to show whether a two, three or four grade system was used in the pathology report to describe the grade. This item is used in conjunction with *Grade Path Value* (NAACCR Item #441).

Instructions for Coding

- This item may be left blank for cases diagnosed prior to 2010.
- Code this item from the same tissue as that used to code *Grade/Differentiation* (NAACCR Item #440)
- Code the value corresponding to the number of grades used in the grading system reported in the pathology report
- Leave the item blank if no pathologic grade is available
- Leave the item blank if only a verbal description of grade is reported (for example, moderately differentiated)
- Leave this item blank if another grading system is used in the pathology report. For example, do not report grading systems such as Bloom-Richardson for breast primaries, Fuhrman for kidney, Gleason for prostate, or WHO grade. Those grading systems are coded in a site-specific factor for the applicable CS schema.
- Leave this item blank for lymphomas and hematopoietic malignancies (9590-9992).
- This item and *Grade Path Value* (NAACCR Item #441) should both be coded or both be blank. If both are coded, *Grade/Differentiation* (NAACCR Item #440) must not be 9.

Code	Definition
Blank	No 2, 3 or 4 grade system available. Unknown.
2	A 2-grade grading system was used (2, II or ii)
3	A 3-grade grading system was used (3, III or iii)
4	A 4-grade grading system was used (4, IV or iv)

Examples

Code	Reason
4	The final pathologic diagnosis indicates that the grade is 1/4
3	Synoptic report says grade ii of iii
3	Microscopic description reports high grade III of III
Blank	No mention of grade at all in the pathology report

GRADE PATH VALUE

Item Length: 1
 Allowable Values: 1–4, blank
 NAACCR Item #441
 New Item: 1/1/2010

Description

Describes the grade assigned according to the grading system in *Grade Path System* (NAACCR Item #49).

Rationale

This item records the numeric grade reported in the pathology report. This item supplements but does not replace *Grade/Differentiation* (NAACCR Item #440).

Instructions for Coding

- This item may be left blank for cases diagnosed before 2010.
- Code this item from the same tissue as that used to code *Grade/Differentiation* (NAACCR Item #440). This item records how the original grade of the tumor was described.
- Code the value of the numeric grade from the pathology report if the *Grade Path System* (NAACCR Item #449) was 2–4. Code the histologic grade in priority over a nuclear or architectural grade.
- Do not convert the terms *well*, *moderately* or *poorly differentiated*, *low/high*, or *anaplastic* into codes in this field. Leave blank if that is all that is available.
- Leave the item blank if a numeric grade is given, but the grading system is not stated (for example, Grade 1, with no information about the grade system)
- Leave this item blank if another grading system is used in the pathology report. For example, do not report grading systems such as Bloom-Richardson for breast primaries, Fuhrman for kidney, Gleason for prostate, or WHO grade. Those grading systems are coded in a site-specific factor for the applicable CS schema.
- Leave this item blank for lymphomas and hematopoietic malignancies (9590-9992).
- This item and *Grade Path System* (NAACCR Item #449) should both be coded or both be blank. If both are coded, *Grade/Differentiation* (NAACCR Item #440) must not be 9. *Grade Path Value* can never be larger than *Grade Path System*.

Code	Definition
Blank	No 2-, 3- or 4-grade system available. Unknown.
1	Recorded as Grade I, i or 1 of a 2–4 grade system
2	Recorded as Grade II, ii or 2 of a 2–4 grade system
3	Recorded as Grade III, iii or 3 of a 3–4 grade system
4	Recorded as Grade IV, iv of a 4 grade system

Examples

Code	Reason
1	The pathology report indicates the grade is 1/4
2	Synoptic report says grade ii of iii
3	Microscopic description reports high grade III of III
Blank	No mention of grade at all in the pathology report
Blank	The pathology report indicates that the grade is 2, but no mention of the system is made

LYMPH-VASCULAR INVASION

Item Length: 1

Allowable Values: 0-1, 8-9

NAACCR Item #1182

New Item: 1/1/2010

Description

Indicates the presence or absence of tumor cells in lymphatic channels (not lymph nodes) or blood vessels within the primary tumor as noted microscopically by the pathologist.

Rationale

Lymph-vascular invasion is an indicator of prognosis. This field is used by the CS algorithm to map AJCC T for some primary sites.

Instructions for Coding

- This item may be left blank for cases diagnosed before 2010.
- The primary source of this information is the College of American Pathologists (CAP) synoptic report or checklist. If that is not available, code from the pathology report or a physician's statement, in that order of priority.
- Use code 1 if lymph-vascular is identified anywhere in a primary tumor specimen.
- Use code 0 if the pathology report indicates no lymph-vascular invasion was found.
- Use code 8 if no pathologic examination of primary site tissue was performed.
- Use code 8 for histologies 9590-9992.
- Use code 9 if primary site tissue was sent to pathology, but no report based on it is available (the report can not be found or surgery was at a different facility and the information was not provided to the reporting facility)
- Use code 9 if the pathology report indicates that the presence of lymph-vascular invasion could not be determined

Code	Definition
0	Lymph-vascular invasion is not present (absent) or is not identified
1	Lymph-vascular invasion is present or identified
8	Not applicable
9	Unknown or indeterminate

DIAGNOSTIC CONFIRMATION

Item Length: 1
 Allowable Values: 1, 2, 4–9
 NAACCR Item #490
 Revised 01/04, 01/10

Description

Records the best method of diagnostic confirmation of the cancer being reported at any time in the patient's history.

Rationale

This item is an indicator of the precision of diagnosis. The percentage of solid tumors that are clinically diagnosed only is an indication of whether casefinding is including sources outside of pathology reports. Full incidence calculations must include both clinically and pathologically confirmed cases.

Instructions for Coding Solid Tumors (all tumors *except* M9590-9992)

- The codes are in **priority order**; code 1 has the highest priority. Always code the procedure with the lower numeric value when presence of cancer is confirmed with multiple diagnostic methods. This data item must be changed to the lower (higher priority) code if a more definitive method confirms the diagnosis *at any time during* the course of the disease.
- Assign code 1 when the microscopic diagnosis is based on tissue specimens from biopsy, frozen section, surgery, autopsy or D&C or from aspiration of biopsy of bone marrow specimens.
- Assign code 2 when the microscopic diagnosis is based on cytologic examination of *cells* such as sputum smears, bronchial brushings, bronchial washings, prostatic secretions, breast secretions, gastric fluid, spinal fluid, peritoneal fluid, pleural fluid, urinary sediment, cervical smears and vaginal smears, or from paraffin block specimens from concentrated spinal, pleural, or peritoneal fluid.
- Code 5 when the diagnosis of cancer is based on laboratory tests or marker studies which are clinically diagnostic for that specific cancer.
- Code 6 when the diagnosis is based only on the surgeon's operative report from a surgical exploration or endoscopy or from gross autopsy findings in the absence of tissue or cytological findings.

Codes for Solid Tumors

Code	Label	Definition
1	Positive histology	Histologic confirmation (tissue microscopically examined).
2	Positive cytology	Cytologic confirmation (no tissue microscopically examined; fluid cells microscopically examined).
4	Positive microscopic confirmation, method not specified	Microscopic confirmation is all that is known. It is unknown if the cells were from histology or cytology.
5	Positive laboratory test/marker study	A clinical diagnosis of cancer is based on laboratory tests/marker studies which are clinically diagnostic for cancer. Examples include alpha-fetoprotein for liver cancer and abnormal electrophoretic spike for multiple myeloma. Elevated PSA is not diagnostic of cancer. If the physician uses the PSA as a basis for diagnosing prostate cancer with no other workup, record as code 5.
6	Direct visualization without microscopic confirmation	The tumor was visualized during a surgical or endoscopic procedure only with no tissue resected for microscopic examination.
7	Radiography and other imaging techniques without microscopic confirmation	The malignancy was reported by the physician from an imaging technique report only.

8	Clinical diagnosis only, other than 5, 6 or 7	The malignancy was reported by the physician in the medical record.
9	Unknown whether or not microscopically confirmed	A statement of malignancy was reported in the medical record, but there is no statement of how the cancer was diagnosed (usually nonanalytic).

Instructions for Coding Hematopoietic or Lymphoid Tumors (9590-9992)

- There is no priority hierarchy for coding *Diagnostic Confirmation* for hematopoietic and lymphoid tumors. Most commonly, the specific histologic type is diagnosed by immunophenotyping or genetic testing. See the *Hematopoietic Database (DB)* for information on the definitive diagnostic confirmation for specific types of tumors.
- Code 1 when the microscopic diagnosis is based on tissue specimens from biopsy, frozen section, surgery, or autopsy or bone marrow specimens from aspiration or biopsy.
- For leukemia only, code 1 when the diagnosis is based only on the complete blood count (CBC), white blood count (WBC) or peripheral blood smear. Do not use code 1 if the diagnosis was based on immunophenotyping or genetic testing using tissue, bone marrow, or blood.
- Use code 2 when the microscopic diagnosis is based on cytologic examination of *cells* (rather than tissue) including but not limited to spinal fluid, peritoneal fluid, pleural fluid, urinary sediment, cervical smears and vaginal smears, or from paraffin block specimens from concentrated spinal, pleural, or peritoneal fluid. These methods are rarely used for hematopoietic or lymphoid tumors.
- Assign code 3 when there is a histology positive for cancer AND positive immunophenotyping and/or positive genetic testing results. Do not use code 3 for neoplasms diagnosed prior to January 1, 2010.
- Assign code 5 when the diagnosis of cancer is based on laboratory tests or marker studies which are clinically diagnostic for that specific cancer, but no positive histologic confirmation.
- Assign code 6 when the diagnosis is based only on the surgeon's report from a surgical exploration or endoscopy or from gross autopsy findings without tissue or cytological findings.
- Assign code 8 when the case was diagnosed by any clinical method that can not be coded as 6 or 7. A number of hematopoietic and lymphoid neoplasms are diagnosed by tests of exclusion where the tests for the disease are equivocal and the physician makes a clinical diagnosis based on the information from the equivocal tests and the patient's clinical presentation.

Codes for Hematopoietic and Lymphoid Neoplasms

Code	Label	Definition
1	Positive histology	Histologic confirmation (tissue microscopically examined).
2	Positive cytology	Cytologic confirmation (no tissue microscopically examined; fluid cells microscopically examined).
3	Positive histology PLUS <ul style="list-style-type: none"> • Positive immunophenotyping AND/OR • Positive genetic studies 	Histology is positive for cancer, and there are also positive immunophenotyping and/or genetic test results. For example, bone marrow examination is positive for acute myeloid leukemia. (9861/3) Genetic testing shows AML with inv(16)(p13.1q22) (9871/3).
4	Positive microscopic confirmation, method not specified	Microscopic confirmation is all that is known. It is unknown if the cells were from histology or cytology.
5	Positive laboratory test/marker study	A clinical diagnosis of cancer is based on laboratory tests/marker studies which are clinically diagnostic for cancer.
6	Direct visualization without microscopic confirmation	The tumor was visualized during a surgical or endoscopic procedure only with no tissue resected for microscopic examination.

7	Radiography and other imaging techniques without microscopic confirmation	The malignancy was reported by the physician from an imaging technique report only.
8	Clinical diagnosis only, other than 5, 6 or 7	The malignancy was reported by the physician in the medical record.
9	Unknown whether or not microscopically confirmed	A statement of malignancy was reported in the medical record, but there is no statement of how the cancer was diagnosed (usually nonanalytic).

AMBIGUOUS TERMINOLOGY DIAGNOSIS

Item Length: 1
Allowable Values: 0, 1, 2, and 9
NAACCR Item #442
Added 09/06, 01/10

Description

Identifies cases for which an ambiguous term is the most definitive word or phrase used to establish a cancer diagnosis.

Rationale

This data item allows cases to be identified within an analysis file. It also allows these cases to be identified and excluded from patient contact studies.

Instructions for Coding

- Apply the instructions in the current version of *Multiple Primary Histology and Coding Rules* to code this item.

DATE OF CONCLUSIVE DIAGNOSIS

Item Length: 8
NAACCR Item #443
Revised 1/10

Description

Records the date when a conclusive cancer diagnosis (based on definitive statement of malignancy) is made 60 days or more following an initial diagnosis that was based only on ambiguous terminology.

Rationale

This data item allows for analysis of the time interval between cancer diagnosis based on ambiguous terminology and confirmation of the cancer diagnosis by conclusive means.

Instructions for Coding

- The date must be more than 60 days from the date of initial diagnosis.
- Record the date a conclusive diagnosis was made based on a definitive statement of malignancy more than 60 days after the date of initial diagnosis. Update the histology code if it is different.
- Apply the instructions in the current version of *Multiple Primary Histology and Coding Rules* to code this item.
- Leave blank for cases diagnosed prior to January 1, 2007.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date of Conclusive Diagnosis* MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date of Conclusive Diagnosis* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *Date of Conclusive DX Flag* (NAACCR Item #448) is used to explain why *Date of Conclusive Diagnosis* is not a known date. See *Date of Conclusive DX Flag* for an illustration of the relationships among these items.

DATE CONCLUSIVE DX FLAG

Item Length: 2
 NAACCR Item #448
 Valid codes: 10-12, 15, Blank
 New Item: 1/1/2010; Revised 05/10

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date of Conclusive Diagnosis* (NAACCR Item #443).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Instructions for Coding

- Leave this item blank if *Date Conclusive Diagnosis* (NAACCR Item #443) has a full or partial date recorded.
- Code 10 if it is unknown whether the diagnosis was based on ambiguous terminology.
- Code 11 if the case was diagnosed originally or within 60 days of initial diagnosis using unambiguous terminology.
- Code 15 if the case was diagnosed using ambiguous terminology and no conclusive (unambiguous) diagnosis followed.
- Code 12 if the *Date Conclusive Diagnosis* can not be determined, but the case was originally diagnosed using ambiguous terminology and was conclusively diagnosed more than 60 days later.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.
- Leave blank for cases diagnosed prior to January 1, 2007.

Code	Description
10	No information whatsoever can be inferred (for example, unknown if the diagnosis was initially based on ambiguous terminology).
11	No proper value is applicable in this context. (for example, not applicable, initial diagnosis made by unambiguous terminology [Code 0 in data item <i>Ambiguous Terminology Diagnosis</i> , NAACCR Item #442]).
12	A proper value is applicable but not known (for example, the date of conclusive diagnosis unknown).
15	Accessioned based on ambiguous terminology only [Code 1 in data item <i>Ambiguous Terminology Diagnosis</i> , NAACCR Item #442].
(blank)	A valid date value is provided in item <i>Date of Conclusive Diagnosis</i> (NAACCR Item #443). Case was diagnosed prior to January 1, 2007.

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date of Conclusive Diagnosis* (NAACCR Item #443) and *Date of Conclusive DX Flag* (NAACCR Item #448). *In this table, the lowercase letter “b” is used to represent each blank space.*

Description	Traditional Date of Conclusive Diagnosis	Interoperable Date of Conclusive Diagnosis	Date of Conclusive DX Flag
	Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999	Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable.	
Full date known	MMDDCCYY (example: 02182009)	CCYYMMDD (example: 20090218)	bb
Month and year known	MM99CCYY (example: 02992009)	CCYYMMbb (example: 200902bb)	bb
Year only known	9999CCYY (example: 99992009)	CCYYbbbb (example: 2009bbbb)	bb
Unknown if Ambiguous Terms	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	10
Not Applicable (non-ambiguous)	88888888 (example: 88888888)	bbbbbbbb (example: bbbbbbbb)	11
Unknown date	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	12
Ambiguous terms only	00000000 (example: 00000000)	bbbbbbbb (example: bbbbbbbb)	15

DATE OF MULTIPLE TUMORS

Item length: 8

NAACCR Item #445

Revised 04/07, 09/08, 1/10

Description

Identifies the date the patient is diagnosed with multiple or subsequent reportable tumor(s) reported as a single primary. Multiple tumors must have the same histologic group as the original tumor and must be located in the same organ or primary site as the original tumor, using the primary site and histology coding rules.

Rationale

This data item allows for the separation of cases with multiple reportable tumors present at the time of initial diagnosis from cases with subsequent reportable tumors. The date allows for tracking the time interval between the date of original diagnosis and the first date of subsequent tumor(s) for specific primary sites and tumor histologies.

Instructions for Coding

- Record the date the patient is diagnosed with synchronous multiple tumors abstracted as a single primary.
- Record the *Date of Initial Diagnosis* as the *Date of Multiple Tumors* when multiple tumors are abstracted and reported as a single primary at the time of initial diagnosis.
- Apply the instructions in the current version of *Multiple Primary Histology and Coding Rules* to code this item.
- Do not assign a date for leukemia, lymphoma, immunoproliferative disease (M9590–M9992), Kaposi sarcoma (M9140), and unknown primaries (C80.9).
- Leave blank for cases diagnosed prior to January 1, 2007.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date of Multiple Tumors* is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date of Multiple Tumors* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *Date of Mult Tumors Flag* (NAACCR Item #349) is used to explain why *Date of Multiple Tumors* is not a known date. See *Date of Mult Tumors Flag* for an illustration of the relationships among these items.

DATE OF MULT TUMORS FLAG

Item length: 2
 NAACCR Item #439
 Valid codes: 11, 12, 15, Blank
 New Item: 01/2010

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date of Multiple Tumors* (NAACCR Item #445).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Instructions for Coding

- Leave this item blank if *Date of Multiple Tumors* (NAACCR Item #445) has a full or partial date recorded.
- Code 15 if there is a single tumor for the primary. This code is changed the first time an additional tumor is diagnosed that is properly coded as the same primary.
- Code 11 if multiple tumors are not collected for this site and histology (code 88 for *Multiplicity Counter* [NAACCR Item #446]).
- Code 12 if the *Date of Multiple Tumors* can not be determined, but it is known that there are multiple tumors in this primary.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.
- Leave blank for cases diagnosed prior to January 1, 2007.

Code	Definition
11	No proper value is applicable in this context. (for example, multiple tumors are not collected for this site and histology; code 01 for <i>Multiplicity Counter</i> [NAACCR Item #446]).
12	A proper value is applicable but not known (that is, the date of multiple tumors is unknown).
15	A single tumor only
(blank)	A valid date value is provided in item <i>Date of Multiple Tumors</i> (NAACCR Item #445). Case was diagnosed prior to January 1, 2007.

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date of Multiple Tumors* (NAACCR Item #445) and *Date of Mult Tumors Flag* (NAACCR Item #439). *In this table, the lowercase letter “b” is used to represent each blank space.*

Description	Traditional Date of Multiple Tumors	Interoperable Date of Multiple Tumors	Date of Mult Tumors Flag
	Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999	Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable.	
Full date known	MMDDCCYY (example: 02182008)	CCYYMMDD (example: 20080218)	bb
Month and year known	MM99CCYY (example: 02992008)	CCYYMMbb (example: 200802bb)	bb
Year only known	9999CCYY (example: 99992008)	CCYYbbbb (example: 2008bbbb)	bb
Not applicable for site and histology	88888888 (example: 88888888)	bbbbbbbb (example: bbbbbbbb)	11
Date is unknown, multiple tumors	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	12
Single tumor only	00000000 (example: 00000000)	bbbbbbbb (example: bbbbbbbb)	15

**TYPE OF MULTIPLE TUMORS REPORTED
AS ONE PRIMARY**

Item Length: 2
Allowable Values: 00, 10–12, 20, 30–32,
40, 80, 88, 99
NAACCR Item #444
Revised 07/07, 09/08, 01/10

Description

Identifies cases with multiple tumors that are abstracted as a single primary using the multiple primary rules in terms of the mix of histologic behaviors represented.

Rationale

Patients with multiple tumors that are reported as a single primary for surveillance purposes may have a worse prognosis or more extensive treatment than patients with a single tumor. This data item makes it possible to identify important information about these cases for data analysis. Data collected for this item are used to assess the number, type, and anatomic location of multiple tumors currently abstracted as a single primary using the rules for determining multiple primary cancers and the impact these cases have on cancer case counts and incidence rates.

Instructions for Coding

- The data item does not apply to metastatic tumors.
- Apply the instructions in the current version of *Multiple Primary Histology and Coding Rules* to code this item.
- Leave blank for cases diagnosed on or before December 31, 2006.

MULTIPLICITY COUNTER

Item length: 2
Allowable Values: 01–88, 99
NAACCR Item #446
Revised 09/08, 01/10

Description

Records the number of tumors (multiplicity) reported as a single primary.

Rationale

Patients with multiple tumors reported as a single primary for surveillance purposes may have a worse prognosis and more extensive treatment than patients with a single tumor. This data item will make it possible to identify important information about these cases for data analysis. Data collected for this item will be used to assess the number, type, and anatomic location of multiple reportable tumors currently abstracted as a single primary and the impact of these cases on cancer case counts and incidence rates.

Instructions for Coding

- This data item does not apply to metastatic tumors.
- Apply the instructions in the current version of *Multiple Primary Histology and Coding Rules* to code this item.
- This data item is used when a physician states that there are two or more primaries, but for surveillance purposes, the case is reported as a single primary.
- Use 88 for leukemia, lymphoma, immunoproliferative disease (M9590–M9992), Kaposi sarcoma (M9140), and unknown primaries (C80.9).
- Leave blank for cases diagnosed on or before December 31, 2006.

REGIONAL LYMPH NODES EXAMINED

Item Length: 2
Allowable Values: 00–90, 95–99
NAACCR Item #830
Revised 09/06, 01/10

Description

Records the total number of regional lymph nodes that were removed and examined by the pathologist. Beginning with cases diagnosed on or after January 1, 2004, this item became a component of the Collaborative Staging System (CS).

Rationale

This data item serves as a quality measure of the pathologic and surgical evaluation and treatment of the patient.

Instructions for Coding

- Refer to the site/histology-specific instructions in the current *CS Manual* for codes and Instructions for Coding.

REGIONAL LYMPH NODES POSITIVE

Item Length: 2
Allowable Values: 00–99
Right Justified, Zero-filled
NAACCR Item #820
Revised 09/06, 01/10

Description

Records the exact number of regional lymph nodes examined by the pathologist and found to contain metastases. Beginning with cases diagnosed on or after January 1, 2004, this item became a component of the Collaborative Staging System (CS).

Rationale

This data item is necessary for pathologic staging, and it serves as a quality measure for pathology reports and the extent of the surgical evaluation and treatment of the patient.

Instructions for Coding

- Refer to the site/histology-specific instructions in the current *CS Manual* for codes and Instructions for Coding.

Stage of Disease at Diagnosis

**DATE OF SURGICAL DIAGNOSTIC
AND STAGING PROCEDURE**

Item Length: 8
NAACCR Item #1280
Revised 1/1/10

Description

Records the date on which the surgical diagnostic and/or staging procedure was performed.

Rationale:

This data item is used to track the use of surgical procedure resources that are not considered treatment.

Coding Instructions:

- Record the date on which the surgical diagnostic and/or staging procedure described in *Surgical Diagnostic and Staging Procedure* (NAACCR Item #1350) was performed at this or any facility.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this modification does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date of Surgical Diagnostic and Staging Procedure* is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date of Surgical Diagnostic and Staging Procedure* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *RX Date-DX/Stg Proc Flag* (NAACCR Item #1281) is used to explain why *Date of Surgical Diagnostic and Staging Procedure* is not a known date. See *RX Date-DX/Stg Proc Flag* for an illustration of the relationships among these items.

RX DATE–DX/STG PROC FLAG

Item Length: 2
 NAACCR Item 281
 Valid codes 10–12, Blank
 New Item: 1/1/2010

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date of Surgical Diagnostic and Staging Procedure* (NAACCR Item #1280).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Coding Instructions

- Leave this item blank if *Date of Surgical Diagnostic and Staging Procedure* (NAACCR Item #1280) has a full or partial date recorded.
- Code 10 if it is unknown whether a surgical diagnostic or staging procedure was performed.
- Code 11 if no surgical diagnostic or staging procedure was performed.
- Code 12 if the *Date of Surgical Diagnostic and Staging Procedure* cannot be determined, but a surgical diagnostic or staging procedure was performed for the patient.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

Code	Definition
10	No information whatsoever can be inferred from this exceptional value (that is, unknown if any diagnostic or staging procedure performed).
11	No proper value is applicable in this context (for example, no diagnostic or staging procedure performed; autopsy only case).
12	A proper value is applicable but not known. This event occurred, but the date is unknown (for example, diagnostic or staging procedure performed but date is unknown).
(blank)	A valid date value is provided in item <i>Date of Surgical Diagnostic and Staging Procedure</i> (NAACCR Item #1280). Case was diagnosed prior to January 1, 2007.

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date of Surgical Diagnostic and Staging Procedure* (NAACCR Item #1280-) and *RX Date–DX/Stg Proc Flag* (NAACCR Item #1281). *In this table, the lower-case letter “b” is used to represent each blank space.*

	Traditional Date of Surgical Diagnostic or Staging Procedure	Interoperable Date of Surgical Diagnostic or Staging Procedure	RX Date–DX/Stg Proc Flag
Description	Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999	Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable.	
Full date known	Date entry MMDDCCYY (example: 02182007)	Date entry CCYYMMDD (example: 20070218)	Flag value bb
Month and year known	MM99CCYY (example: 02992007)	CCYYMMbb (example: 200702bb)	bb
Year only known	9999CCYY (example: 99992007)	CCYYbbbb (example: 2007bbbb)	bb
Unknown if procedure done	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	10
Procedure not done	00000000 (example: 00000000)	bbbbbbbb (example: bbbbbbbb)	11
Date is unknown, procedure done	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	12

**SURGICAL DIAGNOSTIC AND STAGING
PROCEDURE**

Item Length: 2
 Allowable Values: 00–07, 09
 NAACCR Item #1350
 Revised 09/06, 09/08

Description

Identifies the surgical procedure(s) performed in an effort to diagnose and/or stage disease.

Rationale

This data item is used to track the use of surgical procedure resources that are not considered treatment.

Instructions for Coding:

- Record the type of procedure performed as part of the initial diagnosis and workup, whether this is done at your institution or another facility.
- If both an incisional biopsy of the primary site and an incisional biopsy of a metastatic site are done, use code 02 (Incisional biopsy of primary site).
- If a lymph node is biopsied or removed to diagnose or stage *lymphoma*, and that node is NOT the only node involved with lymphoma, use code 02. If there is only a single lymph node involved with lymphoma, use the data item *Surgical Procedure of Primary Site* (NAACCR Item #1290) to code these procedures.
- Do not code surgical procedures which aspirate, biopsy, or remove *regional lymph nodes* in an effort to diagnose and/or stage disease in this data item. Use the data item *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292) to code these procedures. Do not record the date of surgical procedures which aspirate, biopsy, or remove regional lymph nodes in the data item *Date of Surgical Diagnostic and Staging Procedure* (NAACCR Item #1280). See instructions for *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292).
- Code brushings, washings, cell aspiration, and hematologic findings (peripheral blood smears) as positive cytologic diagnostic confirmation in the data item *Diagnostic Confirmation* (NAACCR Item #490). These are not considered surgical procedures and should not be coded in this item.
- Do not code excisional biopsies with clear or microscopic margins in this data item. Use the data item *Surgical Procedure of Primary Site* (NAACCR Item #1290) to code these procedures.
- Do not code palliative surgical procedures in this data item. Use the data item *Palliative Procedure* (NAACCR Item #3270) to code these procedures.

Code	Definition
00	No surgical diagnostic or staging procedure was performed.
01	A biopsy (incisional, needle, or aspiration) was done to a site other than the primary site. No exploratory procedure was done.
02	A biopsy (incisional, needle, or aspiration) was done to the primary site; or biopsy or removal of a lymph node to diagnose or stage lymphoma.
03	A surgical exploration only. The patient was not biopsied or treated.
04	A surgical procedure with a bypass was performed, but no biopsy was done.
05	An exploratory procedure was performed, and a biopsy of either the primary site or another site was done.
06	A bypass procedure was performed, and a biopsy of either the primary site or another site was done.
07	A procedure was done, but the type of procedure is unknown.
09	No information of whether a diagnostic or staging procedure was performed.

Examples:

Code	Reason
00	A lung cancer primary was diagnosed by CT scan. The patient expired. No surgical diagnostic or staging surgical procedure was performed.
00	A sputum sample is examined cytologically to confirm a diagnosis of suspected lung cancer. The procedure is not surgical.
01	A needle biopsy of a liver metastasis in a patient with suspected widespread colon cancer was done. Gross residual tumor is left at the biopsy site.
03	During abdominal exploratory surgery, a gastric lesion and suspicious retroperitoneal lymph nodes were observed. No biopsy or treatment was done.
04	An abdominal exploration of a patient revealed pancreatic carcinoma with extension into surrounding organs and arteries. No attempt to treat. A bypass was performed to alleviate symptoms.
05	An exploratory procedure was performed for primary colon carcinoma with biopsy of suspicious liver lesions.
06	Esophagogastrostomy was performed for infiltrating gastric tumor following a biopsy of the primary site.
07	Stage III lung carcinoma was diagnosed and staged prior to admission.
09	A patient expires in the emergency room with recently diagnosed metastatic melanoma. It is unknown whether a diagnostic or staging procedure was done.

**SURGICAL DIAGNOSTIC AND STAGING
PROCEDURE AT THIS FACILITY**

Item Length: 2
Allowable Values: 00–07, 09
NAACCR Item #740
(Revised 01/04, 09/08)

Description

Identifies the surgical procedure(s) performed in an effort to diagnose and/or stage disease at this facility.

Rationale

This data item is used to track the use of surgical procedure resources that are not considered treatment.

Instructions for Coding

- Record the type of procedure performed as part of the initial diagnosis and workup at this facility.
- If both an incisional biopsy of the primary site and an incisional biopsy of a metastatic site are done, use code 02 (Incisional biopsy of primary site).
- If a lymph node is biopsied or removed to diagnose or stage *lymphoma*, and that node is NOT the only node involved with lymphoma, use code 02. If there is only a single lymph node involved with lymphoma, use the data item *Surgical Procedure of Primary Site at This Facility* (NAACCR Item #670) to code these procedures.
- Do not code surgical procedures which aspirate, biopsy, or remove *regional lymph nodes* in an effort to diagnose and/or stage disease in this data item. Use the data item *Scope of Regional Lymph Node Surgery at This Facility* (NAACCR Item #672) to code these procedures. Do not record the date of surgical procedures which aspirate, biopsy, or remove regional lymph nodes in the data item *Date of Surgical Diagnostic and Staging Procedure* (NAACCR Item #1280). See instructions for *Scope of Regional Lymph Node Surgery at This Facility* (NAACCR Item #672).
- Code brushings, washings, cell aspiration, and hematologic findings (peripheral blood smears) as positive cytologic diagnostic confirmation in the data item *Diagnostic Confirmation* (NAACCR Item #490). These are not considered surgical procedures and should not be coded in this item.
- Do not code excisional biopsies with clear or microscopic margins in this data item. Use the data item *Surgical Procedure of Primary Site at This Facility* (NAACCR Item #670) to code these procedures.
- Do not code palliative surgical procedures in this data item. Use the data item *Palliative Procedure at This Facility* (NAACCR Item #3280) to code these procedures.

Code	Definition
00	No surgical diagnostic or staging procedure was performed.
01	A biopsy (incisional, needle, or aspiration) was done to a site other than the primary site. No exploratory procedure was done.
02	A biopsy (incisional, needle, or aspiration) was done to the primary site; or biopsy or removal of a lymph node to diagnose or stage lymphoma.
03	A surgical exploration only. The patient was not biopsied or treated.
04	A surgical procedure with a bypass was performed, but no biopsy was done.
05	An exploratory procedure was performed, and a biopsy of either the primary site or another site was done.
06	A bypass procedure was performed, and a biopsy of either the primary site or another site was done.
07	A procedure was done, but the type of procedure is unknown.
09	No information of whether a diagnostic or staging procedure was performed.

CLINICAL T

Item Length: 4
 Upper-case Alphanumeric
 Left Justified
 NAACCR Item #940
 Revised 09/06, 01/08, 09/08, 01/10

Description

Evaluates the primary tumor (T) and reflects the tumor size and/or extension of the tumor known *prior* to the start of any therapy.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. Effective January 1, 2008 the CoC requires that AJCC clinical TNM staging be recorded in its accredited cancer program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Instructions for Coding

- The clinical T staging element must be recorded for *Class of Case* 10-22.
- It is strongly recommended that the clinical T staging element be recorded for *Class of Case* 00 cases if the patient's workup at the facility allows coding of clinical T.
- Code clinical T as documented by the first treating physician or the managing physician in the medical record.
- If the managing physician has not recorded clinical T, registrars *will* code this item based on the best available information, without necessarily requiring additional contact with the physician.
- For lung, occult carcinoma is coded TX.
- Refer to the current *AJCC Cancer Staging Manual* for staging rules.

Code	Definition	Code	Definition	Code	Definition
(leave blank)	Not recorded.	1B	T1b	3	T3
X	TX	1B1	T1b1	3A	T3a
0	T0	1B2	T1b2	3B	T3b
A	Ta	1C	T1c	3C	T3c
IS	Tis	1D	T1d	3D	T3d
ISPU	Tispu	2	T2	4	T4
ISPD	Tispd	2A	T2a	4A	T4a
1MI	T1mi, T1 mic	2A1	T2a1	4B	T4b
1	T1	2A2	T2a2	4C	T4c
1A	T1a	2B	T2b	4D	T4d
1A1	T1a1	2C	T2c	4E	T4e
1A2	T1a2	2D	T2d	88	Not applicable

CLINICAL N

Item Length: 4
 Upper-case Alphanumeric
 Left Justified
 NAACCR Item #950
 Revised 09/06, 01/08, 09/08, 01/10

Description

Identifies the absence or presence of regional lymph node (N) metastasis and describes the extent of regional lymph node metastasis of the tumor known *prior* to the start of any therapy.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. Effective January 1, 2008 the CoC requires that AJCC clinical TNM staging be recorded in its accredited cancer program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Instructions for Coding

- The clinical N staging element must be recorded for *Class of Case* 10-22.
- It is strongly recommended that the clinical N staging element be recorded for *Class of Case* 00 cases if the patient's workup at the facility allows coding of clinical N.
- Record clinical N as documented by the first treating physician or the managing physician in the medical record.
- If the managing physician has not recorded clinical N, registrars *will* code this item based on the best available information, without necessarily requiring additional contact with the physician.
- Refer to the current *AJCC Cancer Staging Manual* for staging rules.

Code	Definition	Code	Definition
(leave blank)	Not recorded.	1B	N1b
X	NX	1C	N1c
0	N0	2	N2
0I-	N0i-	2A	N2a
0I+	N0i+	2B	N2b
0M-	N0m-	2C	N2c
0M+	N0m+	3	N3
1MI	N1mi	3A	N3a
0A	N0a	3B	N3b
0B	N0b	3C	N3c
1	N1	4	N4
1A	N1a	88	Not applicable

CLINICAL M

Item Length: 4
 Upper-case Alphanumeric
 Left Justified
 NAACCR Item #960
 Revised 09/06, 01/08, 09/08, 01/10

Description

Identifies the presence or absence of distant metastasis (M) of the tumor known *prior* to the start of any therapy.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Instructions for Coding

- The clinical M staging element must be recorded for *Class of Case* 10-22.
- It is strongly recommended that the clinical M staging element be recorded for *Class of Case* 00 cases if the patient's workup at the facility allows coding of clinical M.
- Record clinical M as documented by the first treating physician or managing physician in the medical record.
- If the managing physician has not recorded clinical M, registrars *will* code this item based on the best available information, without necessarily requiring additional contact with the physician.
- Refer to the current *AJCC Cancer Staging Manual* for staging rules.

Code	Definition
(leave blank)	Not recorded.
X (AJCC editions 1-6 only_)	MX (AJCC editions 1-6 only_)
0	M0
0+	M0+
1	M1
1A	M1a
1B	M1b
1C	M1c
1D	M1d
1E	M1e
88	Not applicable

CLINICAL STAGE GROUP

Item Length: 4
 Upper-case Alphanumeric
 Left Justified
 NAACCR Item #970
 Revised 09/06, 01/08, 09/08, 01/10

Description

Identifies the anatomic extent of disease based on the T, N, and M elements known *prior* to the start of any therapy.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. Effective January 1, 2008 the CoC requires that AJCC clinical TNM staging be recorded in its accredited cancer program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Instructions for Coding

- Record the clinical stage group as documented by the first treating physician or the managing physician in the medical record.
- If the managing physician has not recorded the clinical stage, registrars *will* code this item based on the best available information, without necessarily requiring additional contact with the physician.
- To assign stage group when some, but not all, T, N and/or M components can be determined, interpret missing components as "X".
- If the value is only one digit, then record to the left and leave the second space blank.
- Convert all Roman numerals to Arabic numerals and use upper-case (capital letters) only.
- Refer to the current *AJCC Cancer Staging Manual* for staging rules.

Code	Definition	Code	Definition	Code	Definition
0	Stage 0	1S	Stage IS	3C1	Stage IIIC1
0A	Stage 0A	2	Stage II	3C2	Stage IIIC2
0IS	Stage 0is	2A	Stage IIA	4	Stage IV
1	Stage I	2A1	Stage IIA1	4A	Stage IVA
1A	Stage IA	2A2	Stage IIA2	4A1	Stage IVA1
1A1	Stage IA1	2B	Stage IIB	4A2	Stage IVA2
1A2	Stage IA2	2C	Stage IIC	4B	Stage IVB
1B	Stage IB	3	Stage III	4C	Stage IVC
1B1	Stage IB1	3A	Stage IIIA	OC	Occult
1B2	Stage IB2	3B	Stage IIIB	88	Not applicable
1C	Stage IC	3C	Stage IIIC	99	Unknown

CLINICAL STAGE (PREFIX/SUFFIX) DESCRIPTOR

Item Length: 1

Allowable Values: 03, 5–6, 9

NAACCR Item #980

Revised 09/06, 01/08, 09/08, 01/10, 02/10,
05/10**Description**

Identifies the AJCC clinical stage (prefix/suffix) descriptor of the tumor *prior* to the start of any therapy. Stage descriptors identify special cases that need separate analysis. The descriptors are adjuncts to and do not change the stage group.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. Effective January 1, 2008 the CoC requires that AJCC clinical TNM staging be recorded in its accredited cancer program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Instructions for Coding

- Record the clinical stage (prefix/suffix) descriptor as documented by the first treating physician or the managing physician in the medical record.
- If the managing physician has not recorded the descriptor, registrars *will* code this item based on the best available information, without necessarily requiring additional contact with the physician.
- Refer to the current *AJCC Cancer Staging Manual* for staging rules.
- Previous editions of FORDS included a code 4 for y-classification, and a note that it was not applicable for clinical stage. Code 4 has been removed from the list of valid codes.

Code	Label	Description
0	None	There are no prefix or suffix descriptors that would be used for this case.
1	E–Extranodal, lymphomas only	A lymphoma case involving an extranodal site.
2	S– Spleen, lymphomas only	A lymphoma case involving the spleen.
3	M–Multiple primary tumors in a single site	This is one primary with multiple tumors in the primary site at the time of diagnosis.
5	E&S–Extranodal and spleen, lymphomas only	A lymphoma case with involvement of both an extranodal site and the spleen.
9	Unknown; not stated in patient record	A prefix or suffix would describe this stage, but it is not known which would be correct.

STAGED BY (CLINICAL STAGE)

Item Length: 1
 Allowable Values: 0–9
 NAACCR Item #990
 Revised 09/06, 01/08, 09/08, 01/10

Description

Identifies the person who documented the clinical AJCC staging elements and the Stage Group.

Rationale

Effective January 1, 2008 the CoC requires that AJCC clinical TNM staging be recorded in its accredited cancer program cancer registries. Data captured in this field can be used to evaluate the accuracy and completeness of staging recorded in the registry and form the basis for quality management and improvement studies.

Instructions for Coding

- Record the person who documented the clinical AJCC staging elements and the Stage Group.
- If code 1, 2, or 5 is used, then all of the staging elements (T, N, and M) and Stage Group must be recorded by the same person.
- The staging elements (T, N, M) and the Stage Group must be recorded.

Code	Label	Definition
0	Not staged	Clinical staging was not assigned.
1	Managing physician	Clinical staging was assigned by the managing physician.
2	Pathologist	Clinical staging was assigned by the pathologist only.
3	Pathologist and managing physician	Clinical staging was assigned by the pathologist and the managing physician.
4	Cancer Committee chair, cancer liaison physician, or registry physician advisor	Clinical staging was assigned by the Cancer Committee chair, cancer liaison physician, or the registry physician advisor during a quality control review.
5	Cancer registrar	Clinical staging was assigned by the cancer registrar only.
6	Cancer registrar and physician	Clinical staging was assigned by the cancer registrar and any of the physicians specified in codes 1–4.
7	Staging assigned at another facility	Clinical staging was assigned by a physician at another facility.
8	Case is not eligible for staging	An AJCC staging scheme has not been developed for this site. The histology is excluded from an AJCC site scheme.
9	Unknown; not stated in patient record	It is unknown whether or not the case was staged.

PATHOLOGIC T

Item Length: 4
 Upper-case Alphanumeric
 Left Justified
 NAACCR Item #880
 Revised 09/06, 01/08, 09/08, 01/10

Description

Evaluates the primary tumor (T) and reflects the tumor size and/or extension of the tumor known *following* the completion of surgical therapy.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, to design follow-up strategies, and to assess early detection results.

Instructions for Coding

- Code pathologic T as documented by the treating physician(s) or the managing physician in the medical record.
- If the managing physician has not recorded pathologic T, registrars *should* code this item based on the best available information, without necessarily requiring additional contact with the physician.
- Truncate the least significant subdivision of the category from the right as needed.
- For lung, occult carcinoma is coded TX.
- The CoC recommends that pathologic T be recorded for *Class of Case* 10-22 cases diagnosed on or after January 1, 2008.

Code	Definition	Code	Definition	Code	Definition
(leave blank)	Not recorded.	1B	T1b	3	T3
X	TX	1B1	T1b1	3A	T3a
0	T0	1B2	T1b2	3B	T3b
A	Ta	1C	T1c	3C	T3c
IS	Tis	1D	T1d	3D	T3d
ISPU	Tispu	2	T2	4	T4
ISPD	Tispd	2A	T2a	4A	T4a
1MI	T1mi, T1 mic	2A1	T2a1	4B	T4b
1	T1	2A2	T2a2	4C	T4c
1A	T1a	2B	T2b	4D	T4d
1A1	T1a1	2C	T2c	4E	T4e
1A2	T1a2	2D	T2d	88	Not applicable

PATHOLOGIC N

Item Length: 4
 Upper-case Alphanumeric
 Left Justified
 NAACCR Item #890
 Revised 09/06, 01/08, 09/08, 01/10

Description

Identifies the absence or presence of regional lymph node (N) metastasis and describes the extent of regional lymph node metastasis of the tumor known *following* the completion of surgical therapy.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Instructions for Coding

- Code pathologic N as documented by the treating physician(s) or managing physician in the medical record.
- If the managing physician has not recorded pathologic N, registrars *should* code this item based on the best available information, without necessarily requiring additional contact with the physician.
- Refer to the current *AJCC Cancer Staging Manual* for staging rules.
- The CoC recommends that pathologic N be recorded for *Class of Case 10-22* cases diagnosed on or after January 1, 2008.

Code	Definition	Code	Definition
(leave blank)	Not recorded.	1B	N1b
X	NX	1C	N1c
0	N0	2	N2
0I-	N0i-	2A	N2a
0I+	N0i+	2B	N2b
0M-	N0m-	2C	N2c
0M+	N0m+	3	N3
1MI	N1mi	3A	N3a
0A	N0a	3B	N3b
0B	N0b	3C	N3c
1	N1	4	N4
1A	N1a	88	Not applicable

PATHOLOGIC M

Item Length: 4
 Upper-case Alphanumeric
 Left Justified
 NAACCR Item #900
 Revised 09/06, 01/08, 09/08, 01/10

Description

Identifies the presence or absence of distant metastasis (M) of the tumor known *following* the completion of surgical therapy.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Instructions for Coding

- Code pathologic M as documented by the treating physician(s) or the managing physician in the medical record.
- If the managing physician has not recorded pathologic M, registrars *should* code this item based on the best available information, without necessarily requiring additional contact with the treating physician(s).
- Refer to the current *AJCC Cancer Staging Manual* for staging rules.
- The CoC recommends that pathologic M be recorded for *Class of Case* 10-22 cases diagnosed on or after January 1, 2008.

Code	Definition
(leave blank)	Not recorded.
X (AJCC editions 1-6 only_)	MX (AJCC editions 1-6 only_)
0 (AJCC editions 1-6 only_)	M0 (AJCC editions 1-6 only_)
1	M1
1A	M1a
1B	M1b
1C	M1c
1D	M1d
1E	M1e
88	Not applicable

PATHOLOGIC STAGE GROUP

Item Length: 4
 Upper-case Alphanumeric
 Left Justified
 NAACCR Item #910
 Revised 09/06, 01/08, 09/08, 01/10

Description

Identifies the anatomic extent of disease based on the T, N, and M elements known *following* the completion of surgical therapy.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Instructions for Coding

- Record the pathologic stage group as documented by the treating physician(s) or the managing physician in the medical record.
- If the managing physician has not recorded the pathologic stage, registrars *should* code this item based on the best available information, without necessarily requiring additional contact with the physician(s).
- To assign stage group when some, but not all, T, N and/or M components can be determined, interpret missing components as "X".
- If pathologic M (NAACCR Item #900) is coded as either X or blank and clinical M (NAACCR Item #960) is coded as 0, 1, 1A, 1B, or 1C, then the combination of staging elements pT, pN, and cM (NAACCR Item #880, 890, 960) may be used to complete the pathologic stage group.
- If the value is only one digit, record to the left and leave the second space blank.
- Convert all Roman numerals to Arabic numerals and use upper-case (capital letters) only.
- Refer to the current *AJCC Cancer Staging Manual* for staging rules.
- The CoC recommends that pathologic stage group be recorded for *Class of Case* 10-22 cases diagnosed on or after January 1, 2008.

Code	Definition	Code	Definition	Code	Definition
0	Stage 0	1S	Stage IS	3C1	Stage IIIC1
0A	Stage 0A	2	Stage II	3C2	Stage IIIC2
0IS	Stage 0is	2A	Stage IIA	4	Stage IV
1	Stage I	2A1	Stage IIA1	4A	Stage IVA
1A	Stage IA	2A2	Stage IIA2	4A1	Stage IVA1
1A1	Stage IA1	2B	Stage IIB	4A2	Stage IVA2
1A2	Stage IA2	2C	Stage IIC	4B	Stage IVB
1B	Stage IB	3	Stage III	4C	Stage IVC
1B1	Stage IB1	3A	Stage IIIA	OC	Occult
1B2	Stage IB2	3B	Stage IIIB	88	Not applicable
1C	Stage IC	3C	Stage IIIC	99	Unknown

PATHOLOGIC STAGE (PREFIX/SUFFIX) DESCRIPTOR

Item Length: 1
 Allowable Values: 0–6, 9
 NAACCR Item #920

Revised 09/06, 01/08, 01/10

Description

Identifies the AJCC pathologic stage (prefix/suffix) descriptor known *following* the completion surgical therapy.

Rationale

Stage descriptors identify special cases that need separate analysis. The descriptors are adjuncts to and do not change the stage group. The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Instructions for Coding

- Record the pathologic stage (prefix/suffix) descriptor as documented by the treating physician(s) or the managing physician in the medical record.
- If the managing physician has not recorded the descriptor, registrars *should* code this item based on the best available information, without necessarily requiring additional contact with the physician(s).
- Refer to the current *AJCC Cancer Staging Manual* for staging rules.

Code	Label	Definition
0	None	There are no prefix or suffix descriptors that would be used for this case.
1	E–Extranodal, lymphomas only	A lymphoma case involving an extranodal site.
2	S–Spleen, lymphomas only	A lymphoma case involving the spleen.
3	M–Multiple primary tumors in a single site	This is one primary with multiple tumors in the organ of origin at the time of diagnosis .
4	Y–Classification during or after initial multimodality therapy–pathologic staging only	Not applicable for clinical stage.
5	E&S–Extranodal and spleen, lymphomas only	A lymphoma case with involvement of both an extranodal site and the spleen.
6	M&Y–Multiple primary tumors and initial multimodality therapy	A case meeting the parameters of both codes 3 (multiple primary tumors in a single site) and 4 (classification during or after initial multimodality therapy).
9	Unknown; not stated in patient record	A prefix or suffix would describe this stage, but it is not known which would be correct.

STAGED BY (PATHOLOGIC STAGE)

Item Length: 1

Allowable Values: 0–9

NAACCR Item #930

Revised 09/06, 01/08, 09/08, 01/10

Description

Identifies the person who recorded the pathologic AJCC staging elements.

Rationale

Data captured in this field can be used to evaluate the accuracy and completeness of staging and form the basis for quality management and improvement studies.

Instructions for Coding

- Record the person who documented the pathologic AJCC staging elements and the stage group.
- If code 1, 2, or 5 is used, then all of the staging elements (T, N, and M) and Stage Group must be recorded by the same person.
- The staging elements (T, N, M) and the stage group must be recorded.

Code	Label	Definition
0	Not staged	Pathologic staging was not assigned.
1	Managing physician	Pathologic staging was assigned by the managing physician.
2	Pathologist	Pathologic staging was assigned by the pathologist only.
3	Pathologist and managing physician	Pathologic staging was assigned by the pathologist and the managing physician.
4	Cancer Committee chair, cancer liaison physician, or registry physician advisor	Pathologic staging was assigned by the Cancer Committee chair, cancer liaison physician, or the registry physician advisor during a quality control review.
5	Cancer registrar	Pathologic staging was assigned by the cancer registrar only.
6	Cancer registrar and physician	Pathologic staging was assigned by the cancer registrar and any of the physicians specified in 1–4.
7	Staging assigned at another facility	Pathologic staging was assigned by a physician at another facility.
8	Case is not eligible for staging	An AJCC staging scheme has not been developed for this site. The histology is excluded from an AJCC scheme.
9	Unknown; not stated in patient record	It is unknown whether or not the case was staged.

CS TUMOR SIZE

Item Length: 3

Allowable Values: 000–995, 999

NAACCR Item #2800

Revised 09/06, 09/08, 01/10

Description

Records the largest dimension or diameter of the **primary tumor** in millimeters.

Rationale

Tumor size at diagnosis is an independent prognostic indicator for many tumors and it is used by Collaborative Staging to derive some TNM-T codes.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

CS EXTENSION

Item Length: 2

Allowable Values: 00–80, 95, 99

NAACCR Item #2810

Revised 09/06, 09/08, 01/10

Description

Identifies contiguous growth (extension) of the primary tumor within the organ of origin or its direct extension into neighboring organs. For certain sites such as ovary, discontinuous metastasis is coded in *CS Extension*.

Rationale

Tumor extension at diagnosis is a prognostic indicator used by Collaborative Staging to derive some TNM-T codes and some SEER Summary Stage codes.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

CS TUMOR SIZE/EXT EVAL

Item Length: 1

Allowable Values: 0–3, 5, 6, 8, 9

NAACCR Item #2820

Revised 09/06, 09/08, 01/10

Description

Records how the codes for the two items *CS Tumor Size* (NAACCR Item #2800) and *CS Extension* (NAACCR Item #2810) were determined, based on the diagnostic methods employed.

Rationale

This item is used by Collaborative Staging to describe whether the staging basis for the TNM-T code is clinical or pathological and to record applicable prefix and suffix descriptors used with TNM staging.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

CS LYMPH NODES

Item Length: 2

Allowable Values: 0–80, 90

NAACCR Item #2830

Revised 09/06, 09/08, 01/10

Description

Identifies the regional lymph nodes involved with cancer at the time of diagnosis.

Rationale

The involvement of specific regional lymph nodes is a prognostic indicator used by Collaborative Staging to derive some TNM-N codes and SEER Summary Stage codes.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

CS REG NODES EVAL

Item Length: 1

Allowable Values: 0–3, 5, 6, 8, 9

NAACCR Item #2840

Revised 09/06, 09/08, 01/10

Description

Records how the code for *CS Lymph Nodes* (NAACCR Item #2830) was determined, based on the diagnostic methods employed.

Rationale

This data item is used by Collaborative Staging to describe whether the staging basis for the TNM-N code is clinical or pathological and to record applicable prefix and suffix descriptors used with TNM staging.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

CS METS AT DX

Item Length: 2

Allowable Values: 00, 10, 40, 50, 99

NAACCR Item #2850

Revised 09/06, 09/08, 01/10

Description

Identifies the distant site(s) of metastatic involvement at time of diagnosis.

Rationale

The presence of metastatic disease at diagnosis is an independent prognostic indicator, and it is used by Collaborative Staging to derive TNM-M codes and SEER Summary Stage codes.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

CS METS AT DX–BONE

Item Length: 1
Allowable Values: 0, 1, 8, 9
NAACCR Item #2851
New Item: 01/2010

Description

Identifies the presence of distant metastatic involvement of bone at time of diagnosis.

Rationale

The presence of metastatic bone disease at diagnosis is an independent prognostic indicator, and it is used by Collaborative Staging to derive TNM-M codes and SEER Summary Stage codes for some sites.

Instructions for Coding

- Refer to the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

CS METS AT DX–BRAIN

Item Length: 1
Allowable Values: 0, 1, 8, 9
NAACCR Item #2852
New Item: 01/2010

Description

Identifies the presence of distant metastatic involvement of the brain at time of diagnosis.

Rationale

The presence of metastatic brain disease at diagnosis is an independent prognostic indicator, and it is used by Collaborative Staging to derive TNM-M codes and SEER Summary Stage codes for some sites.

Instructions for Coding

- Refer to the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

CS METS AT DX–LIVER

Item Length: 1
Allowable Values: 0, 1, 8, 9
NAACCR Item #2853
New Item: 01/2010

Description

Identifies the presence of distant metastatic involvement of the liver at time of diagnosis.

Rationale

The presence of metastatic liver disease at diagnosis is an independent prognostic indicator, and it is used by Collaborative Staging to derive TNM-M codes and SEER Summary Stage codes for some sites.

Instructions for Coding

- Refer to the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

CS METS AT DX–LUNG

Item Length: 1
Allowable Values: 0, 1, 8, 9
NAACCR Item #2854
New Item: 01/2010

Description

Identifies the presence of distant metastatic involvement of the lung at time of diagnosis.

Rationale

The presence of metastatic lung disease at diagnosis is an independent prognostic indicator, and it is used by Collaborative Staging to derive TNM-M codes and SEER Summary Stage codes for some sites.

Instructions for Coding

- Refer to the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

CS METS EVAL

Item Length: 1

Allowable Values: 0–3, 5, 6, 8, 9

NAACCR Item #2860

Revised 09/06, 09/08, 01/10

Description

Records how the code for *CS Mets at Dx* (NAACCR Item #2850) was determined based on the diagnostic methods employed.

Rationale

This data item is used by Collaborative Staging to describe whether the staging basis for the TNM-M code is clinical or pathological and to record applicable prefix and suffix descriptors used with TNM staging.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

CS SITE-SPECIFIC FACTOR 1

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2880

Revised 04/07, 09/08, 01/10, 02/10, 03/10

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

For tumors abstracted in CSv2 or diagnosed in 2010, the following Site-Specific Factor 1 (SSF1) items are *required* by CoC to be coded. Registries are *encouraged* to code other prognostic SSF1s used by the facility.

CS Schema	Sites	Histologies	Site-Specific Factor 1
Head and Neck*	See note after this table	8000–8576, 8940–8950, 8980–8981	Size of Lymph Nodes
Mucosal Melanoma**	See note after this table	8720-8790	Size of Lymph Nodes
Esophagus	C15.0-5,8,9	8000-8576, 8940-8950, 8980-8981	Clinical Assessment of Regional Lymph Nodes
EsophagusGE Junction	C16.0-2	8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8576, 8940-8950, 8980-8981	Clinical Assessment of Regional Lymph Nodes
Stomach	C16.1-6,8-9	8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8576, 8940-8950, 8980-8990	Clinical Assessment of Regional Lymph Nodes
NETStomach	C16.0-6,8-9	8153, 8240-8242, 8246, 8249	Clinical Assessment of Regional Lymph Nodes
SmallIntestine	C17.0-3,8-9	8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8576, 8940-8950, 8980-8981	Carcinoembryonic Antigen (CEA)
Colon	C18.0,2-9	8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8576, 8940-8950, 8980-8981	Carcinoembryonic Antigen (CEA)
Appendix	C18.1	8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8576, 8940-8950, 8980-8981	Carcinoembryonic Antigen (CEA)
Rectum	C19.9; C20.9	8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8576, 8940-8950, 8980-8981	Carcinoembryonic Antigen (CEA)
Liver	C22.0-1	8170-8175	Alpha Fetoprotein (AFP) Interpretation
BileDucts Intrahepat	C22.0-1	8160-8161, 8180	Alpha Fetoprotein (AFP) Interpretation
Lung	C34.0-3,8-9	8000-8576, 8940-8950, 8980-8981	Separate Tumor Nodules / Ipsilateral Lung
HeartMediastinum	C38.0-3,8	8800-8936, 8940-9136, 9141-9582	Grade for Sarcomas

Pleura	C38.4	9050-9053	Pleural Effusion
Skin	C44.0,2-9	8000-8246, 8248-8576, 8940-8950, 8980-8981	Measured Thickness (Depth)
MelanomaSkin	C44.0-9; C51.0-2, 8-9; C60.0-2,8-9; C63.2	8270-8290	Measured Thickness (Depth), Breslow's Measurement
MerkelCellSkin	C44.0,2-9	8247	Measured Thickness (Depth)
MerkelCellVulva	C51.0-2,8-9	8247	Measured Thickness (Depth)
MerkelCellPenis	C60.0-2,8-9	8247	Measured Thickness (Depth)
MerkelCellScrotum	C63.2	8247	Measured Thickness (Depth)
SoftTissue	C47.0-6,8-9; C49.0-6,8-9	8800-8936, 8940-9136, 9141-9582	Grade for Sarcomas
Retroperitoneum	C48.0	8800-8921, 8940-9136, 9141-9582	Grade for Sarcomas
Peritoneum	C48.0-2,8	8800-8921, 8940-9055, 9120-9136, 9141-9582	Grade for Sarcomas
Peritoneum FemaleGenital	C48.0-2,8 (Females Only)	8000-8576, 8590-8671, 8930-8934, 8940-9110	Carbohydrate Antigen 125 (CA 125)
Breast	C50.0-6, 8-9	8000-8576, 8940-8950, 8980-8981, 9020	Estrogen Receptor Assay (ERA)
Vagina	C52.9	8000-8576, 8800-8801, 8940-8950, 8980-8981	FIGO Stage
Cervix	C53.0-1, 8-9	8000-8576, 8940-8950, 8980-8981	FIGO Stage
Corpus Adenosarcoma	C54.0-3, 8-9; C55.9	8933	FIGO Stage
Corpus Carcinoma	C54.0-3, 8-9; C55.9	8000-8790, 8980-8981, 9700-9701	FIGO Stage
CorpusSarcoma	C54.0-3, 8-9; C55.9	8890-8898, 8930-8931	FIGO Stage
Ovary	C56.9	8000-8576, 8590-8671, 8930-9110	Carbohydrate Antigen 125 (CA 125)
Fallopian Tube	C57.0	8000-8576, 8940-8950, 8980-8981	FIGO Stage
Placenta	C58.9	9100-9105	Prognostic Scoring Index
Prostate	C61.9	8000-8110, 8140-8576, 8940-8950, 8980-8981	Prostate Specific Antigen (PSA) Lab Value
Scrotum	C63.2	8000-8246, 8248-8576, 8940-8950, 8980-8981	Measured Thickness (Depth)
Kidney Parenchyma	C64.9	8000-8576, 8940-8950, 8980-8981	Invasion Beyond Capsule
KidneyRenal Pelvis	C65.9; C66.9	8000-8576, 8940-8950, 8980-8981	WHO/ISUP Grade
Bladder	C67.0-9	8000-8576, 8940-8950, 8980-8981	WHO/ISUP Grade
Urethra	C68.0	8000-8576, 8940-8950, 8980-8981	WHO/ISUP Grade
Retinoblastoma	C69.0-5,8-9	9510-9514	Extension Evaluated at Enucleation
Lymphoma OcularAdnexa	C44.1; C69.0,5,6	9590-9699, 9702-9738, 9811-9818, 9820-9837	Associated with HIV/AIDS
Conjunctiva	C69.0	8000-8576, 8940-8950, 8980-8981	Tumor Size
Melanoma Conjunctiva	C69.0	8720-8790	Measured Thickness (Depth)
Brain	C70.0, C71.0-9	8000, 8680-9136,9141-9582	WHO Grade Classification
CNSOther	C70.1, 9; C72.0-5,8-9	8000, 8680-9136,9141-9582	WHO Grade Classification
Thyroid	C73.9	8000-8576, 8940-8950, 8980-8981	Solitary vs. Multifocal Tumor
IntracranialGland	C75.1-3	8000, 8680-9136,9141-9582	WHO Grade Classification
Lymphoma	C00.0-C68.9; C70.0-C80.9	9590-9699, 9702-9729, 9735, 9737-9738	Associated with HIV/AIDS
MycosisFungoides	C44.0-C44.9, C51.0-C51.2, C51.8-C51.9, C60.0-C60.2, C60.8-C60.9, C63.2	9700-9701	Peripheral Blood Involvement
Kaposi Sarcoma	M-9140		Associated with HIV/AIDS
HemeRetic	M-9731-9734, 9740-9742, 9750-9758, 9760-9762, 9764-9769, 9800-9801, 9805, 9820, 9826, 9831-9837, 9840, 9860-9861, 9863, 9866-9867, 9870-9876, 9891, 9895-		JAK-2

	9897, 9910, 9920, 9930-9931, 9940, 9945-9946, 9948, 9950, 9960-9964, 9970, 9975, 9980, 9982-9987, 9989. M-9823 and 9827 for C42.0, C42.1, or C42.4 <i>only</i> . See <i>Collaborative Stage</i> for site detail.	
--	--	--

* Head and Neck: C00.0-6,8,9; C01.9; C02.0-4,8,9; C03.0-1,9; C04.0-1,8,9; C05.0-2,8,9; C06.0-2,8,9; C07.9; C08.0-1,8,9; C09.0-1,8,9; C10.0-4,8,9; C11.0; C30.0-1; C31.0-3,8-9; C32.0-3,8,9

** Mucosal Melanoma: C00.0-6,8-9; C01.9; C02.0-4,8-9; C03.0-1,9; C04.0-1,8-9; C05.0-2,8-9; C06.0-2,8-9; C09.0-1,8-9; C10.0-4,8-9; C11.0-3,8-9; C12.9; C13.2,8-9; C14.0,2,8; C30.0,2,8-9; C31.0-3,8-9; C32.0-3,8-9

CS SITE-SPECIFIC FACTOR 2

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2890

Revised 09/06, 09/08, 01/10, 03/10

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

For tumors abstracted in CSv2 or diagnosed in 2010, the following Site-Specific Factor 2 (SSF2) items are *required* by CoC to be coded. Registries are *encouraged* to code other prognostic SSF2s used by the facility.

CS Schema	Sites	Histologies	Site-Specific Factor 2
Colon	C18.0,2-9	8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8576, 8940-8950, 8980-8981	Clinical Assessment of Regional Lymph Nodes
NETColon	C18.0,2-9	8153, 8240-8242, 8246, 8249	Clinical Assessment of Regional Lymph Nodes
Appendix	C18.1	8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8576, 8940-8950, 8980-8981	Clinical Assessment of Regional Lymph Nodes
CarcinoidAppendix	C18.1	8153, 8240-8242, 8246, 8249	Clinical Assessment of Regional Lymph Nodes
Rectum	C19.9; C20.9	8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8576, 8940-8950, 8980-8981	Clinical Assessment of Regional Lymph Nodes
NETRectum	C19.9; C20.9	8153, 8240-8242, 8246, 8249	Clinical Assessment of Regional Lymph Nodes
Small Intestine	C17.0-3,8-9	8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8576, 8940-8950, 8980-8981	Clinical Assessment of Regional Lymph Nodes
Liver	C22.0-1	8170-8175	Fibrosis Score
BileDuctsIntrahepat	C22.0-1	8160-8161, 8180	Fibrosis Score
Lung	C34.0-3,8-9	8000-8576, 8940-8950, 8980-8981	Visceral Pleural Invasion (VPI) / Elastic Layer
Pleura	C38.4	9050-9053	Histologic Subtype
MelanomaSkin	C44.0-9; C51.0-2, 8-9; C60.0-2,8-9; C63.2	8270-8290	Ulceration
Peritoneum FemaleGenital	C48.0-2,8 (Females Only)	8000-8576, 8590-8671, 8930-8934, 8940-9110	FIGO Stage
Breast	C50.0-6, 8-9	8000-8576, 8940-8950, 8980-8981, 9020	Progesterone Receptor Assay (PRA)
Vulva	C51.0-2,8-9	8000-8246, 8248-8576, 8940-8950, 8980-8981	FIGO Stage
Vagina	C52.9	8000-8576, 8800-8801, 8940-8950, 8980-8981	Pelvic Nodal Status

Corpus Adenosarcoma	C54.0-3, 8-9; C55.9	8933	Peritoneal Cytology
CorpusCarcinoma	C54.0-3, 8-9; C55.9	8000-8790, 8980-8981, 9700-9701	Peritoneal Cytology
CorpusSarcoma	C54.0-3, 8-9; C55.9	8890-8898, 8930-8931	Peritoneal Cytology
Ovary	C56.9	8000-8576, 8590-8671, 8930-9110	FIGO Stage
Placenta	C58.9	9100-9105	FIGO Stage
Prostate	C61.9	8000-8110, 8140-8576, 8940-8950, 8980-8981	Prostatic Specific Antigen (PSA) Interpretation
Kidney Parenchyma	C64.9	8000-8576, 8940-8950, 8980-8981	Vein Involvement
KidneyRenal Pelvis	C65.9; C66.9	8000-8576, 8940-8950, 8980-8981	Depth of Renal Parenchymal Invasion
Bladder	C67.0-9	8000-8576, 8940-8950, 8980-8981	Size of Metastasis in Lymph Nodes
Lymphoma OcularAdnexa	C44.1; C69.0,5,6	9590-9699, 9702-9738, 9811-9818, 9820-9837	Systemic Symptoms ad Diagnosis
MelanomaConjunctiva	C69.0	8720-8790	Quadrants
Melanoma Choroid	C69.3	8720-8790	Measured Basal Diameter
MelanomaCiliary Body	C69.4	8720-8790	Measured Basal Diameter
Lymphoma	C00.0-C68.9; C70.0-C80.9	9590-9699, 9702-9729, 9735, 9737-9738	Systemic Symptoms at Diagnosis

CS SITE-SPECIFIC FACTOR 3

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2900

Revised 04/07, 09/08, 01/10, 02/10, 03/10

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

For tumors abstracted in CSv2 or diagnosed in 2010, the following Site-Specific Factor 3 (SSF3) items are *required* by CoC to be coded. Registries are *encouraged* to code other prognostic SSF3s used by the facility.

CS Schema	Sites	Histologies	Site-Specific Factor 3
Head and Neck*	See note after this table	8000–8576, 8940–8950, 8980–8981	Levels I-III Lymph Nodes for Head and Neck
Mucosal Melanoma**	See note after this table	8720-8790	Levels I-III Lymph Nodes for Head and Neck
Colon	C18.0,2-9	8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8576, 8940-8950, 8980-8981	Carcinoembryonic Antigen (CEA) Lab Value
Appendix	C18.1	8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8576, 8940-8950, 8980-8981	Carcinoembryonic Antigen (CEA) Lab Value
Rectum	C19.9; C20.9	8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8576, 8940-8950, 8980-8981	Carcinoembryonic Antigen (CEA) Lab Value
Small Intestine	C17.0-3,8-9	8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8576, 8940-8950, 8980-8981	Carcinoembryonic Antigen (CEA) Lab Value
Liver	C22.0-1	8170-8175	Alpha Fetoprotein (AFP) Lab Value
HeartMediastinum	C38.0-3,8	8800-8936, 8940-9136, 9141-9582	Bone Invasion
Bone	C40.0-3,8-9; C41.0-4,8-9	8800-9136, 9142-9582	% Necrosis Post-Neoadjuvant Chemotherapy
SkinEyelid	C44.1	8000-8576, 8940-8950, 8980-8981	Clinical Status of Lymph Nodes
MelanomaSkin	C44.0-9; C51.0-2, 8-9; C60.0-2,8-9; C63.2	8270-8290	Clinical Status of Lymph Node Mets
MerkelCellSkin	C44.0,2-9	8247	Clinical Status of Lymph Node Mets
MerkelCellVulva	C51.0-2,8-9	8247	Clinical Status of Lymph Node Mets
MerkelCellPenis	C60.0-2,8-9	8247	Clinical Status of Lymph Node Mets
MerkelCellScrotum	C63.2	8247	Clinical Status of Lymph Node Mets
Soft Tissue	C47.0-6,8-9, C49.0-6,8-9	8800-8820, 8823-8935, 8940-9136, 9142-9582	Bone Invasion

Peritoneum FemaleGenital	C48.0-2,8 (Females Only)	8000-8576, 8590-8671, 8930-8934, 8940-9110	Residual Tumor Status and Size After Primary Cytoreduction Surgery
Breast	C50.0-6, 8-9	8000-8576, 8940-8950, 8980-8981, 9020	Number of Positive Ipsilateral Level I-II Axillary Lymph Nodes
Vagina	C52.9	8000-8576, 8800-8801, 8940-8950, 8980-8981	Assessment Method of Nodal Pelvic Status
Corpus Adenosarcoma	C54.0-3, 8-9; C55.9	8000-8576, 8940-8950, 8980-8981	Number of Positive Pelvic Lymph Nodes
CorpusCarcinoma	C54.0-3, 8-9; C55.9	8000-8790, 8980-8981, 9700-9701	Number of Positive Pelvic Lymph Nodes
CorpusSarcoma	C54.0-3, 8-9; C55.9	8890-8898, 8930-8931	Number of Positive Pelvic Lymph Nodes
Ovary	C56.9	8000-8576, 8590-8671, 8930-9110	Residual Tumor Status and Size After Primary Cytoreduction Surgery
Prostate	C61.9	8000-8110, 8140-8576, 8940-8950, 8980-8981	CS Extension - Pathologic Extension
Kidney Parenchyma	C64.9	8000-8576, 8940-8950, 8980-8981	Ipsilateral Adrenal Gland Involvement
Bladder	C67.0-9	8000-8576, 8940-8950, 8980-8981	Extranodal Extension of Regional Lymph Nodes
Lymphoma OcularAdnexa	C44.1; C69.0,5,6	9590-9699, 9702-9738, 9811-9818, 9820-9837	International Prognostic Index (IPI)
Melanoma Choroid	C69.3	8720-8790	Measured Thickness (Depth)
MelanomaCiliary Body	C69.4	8720-8790	Measured Thickness (Depth)
MelanomaIris	C69.4 (Iris)	8720-8790	Measured Thickness (Depth)
Lymphoma	C00.0-C68.9; C70.0-C80.9	9590-9699, 9702-9729, 9735, 9737-9738	International Prognostic Index (IPI)

* Head and Neck: C00.0-6,8,9; C01.9; C02.0-4,8,9; C03.0-1,9; C04.0-1,8,9; C05.0-2,8,9; C06.0-2,8,9; C07.9; C08.0-1,8,9; C09.0-1,8,9; C10.0-4,8,9; C11.0; C30.0-1; C31.0-3,8-9; C32.0-3,8,9

** Mucosal Melanoma: C00.0-6,8-9; C01.9; C02.0-4,8-9; C03.0-1,9; C04.0-1,8-9; C05.0-2,8-9; C06.0-2,8-9; C09.0-1,8-9; C10.0-4,8-9; C11.0-3,8-9; C12.9; C13.2,8-9; C14.0,2,8; C30.0,2,8-9; C31.0-3,8-9; C32.0-3,8-9

CS SITE-SPECIFIC FACTOR 4

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2910

Revised 09/06, 09/08, 01/10, 02/10, 03/10

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.
- The Prostate SSF4 (Prostate Apex Involvement) does not show on this table, because it is considered obsolete in 2010. However, it is required for cases diagnosed through 2009, as it was required in CSv1, even if it is abstracted in CSv2.

For tumors abstracted in CSv2 or diagnosed in 2010, the following Site-Specific Factor 4 (SSF4) items are *required* by CoC to be coded. Registries are *encouraged* to code other prognostic SSF4s used by the facility.

CS Schema	Sites	Histologies	Site-Specific Factor 4
Head and Neck*	See note after this table	8000–8576, 8940–8950, 8980–8981	Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck
Mucosal Melanoma**	See note after this table	8720-8790	Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck
Colon	C18.0,2-9	8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8576, 8940-8950, 8980-8981	Tumor Deposits
Rectum	C19.9; C20.9	8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8576, 8940-8950, 8980-8981	Tumor Deposits
Liver	C22.0-1	8170-8175	Creatinine Value
MelanomaSkin	C44.0-9; C51.0-2, 8-9; C60.0-2,8-9; C63.2	8270-8290	LDH
Breast	C50.0-6, 8-9	8000-8576, 8940-8950, 8980-8981, 9020	Immunohistochemistry (IHC) of Regional Lymph Nodes
Vagina	C52.9	8000-8576, 8800-8801, 8940-8950, 8980-8981	Para-Aortic Nodal Status
Corpus Adenosarcoma	C54.0-3, 8-9; C55.9	8000-8576, 8940-8950, 8980-8981	Number of Examined Pelvic Nodes
CorpusCarcinoma	C54.0-3, 8-9; C55.9	8000-8790, 8980-8981, 9700-9701	Number of Examined Pelvic Nodes
CorpusSarcoma	C54.0-3, 8-9; C55.9	8890-8898, 8930-8931	Number of Examined Pelvic Nodes
FallopianTube	C57.0	8000-8576, 8940-8950, 8980-8981	Number of Positive Pelvic Nodes
Testis	C62.0-1,9	8000-8576, 8590-8593, 8940-8950, 8980-8981, 9060-9090, 9100-9105	Radical Orchiectomy Performed
Kidney Parenchyma	C64.9	8000-8576, 8940-8950, 8980-8981	Sarcomatoid Features

Melanoma Choroid	C69.3	8720-8790	Size of Largest Metastasis
MelanomaIris	C69.4	8720-8790	Size of Largest Metastasis
MelanomaCiliary Body	C69.4	8720-8790	Size of Largest Metastasis
LacrimalGland	C69.5	8000-8576, 8940-8950, 8980-8981	Perineural Invasion
Brain	C70.0, C71.0-9	8000, 8680-9136,9141-9582	MGMT – Methylation of MGMT
CNSOther	C70.1, 9; C72.0-5,8-9	8000, 8680-9136,9141-9582	MGMT – Methylation of MGMT

* Head and Neck: C00.0-6,8,9; C01.9; C02.0-4,8,9; C03.0-1,9; C04.0-1,8,9; C05.0-2,8,9; C06.0-2,8,9; C07.9; C08.0-1,8,9; C09.0-1,8,9; C10.0-4,8,9; C11.0; C30.0-1; C31.0-3,8-9; C32.0-3,8,9

** Mucosal Melanoma: C00.0-6,8-9; C01.9; C02.0-4,8-9; C03.0-1,9; C04.0-1,8-9; C05.0-2,8-9; C06.0-2,8-9; C09.0-1,8-9; C10.0-4,8-9; C11.0-3,8-9; C12.9; C13.2,8-9; C14.0,2,8; C30.0,2,8-9; C31.0-3,8-9; C32.0-3,8-9

CS SITE-SPECIFIC FACTOR 5

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2920

Revised 09/06, 09/08, 01/10, 02/10,
03/10**Description**

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

For tumors abstracted in CSv2 or diagnosed in 2010, the following Site-Specific Factor 5 (SSF5) items are *required* by CoC to be coded. Registries are *encouraged* to code other prognostic SSF5s used by the facility.

CS Schema	Sites	Histologies	Site-Specific Factor 5
Head and Neck*	See note after this table	8000–8576, 8940–8950, 8980–8981	Levels VI-VII and Facial Lymph Nodes of Head and Neck
Mucosal Melanoma**	See note after this table	8720-8790	Levels VI-VII and Facial Lymph Nodes of Head and Neck
Liver	C22.0-1	8170-8175	Creatinine Unit of Measure
NETAmpulla	C24.1	8153, 8240-8242, 8246, 8249	Serum Chromogranin A (CgA) Lab Value
MelanomaSkin	C44.0-9; C51.0-2, 8-9; C60.0-2,8-9; C63.2	8270-8290	LDH Value
GIST Peritoneum	C48.0-2,8	8935-8936	Mitotic Count
Breast	C50.0-6, 8-9	8000-8576, 8940-8950, 8980-8981, 9020	Molecular Studies of Regional Lymph Nodes
Vagina	C52.9	8000-8576, 8800-8801, 8940-8950, 8980-8981	Assessment of Para-Aortic Nodal Status
Corpus Adenosarcoma	C54.0-3, 8-9; C55.9	8000-8576, 8940-8950, 8980-8981	Number of Positive Para-Aortic Lymph Nodes
CorpusCarcinoma	C54.0-3, 8-9; C55.9	8000-8790, 8980-8981, 9700-9701	Number of Positive Para-Aortic Lymph Nodes
CorpusSarcoma	C54.0-3, 8-9; C55.9	8890-8898, 8930-8931	Number of Positive Para-Aortic Lymph Nodes
Fallopian Tube	C57.0	8000-8576, 8940-8950, 8980-8981	Number of Examined Pelvic Lymph Nodes
Testis	C62.0-1,9	8000-8576, 8590-8593, 8940-8950, 8980-8981, 9060-9090, 9100-9105	Size of Metastasis in Lymph Nodes
MelanomaChoroid	C69.3	8720-8790	Chromosome 3 Status
MelanomaIris	C69.4	8720-8790	Chromosome 3 Status
MelanomaCiliary Body	C69.4	8720-8790	Chromosome 3 Status
Brain	C70.0, C71.0-9	8000, 8680-9136,9141-9582	Gene Deletions 1p
CNSOther	C70.1, 9; C72.0-5,8-9	8000, 8680-9136,9141-9582	Gene Deletions 1p

* Head and Neck: C00.0-6,8,9; C01 9; C02.0-4,8,9; C03.0-1,9; C04.0-1,8,9; C05.0-2,8,9; C06.0-2,8,9; C07.9; C08.0-1,8,9; C09.0-1,8,9; C10.0-4,8,9; C11.0; C30.0-1; C31.0-3,8-9; C32.0-3,8,9

** Mucosal Melanoma: C00.0-6,8-9; C01.9; C02.0-4,8-9; C03.0-1,9; C04.0-1,8-9; C05.0-2,8-9; C06.0-2,8-9; C09.0-1,8-9; C10.0-4,8-9; C11.0-3,8-9; C12.9; C13.2,8-9; C14.0,2,8; C30.0,2,8-9; C31.0-3,8-9; C32.0-3,8-9

CS SITE-SPECIFIC FACTOR 6

Item Length: 3
 Allowable Values: 000–999
 NAACCR Item #2930
 Revised 09/06, 09/08, 01/10, 02/10,
 03/10

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

For tumors abstracted in CSv2 or diagnosed in 2010, the following Site-Specific Factor 6 (SSF6) items are *required* by CoC to be coded. Registries are *encouraged* to code other prognostic SSF6s used by the facility.

CS Schema	Sites	Histologies	Site-Specific Factor 6
Head and Neck*	See note after this table	8000–8576, 8940–8950, 8980–8981	Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes
Mucosal Melanoma**	See note after this table	8720-8790	Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes
GISTEsophagus	C15.0-5,8-9	8935-8936	Mitotic Count
GISTStomach	C16.0-6,8-9	8935-8936	Mitotic Count
GISTSmall Intestine	C17.0-3,8-9	8935-8936	Mitotic Count
Colon	C18.0,2-9	8000-8152, 8154-8231, 8243- 8245, 8247-8248, 8250-8576, 8940-8950, 8980-8981	Circumferential Resection Margin (CRM)
Rectum	C19.9; C20.9	8000-8152, 8154-8231, 8243- 8245, 8247-8248, 8250-8576, 8940-8950, 8980-8981	Circumferential Resection Margin (CRM)
Liver	C22.0-1	8170-8175	Total Bilirubin Value
NETAmpulla	C24.1	8153, 8240-8242, 8246, 8249	Urinary 5-HIAA Lab Value
SkinEyelid	C44.1	8000-8576, 8940-8950, 8980- 8981	Perineural Invasion
MelanomaSkin	C44.0-9; C51.0-2, 8-9; C60.0-2,8-9; C63.2	8270-8290	LDH Upper Limits of Normal
GISTPeritoneum	C48.0-2,8	8935-8936	KIT Immunohistochemistry (IHC)
Breast	C50.0-6, 8-9	8000-8576, 8940-8950, 8980- 8981, 9020	Size of Tumor – Invasive Component
Vagina	C52.9	8000-8576, 8800-8801, 8940- 8950, 8980-8981	Distant (mediastinal, scalene) Node Status
Corpus Adenosarcoma	C54.0-3, 8-9; C55.9	8000-8576, 8940-8950, 8980- 8981	Number of Examined Para-Aortic Lymph Nodes
CorpusCarcinoma	C54.0-3, 8-9; C55.9	8000-8790, 8980-8981, 9700- 9701	Number of Examined Para-Aortic Lymph Nodes
CorpusSarcoma	C54.0-3, 8-9; C55.9	8890-8898, 8930-8931	Number of Examined Para-Aortic Lymph Nodes

Fallopian Tube	C57.0	8000-8576, 8940-8950, 8980-8981	Number of Positive Para-Aortic Lymph Nodes
Testis	C62.0-1,9	8000-8576, 8590-8593, 8940-8950, 8980-8981, 9060-9090, 9100-9105	Preorchiectomy Alpha Fetoprotein (AFP) Lab Value
Kidney Parenchyma	C64.9	8000-8576, 8940-8950, 8980-8981	Fuhrman Grade
Lymphoma OcularAdnexa	C44.1; C69.0,5,6	9590-9699, 9702-9738, 9811-9818, 9820-9837	LDH Interpretation
MelanomaChoroid	C69.3	8720-8790	Chromosome 6p Status
MelanomaIris	C69.4	8720-8790	Chromosome 6p Status
MelanomaCiliary Body	C69.4	8720-8790	Chromosome 6p Status
LacrimalGland	C69.5	8000-8576, 8940-8950, 8980-8981	Adenoid Cystic Carcinoma – Presence of Basaloid Pattern
Brain	C70.0, C71.0-9	8000, 8680-9136,9141-9582	Gene Deletions 19q
CNSOther	C70.1, 9; C72.0-5,8-9	8000, 8680-9136,9141-9582	Gene Deletions 19q

* Head and Neck: C00.0-6,8,9; C01.9; C02.0-4,8,9; C03.0-1,9; C04.0-1,8,9; C05.0-2,8,9; C06.0-2,8,9; C07.9; C08.0-1,8,9; C09.0-1,8,9; C10.0-4,8,9; C11.0; C30.0-1; C31.0-3,8-9; C32.0-3,8,9

** Mucosal Melanoma: C00.0-6,8-9; C01.9; C02.0-4,8-9; C03.0-1,9; C04.0-1,8-9; C05.0-2,8-9; C06.0-2,8-9; C09.0-1,8-9; C10.0-4,8-9; C11.0-3,8-9; C12.9; C13.2,8-9; C14.0,2,8; C30.0,2,8-9; C31.0-3,8-9; C32.0-3,8-9

CS SITE-SPECIFIC FACTOR 7

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2861

New Item 01/2010; revised 02/10, 03/10

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

For tumors abstracted in CSv2 or diagnosed in 2010, the following Site-Specific Factor 7 (SSF7) items are *required* by CoC to be coded. Registries are *encouraged* to code other prognostic SSF7s used by the facility.

CS Schema	Sites	Histologies	Site-Specific Factor 7
GIST Eosophagus	C15.0-5,8-9	8935-8936	KIT Immunohistochemistry (IHC)
GIST Stomach	C16.0-6,8-9	8935-8936	KIT Immunohistochemistry (IHC)
GIST Small Intestine	C17.0-3,8-9	8935-8936	KIT Immunohistochemistry (IHC)
Liver	C22.0-1	8170-8175	Total Bilirubin Unit of Measure
MelanomaSkin	C44.0-9; C51.0-2, 8-9; C60.0-2,8-9; C63.2	8270-8290	Primary Tumor Mitotic Count/Rate
Breast	C50.0-6, 8-9	8000-8576, 8940-8950, 8980-8981, 9020	Nottingham or Bloom-Richardson Score / Grade
Vagina	C52.9	8000-8576, 8800-8801, 8940-8950, 8980-8981	Assessment Method of Distant (mediastinal, scalene) Node Status
Fallopian Tube	C57.0	8000-8576, 8940-8950, 8980-8981	Number of Examined Para-Aortic Lymph Nodes
Prostate	C61.9	8000-8110, 8140-8576, 8940-8950, 8980-8981	Gleason Primary and Secondary Pattern Value on Needle Core Biopsy / TURP
Testis	C62.0-1,9	8000-8576, 8590-8593, 8940-8950, 8980-8981, 9060-9090, 9100-9105	Preorchietomy Alpha Fetoprotein (AFP) Interpretation
MelanomaChoroid	C69.3	8720-8790	Chromosome 8q Status
Melanomalris	C69.4	8720-8790	Chromosome 8q Status
MelanomaCiliary Body	C69.4	8720-8790	Chromosome 8q Status

CS SITE-SPECIFIC FACTOR 8

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2862

New Item 01/2010; revised 02/10, 03/10

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

For tumors abstracted in CSv2 or diagnosed in 2010, the following Site-Specific Factor 8 (SSF8) items are *required* by CoC to be coded. Registries are *encouraged* to code other prognostic SSF8s used by the facility.

CS Schema	Sites	Histologies	Site-Specific Factor 8
Colon	C18.0,2-9	8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8576, 8940-8950, 8980-8981	Perineural Invasion
Rectum	C19.9; C20.9	8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8576, 8940-8950, 8980-8981	Perineural Invasion
Liver	C22.0-1	8170-8175	International Normalized Ratio for Prothrombin Time (INR)
SkinEyelid	C44.1	8000-8576, 8940-8950, 8980-8981	Pagetoid Spread
Breast	C50.0-6, 8-9	8000-8576, 8940-8950, 8980-8981, 9020	HER2: IHC Test Lab Value
Prostate	C61.9	8000-8110, 8140-8576, 8940-8950, 8980-8981	Gleason Score on Needle Core Biopsy / TURP
Testis	C62.0-1,9	8000-8576, 8590-8593, 8940-8950, 8980-8981, 9060-9090, 9100-9105	Preorchietomy Human Chorionic Gonadotropin (hCG) Lab Value
Kidney Parenchyma	C64.9	8000-8576, 8940-8950, 8980-8981	Extranodal Extension of Regional Lymph Nodes
LacrimalGland	C69.5	8000-8576, 8940-8950, 8980-8981	Orbital Bone

CS SITE-SPECIFIC FACTOR 9

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2863

New Item 01/2010; revised 02/10, 03/10

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

For tumors abstracted in CSv2 or diagnosed in 2010, the following Site-Specific Factor 9 (SSF9) items are *required* by CoC to be coded. Registries are *encouraged* to code other prognostic SSF9s used by the facility.

CS Schema	Sites	Histologies	Site-Specific Factor 9
Head and Neck*	See note after this table	8000–8576, 8940–8950, 8980–8981	Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck
Mucosal Melanoma**	See note after this table	8720-8790	Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck
Colon	C18.0,2-9	8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8576, 8940-8950, 8980-8981	KRAS
Rectum	C19.9; C20.9	8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8576, 8940-8950, 8980-8981	KRAS
Breast	C50.0-6, 8-9	8000-8576, 8940-8950, 8980-8981, 9020	HER2: IHC Test Interpretation
Prostate	C61.9	8000-8110, 8140-8576, 8940-8950, 8980-8981	Gleason Primary Pattern and Secondary Pattern Value on Prostatectomy / Autopsy
Testis	C62.0-1,9	8000-8576, 8590-8593, 8940-8950, 8980-8981, 9060-9090, 9100-9105	Preorchietomy Human Chorionic Gonadotropin (hCG) Interpretation
MelanomaChoroid	C69.3	8720-8790	Mitotic Count
MelanomaIris	C69.4	8720-8790	Mitotic Count
MelanomaCiliary Body	C69.4	8720-8790	Mitotic Count

* Head and Neck: C00.0-6,8,9; C01.9; C02.0-4,8,9; C03.0-1,9; C04.0-1,8,9; C05.0-2,8,9; C06.0-2,8,9; C07.9; C08.0-1,8,9; C09.0-1,8,9; C10.0-4,8,9; C11.0; C30.0-1; C31.0-3,8-9; C32.0-3,8,9

** Mucosal Melanoma: C00.0-6,8-9; C01.9; C02.0-4,8-9; C03.0-1,9; C04.0-1,8-9; C05.0-2,8-9; C06.0-2,8-9; C09.0-1,8-9; C10.0-4,8-9; C11.0-3,8-9; C12.9; C13.2,8-9; C14.0,2,8; C30.0,2,8-9; C31.0-3,8-9; C32.0-3,8-9

CS SITE-SPECIFIC FACTOR 10

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2864

New Item 01/2010; revised 02/10, 03/10

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

For tumors abstracted in CSv2 or diagnosed in 2010, the following Site-Specific Factor 10 (SSF10) items are *required* by CoC to be coded. Registries are *encouraged* to code other prognostic SSF10s used by the facility.

CS Schema	Sites	Histologies	Site-Specific Factor 10
TongueBase	C01.9, C02.4	8000–8576, 8940–8950, 8980–8981	HPV (Human Papilloma Virus) Status
PalateSoft	C05.1-2	8000–8576, 8940–8950, 8980–8981	HPV (Human Papilloma Virus) Status
Ororopharynx	C09.0-1,8-9; C10.0,2-4,8-9	8000–8576, 8940–8950, 8980–8981	HPV (Human Papilloma Virus) Status
Nasopharynx	11.0-3,8-9	8000–8576, 8940–8950, 8980–8981	HPV (Human Papilloma Virus) Status
Pharyngeal Tonsil	C11.1	8000–8576, 8940–8950, 8980–8981	HPV (Human Papilloma Virus) Status
Hypopharynx	C12.9; C13.0-2,8-9	8000–8576, 8940–8950, 8980–8981	HPV (Human Papilloma Virus) Status
PharynxOther	C14.0-2,8	8000–8576, 8940–8950, 8980–8981	HPV (Human Papilloma Virus) Status
SkinEyelid	C44.1	8000-8576, 8940-8950, 8980-8981	Prior Radiation
GISTPeritoneum	C48.0-2,8	8935-8936	Location of Primary Tumor
Breast	C50.0-6, 8-9	8000-8576, 8940-8950, 8980-8981, 9020	HER2: FISH Test Lab Value
Vulva	C51.0-2,8-9	8000-8246, 8248-8576, 8940-8950, 8980-8981	FIGO Stage
Penis	C60.0-2,8-9	8000-8246, 8248-8576, 8940-8950, 8980-8981, 9020	Involvement of Corpus Spongiosum/Corpus Cavernosum
Prostate	C61.9	8000-8110, 8140-8576, 8940-8950, 8980-8981	Gleason's Score on Prostatectomy / Autopsy
MelanomaChoroid	C69.3	8720-8790	Mean Diameter Nucleoli (MLN)
MelanomaIris	C69.4	8720-8790	Mean Diameter Nucleoli (MLN)
MelanomaCiliary Body	C69.4	8720-8790	Mean Diameter Nucleoli (MLN)

CS SITE-SPECIFIC FACTOR 11

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2865

New Item 01/2010; revised 02/10, 03/10

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

For tumors abstracted in CSv2 or diagnosed in 2010, the following Site-Specific Factor 11 (SSF11) items are *required* by CoC to be coded. Registries are *encouraged* to code other prognostic SSF11s used by the facility.

CS Schema	Sites	Histologies	Site-Specific Factor 11
Head and Neck*	See note after this table	8000–8576, 8940–8950, 8980–8981	Measured Thickness (Depth)
Mucosal Melanoma **	See note after this table	8720-8790	Measured Thickness (Depth)
NETStomach	C16.0-6,8-9	8153, 8240-8242, 8246, 8249	Serum Chromogranin A (CgA) Lab Value
GISTColon	C18.0,2-9	8935-8936	Mitotic Count
Appendix	C18.1	8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8576, 8940-8950, 8980-8981	Histopathologic Grading
GISTAppendix	C18.1	8935-8936	Mitotic Count
NETSmall Intestine	C17.0-3,8-9	8153, 8240-8242, 8246, 8249	Serum Chromogranin A (CgA) Lab Value
GISTRectum	C19.9; C20.9	8935-8936	Mitotic Count
BileDucts Intrahepat	C22.0-1	8160-8161, 8180	Primary Sclerosing Cholangitis
BileDuctsPerihilar	C24.0	8000-8152, 8154-8231, 8243-8245, 8250-8576, 8940-8950, 8980-8981	Primary Sclerosing Cholangitis
Skin	C44.0,2-0	8000-8246, 8248-8576, 8940-8950, 8980-8981	Perineural Invasion
Breast	C50.0-6, 8-9	8000-8576, 8940-8950, 8980-8981, 9020	HER2: FISH Test Interpretation
Vulva	C51.0-2,8-9	8000-8246, 8248-8576, 8940-8950, 8980-8981	Regional Lymph Node - Laterality
MerkelCellVulva	C51.0-2,8-9	8247	Regional Lymph Node - Laterality
Prostate	C61.9	8000-8110, 8140-8576, 8940-8950, 8980-8981	Gleason Tertiary Pattern Value on Prostatectomy / Autopsy
Testis	C62.0-1,9	8000-8576, 8590-8670, 8940-8950, 8980-8981, 9060-9090, 9100-9105	Persistence of Elevated Serum Tumor Markers
MelanomaChoroid	C69.3	8720-8790	Extravascular Matrix Patterns, Loops
MelanomaIris	C69.4	8720-8790	Extravascular Matrix Patterns, Loops
MelanomaCiliary Body	C69.4	8720-8790	Extravascular Matrix Patterns, Loops

* Head and Neck: C00.0-6,8,9; C02.0-3,8-9; C03.0-1,9; C05.8-9; C06.8-9; C30.0; C31.0-3,8-9

** Mucosal Melanoma: C00.0-6,8-9; C01.9; C02.0-4,8-9; C03.0-1,9; C04.0-1,8-9; C05.0-2,8-9; C06.0-2,8-9; C09.0-1,8-9; C10.0-4,8-9; C11.0-3,8-9; C12.9; C13.2,8-9; C14.0,2,8; C30.0,2,8-9; C31.0-3,8-9; C32.0-3,8-9

CS SITE-SPECIFIC FACTOR 12

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2866

New Item 01/2010; revised 02/10, 03/10

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

For tumors abstracted in CSv2 or diagnosed in 2010, the following Site-Specific Factor 12 (SSF12) items are *required* by CoC to be coded. Registries are *encouraged* to code other prognostic SSF1s used by the facility.

CS Schema	Sites	Histologies	Site-Specific Factor 12
NETStomach	C16.0-6,8-9	8153, 8240-8242, 8246, 8249	Urinary 5-HIAA Lab Value Level
NETSmallIntestine	C17.0-3,8-9	8153, 8240-8242, 8246, 8249	Urinary 5-HIAA Lab Value Level
GISTColon	C18.0,2-9	8935-8936	KIT Immunohistochemistry (IHC)
GISTAppendix	C18.1	8935-8936	KIT Immunohistochemistry (IHC)
GISTRectum	C19.9; C20.9	8935-8936	KIT Immunohistochemistry (IHC)
Skin	C44.0,2-9	8000-8246, 8248-8576, 8940-8950, 8980-8981	High Risk Features
Breast	C50.0-6, 8-9	8000-8576, 8940-8950, 8980-8981, 9020	HER2: CISH Test Lab Value
Prostate	C61.9	8000-8110, 8140-8576, 8940-8950, 8980-8981	Number of Cores Positive
Scrotum	C63.2	8000-8246, 8248-8576, 8940-8950, 8980-8981	High Risk Features
MelanomaChoroid	C69.3	8720-8790	Extravascular Matrix Patterns, Networks
MelanomaIris	C69.4	8720-8790	Extravascular Matrix Patterns, Networks
MelanomaCiliary Body	C69.4	8720-8790	Extravascular Matrix Patterns, Networks

CS SITE-SPECIFIC FACTOR 13

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2867

New Item 01/2010; revised 02/10, 03/10

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

For tumors abstracted in CSv2 or diagnosed in 2010, the following Site-Specific Factor 13 (SSF13) items are *required* by CoC to be coded. Registries are *encouraged* to code other prognostic SSF13s used by the facility.

CS Schema	Sites	Histologies	Site-Specific Factor 13
Breast	C50.0-6, 8-9	8000-8576, 8940-8950, 8980-8981, 9020	HER2: CISH Test Interpretation
Prostate	C61.9	8000-8110, 8140-8576, 8940-8950, 8980-8981	Number of Cores Examined
MelanomaChoroid	C69.3	8720-8790	Microvascular density (MVD)
MelanomaIris	C69.4	8720-8790	Microvascular density (MVD)
MelanomaCiliary Body	C69.4	8720-8790	Microvascular density (MVD)

CS SITE-SPECIFIC FACTOR 14

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2868

New Item 01/2010; revised 02/10, 03/10

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

For tumors abstracted in CSv2 or diagnosed in 2010, the following Site-Specific Factor 14 (SSF14) items are *required* by CoC to be coded. Registries are *encouraged* to code other prognostic SSF14s used by the facility.

CS Schema	Sites	Histologies	Site-Specific Factor 14
Breast	C50.0-6, 8-9	8000-8576, 8940-8950, 8980-8981, 9020	HER2: Result of Other or Unknown Test

CS SITE-SPECIFIC FACTOR 15

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2869

New Item 01/2010; revised 03/10

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

For tumors abstracted in CSv2 or diagnosed in 2010, no Site-Specific Factor 15 (SSF15) items are *required* by CoC to be coded. Registries are *encouraged* to code prognostic SSF15s used by the facility.

CS SITE-SPECIFIC FACTOR 16

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2870

New Item 01/2010; revised 03/10

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

For tumors abstracted in CSv2 or diagnosed in 2010, the following Site-Specific Factor 16 (SSF16) items are *required* by CoC to be coded. Registries are *encouraged* to code other prognostic SSF16s used by the facility.

CS Schema	Sites	Histologies	Site-Specific Factor 16
NETColon	C18.0,2-9	8153, 8240-8242, 8246, 8249	Serum Chromogranin A (CgA) Lab Value
NETRectum	C19.9; C20.9	8153, 8240-8242, 8246, 8249	Serum Chromogranin A (CgA) Lab Value
Skin	C44.0,2-9	8000-8246, 8248-8576, 8940-8950, 8980-8981	Size of Lymph Nodes
MerkelCellSkin	C44.0,2-9	8247	Size of Metastases in Lymph Nodes
MerkelCellVulva	C51.0-2,8-9	8247	Size of Metastases in Lymph Nodes
MerkelCellPenis	C60.0-2,8-9	8247	Size of Metastases in Lymph Nodes
MerkelCellScrotum	C63.2	8247	Size of Metastases in Lymph Nodes
Scrotum	C63.2	8000-8246, 8248-8576, 8940-8950, 8980-8981	Size of Lymph Nodes

CS SITE-SPECIFIC FACTOR 17

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2871

New Item 01/2010; revised 03/10

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

For tumors abstracted in CSv2 or diagnosed in 2010, the following Site-Specific Factor 17 (SSF17) items are *required* by CoC to be coded. Registries are *encouraged* to code other prognostic SSF17s used by the facility.

CS Schema	Sites	Histologies	Site-Specific Factor 17
NETColon	C18.0,2-9	8153, 8240-8242, 8246, 8249	Urinary 5-HIAA Lab Value Level
NETRectum	C19.9; C20.9	8153, 8240-8242, 8246, 8249	Urinary 5-HIAA Lab Value Level
MerkelCellSkin	C44.0,2-9	8247	Extracapsular Extension of Regional Lymph Nodes
MerkelCellVulva	C51.0-2,8-9	8247	Extracapsular Extension of Regional Lymph Nodes
MerkelCellPenis	C60.0-2,8-9	8247	Extracapsular Extension of Regional Lymph Nodes
MerkelCellScrotum	C63.2	8247	Extracapsular Extension of Regional Lymph Nodes
Penis	C60.0-2,8-9	8000-8246, 8248-8576, 8940-8950, 8980-8981, 9020	Extranodal Extension of Regional Lymph Nodes

CS SITE-SPECIFIC FACTOR 18

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2872

New Item 01/2010; revised 03/10

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

For tumors abstracted in CSv2 or diagnosed in 2010, the following Site-Specific Factor 18 (SSF18) items are *required* by CoC to be coded. Registries are *encouraged* to code other prognostic SSF18s used by the facility.

CS Schema	Sites	Histologies	Site-Specific Factor 18
MerkelCellSkin	C44.0,2-9	8247	Isolated Tumor Cells (ITCs) in Regional Lymph Node(s)
MerkelCellVulva	C51.0-2,8-9	8247	Isolated Tumor Cells (ITCs) in Regional Lymph Node(s)
MerkelCellPenis	C60.0-2,8-9	8247	Isolated Tumor Cells (ITCs) in Regional Lymph Node(s)
MerkelCellScrotum	C63.2	8247	Isolated Tumor Cells (ITCs) in Regional Lymph Node(s)

CS SITE-SPECIFIC FACTOR 19

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2873

New Item 01/2010; revised 03/10

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

For tumors abstracted in CSv2 or diagnosed in 2010, no Site-Specific Factor 19 (SSF19) items are *required* by CoC to be coded. Registries are *encouraged* to code prognostic SSF19s used by the facility.

CS SITE-SPECIFIC FACTOR 20

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2874

New Item 01/2010; revised 03/10

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

For tumors abstracted in CSv2 or diagnosed in 2010, no Site-Specific Factor 20 (SSF20) items are *required* by CoC to be coded. Registries are *encouraged* to code prognostic SSF20s used by the facility.

CS SITE-SPECIFIC FACTOR 21

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2875

New Item 01/2010; revised 03/10

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

For tumors abstracted in CSv2 or diagnosed in 2010, the following Site-Specific Factor 21 (SSF21) items are *required* by CoC to be coded. Registries are *encouraged* to code other prognostic SSF21s used by the facility.

CS Schema	Sites	Histologies	Site-Specific Factor 21
Breast	C50.0-6, 8-9	8000-8576, 8940-8950, 8980-8981, 9020	Response to Neoadjuvant Therapy

CS SITE-SPECIFIC FACTOR 22

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2876

New Item 01/2010; revised 03/10

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

For tumors abstracted in CSv2 or diagnosed in 2010, the following Site-Specific Factor 22 (SSF22) items are *required* by CoC to be coded. Registries are *encouraged* to code other prognostic SSF22s used by the facility.

CS Schema	Sites	Histologies	Site-Specific Factor 22
MerkelCellSkin	C44.0,2-9	8247	Profound Immune Suppression
MerkelCellVulva	C51.0-2,8-9	8247	Profound Immune Suppression
MerkelCellPenis	C60.0-2,8-9	8247	Profound Immune Suppression
MerkelCellScrotum	C63.2	8247	Profound Immune Suppression
Breast	C50.0-6, 8-9	8000-8576, 8940-8950, 8980-8981, 9020	Multigene Signature Method

CS SITE-SPECIFIC FACTOR 23

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2877

New Item 01/2010; revised 03/10

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

For tumors abstracted in CSv2 or diagnosed in 2010, the following Site-Specific Factor 23 (SSF23) items are *required* by CoC to be coded. Registries are *encouraged* to code other prognostic SSF23s used by the facility.

CS Schema	Sites	Histologies	Site-Specific Factor 23
Breast	C50.0-6, 8-9	8000-8576, 8940-8950, 8980-8981, 9020	Result/Score of the Multigene Signature

CS SITE-SPECIFIC FACTOR 24

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2878

New Item 01/2010; revised 03/10

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

For tumors abstracted in CSv2 or diagnosed in 2010, no Site-Specific Factor 24 (SSF24) items are *required* by CoC to be coded. Registries are *encouraged* to code prognostic SSF24s used by the facility.

CS SITE-SPECIFIC FACTOR 25

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2879

New Item 01/2010, revised 02/2010

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

CS Site-Specific Factor 25 is used to discriminate between CS staging schema or between AJCC chapters where site and histology alone are insufficient to identify the tumor type or location to identify the applicable staging method. Use of this item is limited to specific subsites and histologies as shown below.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.

The following Site-Specific Factor 25 (SSF25) items are *required* by CoC to be coded.

CS Schema	Sites	Histologies	Site-Specific Factor 25
Nasopharynx	C11.1	8000-8576, 8940-8950, 8980-8981	Schema Discriminator
PharyngealTonsil	C11.1	8000-8576, 8940-8950, 8980-8981	Schema Discriminator
EsophagusGE Junction	C16.1-2	8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8576, 8940-8950, 8980-8981	Involvement of Cardia and Distance from Esophagogastric Junction (EGJ)
Stomach	C16.1-2	8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8576, 8940-8950, 8980-8990	Involvement of Cardia and Distance from Esophagogastric Junction (EGJ)
Cystic Duct	C24.0	8000-8152, 8154-8231, 8243-8245, 8250-8576, 8940-8950, 8980-8981	Schema Discriminator: Subsite of Extrahepatic Bile Ducts
BileDuctsPerihilar	C24.0	8000-8152, 8154-8231, 8243-8245, 8250-8576, 8940-8950, 8980-8981	Schema Discriminator: Subsite of Extrahepatic Bile Ducts
BileDuctsDistal	C24.0	8000-8152, 8154-8231, 8243-8245, 8250-8576, 8940-8950, 8980-8981	Schema Discriminator: Subsite of Extrahepatic Bile Ducts
Peritoneum	C48.1-2,8	8000-8576, 8590-8671, 8930-8934, 8940-9110	Schema Discriminator
PeritoneumFemaleGen	C48.1-2,8	8000-8576, 8590-8671, 8930-8934, 8940-9110	Schema Discriminator
MelanomaCiliaryBody	C69.4	8720-8790	Schema Discriminator: Melanoma Ciliary Body / Melanoma Iris
MelanomaIris	C69.4	8720-8790	Schema Discriminator: Melanoma Ciliary Body / Melanoma Iris
Lacrimal Gland	C69.5	8000-8576, 8940-8950, 8980-8981	Schema Discriminator: Lacrimal Gland/Lacrimal Sac
Lacrimal Sac	C69.5	8000-8576, 8940-8950, 8980-8981	Schema Discriminator: Lacrimal Gland/Lacrimal Sac

DERIVED AJCC-6 T

Item Length: 2
NAACCR Item #2940
Revised 09/08, 01/10

Description

This item is the derived AJCC “T” staging element from coded fields using the CS algorithm.

Rationale

Derived AJCC-6 T can be used to evaluate disease spread at diagnosis, plan and track treatment patterns, and analyze outcomes.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- The two-digit storage codes are designed for analytic purposes.
- Refer to the current *CS Manual* for the display equivalent of the storage codes.
- Refer to the *AJCC Cancer Staging Manual, 6th Edition* for the site-specific “T” descriptions.

DERIVED AJCC-6 T DESCRIPT

Item Length: 1
 NAACCR Item #2950
 Revised 09/04, 01/10

Description

This item is the derived AJCC “T Descriptor” from coded fields using the CS algorithm.

Rationale

Derived AJCC-6 T Descriptor can be used in analysis to differentiate the timing of staging with respect to the treatment process.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- Refer to the *AJCC Cancer Staging Manual, 6th Edition* for prefix definitions for codes c, p, a, and y.
- Refer to the current *CS Manual* for the calculation procedures for all codes.

Code	Description
c	Clinical stage.
p	Pathologic stage.
a	Autopsy stage.
y	Surgical resection performed after pre-surgical systemic treatment or radiation; tumor size/extension based on pathologic evidence.
N	Not applicable.
0	Not derived.

DERIVED AJCC-6 N

Item Length: 2
NAACCR Item #2960
Revised 01/10

Description

This item is the derived AJCC “N” staging element from coded fields using the CS algorithm.

Rationale

The CS *Derived AJCC-6 N* can be used to evaluate disease spread at diagnosis, plan and track treatment patterns, and analyze outcomes.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- The two-digit storage codes are designed for analytic purposes.
- Refer to the current *CS Manual* for the display equivalent of the storage codes.
- Refer to the *AJCC Cancer Staging Manual, 6th Edition* for the site-specific “N” descriptions.

DERIVED AJCC-6 N DESCRIPT

Item Length: 1
 NAACCR Item #2970
 Revised 09/04, 01/10

Description

This item is the derived AJCC “N Descriptor” from coded fields using the CS algorithm.

Rationale

Derived AJCC-6 N Descriptor can be used in analysis to differentiate the timing of staging with respect to the treatment process.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- Refer to the *AJCC Cancer Staging Manual, 6th Edition* for prefix definitions for codes c, p, a, and y.
- Refer to the current *CS Manual* for the calculation procedures for all codes.

Code	Description
c	Clinical stage.
p	Pathologic stage.
a	Autopsy stage.
y	Lymph nodes removed for examination after pre-surgical systemic treatment or radiation and lymph node evaluation based on pathologic evidence.
N	Not applicable.
0	Not derived.

DERIVED AJCC-6 M

Item Length: 2
NAACCR Item #2980
Revised 01/10

Description

This item is the derived AJCC “M” staging element from coded fields using the CS algorithm.

Rationale

Derived AJCC-6 M can be used to evaluate disease spread at diagnosis, plan and track treatment patterns, and analyze outcomes.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- The two-digit storage codes are designed for analytic purposes.
- Refer to the current *CS Manual* for the display equivalent of the storage codes.
- Refer to the *AJCC Cancer Staging Manual, 6th Edition* for the site-specific “M” descriptions.

DERIVED AJCC-6 M DESCRIPT

Item Length: 1
 NAACCR Item #2990
 Revised 09/04, 01/10

Description

This item is the derived AJCC “M Descriptor” from coded fields using the CS algorithm.

Rationale

Derived AJCC-6 M Descript can be used in analysis to differentiate the timing of staging with respect to the treatment process.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- Refer to the *AJCC Cancer Staging Manual, 6th Edition* for prefix definitions for codes c, p, a, and y.
- Refer to the current *CS Manual* for the calculation procedures for all codes.

Code	Description
c	Clinical stage.
p	Pathologic stage.
a	Autopsy stage.
y	Pathologic examination of metastatic tissue performed after pre-surgical systemic treatment or radiation and extension based on pathologic evidence.
N	Not applicable.
0	Not derived.

DERIVED AJCC-6 STAGE GROUP

Item Length: 2
NAACCR Item #3000
Revised 01/10

Description

This item is the derived AJCC “Stage Group” from coded fields using the CS algorithm.

Rationale

The CS *Derived AJCC-6 Stage Group* can be used to evaluate disease spread at diagnosis, plan and track treatment patterns, and analyze outcomes.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- The two-digit storage codes are designed for analytic purposes.
- Refer to the current *CS Manual* for the display equivalent of the storage codes.
- Refer to the *AJCC Cancer Staging Manual, 6th Edition* for the site-specific “M” descriptions.

DERIVED AJCC-7 T

Item Length: 2
NAACCR Item #3400
New Item 01/2010

Description

This item is the derived AJCC “T” staging element from coded fields using the CS algorithm.

Rationale

Derived AJCC-7 T can be used to evaluate disease spread at diagnosis, plan and track treatment patterns, and analyze outcomes.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- The two-digit storage codes are designed for analytic purposes.
- Refer to the current *CS Manual* for the display equivalent of the storage codes.
- Refer to the *AJCC Cancer Staging Manual, 7th Edition* for the site-specific “T” descriptions.

DERIVED AJCC-7 T DESCRIPT

Item Length: 1
 NAACCR Item #3402
 New Item 01/2010

Description

This item is the derived AJCC “T Descriptor” from coded fields using the CS algorithm.

Rationale

Derived AJCC-7 T Descript can be used in analysis to differentiate the timing of staging with respect to the treatment process.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- Refer to the *AJCC Cancer Staging Manual, 7th Edition* for prefix definitions for codes c, p, a, and y.
- Refer to the current *CS Manual* for the calculation procedures for all codes.

Code	Description
c	Clinical stage.
p	Pathologic stage.
a	Autopsy stage.
y	Surgical resection performed after pre-surgical systemic treatment or radiation; tumor size/extension based on pathologic evidence.
N	Not applicable.
0	Not derived.

DERIVED AJCC-7 N

Item Length: 2
NAACCR Item #3410
New Item 01/2010

Description

This item is the derived AJCC “N” staging element from coded fields using the CS algorithm.

Rationale

The CS *Derived AJCC-7 N* can be used to evaluate disease spread at diagnosis, plan and track treatment patterns, and analyze outcomes.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- The two-digit storage codes are designed for analytic purposes.
- Refer to the current *CS Manual* for the display equivalent of the storage codes.
- Refer to the *AJCC Cancer Staging Manual, 7th Edition* for the site-specific “N” descriptions.

DERIVED AJCC-7 N DESCRIPT

Item Length: 1
 NAACCR Item #3412
 New Item 01/2010

Description

This item is the derived AJCC “N Descriptor” from coded fields using the CS algorithm.

Rationale

Derived AJCC-7 N Descript can be used in analysis to differentiate the timing of staging with respect to the treatment process.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- Refer to the *AJCC Cancer Staging Manual, 7th Edition* for prefix definitions for codes c, p, a, and y.
- Refer to the current *CS Manual* for the calculation procedures for all codes.

Code	Description
c	Clinical stage.
p	Pathologic stage.
a	Autopsy stage.
y	Lymph nodes removed for examination after pre-surgical systemic treatment or radiation and lymph node evaluation based on pathologic evidence.
N	Not applicable.
0	Not derived.

DERIVED AJCC-7 M

Item Length: 2
NAACCR Item #3420
New Item 01/2010

Description

This item is the derived AJCC “M” staging element from coded fields using the CS algorithm.

Rationale

Derived AJCC-7 M can be used to evaluate disease spread at diagnosis, plan and track treatment patterns, and analyze outcomes.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- The two-digit storage codes are designed for analytic purposes.
- Refer to the current *CS Manual* for the display equivalent of the storage codes.
- Refer to the *AJCC Cancer Staging Manual, 7th Edition* for the site-specific “M” descriptions.

DERIVED AJCC-7 M DESCRIPT

Item Length: 1
 NAACCR Item #3422
 New Item 01/2010

Description

This item is the derived AJCC “M Descriptor” from coded fields using the CS algorithm.

Rationale

Derived AJCC-7 M Descript can be used in analysis to differentiate the timing of staging with respect to the treatment process.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- Refer to the *AJCC Cancer Staging Manual, 7th Edition* for prefix definitions for codes c, p, a, and y.
- Refer to the current *CS Manual* for the calculation procedures for all codes.

Code	Description
c	Clinical stage.
p	Pathologic stage.
a	Autopsy stage.
y	Pathologic examination of metastatic tissue performed after pre-surgical systemic treatment or radiation and extension based on pathologic evidence.
N	Not applicable.
0	Not derived.

DERIVED AJCC-7 STAGE GROUP

Item Length: 2
NAACCR Item #3430
New Item 01/2010

Description

This item is the derived AJCC “Stage Group” from coded fields using the CS algorithm.

Rationale

The CS *Derived AJCC-7 Stage Group* can be used to evaluate disease spread at diagnosis, plan and track treatment patterns, and analyze outcomes.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- The two-digit storage codes are designed for analytic purposes.
- Refer to the current *CS Manual* for the display equivalent of the storage codes.
- Refer to the *AJCC Cancer Staging Manual, 7th Edition* for the site-specific “M” descriptions.

DERIVED SS1977

Item Length: 1
 Allowable Values: 0–5, 7, 9
 NAACCR Item #3010
 Revised 09/08, 01/10

Description

This item is the derived “SEER Summary Stage 1977” from the CS algorithm.

Rationale

Derived SS1977 can be used to evaluate patterns of disease spread at diagnosis, track treatment patterns, and analyze outcomes, especially when comparing or combining cases diagnosed prior to 2001 (when an updated version was implemented) with those diagnosed later.

Instructions for Coding

- Refer to the *SEER Summary Staging Manual, 1977* for descriptions of the site-specific categories.
- Refer to the current *CS Manual* for the calculation procedures for this item.

Code	Description
0	In situ
1	Localized
2	Regional, direct extension only.
3	Regional, regional lymph nodes only.
4	Regional, direct extension and regional lymph nodes.
5	Regional, NOS.
7	Distant metastases/systemic disease.
8	Not applicable
9	Unstaged, unknown, or unspecified.
(blank)	Not derived.

DERIVED SS2000

Item Length: 1
 Allowable Values: 0–5, 7, 9
 NAACCR Item #3020
 Revised 09/08, 01/10

Description

This item is the derived “SEER Summary Stage 2000” from the CS algorithm.

Rationale

Derived SS2000 can be used to evaluate patterns of disease spread at diagnosis, track treatment patterns, and analyze outcomes.

Instructions for Coding

- Refer to the *SEER Summary Staging Manual, 2000* for descriptions of the site-specific categories.
- Refer to the current *CS Manual* for the calculation procedures for this item.

Code	Description
0	In situ
1	Localized
2	Regional, direct extension only.
3	Regional, regional lymph nodes only.
4	Regional, direct extension and regional lymph nodes.
5	Regional, NOS.
7	Distant metastases/systemic disease.
8	Not applicable
9	Unstaged, unknown, or unspecified.
(blank)	Not derived.

First Course of Treatment

DATE OF FIRST COURSE OF TREATMENT

Item Length: 8
 NAACCR Item #1270
 Revised 1/1/10

Description

Records the date on which treatment (surgery, radiation, systemic, or other therapy) of the patient began at any facility.

Rationale

It is important to be able to measure the delay between diagnosis and the onset of treatment. A secondary use for this date is as a starting point for survival statistics (rather than using the diagnosis date). This date cannot be calculated from the respective first course treatment modality dates if no treatment was given. Therefore, providing the date on which active surveillance is chosen, a physician decides not to treat a patient, or a patient's family or guardian declines treatment is important.

Instructions for Coding

- Record the earliest of the following dates: *Date of First Surgical Procedure* (NAACCR Item #1200), *Date Radiation Started* (NAACCR Item #1210), *Date Systemic Therapy Started* (NAACCR Item #3230), or *Date Other Treatment Started* (NAACCR Item #1250).
- If active surveillance or watchful waiting is selected as the first course of treatment (*RX Summ–Treatment Status* [NAACCR Item #1285] = 2) record the date this decision is made.
- In cases of nontreatment (*RX Summ–Treatment Status* [NAACCR Item #1285] = 0), in which a physician decides not to treat a patient or a patient's family or guardian declines all treatment, the date of first course of treatment is the date this decision was made.
- Leave this item blank if the cancer was diagnosed at autopsy and not suspected prior to that.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date of First Course of Treatment* is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date of First Course of Treatment* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *Date 1st Crs Rx Flag* (NAACCR Item #1271) is used to explain why *Date of First Course of Treatment* is not a known date. See *Date 1st Crs Rx Flag* for an illustration of the relationships among these items.

Examples

A patient has a core biopsy on February 12, 2004 and subsequently undergoes an excisional biopsy on February 14, 2004	February 14, 2004
A patient begins receiving preoperative radiation therapy elsewhere on April 21, 2005 and subsequent surgical therapy at this facility on June 2, 2005	April 21, 2005

DATE 1st CRS RX FLAG

Item Length: 2
 NAACCR Item #1271
 Valid Codes: 10-12, Blank
 New Item: 1/1/2010

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date of First Course of Treatment* (NAACCR Item #1270).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Coding Instructions

- Leave this item blank if *Date of First Course of Treatment* (NAACCR Item #1270) has a full or partial date recorded.
- Code 12 if the *Date of First Course of Treatment* can not be determined, but the patient did receive first course treatment.
- Code 10 if it is unknown whether any treatment was administered.
- Code 11 if the initial diagnosis was at autopsy.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

Code	Definition
10	No information whatsoever can be inferred from this exceptional value (that is, unknown if any treatment was given).
11	No proper value is applicable in this context (for example, autopsy only).
12	A proper value is applicable but not known. This event occurred, but the date is unknown (for example, treatment was given but the date is unknown).
(blank)	A valid date value is provided in item <i>Date of First Course of Treatment</i> (NAACCR Item #1270).

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date of First Course of Treatment* (NAACCR Item #1270) and *Date 1st Crs Rx Flag* (NAACCR Item #1271). ***In this table, the lower-case letter “b” is used to represent each blank space.***

Description	Traditional Date of First Course of Treatment	Interoperable Date of First Course of Treatment	Date 1 st Crs Rx Flag
	Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999	Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable.	
Full date known	MMDDCCYY (example: 02182007)	CCYYMMDD (example: 20070218)	bb
Month and year known	MM99CCYY (example: 02992007)	CCYYMMbb (example: 200702bb)	bb
Year only known	9999CCYY (example: 99992007)	CCYYbbbb (example: 2007bbbb)	bb
Unknown if any treatment given	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	10
Diagnosis at autopsy only	00000000 (example: 00000000)	bbbbbbbb (example: bbbbbbbb)	11
Date is unknown, treatment given	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	12

RX SUMM – TREATMENT STATUS

Item Length: 1

Allowable Values: 0-2, 9

NAACCR Item #1285

New Item: 1/1/2010

Description

This data item summarizes whether the patient received any treatment or the tumor was under active surveillance.

Rationale

This item documents active surveillance (watchful waiting) and eliminate searching each treatment modality to determine whether treatment was given. It is used in conjunction with *Date of First Course of Treatment* [NAACCR Item #1270] to document whether treatment was or was not given, it is unknown if treatment was given, or treatment was given on an unknown date.

Instructions for Coding

- This item may be left blank for cases diagnosed prior to 2010.
- Treatment given after a period of active surveillance is considered subsequent treatment and it not coded in this item.

Code	Definition
0	No treatment given
1	Treatment given
2	Active surveillance (watchful waiting)
9	Unknown if treatment was given

Examples:

Code	Reason
0	An elderly patient with pancreatic cancer requested no treatment.
0	Patient is expected to receive radiation, but it has not occurred yet (<i>Reason for No Radiation</i> [NAACCR Item #1430] = 8)
2	Treatment plan for a lymphoma patient is active surveillance.

DATE OF FIRST SURGICAL PROCEDURE

Item Length: 8
 NAACCR Item #1200
 Revised 1/1/2010

Description

Records the earliest date on which any first course surgical procedure was performed. Formerly called “Date of Cancer-Directed Surgery.”

Rationale

This item can be used to sequence multiple treatment modalities and to evaluate the time intervals between treatments.

Instructions for Coding

- Record the date of the first surgical procedure of the types coded as *Surgical Procedure of Primary Site* (NAACCR Item #1290), *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292) or *Surgical Procedure/Other Site* (NAACCR Item #1294) performed at this or any facility.
- The date in this item may be the same as that in *Date of Most Definitive Surgical Resection of the Primary Site* (NAACCR Item #3170), if the patient received only one surgical procedure and it was a resection of the primary site.
- If surgery is the first or only treatment administered to the patient, then the date of surgery should be the same as the date entered into the item *Date of First Course Treatment* (NAACCR Item #1270).
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date of First Surgical Procedure* is MMDDCCYY, with 99 indentifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date of First Surgical Procedure* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *Rx Date–Surgery Flag* (NAACCR Item #1201) is used to explain why *Date of First Surgical Procedure* is not a known date. See *Rx Date–Surgery Flag* for an illustration of the relationships among these items.

Examples

A melanoma patient had an excisional biopsy on March 23, 2008, then a wide excision on March 28, 2008.	March 23, 2008
The patient had a small (0.5 cm) lump removed from her breast on November 16, 2009.	November 16, 2009
The patient’s primary tumor was treated with radiation beginning on April 16, 2007, after a distant metastasis was removed surgically on March 27, 2007.	March 27, 2007

RX DATE–SURGERY FLAG

Item Length: 2
 NAACCR Item #1201
 Valid Codes: 10-12, Blank
 New Item: 1/1/2010

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date of First Surgical Procedure* (NAACCR Item #1200).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Coding Instructions

- Leave this item blank if *Date of First Surgical Procedure* (NAACCR Item #1200) has a full or partial date recorded.
- Code 12 if the *Date of First Surgical Procedure* can not be determined, but the patient did receive first course surgery.
- Code 10 if it is unknown whether any surgery was performed.
- Code 11 if no surgical procedure was performed.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

Code	Definition
10	No information whatsoever can be inferred from this exceptional value (that is, unknown if any surgery performed).
11	No proper value is applicable in this context (for example, no surgery performed).
12	A proper value is applicable but not known. This event occurred, but the date is unknown (that is, surgery was performed but the date is unknown).
(blank)	A valid date value is provided in item <i>Date of First Surgical Procedure</i> (NAACCR Item #1200).

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date of First Surgical Procedure* (NAACCR Item #1200) and *Rx Date–Surgery Flag* (NAACCR Item #1201). ***In this table, the lower-case letter “b” is used to represent each blank space.***

Description	Traditional Date of First Surgical Procedure	Interoperable Date of First Surgical Procedure	Rx Date–Surgery Flag
	Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999	Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable.	
Full date known	MMDDCCYY (example: 02182007)	CCYYMMDD (example: 20070218)	bb
Month and year known	MM99CCYY (example: 02992007)	CCYYMMbb (example: 200702bb)	bb
Year only known	9999CCYY (example: 99992007)	CCYYbbbb (example: 2007bbbb)	bb
Unknown if any surgery performed	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	10
No surgery performed	00000000 (example: 00000000)	bbbbbbbb (example: bbbbbbbb)	11
Date is unknown, surgery performed	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	12

**DATE OF MOST DEFINITIVE SURGICAL RESECTION
OF THE PRIMARY SITE**

Item Length: 8
NAACCR Item #3170
Revised 09/08, 01/10

Description

Records the date of the most definitive surgical procedure of the primary site performed as part of the first course of treatment.

Rationale

This item is used to measure the lag time between diagnosis and the most definitive surgery of the primary site. It is also used in conjunction with *Date of Surgical Discharge* (NAACCR Item #3180) to calculate the duration of hospitalization following the most definitive primary site surgical procedure. This can then be used to evaluate treatment efficacy.

Instructions for Coding

- Record the date on which the surgery described by *Surgical Procedure of Primary Site* (NAACCR Item #1290) was performed at this or any facility.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date of Most Definitive Surgical Resection of the Primary Site* is MMDDCCYY, with 99 indentifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date of Most Definitive Surgical Resection of the Primary Site* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *RX Date Mst Defn Srg Flag* (NAACCR Item #3171) is used to explain why *Date of Most Definitive Surgical Resection of the Primary Site* is not a known date. See *RX Date Mst Defn Srg Flag* for an illustration of the relationships among these items.

RX DATE MST DEFN SRG FLAG

Item Length: 2
 NAACCR Item #3171
 Valid Codes: 10-12, Blank
 New Item: 01/2010

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date of Most Definitive Surgical Resection of the Primary Site* (NAACCR Item #3170).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Coding Instructions

- Leave this item blank if *Date of Most Definitive Surgical Resection of the Primary Site* (NAACCR Item #3170) has a full or partial date recorded.
- Code 12 if the *Date of Most Definitive Surgical Resection of the Primary Site* can not be determined, but the patient did receive first course surgery.
- Code 10 if it is unknown whether any surgery was performed.
- Code 11 if no surgical procedure was performed.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.
- Leave blank for cases diagnosed prior to January 1, 2003.

Code	Description
10	No information whatsoever can be inferred from this exceptional value (that is, unknown if any surgery performed).
11	No proper value is applicable in this context (for example, no surgery performed).
12	A proper value is applicable but not known. This event occurred, but the date is unknown (that is, surgery was performed but the date is unknown).
(blank)	A valid date value is provided in item <i>Date of Most Definitive Surgical Resection of the Primary Site</i> (NAACCR Item #3170). Case was diagnosed prior to January 1, 2003.

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date of Most Definitive Surgical Resection of the Primary Site* (NAACCR Item #3170) and *Rx Date Mst Defn Srg Flag* (NAACCR Item #3171). *In this table, the lower-case letter “b” is used to represent each blank space.*

Description	Traditional Date of Most Definitive Surgical Resection of the Primary Site	Interoperable Date of Most Definitive Surgical Resection of the Primary Site	Rx Date Mst Defn Srg Flag
	Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999	Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable.	
Full date known	MMDDCCYY (example: 02182007)	CCYYMMDD (example: 20070218)	bb
Month and year known	MM99CCYY (example: 02992007)	CCYYMMbb (example: 200702bb)	bb
Year only known	9999CCYY (example: 99992007)	CCYYbbbb (example: 2007bbbb)	bb
Unknown if any surgery performed	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	10
No surgery performed	00000000 (example: 00000000)	bbbbbbbb (example: bbbbbbbb)	11
Date is unknown, surgery performed	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	12

SURGICAL PROCEDURE OF PRIMARY SITE

Item Length: 2

Allowable Values: 00, 10–80, 90, 98, 99

L/R Justified, Zero-filled

NAACCR Item #1290

Revised 06/05, 01/10

Description

Records the surgical procedure(s) performed to the primary site.

Rationale

This data item can be used to compare the efficacy of treatment options.

Instructions for Coding

- Site-specific codes for this data item are found in Appendix B.
- If registry software allows only one procedure to be collected, document the most invasive surgical procedure for the primary site.
- If registry software allows multiple procedures to be recorded, this item refers to the most invasive surgical procedure of the primary site.
- For codes 00 through 79, the response positions are hierarchical. Last-listed responses take precedence over responses written above. Code 98 takes precedence over code 00. Use codes 80 and 90 only if more precise information about the surgery is not available.
- Excisional biopsies (those that remove the entire tumor and/or leave only microscopic margins) are to be coded in this item.
- Surgery to remove regional tissue or organs is coded in this item only if the tissue/organs are removed in continuity with the primary site, except where noted in Appendix B.
- If a previous surgical procedure to remove a portion of the primary site is followed by surgery to remove the remainder of the primary site, then code the total or final results.
- If the procedure coded in this item was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record this surgery in the item *Palliative Care* (NAACCR Item #3270).
- There may be times when the first course of treatment information is incomplete. Therefore, it is important to continue follow-up efforts to be certain the complete treatment information is collected.

Code	Label	Definition
00	None	No surgical procedure of primary site. Diagnosed at autopsy.
10–19	Site-specific codes; tumor destruction	Tumor destruction, no pathologic specimen produced. Refer to Appendix B for the correct site-specific code for the procedure.
20–80	Site-specific codes; resection	Refer to Appendix B for the correct site-specific code for the procedure.
90	Surgery, NOS	A surgical procedure to the primary site was done, but no information on the type of surgical procedure is provided.
98	Site-specific codes; special	Special code. Refer to Appendix B for the correct site-specific code for the procedure.
99	Unknown	Patient record does not state whether a surgical procedure of the primary site was performed and no information is available. Death certificate only.

**SURGICAL PROCEDURE OF PRIMARY SITE
AT THIS FACILITY**

Item Length: 2
Allowable Values: 00, 10–80, 90, 98, 99
L/R Justified, Zero-filled
NAACCR Item #670
Revised 09/04, 01/10

Description

Records the surgical procedure(s) performed to the primary site at this facility.

Rationale

This data item can be used to compare the efficacy of treatment options.

Instructions for Coding

- Site-specific codes for this data item are found in Appendix B.
- If registry software allows only one procedure to be collected, document the most invasive surgical procedure for the primary site.
- If registry software allows multiple procedures to be collected, this item refers to the most invasive surgical procedure for the primary site.
- For codes 00 through 79, the response positions are hierarchical. Last-listed responses take precedence over responses written above. Code 98 takes precedence over code 00. Use codes 80 and 90 only if more precise information about the surgery is not available.
- Excisional biopsies (those that remove the entire tumor and/or leave only microscopic margins) are to be coded in this item.
- Surgery to remove regional tissue or organs is coded in this item only if the tissue/organs are removed in continuity with the primary site.
- If a previous surgical procedure to remove a portion of the primary site is followed by surgery to remove the remainder of the primary site, then code the total or final results.
- If the procedure coded in this item was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record this surgery in the item *Palliative Care at This Facility* (NAACCR Item #3280).

Code	Label	Definition
00	None	No surgical procedure of primary site. Diagnosed at autopsy.
10–19	Site-specific codes; tumor destruction	Tumor destruction, no pathologic specimen produced. Refer to Appendix B for the correct site-specific code for the procedure.
20–80	Site-specific codes; resection	Refer to Appendix B for the correct site-specific code for the procedure.
90	Surgery, NOS	A surgical procedure to primary site was done, but no information on the type of surgical procedure is provided.
98	Site-specific codes; special	Special code. Refer to Appendix B for the correct site-specific code for the procedure.
99	Unknown	Patient record does not state whether a surgical procedure of the primary site was performed and no information is available. Death certificate only.

**APPROACH – SURGERY OF THE PRIMARY SITE AT THIS FACILITY
(RX HOSP – SURG APP 2010)**

Item Length: 1
Allowable Values: 0-5, 9
NAACCR Item #668
New Item: 1/1/2010; Revised 05/10

Description

This item is used to describe the surgical method used to approach the primary site for patients undergoing surgery of the primary site at this facility.

Rationale

This item is used to monitor patterns and trends in the adoption and utilization of minimally-invasive surgical techniques.

Instructions for Coding

- This item may be left blank for cases diagnosed prior to 2010.
- If the patient has multiple surgeries of the primary site, this item describes the approach used for the most invasive, definitive surgery.
- Assign code 2 or 4 if the surgery began as robotic assisted or endoscopic and was converted to open.
- If both robotic and endoscopic surgery were used, code to robotic (codes 1 or 2).
- This item should not be confused with the obsolete item published in Registry Operations and Data Standards (ROADS), *Surgical Approach* (NAACCR Item #1310)

Code	Definition
0	No surgical procedure of primary site at this facility; Diagnosed at autopsy
1	Robotic assisted
2	Robotic converted to open
3	Endoscopic
4	Endoscopic converted to open.
5	Open or approach unspecified
9	Unknown whether surgery was performed at this facility

Examples:

Code	Reason
0	Patient received radiation at this facility after having surgery elsewhere
3	Surgery was performed endoscopically
5	The surgical report described conventional open surgery, but did not use the term “open”

SURGICAL MARGINS OF THE PRIMARY SITE

Item Length: 1

Allowable Values: 0–3, 7–9

NAACCR Item #1320

Revised 08/02, 01/10, 02/10

Description

Records the final status of the surgical margins after resection of the primary tumor.

Rationale

This data item serves as a quality measure for pathology reports and is used for staging, and may be a prognostic factor in recurrence.

Instructions for Coding

- Record the margin status as it appears in the pathology report.
- Codes 0–3 are hierarchical; if two codes describe the margin status, use the numerically higher code.
- Code 7 if the pathology report indicates the margins could not be determined.
- If no surgery of the primary site was performed, code 8.
- Code 9 if the pathology report makes no mention of margins.
- For lymphomas (M-9590-9726, 9728-9732, 9734-9740, 9750-9762, 9811-9831, 9940, 9948 and 9971) with a lymph node primary site (C77.0–C77.9), code 9.
- For an unknown or ill-defined primary site (C76.0–C76.8, C80.9) or for hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease (C42.0, C42.1, C42.3, C42.4, or M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992), code 9.

Code	Label	Definition
0	No residual tumor	All margins are grossly and microscopically negative.
1	Residual tumor, NOS	Involvement is indicated, but not otherwise specified.
2	Microscopic residual tumor	Cannot be seen by the naked eye.
3	Macroscopic residual tumor	Gross tumor of the primary site which is visible to the naked eye.
7	Margins not evaluable	Cannot be assessed (indeterminate).
8	No primary site surgery	No surgical procedure of the primary site. Diagnosed at autopsy.
9	Unknown or not applicable	It is unknown whether a surgical procedure to the primary site was performed; death certificate-only; for lymphomas with a lymph node primary site; an unknown or ill-defined primary; or for hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease.

Example:

Code	Reason
3	(C18-Colon) The pathology report from a colon resection describes the proximal margin as grossly involved with tumor (code 3) and the distal margin as microscopically involved (code 2). Code macroscopic involvement (code 3).

SCOPE OF REGIONAL LYMPH NODE SURGERY

Item Length: 1

Allowable Values: 0–7, 9

NAACCR Item #1292

Revised 01/04, 09/08, 02/10

Description

Identifies the removal, biopsy, or aspiration of regional lymph node(s) at the time of surgery of the primary site or during a separate surgical event.

Rationale

This data item can be used to compare and evaluate the extent of surgical treatment.

Instructions for Coding

- The scope of regional lymph node surgery is collected for each surgical event even if surgery of the primary site was not performed.
- Record surgical procedures which aspirate, biopsy, or remove regional lymph nodes in an effort to diagnose or stage disease in this data item. Record the date of this surgical procedure in data item *Date of First Course of Treatment* (NAACCR Item #1270) and/or *Date of First Surgical Procedure* (NAACCR Item #1200) as appropriate.
- Codes 0–7 are hierarchical. If only one procedure can be recorded, code the procedure that is numerically higher.
- For intracranial and central nervous system primaries (C70.0–C70.9, C71.0–C71.9, C72.0–C72.9, C75.1–C75.3), code 9.
- For lymphomas (M-9590-9726, 9728-9732, 9734-9740, 9750-9762, 9811-9831, 9940, 9948 and 9971) with a lymph node primary site (C77.0–C77.9), code 9.
- For an unknown or ill-defined primary site (C76.0–C76.8, C80.9) or for hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease (C42.0, C42.1, C42.3, C42.4 or M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992), code 9.
- Do not code *distant* lymph nodes removed during surgery to the primary site for this data item. Distant nodes are coded in the data field *Surgical Procedure/Other Site* (NAACCR Item #1294).
- Refer to the current *AJCC Cancer Staging Manual* for site-specific identification of regional lymph nodes.
- If the procedure coded in this item was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record this surgery in the item *Palliative Care* (NAACCR Item #3270).

Code	Label	Definition
0	None	No regional lymph node surgery. No lymph nodes found in the pathologic specimen. Diagnosed at autopsy.
1	Biopsy or aspiration of regional lymph node, NOS	Biopsy or aspiration of regional lymph node(s) regardless of the extent of involvement of disease.
2	Sentinel lymph node biopsy	Biopsy of the first lymph node or nodes that drain a defined area of tissue within the body. Sentinel node(s) are identified by the injection of a dye or radio label at the site of the primary tumor.
3	Number of regional nodes removed unknown or not stated; regional lymph nodes removed, NOS	Sampling or dissection of regional lymph node(s) and the number of nodes removed is unknown or not stated. The procedure is not specified as sentinel node biopsy.
4	1–3 regional lymph nodes removed	Sampling or dissection of regional lymph node(s) with fewer than four lymph nodes found in the specimen. The procedure is not specified as sentinel node biopsy.

Code	Label	Definition
5	4 or more regional lymph nodes removed	Sampling or dissection of regional lymph nodes with at least four lymph nodes found in the specimen. The procedure is not specified as sentinel node biopsy.
6	Sentinel node biopsy and code 3, 4, or 5 at same time, or timing not stated	Code 2 was performed in a single surgical event with code 3, 4, or 5. Or, code 2 and 3, 4, or 5 were performed, but timing was not stated in patient record.
7	Sentinel node biopsy and code 3, 4, or 5 at different times	Code 2 was followed in a subsequent surgical event by procedures coded as 3, 4, or 5.
9	Unknown or not applicable	It is unknown whether regional lymph node surgery was performed; death certificate-only; for lymphomas with a lymph node primary site; an unknown or ill-defined primary; or for hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease.

Examples

Code	Reason
0	There was an attempt at regional lymph node dissection or sentinel lymph node dissection, but no lymph nodes were found in the pathological specimen.
1	(C14.0-Pharynx) Aspiration of regional lymph node to confirm histology of widely metastatic disease.
2	(C44.5-Skin of Back) Patient has melanoma of the back. A sentinel lymph node dissection was done with the removal of one lymph node. This node was negative for disease.
3	(C61.9-Prostate) Bilateral pelvic lymph node dissection for prostate cancer.
6	(C50.3-Breast) Sentinel lymph node biopsy of right axilla, followed by right axillary lymph node dissection during the same surgical event.
9	(C34.9-Lung) Patient was admitted for radiation therapy following surgery for lung cancer. There is no documentation on the extent of surgery in patient record.

Note: One important use of registry data is the tracking of treatment patterns over time. In order to compare contemporary treatment with previously published treatment based on former codes, or to data unmodified from pre-1998 definitions, the ability to differentiate surgeries in which four or more regional lymph nodes are removed is desirable. However, it is *very important* to note that the distinction between codes 4 and 5 is made to permit comparison of current surgical procedures with procedures coded in the past when the removal of fewer than 4 lymph nodes was not reflected in surgery codes. *It is not intended to reflect clinical significance* when applied to a particular surgical procedure. It is important to *avoid inferring, by data presentation or other methods, that one category is preferable to another within the intent of these items.*

**SCOPE OF REGIONAL LYMPH NODE SURGERY
AT THIS FACILITY**

Item Length: 1

Allowable Values: 0–7, 9

NAACCR Item #672

Revised 01/04, 09/08, 02/10

Description

Identifies the removal, biopsy, or aspiration of regional lymph node(s) at the time of surgery of the primary site or during a separate surgical event at this facility.

Rationale

This item can be used to compare and evaluate the extent of surgical treatment.

Instructions for Coding

- The scope of regional lymph node surgery is collected for each surgical event even if surgery of the primary site was not performed.
- If a surgical procedure which aspirates, biopsies, or removes regional lymph nodes to diagnose or stage this cancer, record the scope of regional lymph nodes surgery in this data item. Record the date of this surgical procedure in data item *Date of First Course of Treatment* (NAACCR Item #1270) and/or *Date of First Surgical Procedure* (NAACCR Item #1200) as appropriate.
- Codes 0–7 are hierarchical. If only one procedure can be recorded, code the procedure that is numerically higher.
- For primaries of the meninges, brain, spinal cord, cranial nerves, and other parts of the central nervous system (C70.0–C70.9, C71.0–C71.9, C72.0–C72.9, C75.1–C75.3), code 9.
- For lymphomas (M-9590-9726, 9728-9732, 9734-9740, 9750-9762, 9811-9831, 9940, 9948 and 9971) with a lymph node primary site (C77.0–C77.9), code 9.
- For all unknown or ill-defined primary sites (C76.0–76.8, C80.9) or for hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease (C42.0, C42.1, C42.3, C42.4 or M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992), code 9.
- Do not code *distant* lymph nodes removed during surgery to the primary site for this data item. They are coded in the data field *Surgical Procedure/Other Site* (NAACCR Item #1294).
- Refer to the current *AJCC Cancer Staging Manual* for site-specific identification of regional lymph nodes.
- If the procedure coded in this item was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record this surgery in the item *Palliative Care at This Facility* (NAACCR Item #3280).

Code	Label	Definition
0	None	No regional lymph node surgery. No lymph nodes found in the pathologic specimen. Diagnosed at autopsy.
1	Biopsy or aspiration of regional lymph node, NOS	Biopsy or aspiration of regional lymph node(s) regardless of the extent of involvement of disease.
2	Sentinel lymph node biopsy	Biopsy of the first lymph node or nodes that drain a defined area of tissue within the body. Sentinel node(s) are identified by the injection of a dye or radio label at the site of the primary tumor.
3	Number of regional nodes removed unknown or not stated; regional lymph nodes removed, NOS	Sampling or dissection of regional lymph node(s) and the number of nodes removed is unknown or not stated. The procedure is not specified as sentinel node biopsy.
4	1–3 regional lymph nodes removed	Sampling or dissection of regional lymph node(s) with fewer than four lymph nodes found in the specimen. The procedure is not specified as sentinel node biopsy.

Code	Label	Definition
5	4 or more regional lymph nodes removed	Sampling or dissection of regional lymph nodes with at least four lymph nodes found in the specimen. The procedure is not specified as sentinel node biopsy.
6	Sentinel node biopsy and code 3, 4, or 5 at same time, or timing not stated	Code 2 was performed in a single surgical event with code 3, 4, or 5. Or, code 2 and 3, 4, or 5 were performed, but timing was not stated in patient record.
7	Sentinel node biopsy and code 3, 4, or 5 at different times	Code 2 was followed in a subsequent surgical event by procedures coded as 3, 4, or 5.
9	Unknown or not applicable	It is unknown whether regional lymph node surgery was performed; death certificate-only; for lymphomas with a lymph node primary site; an unknown or ill-defined primary; or for hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease.

Note: One important use of registry data is the tracking of treatment patterns over time. In order to compare contemporary treatment with previously published treatment based on former codes, or to data unmodified from pre-1998 definitions, the ability to differentiate surgeries in which four or more regional lymph nodes are removed is desirable. However, it is *very important* to note that the distinction between codes 4 and 5 is made to permit comparison of current surgical procedures with procedures coded in the past when the removal of fewer than 4 lymph nodes was not reflected in surgery codes. *It is not intended to reflect clinical significance* when applied to a particular surgical procedure. It is important *to avoid inferring, by data presentation or other methods, that one category is preferable to another within the intent of these items.*

SURGICAL PROCEDURE/OTHER SITE

Item Length: 1

Allowable Values: 0–5, 9

NAACCR Item #1294

Revised 01/04, 09/08, 01/10, 02/10

Description

Records the surgical removal of *distant lymph nodes* or other tissue(s) or organ(s) removed beyond the primary site

Rationale

The removal of nonprimary tissue documents the extent of surgical treatment and is useful in evaluating the extent of metastatic involvement.

Instructions for Coding

- If other tissue or organs are removed during primary site surgery that are not specifically defined by the site-specific *Surgical Procedure of the Primary Site* (NAACCR Item #1290 or #670) code, assign the highest numbered code that describes the surgical resection of other tissue or organs beyond the primary site surgical code.
- Assign the highest numbered code that describes the surgical resection of other tissue or organs beyond the primary site surgical code.
- Assign the highest numbered code that describes the surgical resection of *distant lymph node(s)*.
- Incidental removal of tissue or organs is not a “Surgical Procedure/Other Site.”
- *Surgical Procedure/Other Site* is collected for each surgical event even if surgery of the primary site was not performed.
- Code 1 if any surgery is performed to treat tumors of unknown or ill-defined primary sites (C76.0–76.8, C80.9) or for hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease (C42.0, C42.1, C42.3, C42.4 or M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992).
- If the procedure coded in this item was provided to prolong a patient’s life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record this surgery in the item *Palliative Care* (NAACCR Item #3270).

Code	Label	Definition
0	None	No surgical procedure of nonprimary site was performed. Diagnosed at autopsy.
1	Nonprimary surgical procedure performed	Nonprimary surgical resection to other site(s), unknown if whether the site(s) is regional or distant.
2	Nonprimary surgical procedure to other regional sites	Resection of regional site.
3	Nonprimary surgical procedure to <i>distant lymph node(s)</i>	Resection of <i>distant lymph node(s)</i> .
4	Nonprimary surgical procedure to distant site	Resection of distant site.
5	Combination of codes	Any combination of surgical procedures 2, 3, or 4.
9	Unknown	It is unknown whether any surgical procedure of a nonprimary site was performed. Death certificate only.

Examples

Code	Reason
0	(C18.1–Colon) The incidental removal of the appendix during a surgical procedure to remove a primary malignancy in the right colon.
1	Surgical removal of metastatic lesion from liver; unknown primary.
2	(C18.3–Colon) Surgical ablation of solitary liver metastasis, hepatic flexure primary.
4	(C34.9–Lung) Removal of solitary brain metastasis.
5	(C21.0–Anus) Excision of solitary liver metastasis and one large hilar lymph node.

**SURGICAL PROCEDURE/OTHER SITE
AT THIS FACILITY**

Item Length: 1
 Allowable Values: 0–5, 9
 NAACCR Item #674
 Revised 01/04, 01/10, 02/10

Description

Records the surgical removal of *distant lymph nodes* or other tissue(s)/organ(s) beyond the primary site at this facility.

Rationale

The removal of nonprimary tissue documents the extent of surgical treatment and is useful in evaluating the extent of metastatic involvement.

Instructions for Coding

- If other tissue or organs are removed during primary site surgery that are not specifically defined by the site-specific *Surgical Procedure of the Primary Site* (NAACCR Item #1290 or #670) code, assign the highest numbered code that describes the surgical resection of other tissue or organs beyond the primary site surgical code.
- Assign the highest numbered code that describes the surgical resection of other tissue or organs beyond the primary site surgical code.
- Assign the highest numbered code that describes the surgical resection of *distant lymph node(s)*.
- Incidental removal of tissue or organs is not a “Surgical Procedure/Other Site.”
- *Surgical Procedure/Other Site* is collected for each surgical event even if surgery of the primary site was not performed.
- Code 1 if any surgery is performed to treat tumors of unknown or ill-defined primary sites (C76.0–76.8, C80.9) or for hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease (C42.0, C42.1, C42.3, C42.4 or M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992).
- If the procedure coded in this item was provided to prolong a patient’s life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record this surgery in the item *Palliative Care* (NAACCR Item #3270).

Code	Label	Definition
0	None	No nonprimary surgical site resection was performed. Diagnosed at autopsy.
1	Nonprimary surgical procedure performed	Nonprimary surgical resection to other site(s), unknown if whether the site(s) is regional or distant.
2	Nonprimary surgical procedure to other regional sites	Resection of regional site.
3	Nonprimary surgical procedure to <i>distant lymph node(s)</i>	Resection of <i>distant lymph node(s)</i> .
4	Nonprimary surgical procedure to distant site	Resection of distant site.
5	Combination of codes	Any combination of surgical procedures 2, 3, or 4.
9	Unknown	It is unknown whether any surgical procedure of a nonprimary site was performed. Death certificate only.

DATE OF SURGICAL DISCHARGE

Item Length: 8
NAACCR Item #3180
Revised 01/10

Description

Records the date the patient was discharged following primary site surgery. The date corresponds to the event recorded in *Surgical Procedure of Primary Site* (NAACCR Item #1290), and *Date of Most Definitive Surgical Resection* (NAACCR Item #3170).

Rationale

Length of stay is an important quality of care and financial measure among hospital administrations, those who fund public and private health care, and public health users. This date, in conjunction with the data item *Date of Most Definitive Surgical Resection* (NAACCR Item #3170), will allow for the calculation of a patient's length of hospitalization associated with primary site surgery.

Instructions for Coding

- Record the date the patient was discharged from the hospital following the event recorded in *Surgical Procedure of Primary Site* (NAACCR Item #1290).
- If the patient died following the event recorded in *Surgical Procedure of Primary Site* (NAACCR Item #1290), but before being discharged from the treating facility, then the *Date of Surgical Discharge* is the same as the date recorded in the data item *Date of Last Contact or Death* (NAACCR Item #1750).
- If the patient received out-patient surgery, then the date of surgical discharge is the same as the date recorded in the data item *Date of Most Definitive Surgical Resection of the Primary Site* (NAACCR Item #3170).
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date of Surgical Discharge* is MMDDCCYY, with 99 indentifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date of Surgical Discharge* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *RX Date Surg Disch Flag* (NAACCR ITEM #3181) is used to explain why *Date of Surgical Discharge* is not a known date. See *RX Date Surg Disch Flag* for an illustration of the relationships among these items.

RX DATE SURG DISCH FLAG

Item Length: 2
 NAACCR Item #3181
 Valid Codes: 10-12, Blank
 New Item: 01/2010

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date of Surgical Discharge* (NAACCR Item #3180).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Coding Instructions

- Leave this item blank if *Date of Surgical Discharge* (NAACCR Item #3180) has a full or partial date recorded.
- Code 12 if the *Date of Surgical Discharge* can not be determined, but the patient did receive first course surgery.
- Code 10 if it is unknown whether any surgery was performed.
- Code 11 if no surgical procedure was performed.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.
- Leave blank for cases diagnosed prior to January 1, 2003.

Code	Description
10	No information whatsoever can be inferred from this exceptional value (that is, unknown if any surgery was performed).
11	No proper value is applicable in this context (for example, no surgery performed).
12	A proper value is applicable but not known. This event occurred, but the date is unknown (that is, surgery was performed but the date is unknown).
(blank)	A valid date value is provided in item <i>Date of Surgical Discharge</i> (NAACCR Item #3180). The case was diagnosed prior to January 1, 2003.

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date of Surgical Discharge* (NAACCR Item #3180) and *Rx Date Surg Disch Flag* (NAACCR Item #3181). ***In this table, the lower-case letter “b” is used to represent each blank space.***

Description	Traditional Date of Surgical Discharge	Interoperable Date of Surgical Discharge	Rx Date Surg Disch Flag
	Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999	Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable.	
Full date known	MMDDCCYY (example: 02182007)	CCYYMMDD (example: 20070218)	bb
Month and year known	MM99CCYY (example: 02992007)	CCYYMMbb (example: 200702bb)	bb
Year only known	9999CCYY (example: 99992007)	CCYYbbbb (example: 2007bbbb)	bb
Unknown if any surgery performed	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	10
No primary site surgery performed	00000000 (example: 00000000)	bbbbbbbb (example: bbbbbbbb)	11
Date is unknown, primary site surgery performed	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	12

**READMISSION TO THE SAME HOSPITAL
WITHIN 30 DAYS OF SURGICAL DISCHARGE**

Item Length: 1
 Allowable Values: 0–3, 9
 NAACCR Item #3190
 Revised 06/05, 01/10

Description

Records a readmission to the same hospital, for the same illness, within 30 days of discharge following hospitalization for surgical resection of the primary site.

Rationale

This data item provides information related to the quality of care. A patient may have a readmission related to the primary diagnosis on discharge if the length of stay was too short, and then he/she needed to return due to problems or complications. A patient may also need to be readmitted if discharge planning and/or follow-up instructions were ineffective. It is important to distinguish a planned from an unplanned readmission, since a planned readmission is not an indicator of quality of care problems.

Instructions for Coding

- Consult patient record or information from the billing department to determine if a readmission to the same hospital occurred within 30 days of the date recorded in the item *Date of Surgical Discharge* (NAACCR Item #3180).
- Only record a readmission related to the treatment of this cancer.
- Review the treatment plan to determine whether the readmission was planned.
- If there was an unplanned admission following surgical discharge, check for an ICD-9-CM “E” code and record it, space allowing, as an additional *Comorbidities and Complications* (NAACCR Item #3110, 3120, 3130, 3140, 3150, 3160, 3161, 3162, 3163, 3124).
- There may be times when the first course of treatment information is incomplete. Therefore, it is important to continue follow-up efforts to be certain the complete treatment information is collected.

Code	Definition
0	No surgical procedure of the primary site was performed, or the patient was not readmitted to the same hospital within 30 days of discharge.
1	A patient was surgically treated and was readmitted to the same hospital within 30 days of being discharged. This readmission was unplanned.
2	A patient was surgically treated and was then readmitted to the same hospital within 30 days of being discharged. This readmission was planned (chemotherapy port insertion, revision of colostomy, etc.)
3	A patient was surgically treated and, within 30 days of being discharged, the patient had both a planned and an unplanned readmission to the same hospital.
9	It is unknown whether surgery of the primary site was recommended or performed. It is unknown whether the patient was readmitted to the same hospital within 30 days of discharge. Death certificate only.

Examples

Code	Reason
0	A patient does not return to the hospital following a local excision for a Stage I breast cancer.
0	A patient was surgically treated and, upon discharge from acute hospital care, was admitted/transferred to an extended care ward of the hospital.
1	A patient is readmitted to the hospital three weeks (21 days) following a colon resection due to unexpected perirectal bleeding.
2	Following surgical resection the patient returns to the hospital for the insertion of a chemotherapy port.

**REASON FOR NO SURGERY
OF PRIMARY SITE**

Item Length: 1
 Allowable Values: 0–2, 5–9
 Revised 01/04

Description

Records the reason that no surgery was performed on the primary site.

Rationale

This data item provides information related to the quality of care and describes why primary site surgery was not performed.

Instructions for Coding

- If *Surgical Procedure of Primary Site* (NAACCR Item #1290) is coded 00, then record the reason based on documentation in the patient record.
- Code 1 if the treatment plan offered multiple options and the patient selected treatment that did not include surgery of the primary site, or if the option of “no treatment” was accepted by the patient.
- Code 1 if *Surgical Procedure of Primary Site* (NAACCR Item #1290) is coded 98.
- Code 7 if the patient refused recommended surgical treatment, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 8 if it is known that a physician recommended primary site surgery, but no further documentation is available yet to determine whether surgery was performed.
- Cases coded 8 should be followed and updated to a more definitive code as appropriate.
- Code 9 if the treatment plan offered multiple choices, but it is unknown which treatment, if any was provided.

Code	Definition
0	Surgery of the primary site was performed.
1	Surgery of the primary site was not performed because it was not part of the planned first course treatment.
2	Surgery of the primary site was not recommended/performed because it was contraindicated due to patient risk factors (comorbid conditions, advanced age, progression of tumor prior to planned surgery etc.)
5	Surgery of the primary site was not performed because the patient died prior to planned or recommended surgery.
6	Surgery of the primary site was not performed; it was recommended by the patient’s physician, but was not performed as part of the first course of therapy. No reason was noted in patient record.
7	Surgery of the primary site was not performed; it was recommended by the patient’s physician, but this treatment was refused by the patient, the patient’s family member, or the patient’s guardian. The refusal was noted in patient record.
8	Surgery of the primary site was recommended, but it is unknown if it was performed. Further follow-up is recommended.
9	It is unknown whether surgery of the primary site was recommended or performed. Diagnosed at autopsy or death certificate only.

Examples

Code	Reason
2	A patient with a primary tumor of the liver is not recommended for surgery due to advanced cirrhosis.
8	A patient is referred to another facility for recommended surgical resection of a gastric carcinoma, but further information from the facility to which the patient was referred is not available.

DATE RADIATION STARTED

Item Length: 8
 NAACCR Item #1210
 Revised 06/05, 01/10

Description

Records the date on which radiation therapy began at any facility that is part of the first course of treatment.

Rationale

It is important to be able to sequence the use of multiple treatment modalities and to evaluate the time intervals between the treatments. For some diseases, the sequence of radiation and surgical therapy is important when determining the analytic utility of pathologic stage information.

Instructions for Coding

- If radiation therapy is the first or only treatment administered to the patient, then the date radiation started should be the same as the date entered into the item *Date of First Course of Treatment* (NAACCR Item #1270).
- The date when treatment started will typically be found in the radiation oncologist's summary letter for the first course of treatment.
- There may be times when the first course of treatment information is incomplete. Therefore, it is important to continue follow-up efforts to be certain the complete treatment information is collected.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date Radiation Started* is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date Radiation Started* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *RX Date–Radiation Flag* (NAACCR ITEM #1211) is used to explain why *Date Radiation Started* is not a known date. See *RX Date–Radiation Flag* for an illustration of the relationships among these items.

Examples

A patient has external beam radiation on December 15, 2003.	December 15, 2003
A patient with a primary tumor of the brain undergoes stereotactic radiosurgery using a Gamma Knife on October 12, 2003.	October 12, 2003
A patient enters the facility for interstitial radiation boost for prostate cancer that is performed on August 6, 2003. Just prior to this, the patient had external beam therapy to the lower pelvis that was started on June 2, 2003 at another facility.	June 2, 2003

RX DATE–RADIATION FLAG

Item Length: 2
 NAACCR Item #1211
 Valid Codes: 10-12, 15, Blank
 New Item: 01/2010

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date Radiation Started* (NAACCR Item #1210).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Coding Instructions

- Leave this item blank if *Date Radiation Started* (NAACCR Item #1210) has a full or partial date recorded.
- Code 12 if the *Date Radiation Started* can not be determined, but the patient did receive first course radiation.
- Code 10 if it is unknown whether any radiation was given.
- Code 11 if no radiation is planned or given.
- Code 15 if radiation is planned, but has not yet started and the start date is not yet available. Follow this patient for radiation treatment and update this item, *Date Radiation Started*, and all other radiation items.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

Code	Description
10	No information whatsoever can be inferred from this exceptional value (that is, unknown if any radiation was given).
11	No proper value is applicable in this context (for example, no radiation given).
12	A proper value is applicable but not known. This event occurred, but the date is unknown (that is, radiation was given but the date is unknown).
15	Information is not available at this time, but it is expected that it will be available later (for example, radiation therapy is planned as part of the first course of therapy, but had not been started at the time of the most recent follow-up).
(blank)	A valid date value is provided in item <i>Date Radiation Started</i> (NAACCR Item #1210).

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date Radiation Started* (NAACCR Item #1210) and *Rx Date–Radiation Flag* (NAACCR Item #1211). ***In this table, the lower-case letter “b” is used to represent each blank space.***

Description	Traditional Date Radiation Started	Interoperable Date Radiation Started	Rx Date–Radiation Flag
	Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999	Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable.	
Full date known	MMDDCCYY (example: 02182007)	CCYYMMDD (example: 20070218)	bb
Month and year known	MM99CCYY (example: 02992007)	CCYYMMbb (example: 200702bb)	bb
Year only known	9999CCYY (example: 99992007)	CCYYbbbb (example: 2007bbbb)	bb
Unknown if any radiation given	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	10
No radiation given	00000000 (example: 00000000)	bbbbbbbb (example: bbbbbbbb)	11
Date is unknown, radiation given	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	12
Radiation not started yet	88888888 (example: 88888888)	bbbbbbbb (example: bbbbbbbb)	15

LOCATION OF RADIATION TREATMENT

Item Length: 1
 Allowable Values: 0–4, 8, 9
 NAACCR Item #1550
 Revised 01/04

Description

Identifies the location of the facility where radiation therapy was administered during the first course of treatment.

Rationale

This data item provides information useful to understanding the referral patterns for radiation therapy services and for assessing the quality and outcome of radiation therapy by delivery site.

Instructions for Coding

If the radiation treatment was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the radiation administered in the items *Palliative Care* (NAACCR Item #3270) and/or *Palliative Care at This Facility* (NAACCR Item #3280), as appropriate.

Code	Label	Definition
0	No radiation treatment	No radiation therapy was administered to the patient. Diagnosed at autopsy.
1	All radiation treatment at this facility	All radiation therapy was administered at the reporting facility.
2	Regional treatment at this facility, boost elsewhere	Regional treatment was administered at the reporting facility; a boost dose was administered elsewhere.
3	Boost radiation at this facility, regional elsewhere	Regional treatment was administered elsewhere; a boost dose was administered at the reporting facility.
4	All radiation treatment elsewhere	All radiation therapy was administered elsewhere.
8	Other	Radiation therapy was administered, but the pattern does not fit the above categories.
9	Unknown	Radiation therapy was administered, but the location of the treatment facility is unknown or not stated in patient record; it is unknown whether radiation therapy was administered. Death certificate only.

Examples

Code	Reason
2	A patient received radiation therapy to the entire head and neck region at the reporting facility and is then referred to another facility for a high-dose-rate (HDR) intracavitary boost.
3	A patient was diagnosed with breast cancer at another facility and received surgery and regional radiation therapy at that facility before being referred to the reporting facility for boost dose therapy.
8	Regional treatment was initiated at another facility and midway through treatment the patient was transferred to the reporting facility to complete the treatment regime.
9	Patient is known to have received radiation therapy, but records do not define the facility or facility(s) where the treatment was administered.

RADIATION TREATMENT VOLUME

Item Length: 2

Allowable Values: 00–41, 50, 60, 98, 99

NAACCR Item #1540

Revised 01/04

Description

Identifies the volume or anatomic target of the most clinically significant regional radiation therapy delivered to the patient during the first course of treatment.

Rationale

This data item provides information describing the anatomical structures targeted by the regional radiation therapy and can be used to determine whether the site of the primary disease was treated with radiation or if other regional or distant sites were targeted. This information is useful in evaluating the patterns of care within a facility (local analysis of physician practices) and on a regional or national basis.

Instructions for Coding

Radiation treatment volume will typically be found in the radiation oncologist's summary letter for the first course of treatment. Determination of the exact treatment volume may require assistance from the radiation oncologist for consistent coding.

Code	Label	Definition
00	No radiation treatment	Radiation therapy was not administered to the patient. Diagnosed at autopsy.
01	Eye/orbit	The radiation therapy target volume is limited to the eye and/or orbit.
02	Pituitary	The target volume is restricted to the pituitary gland and all adjacent volumes are irradiated incidentally.
03	Brain (NOS)	Treatment is directed at tumors lying within the substance of the brain, or its meninges.
04	Brain (limited)	The treatment volume encompasses less than the total brain, or less than all of the meninges.
05	Head and neck (NOS)	The treatment volume is directed at a primary tumor of the oropharyngeal complex, usually encompassing regional lymph nodes.
06	Head and neck (limited)	Limited volume treatment of a head and neck primary with the exception of glottis (code 7), sinuses (code 8), or parotid (code 9).
07	Glottis	Treatment is limited to a volume in the immediate neighborhood of the vocal cords.
08	Sinuses	The primary target is one or both of the maxillary sinuses or the ethmoidal frontal sinuses. In some cases, the adjacent lymph node regions may be irradiated.
09	Parotid	The primary target is one of the parotid glands. There may be secondary regional lymph node irradiation as well.
10	Chest/lung (NOS)	Radiation therapy is directed to some combination of hilar, mediastinal, and/or supraclavicular lymph nodes, and/or peripheral lung structures.
11	Lung (limited)	Radiation therapy is directed at one region of the lung without nodal irradiation.
12	Esophagus	The primary target is some portion of the esophagus. Regional lymph nodes may or may not be included in the treatment. Include tumors of the gastroesophageal junction.

Code	Label	Definition
13	Stomach	The primary malignancy is in the stomach. Radiation is directed to the stomach and possibly adjacent lymph nodes.
14	Liver	The primary target is all or a portion of the liver, for either primary or metastatic disease.
15	Pancreas	The primary tumor is in the pancreas. The treatment field encompasses the pancreas and possibly adjacent lymph node regions.
16	Kidney	The target is primary or metastatic disease in the kidney or the kidney bed after resection of a primary kidney tumor. Adjacent lymph node regions may be included in the field.
17	Abdomen (NOS)	Include all treatment of abdominal contents that do not fit codes 12–16.
18	Breast	The primary target is the intact breast and no attempt has been made to irradiate the regional lymph nodes. Intact breast includes breast tissue that either was not surgically treated or received a lumpectomy or partial mastectomy (C50.0–C50.9, Surgical Procedure of Primary Site [NAACCR Item #1290] codes 0–24).
19	Breast/lymph nodes	A deliberate attempt has been made to include regional lymph nodes in the treatment of an intact breast. See definition of intact breast above.
20	Chest wall	Treatment encompasses the chest wall (following mastectomy).
21	Chest wall/lymph nodes	Treatment encompasses the chest wall (following mastectomy) plus fields directed at regional lymph nodes.
22	Mantle, Mini-mantle	Treatment consists of a large radiation field designed to encompass all of the regional lymph nodes above the diaphragm, including cervical, supraclavicular, axillary, mediastinal, and hilar nodes (mantle), or most of them (mini-mantle). This code is used exclusively for patients with Hodgkin's or non-Hodgkin's lymphoma.
23	Lower extended field	The target zone includes lymph nodes below the diaphragm along the paraaortic chain. It may include extension to one side of the pelvis. This code includes the "hockey stick" field utilized to treat seminomas.
24	Spine	The primary target relates to the bones of the spine, including the sacrum. Spinal cord malignancies should be coded 40 (Spinal cord).
25	Skull	Treatment is directed at the bones of the skull. Any brain irradiation is a secondary consequence.
26	Ribs	Treatment is directed toward metastatic disease in one or more ribs. Fields may be tangential or direct.
27	Hip	The target includes the proximal femur for metastatic disease. In may cases there may be acetabular disease as well.
28	Pelvic bones	The target includes structures of the bones of the pelvis other than the hip or sacrum.
29	Pelvis (NOS)	Irradiation is directed at soft tissues within the pelvic region and codes 34–36 do not apply.
30	Skin	The primary malignancy originates in the skin and the skin is the primary target. So-called skin metastases are usually subcutaneous and should be coded 31 (Soft tissue).

Code	Label	Definition
31	Soft tissue	All treatment of primary or metastatic soft tissue malignancies not fitting other categories.
32	Hemibody	A single treatment volume encompassing either all structures above the diaphragm, or all structures below the diaphragm. This is almost always administered for palliation of widespread bone metastasis in patients with prostate or breast cancer.
33	Whole body	Entire body included in a single treatment.
34	Bladder and pelvis	The primary malignancy originated in the bladder, all or most of the pelvis is treated as part of the plan, typically with a boost to the bladder.
35	Prostate and pelvis	The primary malignancy originated in the prostate, all or most of the pelvis is treated as part of the plan, typically with a boost to the prostate.
36	Uterus and cervix	Treatment is confined to the uterus and cervix or vaginal cuff, usually by intracavitary or interstitial technique. If entire pelvis is included in a portion of the treatment, then code 29 (Pelvis, NOS).
37	Shoulder	Treatment is directed to the proximal humerus, scapula, clavicle, or other components of the shoulder complex. This is usually administered for control of symptoms for metastases.
38	Extremity bone, NOS	Bones of the arms or legs. This excludes the proximal femur, code 27 (Hip). This excludes the proximal humerus, code 37 (Shoulder).
39	Inverted Y	Treatment has been given to a field that encompasses the paraaortic and bilateral inguinal or inguinofemoral lymph nodes in a single port.
40	Spinal cord	Treatment is directed at the spinal cord or its meninges.
41	Prostate	Treatment is directed at the prostate with or without the seminal vesicles, without regional lymph node treatment.
50	Thyroid	Treatment is directed at the thyroid gland.
60	Lymph node region, NOS	The target is a group of lymph nodes not listed above. Examples include isolated treatment of a cervical, supraclavicular, or inguinofemoral region.
98	Other	Radiation therapy administered, treatment volume other than those previously categorized.
99	Unknown	Radiation therapy administered, treatment volume unknown or not stated in patient record; it is unknown whether radiation therapy was administered. Death certificate only.

Examples

Code	Reason
01	Lymphoma of the orbit treated with 4 cm x 4 cm portals.
02	Pituitary adenomas receiving small opposed field or rotational treatment.
03	The entire brain is treated for metastatic disease.

Code	Reason
04	Limited field irradiation of an oligodendroglioma or glioblastoma.
05	Carcinoma of the left tonsil treated with opposed lateral fields to the neck and an anterior supraclavicular field.
06	Interstitial implant utilized to treat a small carcinoma of the lateral tongue.
07	Small lateral fields utilized to treat a T1 or T2 glottic tumor.
11	Small portal treatment is delivered to the right bronchial/hilar region to stop hemoptysis.
17	Irradiation for hypersplenism due to lymphoma.
19	Tangential fields deliberately arranged in a manner that will encompass internal mammary lymph nodes in a patient with a medial primary; breast tangential fields plus supraclavicular and/or axillary field in a patient with five positive lymph nodes.
20	Following mastectomy, a patient has prophylactic chest wall irradiation to prevent local recurrence; a thoracotomy scar is irradiated because of known contamination with tumor.
24	An inverted "T" field is utilized to treat painful metastases in the lumbar vertebrae and sacrum in a patient with prostate cancer.
25	Patient with myeloma receives total skull irradiation for numerous "punched out" lesions that are causing discomfort.
33	Patient with chronic lymphocytic leukemia receives five treatments of 10 cGy each to reduce adenopathy or lymphocyte count.
36	Patient receives intracavitary therapy alone for a high-grade Stage IA carcinoma of the endometrium.
38	The distal forearm is treated for a metastatic lesion involving the radius.
39	Stage IA Hodgkin's disease presenting in an inguinal lymph node.
40	A portion of the spinal cord is treated for a primary ependymoma.
60	Ovarian carcinoma presenting with left supraclavicular lymphadenopathy as the only documented site of metastatic disease. The supraclavicular region is treated to prevent neurologic complications.
98	Anterior neck is treated for a primary thyroid lymphoma.

REGIONAL TREATMENT MODALITY

Item Length: 2

Allowable Values: 00, 20–32, 40–43,
50–55, 60–62, 98, 99

NAACCR Item #1570

Revised 09/06, 09/08

Description

Records the dominant modality of radiation therapy used to deliver the most clinically significant regional dose to the primary volume of interest during the first course of treatment.

Rationale

Radiation treatment is frequently delivered in two or more phases which can be summarized as “regional” and “boost” treatments. To evaluate patterns of radiation oncology care, it is necessary to know which radiation resources were employed in the delivery of therapy. For outcomes analysis, the modalities used for each of these phases can be very important.

Instructions for Coding

- Radiation treatment modality will typically be found in the radiation oncologist’s summary letter for the first course of treatment. Segregation of treatment components into regional and boost and determination of the respective treatment modality may require assistance from the radiation oncologist to ensure consistent coding.
- In the event multiple radiation therapy modalities were employed in the treatment of the patient, record only the dominant modality.
- Note that in some circumstances the boost treatment may precede the regional treatment.
- For purposes of this data item, photons and x-rays are equivalent.
- Code IMRT or conformal 3D whenever either is explicitly mentioned.
- Code radioembolization as brachytherapy.

Code	Label	Definition
00	No radiation treatment	Radiation therapy was not administered to the patient. Diagnosed at autopsy.
20	External beam, NOS	The treatment is known to be by external beam, but there is insufficient information to determine the specific modality.
21	Orthovoltage	External beam therapy administered using equipment with a maximum energy of less than one (1) million volts (MV). Orthovoltage energies are typically expressed in units of kilovolts (kV).
22	Cobalt-60, Cesium-137	External beam therapy using a machine containing either a Cobalt- 60 or Cesium-137 source. Intracavitary use of these sources is coded either 50 or 51.
23	Photons (2–5 MV)	External beam therapy using a photon producing machine with a beam energy in the range of 2–5 MV.
24	Photons (6–10 MV)	External beam therapy using a photon producing machine with a beam energy in the range of 6–10 MV.
25	Photons (11–19 MV)	External beam therapy using a photon producing machine with a beam energy in the range of 11–19 MV.
26	Photons (>19 MV)	External beam therapy using a photon producing machine with a beam energy of more than 19 MV.
27	Photons (mixed energies)	External beam therapy using more than one energy over the course of treatment.
28	Electrons	Treatment delivered by electron beam.

Code	Label	Definition
29	Photons and electrons mixed	Treatment delivered using a combination of photon and electron beams.
30	Neutrons, with or without photons/electrons	Treatment delivered using neutron beam.
31	IMRT	Intensity modulated radiation therapy, an external beam technique that should be clearly stated in patient record.
32	Conformal or 3-D therapy	An external beam technique using multiple, fixed portals shaped to conform to a defined target volume. Should be clearly described as conformal or 3-D therapy in patient record.
40	Protons	Treatment delivered using proton therapy.
41	Stereotactic radiosurgery, NOS	Treatment delivered using stereotactic radiosurgery, type not specified in patient record.
42	Linac radiosurgery	Treatment categorized as using stereotactic technique delivered with a linear accelerator.
43	Gamma Knife	Treatment categorized as using stereotactic technique delivered using a Gamma Knife machine.
50	Brachytherapy, NOS	Brachytherapy, interstitial implants, molds, seeds, needles, radioembolization, or intracavitary applicators of radioactive materials not otherwise specified.
51	Brachytherapy, Intracavitary, LDR	Intracavitary (no direct insertion into tissues) radio-isotope treatment using low dose rate applicators and isotopes (Cesium-137, Fletcher applicator).
52	Brachytherapy, Intracavitary, HDR	Intracavitary (no direct insertion into tissues) radioisotope treatment using high dose rate after-loading applicators and isotopes.
53	Brachytherapy, Interstitial, LDR	Interstitial (direct insertion into tissues) radioisotope treatment using low dose rate sources.
54	Brachytherapy, Interstitial, HDR	Interstitial (direct insertion into tissues) radioisotope treatment using high dose rate sources.
55	Radium	Infrequently used for low dose rate (LDR) interstitial and intracavitary therapy.
60	Radioisotopes, NOS	Iodine-131, Phosphorus-32, etc.
61	Strontium-89	Treatment primarily by intravenous routes for bone metastases.
62	Strontium-90	
80*	Combination modality, specified*	Combination of external beam radiation and either radioactive implants or radioisotopes*
85*	Combination modality, NOS*	Combination of radiation treatment modalities not specified in code 80.*
98	Other, NOS	Other radiation, NOS; Radiation therapy administered, but the treatment modality is not specified or is unknown.
99	Unknown	It is unknown whether radiation therapy was administered.

Examples

Code	Reason
20	A patient with prostate carcinoma receives pelvic irradiation at the reporting facility, and is then referred to a major medical center for experimental proton therapy boost.
24	A patient treated with breast conserving surgery has an interstitial boost at the time of the excisional biopsy. The implant uses Ir-192 and is left in place for three days. This is followed by 6 MV photon treatment of the entire breast. In this case, the “boost” precedes the regional treatment.
25	In an experimental program, a patient with as Stage III carcinoma of the prostate receives 4,500 cGy to the pelvis using 15 MV photons, and then the prostate receives a 600 cGy boost with neutrons.
25	Patient receives 15 MV external pelvic treatment to 4,500 cGy for cervical carcinoma, and then receives two Fletcher intracavitary implants.
29	A patient with carcinoma of the parotid receives daily treatments of which 60% are delivered by 15 MV photons and 40% of the dose is delivered by 16 MV electrons.
98	A patient with a head and neck cancer underwent regional radiation treatment elsewhere and was referred to reported facility for an HDR brachytherapy boost. Detailed treatment records from the other facility are not available.

***Note:** For cases diagnosed prior to January 1, 2003, the codes reported in this data item describe any radiation administered to the patient as part or all of the first course of therapy. Codes 80 and 85 describe specific converted descriptions of radiation therapy coded according to *Vol. II, ROADS*, and *DAM* rules and **should not** be used to record regional radiation for cases diagnosed on or later than January 1, 2003.

REGIONAL DOSE: cGy

Item Length: 5
 Right Justified, Zero-filled
 NAACCR Item #1510
 Revised 01/04

Description

Records the dominant or most clinically significant total dose of regional radiation therapy delivered to the patient during the first course of treatment. The unit of measure is centiGray (cGy).

Rationale

To evaluate patterns of radiation oncology care, it is necessary to capture information describing the prescribed regional radiation dose. Outcomes are strongly related to the dose delivered.

Instructions for Coding

- The International Council for Radiation Protection (ICRP) recommends recording doses at the axis point where applicable (opposed fields, four field box, wedged pair, and so on). For maximum consistency in this data item, the ICRP recommendations should be followed whenever possible. Where there is no clear axis point, record the dose as indicated in the summary chart. Determining the exact dose may be highly subjective and require assistance from the radiation oncologist for consistent coding.
- Regional dose will typically be found in the radiation oncologist's summary letter for the first course of treatment. Determination of the total dose of regional radiation therapy may require assistance from the radiation oncologist for consistent coding.
- Do not include the boost dose, if one was administered.
- Code 88888 when brachytherapy or radioisotopes—codes 50–62 for *Regional Treatment Modality* (NAACCR Item #1570)—were administered to the patient.
- Note that dose is still occasionally specified in “rads.” One rad is equivalent to one centiGray (cGy).

Code	Definition
(fill spaces)	Record the actual regional dose delivered.
00000	Radiation therapy was not administered. Diagnosed at autopsy.
88888	Not applicable, brachytherapy or radioisotopes administered to the patient.
99999	Regional radiation therapy was administered, but the dose is unknown; it is unknown whether radiation therapy was administered. Death certificate only.

Examples

Code	Reason
05000	A patient with Stage III prostate carcinoma received pelvic irradiation to 5,000 cGy followed by a prostate boost to 7,000 cGy. Record the regional dose as 5,000 cGy.
06000	A patient with a left supraclavicular metastasis from a gastric carcinoma received 6,000 cGy to the left supraclavicular region. The dose is calculated at a prescribed depth of 3 cm. A secondary calculation shows a D_{max} dose of 6,450 cGy. Record the regional dose reflecting the prescribed dose of 6,000 cGy.
05500	A patient with a Stage II breast carcinoma is treated with the breast intact. Tangent fields are utilized to bring the dose of the breast to 5,500 cGy. The supraclavicular lymph nodes are treated 4,500 cGy, calculated to a depth of 3 cm, and an interstitial boost in the primary tumor bed is delivered to a small volume in the breast. Record the primary target of the breast as 5,500cGy.

BOOST TREATMENT MODALITY

Item Length: 2
 Allowable Values: 00, 20–32, 40–43,
 50–55, 60–62, 98, 99
 NAACCR Item #3200
 Revised 01/04, 09/08

Description

Records the dominant modality of radiation therapy used to deliver the most clinically significant boost dose to the primary volume of interest during the first course of treatment. This is accomplished with external beam fields of reduced size (relative to the regional treatment fields), implants, stereotactic radiosurgery, conformal therapy, or IMRT. External beam boosts may consist of two or more successive phases with progressively smaller fields generally coded as a single entity.

Rationale

Radiation treatment is frequently delivered in two or more phases which can be summarized as “regional” and “boost” treatments. To evaluate patterns of radiation oncology care, it is necessary to know which radiation resources were employed in the delivery of therapy. For outcomes analysis, the modalities used for each of these phases can be very important.

Instructions for Coding

- Radiation boost treatment modalities will typically be found in the radiation oncologist’s summary letter for the first course of treatment. Segregation of treatment components into regional and boost and determination of the respective treatment modality may require assistance from the radiation oncologist to ensure consistent coding.
- In the event that multiple radiation therapy boost modalities were employed during the treatment of the patient, record only the dominant modality.
- Note that in some circumstances, the boost treatment may precede the regional treatment.
- For purposes of this field, photons and x-rays are equivalent.
- Code radioembolization as brachytherapy.

Code	Label	Definition
00	No boost treatment	A boost dose was not administered to the patient. Diagnosed at autopsy.
20	External beam, NOS	The treatment is known to be by external beam, but there is insufficient information to determine the specific modality.
21	Orthovoltage	External beam therapy administered using equipment with a maximum energy of less than one (1) million volts (MV). Orthovoltage energies are typically expressed in units of kilovolts (kV).
22	Cobalt-60, Cesium-137	External beam therapy using a machine containing either a Cobalt-60 or Cesium-137 source. Intracavitary use of these sources is coded either 50 or 51.
23	Photons (2–5 MV)	External beam therapy using a photon producing machine with a beam energy in the range of 2–5 MV.
24	Photons (6–10 MV)	External beam therapy using a photon producing machine with a beam energy in the range of 6–10 MV.
25	Photons (11–19 MV)	External beam therapy using a photon producing machine with a beam energy in the range of 11–19 MV.
26	Photons (>19 MV)	External beam therapy using a photon producing machine with a beam energy of more than 19 MV.
27	Photons (mixed energies)	External beam therapy using more than one energy over the course of treatment.

Code	Label	Definition
28	Electrons	Treatment delivered by electron beam.
29	Photons and electrons mixed	Treatment delivered using a combination of photon and electron beams.
30	Neutrons, with or without photons/electrons	Treatment delivered using neutron beam.
31	IMRT	Intensity modulated radiation therapy, an external beam technique that should be clearly stated in patient record.
32	Conformal or 3-D therapy	An external beam technique using multiple, fixed portals shaped to conform to a defined target volume. Should be clearly described as conformal or 3-D therapy in patient record.
40	Protons	Treatment delivered using proton therapy.
41	Stereotactic radiosurgery, NOS	Treatment delivered using stereotactic radiosurgery, type not specified in patient record.
42	Linac radiosurgery	Treatment categorized as using stereotactic technique delivered with a linear accelerator.
43	Gamma Knife	Treatment categorized as using stereotactic technique delivered using a Gamma Knife machine.
50	Brachytherapy, NOS	Brachytherapy, interstitial implants, molds, seeds, needles, radioembolization, or intracavitary applicators of radioactive materials not otherwise specified.
51	Brachytherapy, Intracavitary, LDR	Intracavitary (no direct insertion into tissues) radio-isotope treatment using low dose rate applicators and isotopes (Cesium-137, Fletcher applicator).
52	Brachytherapy, Intracavitary, HDR	Intracavitary (no direct insertion into tissues) radioisotope treatment using high dose rate after-loading applicators and isotopes.
53	Brachytherapy, Interstitial, LDR	Interstitial (direct insertion into tissues) radioisotope treatment using low dose rate sources.
54	Brachytherapy, Interstitial, HDR	Interstitial (direct insertion into tissues) radioisotope treatment using high dose rate sources.
55	Radium	Infrequently used for low dose rate (LDR) interstitial and intracavitary therapy.
60	Radioisotopes, NOS	Iodine-131, Phosphorus-32, etc.
61	Strontium-89	Treatment primarily by intravenous routes for bone metastases.
62	Strontium-90	
98	Other, NOS	Radiation therapy administered, but the treatment modality is not specified or is unknown.
99	Unknown	It is unknown whether radiation therapy was administered. Death certificate only.

Examples

Code	Reason
29	A patient with carcinoma of the tonsil receives 4,500 cGy to the head and neck region with 6 MV photons. The primary site and involved regional lymph nodes are then boosted, ie, taken to a maximum dose of 7,400 cGy, using a sequence of beam arrangements involving 6 MV photons, 15 MV photons, and 12 MV electrons.

Code	Reason

Code	Reason
30	In an experimental program, a patient with Stage III carcinoma of the prostate receives 4,500 cGy to the pelvis using 15 MV photons, and then the prostate receives a 600 cGy boost with neutrons.
40	A patient with prostate carcinoma receives pelvic irradiation at the reporting facility and is referred to a major medical center for experimental proton therapy boost.
51	A patient receives external pelvic treatment to 4,500 cGy for cervical carcinoma, then receives two Fletcher intracavitary implants as boost treatment.
55	A patient treated with breast conserving surgery has an interstitial boost at the time of the excisional biopsy. The implant uses Ir-192 and is left in place for three days.
99	A patient with a head and neck cancer is referred to another institution for an HDR brachytherapy boost. Detailed treatment records from the other institution are not available.

BOOST DOSE: cGy

Item Length: 5
 Right Justified, Zero-filled
 NAACCR Item #3210
 Revised 06/05

Description

Records the additional dose delivered to that part of the treatment volume encompassed by the boost fields or devices. The unit of measure is centiGray (cGy).

Rationale

To evaluate patterns of radiation oncology care, it is necessary to capture information describing the prescribed boost radiation dose. Outcomes are strongly related to the dose delivered.

Instructions for Coding

- The International Council for Radiation Protection (ICRP) recommends recording doses at the axis point where applicable (opposed fields, four field box, wedged pair, and so on). For maximum consistency in this data item, the ICRP recommendations should be followed whenever possible. Where there is no clear axis point, record the dose as indicated in the summary chart. Consult the radiation oncologist for the exact dose, if necessary.
- Radiation boost treatment dose will typically be found in the radiation oncologist's summary letter for the first course of treatment. Determination of the additional boost dose of radiation therapy may require assistance from the radiation oncologist for consistent coding.
- Do not include the regional dose. In general, the boost dose will be calculated as the difference between the maximum prescribed dose and the regional dose. Many patients will not have a boost.
- Code 88888 when brachytherapy or radioisotopes—codes 50–62 for *Boost Treatment Modality* (NAACCR Item #3200)—were administered to the patient.
- Note that dose is still occasionally specified in “rads.” One rad is equivalent to one centiGray (cGy).
- There may be times when the first course of treatment information is incomplete. Therefore, it is important to continue follow-up efforts to be certain the complete treatment information is collected.

Code	Definition
(fill spaces)	Record the actual boost dose delivered.
00000	Boost dose therapy was not administered. Diagnosed at autopsy.
88888	Not applicable, brachytherapy or radioisotopes administered to the patient.
99999	Boost radiation therapy was administered, but the dose is unknown. Death certificate only.

Examples

Code	Reason
02000	A patient with Stage III prostate carcinoma receives pelvic irradiation to 5,000 cGy followed by a conformal prostate boost to 7,000 cGy. Record the prescribed (and delivered) boost dose, 2,000 cGy (7,000 cGy minus 5,000 cGy).
00000	A patient with a left supraclavicular metastasis from a gastric carcinoma receives 6,000 cGy to the left supraclavicular region. The dose is calculated at a prescribed depth of 3 cm. A secondary calculation shows a D_{max} dose (dose at depth of maximum dose) of 6,450 cGy. Do not confuse D_{max} doses with boost doses. In this case, there is no planned boost. Record the boost dose as 00000 cGy.
88888	A patient with a Stage II breast carcinoma is treated with the breast intact. Tangent fields are utilized to bring the central axis dose in the breast to 5,040 cGy. The supraclavicular lymph nodes are treated 4,500 cGy, calculated to a depth of 3 cm, and an interstitial boost in the primary tumor bed is delivered to a small volume in the breast. Record the boost dose as 88888. Note that standards for describing an interstitial or intracavitary treatment with a single number are somewhat variable.

NUMBER OF TREATMENTS TO THIS VOLUME

Item Length: 3
 Allowable Values: 000–999
 Right Justified, Zero-filled
 NAACCR Item #1520
 Revised 09/04, 01/10, 05/10

Description

Records the total number of treatment sessions (fractions) administered during the first course of treatment.

Rationale

This data item is used to evaluate patterns of radiation therapy and the treatment schedules.

Instructions for Coding

- The number of treatments or fractions will typically be found in the radiation oncologist's summary letter for the first course of treatment. Determination of the exact number of treatments or fractions delivered to the patient may require assistance from the radiation oncologist for consistent coding.
- Although a treatment session may include several treatment portals delivered within a relatively confined period of time—usually a few minutes—it is still considered one session.
- The total number of treatment sessions (fractions) is the sum of the number of fractions of regional treatment and the number of fractions of boost treatment.
- Count each separate administration of brachytherapy or implants as a single treatment or fraction.

Code	Label	Definition
000	None	Radiation therapy was not administered to the patient. Diagnosed at autopsy.
001–998	Number of treatments	Total number of treatment sessions administered to the patient.
999	Unknown	Radiation therapy was administered, but the number of treatments is unknown. Or, it is unknown whether radiation therapy was administered. Death certificate only.

Examples

Code	Reason
025	A patient with breast carcinoma had treatment sessions in which treatment was delivered to the chest wall and separately to the ipsilateral supraclavicular region for a total of three treatment portals. Twenty-five treatment sessions were given. Record 25 treatments.
035	A patient with Stage IIIB bronchogenic carcinoma received 25 treatments to the left hilum and mediastinum, given in 25 daily treatments over five weeks. A left hilar boost was then given in 10 additional treatments. Record 35 treatments.
050	A patient with advanced head and neck cancer was treated using “hyperfractionation.” Three fields were delivered in each session, two sessions were given each day, six hours apart, with each session delivering a total dose of 150 cGy. Treatment was given for a total of 25 days. Record 50 treatments.

RADIATION/SURGERY SEQUENCE

Item Length: 1

Allowable Values: 0, 2–6, 9

NAACCR Item #1380

Revised 01/04, 01/10

Description

Records the sequencing of radiation and surgical procedures given as part of the first course of treatment.

Rationale

The sequence of radiation and surgical procedures given as part of the first course of treatment cannot always be determined using the date on which each modality was started or performed. This data item can be used to more precisely evaluate the timing of delivery of treatment to the patient.

Instructions for Coding

- Surgical procedures include *Surgical Procedure of Primary Site* (NAACCR Item #1290); *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292); *Surgical Procedure/Other Site* (NAACCR Item #1294). If all of these procedures are coded 0, or it is not known whether the patient received both surgery and radiation, then this item should be coded 0.
- If the patient received both radiation therapy and any one or a combination of the following surgical procedures: *Surgical Procedure of Primary Site*, *Regional Lymph Node Surgery*, or *Surgical Procedure/Other Site*, then code this item 2–9, as appropriate.

Code	Label	Definition
0	No radiation therapy and/or surgical procedures	No radiation therapy given or unknown if radiation therapy given; and/or no surgery of the primary site; no scope of regional lymph node surgery; no surgery to other regional site(s), distant site(s), or distant lymph node(s) or it is unknown whether any surgery given.
2	Radiation therapy before surgery	Radiation therapy given before surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s).
3	Radiation therapy after surgery	Radiation therapy given after surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s).
4	Radiation therapy both before and after surgery	Radiation therapy given before and after any surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s).
5	Intraoperative radiation therapy	Intraoperative therapy given during surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s).
6	Intraoperative radiation therapy with other therapy administered before or after surgery	Intraoperative radiation therapy given during surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s) with other radiation therapy administered before or after surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s).
9	Sequence unknown	Administration of radiation therapy and surgery to primary site, scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s) were performed and the sequence of the treatment is not stated in the patient record.

Code	Reason
0	Due to other medical conditions surgery was not performed. The patient received palliative radiation therapy to alleviate pain.
2	A large lung lesion received radiation therapy prior to resection.
3	A patient received a wedge resection of a right breast mass with axillary lymph node dissection followed by radiation to right breast.
4	Preoperative radiation therapy was given to a large, bulky vulvar lesion and was followed by a lymph node dissection. This was then followed by radiation therapy to treat positive lymph nodes.
5	A cone biopsy of the cervix was followed by intracavitary implant for IIB cervical carcinoma.
6	Stage IV vaginal carcinoma was treated with 5,000 cGy to the pelvis followed by a lymph node dissection and 2,500 cGy of intracavitary brachytherapy.
9	An unknown primary of the head and neck was treated with surgery and radiation prior to admission, but the sequence is unknown. The patient enters for chemotherapy.

DATE RADIATION ENDED

Item Length: 8
 NAACCR Item #3220
 Revised 06/05, 01/10

Description

The date on which the patient completes or receives the last radiation treatment at any facility.

Rationale

The length of time over which radiation therapy is administered to a patient is a factor in tumor control and treatment morbidity. It is useful to evaluate the quality of care and the success of patient support programs designed to maintain continuity of treatment.

Instructions for Coding

- The date when treatment ended will typically be found in the radiation oncologist's summary letter for the first course of treatment.
- For brachytherapy if the treatment is applied only once, this date will be the same as *Date Radiation Started* (NAACCR Item #1210).
- There may be times when the first course of treatment information is incomplete. Therefore, it is important to continue follow-up efforts to be certain the complete treatment information is collected.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date Radiation Ended* is MMDDCCYY, with 99 indentifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date Radiation Ended* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *RX Date–Radiation Flag* (NAACCR Item #1211) is used to explain why *Date Radiation Ended* is not a known date. See *RX Date–Radiation Flag* for an illustration of the relationships among these items.

Examples

A patient starts IMRT radiation treatment on December 15, 2004 and treatment continues until January 4, 2005.	January 4, 2005
A patient receives one radiation treatment on October 2, 2009, then refuses further treatments.	October 2, 2009
A patient with a primary tumor of the brain undergoes stereotactic radiosurgery using a Gamma Knife on April 4, 2006.	April 4, 2006

RX DATE RAD ENDED FLAG

Item Length: 2
 NAACCR Item #3221
 Valid Codes: 10-12, 15, Blank
 New Item: 01/2010, revised 02/10, 03/10

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date Radiation Ended* (NAACCR Item #3200).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Coding Instructions

- Leave this item blank if *Date Radiation Ended* (NAACCR Item #3200) has a full or partial date recorded.
- Code 12 if the *Date Radiation Ended* can not be determined, but the patient did receive first course radiation.
- Code 10 if it is unknown whether any radiation was given.
- Code 11 if no radiation is planned or given..
- Code 15 if radiation is ongoing. Follow this patient for radiation treatment and update this item, *Date Radiation Ended*, and all other radiation items.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

Code	Description
10	No information whatsoever can be inferred from this exceptional value (that is, unknown if any radiation was given).
11	No proper value is applicable in this context (for example, no radiation was administered).
12	A proper value is applicable but not known. This event occurred, but the date is unknown (that is, radiation was given but the date is unknown).
15	Information is not available at this time, but it is expected that it will be available later (that is, radiation therapy had begun at the time of the most recent follow-up but was not yet completed).
(blank)	A valid date value is provided in item <i>Date Radiation Ended</i> (NAACCR Item #3200).

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date Radiation Ended* (NAACCR Item #3200) and *Rx Date Rad Ended Flag* (NAACCR ITEM #3201). ***In this table, the lower-case letter “b” is used to represent each blank space.***

Description	Traditional Date Radiation Ended	Interoperable Date Radiation Ended	Rx Date–Rad Ended Flag
	Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999	Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable.	
Full date known	MMDDCCYY (example: 02182007)	CCYYMMDD (example: 20070218)	bb
Month and year known	MM99CCYY (example: 02992007)	CCYYMMbb (example: 200702bb)	bb
Year only known	9999CCYY (example: 99992007)	CCYYbbbb (example: 2007bbbb)	bb
Unknown if any radiation given	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	10
No radiation given	00000000 (example: 00000000)	bbbbbbbb (example: bbbbbbbb)	11
Date is unknown, radiation given	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	12
Radiation is ongoing	88888888 (example: 88888888)	bbbbbbbb (example: bbbbbbbb)	15

REASON FOR NO RADIATION

Item Length: 1
 Allowable Values: 0–2, 5–9
 NAACCR Item #1430
 Revised 09/04

Description

Records the reason that no regional radiation therapy was administered to the patient.

Rationale

When evaluating the quality of care, it is useful to know the reason that various methods of therapy were not used, and whether the failure to provide a given type of therapy was due to the physician's failure to recommend that treatment, or due to the refusal of the patient, a family member, or the patient's guardian.

Instructions for Coding

- If *Regional Treatment Modality* (NAACCR Item #1570) is coded 00, then record the reason based on documentation in patient record.
- Code 1 if the treatment plan offered multiple options and the patient selected treatment that did not include radiation therapy.
- Code 7 if the patient refused recommended radiation therapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 8 if it is known that a physician recommended radiation treatment, but no further documentation is available yet to confirm its administration.
- Code 8 to indicate referral to a radiation oncologist was made and the registry should follow to determine whether radiation was administered. If follow-up to the specialist or facility determines the patient was never there and no other documentation can be found, code 1.
- Cases coded 8 should be followed and updated to a more definitive code as appropriate.
- Code 9 if the treatment plan offered multiple options, but it is unknown which treatment, if any, was provided.

Code	Definition
0	Radiation therapy was administered.
1	Radiation therapy was not administered because it was not part of the planned first course treatment.
2	Radiation therapy was not recommended/administered because it was contraindicated due to other patient risk factors (comorbid conditions, advanced age, progression of tumor prior to planned radiation etc.).
5	Radiation therapy was not administered because the patient died prior to planned or recommended therapy.
6	Radiation therapy was not administered; it was recommended by the patient's physician, but was not administered as part of first course treatment. No reason was noted in patient record.
7	Radiation therapy was not administered; it was recommended by the patient's physician, but this treatment was refused by the patient, the patient's family member, or the patient's guardian. The refusal was noted in patient record.
8	Radiation therapy was recommended, but it is unknown whether it was administered.
9	It is unknown if radiation therapy was recommended or administered. Death certificate and autopsy cases only.

Example

Code	Reason
1	A patient with Stage I prostate cancer is offered either surgery or brachytherapy to treat his disease. The patient elects to be surgically treated.

DATE SYSTEMIC THERAPY STARTED

Item Length: 8
 NAACCR Item #3230
 Revised 01/10

Description

Records the date of initiation for systemic therapy that is part of the first course of treatment. Systemic therapy includes the administration of chemotherapy agents, hormonal agents, biological response modifiers, bone marrow transplants, stem cell harvests, and surgical and/or radiation endocrine therapy.

Rationale

Collecting dates for each treatment modality allows the sequencing of multiple treatments and aids in the evaluation of time intervals from diagnosis to treatment and from treatment to recurrence.

Instructions for Coding

- Record the first or earliest date on which systemic therapy was administered. Systemic therapy includes *Chemotherapy* (NAACCR Item #1390), *Hormone Therapy* (NAACCR Item #1400), *Immunotherapy* (NAACCR Item #1410), and *Hematologic Transplant and Endocrine Procedures* (NAACCR Item #3250).
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date Systemic Therapy Started* is MMDDCCYY, with 99 indentifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date Systemic Therapy Started* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *RX Date Systemic Flag* (NAACCR Item #1231) is used to explain why *Date Systemic Therapy Started* is not a known date. See *RX Date Systemic Flag* for an illustration of the relationships among these items.

Examples

A patient with breast cancer begins her regimen of chemotherapy on December 15, 2003, and is subsequently given Tamoxifen on January 20, 2004.	December 15, 2003
A patient with Stage IV prostate cancer has an orchiectomy on June 2, 2003. He is then started on a regime of hormonal agents on June 9, 2003.	June 2, 2003

RX DATE SYSTEMIC FLAG

Item Length: 2
 NAACCR Item #3231
 Valid Codes: 10-12, 15, Blank
 New Item: 01/2010

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date Systemic Therapy Started* (NAACCR Item #3230).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Coding Instructions

- Leave this item blank if *Date Systemic Therapy Started* (NAACCR Item #3230) has a full or partial date recorded.
- Code 12 if the *Date Systemic Therapy Started* can not be determined, but the patient did receive first course systemic therapy.
- Code 10 if it is unknown whether any systemic therapy was given.
- Code 11 if no systemic therapy is planned or given.
- Code 15 if systemic therapy is planned, but not yet started. Follow this patient for systemic therapy and update this item, *Date Systemic Therapy Started*, and all relevant systemic therapy items.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

Code	Description
10	No information whatsoever can be inferred from this exceptional value (that is, unknown if any systemic therapy was given).
11	No proper value is applicable in this context (for example, no systemic therapy given).
12	A proper value is applicable but not known. This event occurred, but the date is unknown (that is, systemic therapy was given but the date is unknown).
15	Information is not available at this time, but it is expected that it will be available later (that is, systemic therapy is planned as part of first course treatment, but had not yet started at the time of the last follow-up).
(blank)	A valid date value is provided in item <i>Date Systemic Therapy Started</i> (NAACCR Item #3230).

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date Systemic Therapy Started* (NAACCR Item #3230) and *Rx Date Systemic Flag* (NAACCR Item #3201). ***In this table, the lower-case letter “b” is used to represent each blank space.***

Description	Traditional Date Systemic Therapy Started	Interoperable Date Systemic Therapy Started	Rx Date Systemic Flag
	Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999	Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable.	
Full date known	MMDDCCYY (example: 02182007)	CCYYMMDD (example: 20070218)	bb
Month and year known	MM99CCYY (example: 02992007)	CCYYMMbb (example: 200702bb)	bb
Year only known	9999CCYY (example: 99992007)	CCYYbbbb (example: 2007bbbb)	bb
Unknown if any systemic therapy given	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	10
No systemic therapy given	00000000 (example: 00000000)	bbbbbbbb (example: bbbbbbbb)	11
Date is unknown, systemic therapy given	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	12
Systemic therapy is planned, not yet begun	88888888 (example: 88888888)	bbbbbbbb (example: bbbbbbbb)	15

DATE CHEMOTHERAPY STARTED

Item Length: 8
NAACCR Item #1220
New Item: 01/2010

Description

Records the date of initiation of chemotherapy that is part of the first course of treatment.

Rationale

Collecting dates for each treatment modality allows the sequencing of multiple treatments and aids in the evaluation of time intervals from diagnosis to treatment and from treatment to recurrence.

Instructions for Coding

- Record the first or earliest date on which chemotherapy was administered by any facility. This date corresponds to administration of the agents coded in *Chemotherapy* (NAACCR Item #1390).
- This item was required in the past but discontinued in FORDS as a required item in 2003. If the date was not collected between 2003 and 2009, this field may be left blank. However, if it was collected for cases diagnosed in those years, it should be retained in this field.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date Chemotherapy Started* is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date Chemotherapy Started* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *RX Date-Chemo Flag* (NAACCR Item #1221) is used to explain why *Date Chemotherapy Started* is not a known date. See *RX Date-Chemo Flag* for an illustration of the relationships among these items.

RX DATE–CHEMO FLAG

Item Length: 2
 NAACCR Item #1221
 Valid Codes: 10-12, 15, Blank
 New Item: 01/2010

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date Chemotherapy Started* (NAACCR Item #1220).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Coding Instructions

- Leave this item blank if *Date Chemotherapy Started* (NAACCR Item #1220) has a full or partial date recorded.
- Code 12 if the *Date Chemotherapy Started* can not be determined, but the patient did receive first course chemotherapy.
- Code 10 if it is unknown whether any chemotherapy was given.
- Code 11 if no chemotherapy is planned or given.
- Code 15 if chemotherapy is planned, but not yet started. Follow this patient for chemotherapy and update this item, *Date Chemotherapy Started*, and the relevant chemotherapy items.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.
- Leave this item blank for diagnoses between 2003 and 2009 (inclusive) if this facility did not collect *Date Chemotherapy Started* at that time.

Code	Description
10	No information whatsoever can be inferred from this exceptional value (that is, unknown if any chemotherapy was given).
11	No proper value is applicable in this context (for example, no chemotherapy given).
12	A proper value is applicable but not known. This event occurred, but the date is unknown (that is, chemotherapy was given but the date is unknown).
15	Information is not available at this time, but it is expected that it will be available later (that is, chemotherapy is planned as part of first course treatment, but had not yet started at the time of the last follow-up).
(blank)	A valid date value is provided in item <i>Date Chemotherapy Started</i> (NAACCR Item #1220). Case was diagnosed between 2003 and 2009 and the facility did not record <i>Date Chemotherapy Started</i> (NAACCR Item #1220) at that time.

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date Chemotherapy Started* (NAACCR Item #1220) and *Rx Date-Chemo Flag* (NAACCR Item #1221). ***In this table, the lower-case letter “b” is used to represent each blank space.***

Description	Traditional Date Chemotherapy Started	Interoperable Date Chemotherapy Started	Rx Date-Chemo Flag
	Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999	Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable.	
Full date known	MMDDCCYY (example: 02182007)	CCYYMMDD (example: 20070218)	bb
Month and year known	MM99CCYY (example: 02992007)	CCYYMMbb (example: 200702bb)	bb
Year only known	9999CCYY (example: 99992007)	CCYYbbbb (example: 2007bbbb)	bb
Unknown if any chemotherapy given	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	10
No chemotherapy given	00000000 (example: 00000000)	bbbbbbbb (example: bbbbbbbb)	11
Date is unknown, chemotherapy given	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	12
Chemotherapy is planned, not yet begun	88888888 (example: 88888888)	bbbbbbbb (example: bbbbbbbb)	15

CHEMOTHERAPY

Item Length: 2

Allowable Values: 00–03, 82, 85–88, 99

NAACCR Item #1390

Revised 06/05, 09/08, 01/10

Description

Records the type of chemotherapy administered as first course treatment at this and all other facilities. If chemotherapy was not administered, then this item records the reason it was not administered to the patient. Chemotherapy consists of a group of anticancer drugs that inhibit the reproduction of cancer cells by interfering with DNA synthesis and mitosis.

Rationale

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of chemotherapeutic agents as part of the first course of therapy. In addition, when evaluating the quality of care, it is useful to know the reason if chemotherapy was not administered.

Instructions for Coding

- Code 00 if chemotherapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer.
- Code 00 if the treatment plan offered multiple options, and the patient selected treatment that did not include chemotherapy.
- If it is known that chemotherapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused recommended chemotherapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended the patient receive chemotherapy but no further documentation is available yet to confirm its administration
- Code 88 to indicate referral was made medical oncologist and the registry must follow to determine whether it was given. If follow-up with the specified specialist or facility indicates the patient was never there, code 00.
- Cases coded 88 must be followed to determine what kind of chemotherapy was administered or why it was not.
- Code 99 if it is not known whether chemotherapy is usually administered for this type and stage of cancer and there is no mention in the patient record whether it was recommended or administered.
- Code chemoembolization as 01, 02, or 03 depending on the number of chemotherapeutic agents involved.
- If the managing physician changes one of the agents in a combination regimen, and the replacement agent belongs to a different group (chemotherapeutic agents are grouped as alkylating agents, antimetabolites, natural products, or other miscellaneous) than the original agent, the new regimen represents the start of subsequent therapy, and *only the original agent or regimen is recorded as first course therapy*.
- Refer to the *SEER*Rx Interactive Drug Database* (<http://seer.cancer.gov/>) for a list of chemotherapeutic agents.
- If chemotherapy was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the chemotherapy administered in the item Palliative Care (NAACCR Item #3270).

Code	Definition
00	None, chemotherapy was not part of the planned first course of therapy. Diagnosed at autopsy.
01	Chemotherapy administered as first course therapy, but the type and number of agents is not documented in patient record.
02	Single-agent chemotherapy administered as first course therapy.
03	Multiagent chemotherapy administered as first course therapy.
82	Chemotherapy was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age progression of tumor prior to administration, etc.).
85	Chemotherapy was not administered because the patient died prior to planned or recommended therapy.

Code	Definition
86	Chemotherapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record.
87	Chemotherapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record.
88	Chemotherapy was recommended, but it is unknown if it was administered.
99	It is unknown whether a chemotherapeutic agent(s) was recommended or administered because it is not stated in patient record. Death certificate only.

Examples

Code	Reason
01	A patient with primary liver cancer is known to have received chemotherapy, however, the name(s) of agent(s) administered is not stated in patient record.
02	A patient with Stage III colon cancer is treated with a combination of fluorouracil and levamisole. Code the administration of fluorouracil as single agent chemotherapy, and levamisole as an immunotherapeutic agent.
02	A patient with non-Hodgkin's lymphoma is treated with fludarabine.
03	A patient with early stage breast cancer receives chemotherapy. The patient chart indicates that a regimen containing doxorubicin is to be administered.
86	After surgical resection of an ovarian mass the following physician recommends chemotherapy. The patient record states that chemotherapy was not subsequently administered to the patient, but the reason why chemotherapy was not administered is not given.

CHEMOTHERAPY AT THIS FACILITY

Item Length: 2

Allowable Values: 00–03, 82, 85–88, 99

NAACCR Item #700

Revised 06/05, 09/08, 01/10

Description

Records the type of chemotherapy administered as first course treatment at this facility. If chemotherapy was not administered, then this item records the reason it was not administered to the patient. Chemotherapy consists of a group of anticancer drugs that inhibit the reproduction of cancer cells by interfering with DNA synthesis and mitosis.

Rationale

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of chemotherapeutic agents as part of the first course of therapy. In addition, when evaluating the quality of care, it is useful to know the reason if chemotherapy was not administered.

Instructions for Coding

- Record only chemotherapy received at this facility. Do not record agents administered at other facilities.
- Code 00 if chemotherapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer.
- Code 00 if the treatment plan offered multiple options, and the patient selected treatment that did not include chemotherapy.
- If it is known that chemotherapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused recommended chemotherapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended the patient receive chemotherapy but no further documentation is available yet to confirm its administration
- Cases coded 88 must be followed to determine what kind of chemotherapy was administered or why it was not.
- Code 99 if it is not known whether chemotherapy is usually administered for this type and stage of cancer and there is no mention in the patient record whether it was recommended or administered.
- Code chemoembolization as 01, 02, or 03 depending on the number of chemotherapeutic agents involved.
- If the managing physician changes one of the agents in a combination regimen, and the replacement agent belongs to a different group (chemotherapeutic agents are grouped as alkylating agents, antimetabolites, natural products, or other miscellaneous) than the original agent, the new regimen represents the start of subsequent therapy, and *only the original agent or regimen is recorded as first course therapy*.
- Refer to the *SEER*Rx Interactive Drug Database* (<http://seer.cancer.gov/>) for a list of chemotherapeutic agents.
- If chemotherapy was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the chemotherapy administered in the item Palliative Care (NAACCR Item #3270).

Code	Definition
00	None, chemotherapy was not part of the planned first course of therapy. Diagnosed at autopsy.
01	Chemotherapy administered as first course therapy; but the type and number of agents is not documented in patient record.
02	Single-agent chemotherapy administered as first course therapy.
03	Multiagent chemotherapy administered as first course therapy
82	Chemotherapy was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age, progression of tumor prior to planned administration).
85	Chemotherapy was not administered because the patient died prior to planned or recommended therapy.
86	Chemotherapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record.

Code	Definition
87	Chemotherapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record.
88	Chemotherapy was recommended, but it is unknown if it was administered.
99	It is unknown whether a chemotherapeutic agent(s) was recommended or administered because it is not stated in patient record. Death certificate only.

DATE HORMONE THERAPY STARTED

Item Length: 8
NAACCR Item #710
New Item: 01/2010

Description

Records the date of initiation of hormone therapy that is part of the first course of treatment.

Rationale

Collecting dates for each treatment modality allows the sequencing of multiple treatments and aids in the evaluation of time intervals from diagnosis to treatment and from treatment to recurrence.

Instructions for Coding

- Record the first or earliest date on which hormone therapy was administered by any facility. This date corresponds to administration of the agents coded in *Hormone Therapy* (NAACCR Item #1390).
- This item was required in the past but discontinued in FORDS as a required item in 2003. If the date was not collected between 2003 and 2009, this field may be left blank. However, if it was collected for cases diagnosed in those years, it should be retained in this field.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date Hormone Therapy Started* is MMDDCCYY, with 99 indentifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date Hormone Therapy Started* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *RX Date–Hormone Flag* (NAACCR Item #1231) is used to explain why *Date Hormone Therapy Started* is not a known date. See *RX Date–Hormone Flag* for an illustration of the relationships among these items.

RX DATE–HORMONE FLAG

Item Length: 2
 NAACCR Item #1231
 Valid Codes: 10-12, 15, Blank
 New Item: 01/2010

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date Hormone Therapy Started* (NAACCR Item #1230).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Coding Instructions

- Leave this item blank if *Date Hormone Therapy Started* (NAACCR Item #1230) has a full or partial date recorded.
- Code 12 if the *Date Hormone Therapy Started* can not be determined, but the patient did receive first course hormone therapy.
- Code 10 if it is unknown whether any hormone therapy was given.
- Code 11 if no hormone therapy is planned or given.
- Code 15 if hormone therapy is planned, but not yet started. Follow this patient for hormone therapy and update this item, *Date Hormone Therapy Started*, and the relevant hormone therapy items.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.
- Leave this item blank for diagnoses between 2003 and 2009 if this facility did not collect *Date Hormone Therapy Started* at that time.

Code	Description
10	No information whatsoever can be inferred from this exceptional value (that is, unknown if any hormone therapy was given).
11	No proper value is applicable in this context (for example, no hormone therapy given).
12	A proper value is applicable but not known. This event occurred, but the date is unknown (that is, hormone therapy was given but the date is unknown).
15	Information is not available at this time, but it is expected that it will be available later (that is, hormone therapy is planned as part of first course treatment, but had not yet started at the time of the last follow-up).
(blank)	A valid date value is provided in item <i>Date Hormone Therapy Started</i> (NAACCR Item #1230). Case was diagnosed between 2003 and 2009 and the facility did not record <i>Date Hormone Therapy Started</i> (NAACCR Item #1230) at that time.

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date Hormone Therapy Started* (NAACCR Item #1230) and *Rx Date–Hormone Flag* (NAACCR Item #1231). ***In this table, the lower-case letter “b” is used to represent each blank space.***

Description	Traditional Date Hormone Therapy Started	Interoperable Date Hormone Therapy Started	Rx Date–Chemo Flag
	Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999	Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable.	
Full date known	MMDDCCYY (example: 02182007)	CCYYMMDD (example: 20070218)	bb
Month and year known	MM99CCYY (example: 02992007)	CCYYMMbb (example: 200702bb)	bb
Year only known	9999CCYY (example: 99992007)	CCYYbbbb (example: 2007bbbb)	bb
Unknown if any hormone therapy given	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	10
No hormone therapy given	00000000 (example: 00000000)	bbbbbbbb (example: bbbbbbbb)	11
Date is unknown, hormone therapy given	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	12
Hormone therapy is planned, not yet begun	88888888 (example: 88888888)	bbbbbbbb (example: bbbbbbbb)	15

**HORMONE THERAPY
(HORMONE/STEROID THERAPY)**

Item Length: 2
Allowable Values: 00, 01, 82,
85–88, 99
NAACCR Item #1400
Revised 06/05, 09/08, 01/10

Description

Records the type of hormone therapy administered as first course treatment at this and all other facilities. If hormone therapy was not administered, then this item records the reason it was not administered to the patient. Hormone therapy consists of a group of drugs that may affect the long-term control of a cancer's growth. It is not usually used as a curative measure.

Rationale

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of hormonal agents as part of the first course of therapy. In addition, when evaluating the quality of care, it is useful to know the reason if hormone therapy was not administered.

Instructions for Coding

- Record prednisone as hormonal therapy when administered in combination with chemotherapy, such as MOPP (mechlorethamine, vincristine, procarbazine, prednisone) or COPP (cyclophosphamide, vincristine, procarbazine, prednisone).
- Do not code prednisone as hormone therapy when it is administered for reasons other than chemotherapeutic treatment.
- Tumor involvement or treatment may destroy hormone-producing tissue. Hormone replacement therapy will be given if the hormone is necessary to maintain normal metabolism and body function. Do not code hormone replacement therapy as part of first course therapy.
- Code 00 if hormone therapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer.
- Code 00 if the treatment plan offered multiple options, and the patient selected treatment that did not include hormone therapy.
- Code 01 for thyroid replacement therapy which inhibits TSH (thyroid-stimulating hormone). TSH is a product of the pituitary gland that can stimulate tumor growth.
- If it is known that hormone therapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused recommended hormone therapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended hormone therapy, but no further documentation is available yet to confirm its administration.
- Code 88 to indicate the patient was referred to a medical oncologist and the registry should follow the case for hormone therapy. If follow-up with the specified specialist or facility indicates the patient was never there, code 00.
- Cases coded 88 should be followed to determine whether they received hormone therapy or why not.
- Code 99 if it is not known whether hormone therapy is usually administered for this type and stage of cancer, and there is no mention in the patient record whether it was recommended or administered.
- Refer to the *SEER*Rx Interactive Drug Database* (<http://seer.cancer.gov/>) for a list of hormonal agents.
- If hormone therapy was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the hormone therapy administered in the item *Palliative Care* (NAACCR Item #3270).

Code	Definition
00	None, hormone therapy was not part of the planned first course of therapy. Diagnosed at autopsy.
01	Hormone therapy administered as first course therapy.
82	Hormone therapy was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age, progression of tumor prior to administration, etc.).
85	Hormone therapy was not administered because the patient died prior to planned or recommended therapy.
86	Hormone therapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record.
87	Hormone therapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record.
88	Hormone therapy was recommended, but it is unknown if it was administered.
99	It is unknown whether a hormonal agent(s) was recommended or administered because it is not stated in patient record. Death certificate only.

Examples

Code	Reason
00	A patient has advanced lung cancer with multiple metastases to the brain. The physician orders Decadron to reduce the edema in the brain and relieve the neurological symptoms. Decadron is not coded as hormonal therapy.
00	A patient with breast cancer may be treated with aminoglutethimide (Cytadren, Elipten), which suppresses the production of glucocorticoids and mineralocorticoids. This patient must take glucocorticoid (hydrocortisone) and may also need a mineralocorticoid (Florinef) as a replacement therapy.
00	A patient with advanced disease is given prednisone to stimulate the appetite and improve nutritional status. Prednisone is not coded as hormone therapy.
01	A patient with metastatic prostate cancer is administered flutamide (an antiestrogen).
87	A patient with metastatic prostate cancer declines the administration of Megace (a progestational agent) and the refusal is noted in the patient record.

**HORMONE THERAPY AT THIS FACILITY
(HORMONE/STEROID THERAPY)**

Item Length: 2
 Allowable Values: 00, 01, 82,
 85–88, 99
 NAACCR Item #710
 Revised 06/05, 09/08, 01/10

Description

Records the type of hormone therapy administered as first course treatment at this facility. If hormone therapy was not administered, then this item records the reason it was not administered to the patient. Hormone therapy consists of a group of drugs that may affect the long-term control of a cancer's growth. It is not usually used as a curative measure.

Rationale

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of hormonal agents as part of the first course of therapy. In addition, when evaluating the quality of care, it is useful to know the reason if hormone therapy was not administered.

Instructions for Coding

- Record only hormone therapy received at this facility. Do not record procedures done at other facilities.
- Record prednisone as hormonal therapy when administered in combination with chemotherapy, such as MOPP (mechlorethamine, vincristine, procarbazine, prednisone) or COPP (cyclophosphamide, vincristine, procarbazine, prednisone).
- Do not code prednisone as hormone therapy when it is administered for reasons other than chemotherapeutic treatment.
- Tumor involvement or treatment may destroy hormone-producing tissue. Hormone replacement therapy will be given if the hormone is necessary to maintain normal metabolism and body function. Do not code hormone replacement therapy as part of first course therapy.
- Code 00 if hormone therapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer.
- Code 00 if the treatment plan offered multiple options, and the patient selected treatment that did not include hormone therapy.
- Code 01 for thyroid replacement therapy which inhibits TSH (thyroid-stimulating hormone). TSH is a product of the pituitary gland that can stimulate tumor growth.
- If it is known that hormone therapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused recommended hormone therapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended hormone therapy, but no further documentation is available yet to confirm its administration.
- Cases coded 88 should be followed to determine whether they received hormone therapy or why not.
- Code 99 if it is not known whether hormone therapy is usually administered for this type and stage of cancer, and there is no mention in the patient record whether it was recommended or administered.
- Refer to the *SEER*Rx Interactive Drug Database* (<http://seer.cancer.gov/>) for a list of hormonal agents.
- If hormone therapy was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the hormone therapy administered in the item *Palliative Care* (NAACCR Item #3270).

Code	Definition
00	None, hormone therapy was not part of the planned first course of therapy. Diagnosed at autopsy.
01	Hormone therapy administered as first course therapy.
82	Hormone therapy was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age, progression of tumor prior to administration, etc.).
85	Hormone therapy was not administered because the patient died prior to planned or recommended therapy.

Code	Definition
86	Hormone therapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record.
87	Hormone therapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record.
88	Hormone therapy was recommended, but it is unknown if it was administered.
99	It is unknown whether a hormonal agent(s) was recommended or administered because it is not stated in patient record. Death certificate only.

DATE IMMUNOTHERAPY STARTED

Item Length: 8
NAACCR Item #1240
Valid Codes: 10-12, 15, Blank
New Item: 01/2010

Description

Records the date of initiation of immunotherapy or a biologic response modifier (BRM) that is part of the first course of treatment.

Rationale

Collecting dates for each treatment modality allows the sequencing of multiple treatments and aids in the evaluation of time intervals from diagnosis to treatment and from treatment to recurrence.

Instructions for Coding

- Record the first or earliest date on which immunotherapy or a biologic response modifier was administered by any facility. This date corresponds to administration of the agents coded in *Immunotherapy* (NAACCR Item #1410).
- This item was required in the past but discontinued in FORDS as a required item in 2003. If the date was not collected between 2003 and 2009, this field may be left blank. However, if it was collected for cases diagnosed in those years, it should be retained in this field.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date Immunotherapy Started* is MMDDCCYY, with 99 indentifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date Immunotherapy Started* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *RX Date–BRM Flag* (NAACCR Item #1241) is used to explain why *Date Immunotherapy Started* is not a known date. See *RX Date–BRM Flag* for an illustration of the relationships among these items.

RX DATE–BRM FLAG

Item Length: 2
 NAACCR Item #1241
 Valid Codes: 10-12, 15, Blank
 New Item: 01/2010

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date Immunotherapy Started* (NAACCR Item #1240).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Coding Instructions

- Leave this item blank if *Date Immunotherapy Started* (NAACCR Item #1240) has a full or partial date recorded.
- Code 12 if the *Date Immunotherapy Started* can not be determined, but the patient did receive first course immunotherapy or a biologic response modifier.
- Code 10 if it is unknown whether any immunotherapy or a biologic response modifier was given.
- Code 11 if no immunotherapy or biologic response modifier is planned or given.
- Code 15 if immunotherapy or a biologic response modifier is planned, but not yet started. Follow this patient for immunotherapy and update this item, *Date Immunotherapy Started*, and the relevant immunotherapy items.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.
- Leave this item blank for diagnoses between 2003 and 2009 if this facility did not collect *Date Immunotherapy Started* at that time.

Code	Description
10	No information whatsoever can be inferred from this exceptional value (that is, unknown if any immunotherapy was given).
11	No proper value is applicable in this context (for example, no immunotherapy given).
12	A proper value is applicable but not known. This event occurred, but the date is unknown (that is, immunotherapy was given but the date is unknown).
15	Information is not available at this time, but it is expected that it will be available later (that is, immunotherapy is planned as part of first course treatment, but had not yet started at the time of the last follow-up).
(blank)	A valid date value is provided in item <i>Date Immunotherapy Started</i> (NAACCR Item #1240). Case was diagnosed between 2003 and 2009 and the facility did not record <i>Date Immunotherapy Started</i> (NAACCR Item #1240) at that time.

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date Immunotherapy Started* (NAACCR Item #1240) and *Rx Date–BRM Flag* (NAACCR Item #1241). ***In this table, the lower-case letter “b” is used to represent each blank space.***

Description	Traditional Date Immunotherapy Started	Interoperable Date Immunotherapy Started	Rx Date–BRM Flag
	Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999	Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable.	
Full date known	MMDDCCYY (example: 02182007)	CCYYMMDD (example: 20070218)	bb
Month and year known	MM99CCYY (example: 02992007)	CCYYMMbb (example: 200702bb)	bb
Year only known	9999CCYY (example: 99992007)	CCYYbbbb (example: 2007bbbb)	bb
Unknown if any immunotherapy given	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	10
No immunotherapy given	00000000 (example: 00000000)	bbbbbbbb (example: bbbbbbbb)	11
Date is unknown, immunotherapy given	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	12
Immunotherapy is planned, not yet begun	88888888 (example: 88888888)	bbbbbbbb (example: bbbbbbbb)	15

IMMUNOTHERAPY

Item Length: 2

Allowable Values: 00, 01, 82, 85–88, 99

NAACCR Item #1410

Revised 06/05, 09/08, 01/10

Description

Records the type of immunotherapy administered as first course treatment at this and all other facilities. If immunotherapy was not administered, then this item records the reason it was not administered to the patient. Immunotherapy consists of biological or chemical agents that alter the immune system or change the host's response to tumor cells.

Rationale

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of immunotherapeutic agents as part of the first course of therapy. In addition, when evaluating the quality of care, it is useful to know the reason if immunotherapy was not administered.

Instructions for Coding

- • Code 00 if immunotherapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer.
- Code 00 if the treatment plan offered multiple options, and the patient selected treatment that did not include immunotherapy.
- If it is known that immunotherapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused recommended immunotherapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended immunotherapy but no further documentation is available yet to confirm its administration.
- Code 88 to indicate a referral was made to a medical oncologist about immunotherapy and the registry should follow the case to determine whether it was given or why not. If follow-up to the specialist or facility determines the patient was never there, code 00.
- Cases coded 88 should be followed and the code updated as appropriate.
- Code 99 if it is not known whether immunotherapy is usually administered for this type and stage of cancer, and there is no mention in the patient record whether it was recommended or administered.
- • Refer to the *SEER*Rx Interactive Drug Database* (<http://seer.cancer.gov/>) for a list of immunotherapeutic agents.
- If immunotherapy was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the immunotherapy administered in the item *Palliative Care* (NAACCR Item #3270).

Code	Definition
00	None, immunotherapy was not part of the planned first course of therapy. Diagnosed at autopsy.
01	Immunotherapy administered as first course therapy.
82	Immunotherapy was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age, progression of tumor prior to administration, etc.).
85	Immunotherapy was not administered because the patient died prior to planned or recommended therapy.
86	Immunotherapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record.
87	Immunotherapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record.
88	Immunotherapy was recommended, but it is unknown if it was administered.

99	It is unknown whether an immunotherapeutic agent(s) was recommended or administered because it is not stated in patient record. Death certificate only.
----	---

Examples

Code	Reason
01	A patient with malignant melanoma is treated with interferon.
85	Before recommended immunotherapy could be administered, the patient died from cancer.

IMMUNOTHERAPY AT THIS FACILITY

Item Length: 2
 Allowable Values: 00, 01, 82,
 85–88, 99
 NAACCR Item #720
 Revised 06/05, 09/08, 01/10

Description

Records the type of immunotherapy administered as first course treatment at this facility. If immunotherapy was not administered, then this item records the reason it was not administered to the patient. Immunotherapy consists of biological or chemical agents that alter the immune system or change the host's response to tumor cells.

Rationale

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of immunotherapeutic agents as part of the first course of therapy. In addition, when evaluating the quality of care, it is useful to know the reason if immunotherapy was not administered.

Instructions for Coding

- Record only immunotherapy received at this facility. Do not record agents administered at other facilities.
- Code 00 if immunotherapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer.
- Code 00 if the treatment plan offered multiple options, and the patient selected treatment that did not include immunotherapy.
- If it is known that immunotherapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused recommended immunotherapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended the patient receive immunotherapy but no further documentation is available yet to confirm its administration.
- Cases coded 88 should be followed to determine whether they received immunotherapy or why not.
- Code 99 if it is not known whether immunotherapy is usually administered for this type and stage of cancer, and there is no mention in the patient record whether it was recommended or administered.
- Refer to the *SEER*Rx Interactive Drug Database* (<http://seer.cancer.gov/>) for a list of immunotherapeutic agents.
- If immunotherapy was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the immunotherapy administered in the item *Palliative Care at This Facility* (NAACCR Item #3280).

Code	Definition
00	None, immunotherapy was not part of the planned first course of therapy. Diagnosed at autopsy.
01	Immunotherapy administered as first course therapy.
82	Immunotherapy was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age).
85	Immunotherapy was not administered because the patient died prior to planned or recommended therapy.
86	Immunotherapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record.
87	Immunotherapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record.
88	Immunotherapy was recommended, but it is unknown if it was administered.
99	It is unknown whether an immunotherapeutic agent(s) was recommended or administered because it is not stated in patient record. Death certificate only.

**HEMATOLOGIC TRANSPLANT
AND ENDOCRINE PROCEDURES**

Item Length: 2
Allowable Values: 00, 10–12, 20, 30,
40, 82, 85–88, 99
NAACCR Item #3250
Revised 06/05, 01/10

Description

Identifies systemic therapeutic *procedures* administered as part of the first course of treatment at this and all other facilities. If none of these *procedures* were administered, then this item records the reason they were not performed. These include bone marrow transplants, stem cell harvests, surgical and/or radiation endocrine therapy.

Rationale

This data item allows the evaluation of patterns of treatment which involve the alteration of the immune system or change the patient's response to tumor cells but does not involve the administration of antineoplastic agents. In addition, when evaluating the quality of care, it is useful to know the reason if these *procedures* were not performed.

Instructions for Coding

- Bone marrow transplants should be coded as either autologous (bone marrow originally taken from the patient) or allogeneic (bone marrow donated by a person other than the patient). For cases in which the bone marrow transplant was syngeneic (transplanted marrow from an identical twin), the item is coded as allogeneic.
- Stem cell harvests involve the collection of immature blood cells from the patient and the reintroduction by transfusion of the harvested cells following chemotherapy or radiation therapy.
- Endocrine irradiation and/or endocrine surgery are procedures which suppress the naturally occurring hormonal activity of the patient and thus alter or affect the long-term control of the cancer's growth. These procedures must be bilateral to qualify as endocrine surgery or endocrine radiation. If only one gland is intact at the start of treatment, surgery and/or radiation to that remaining gland qualifies as endocrine surgery or endocrine radiation.
- Code 00 if a transplant or endocrine procedure was not administered to the patient, and it is known that these procedures are not usually administered for this type and stage of cancer.
- Code 00 if the treatment plan offered multiple options, and the patient selected treatment that did not include a transplant or endocrine procedure.
- If it is known that a transplant or endocrine procedure is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused a recommended transplant or endocrine procedure, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended a hematologic transplant or endocrine procedure, but no further documentation is available yet to confirm its administration.
- Code 88 to indicate referral to a specialist for hematologic transplant or endocrine procedures and the registry should follow the case. If follow-up to the specified specialist or facility determines the patient was never there, code 00.
- Cases coded 88 should be followed to determine whether they were given a hematologic transplant or endocrine procedure or why not.
- Code 99 if it is not known whether a transplant or endocrine procedure is usually administered for this type and stage of cancer, and there is no mention in the patient record whether it was recommended or administered.
- If the hematologic transplant or endocrine procedure coded in this item was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the hematologic transplant or endocrine procedure provided in the items *Palliative Care* (NAACCR Item #3270) and/or *Palliative Care at This Facility* (NAACCR Item #3280), as appropriate.

Code	Definition
00	No transplant procedure or endocrine therapy was administered as part of first course therapy. Diagnosed at autopsy.
10	A bone marrow transplant procedure was administered, but the type was not specified.
11	Bone marrow transplant–autologous.
12	Bone marrow transplant–allogeneic.
20	Stem cell harvest and infusion. Umbilical cord stem cell transplant.
30	Endocrine surgery and/or endocrine radiation therapy.
40	Combination of endocrine surgery and/or radiation with a transplant procedure. (Combination of codes 30 and 10, 11, 12, or 20.)
82	Hematologic transplant and/or endocrine surgery/radiation was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age, progression of disease prior to administration, etc.).
85	Hematologic transplant and/or endocrine surgery/radiation was not administered because the patient died prior to planned or recommended therapy.
86	Hematologic transplant and/or endocrine surgery/radiation was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record.
87	Hematologic transplant and/or endocrine surgery/radiation was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record.
88	Hematologic transplant and/or endocrine surgery/radiation was recommended, but it is unknown if it was administered.
99	It is unknown whether hematologic transplant and/or endocrine surgery/radiation was recommended or administered because it is not stated in patient record. Death certificate only.

SYSTEMIC/SURGERY SEQUENCE

Item Length: 1

Allowable Values: 0, 2–6, 9

NAACCR Item #1639

Added 06/05, 01/10

Description

Records the sequencing of systemic therapy and surgical procedures given as part of the first course of treatment.

Rationale

The sequence of systemic therapy and surgical procedures given as part of the first course of treatment cannot always be determined using the date on which each modality was started or performed. This data item can be used to more precisely evaluate the timing of delivery of treatment to the patient.

Instructions for Coding

- *Systemic/Surgery Sequence* is to be used for patients diagnosed on or after January 1, 2006.
- Code the administration of systemic therapy in sequence with the first surgery performed, described in the item *Date of First Surgical Procedure* (NAACCR Item #1200).
- If none of the following surgical procedures was performed: *Surgical Procedure of Primary Site* (NAACCR Item #1290), *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292), *Surgical Procedure/Other Site* (NAACCR Item #1294), then this item should be coded 0.
- If the patient received both systemic therapy and any one or a combination of the following surgical procedures: *Surgical Procedure of Primary Site* (NAACCR Item #1290), *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292), or *Surgical Procedure/Other Site* (NAACCR Item #1294), then code this item 2–9, as appropriate.

Code	Label	Definition
0	No systemic therapy and/or surgical procedures	No systemic therapy was given; and/or no surgical procedure of primary site; no scope of regional lymph node surgery; no surgery to other regional site(s), distant site(s), or distant lymph node(s); or no reconstructive surgery was performed. It is unknown whether both surgery and systemic treatment were provided.
2	Systemic therapy before surgery	Systemic therapy was given before surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s) was performed.
3	Systemic therapy after surgery	Systemic therapy was given after surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s) was performed.
4	Systemic therapy both before and after surgery	Systemic therapy was given before and after any surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s) was performed.
5	Intraoperative systemic therapy	Intraoperative systemic therapy was given during surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s).
6	Intraoperative systemic therapy with other systemic therapy administered before or after surgery	Intraoperative systemic therapy was given during surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s) with other systemic therapy administered before or after surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s) was performed.
9	Sequence unknown	Both surgery and systemic therapy were provided, but the sequence is unknown.

Examples

Code	Reason
0	Due to other medical conditions surgery was not performed. The patient received palliative radiation therapy to alleviate pain.
2	Patient with prostate cancer received hormone therapy prior to a radical prostatectomy.
3	Patient underwent a colon resection followed by a 5-FU based chemotherapy regimen.
4	Patient with breast cancer receives pre-operative chemotherapy followed by post-operative Tamoxifen.
5	Patient with a intracranial primary undergoes surgery at which time a glial wafer is implanted into the resected cavity.
6	Patient with metastatic colon cancer receives intraoperative chemotherapy to the liver.
9	An unknown primary of the head and neck was treated with surgery and chemotherapy prior to admission, but the sequence is unknown. The patient enters for radiation therapy.

DATE OTHER TREATMENT STARTED

Item Length: 8
 NAACCR Item #1250
 Revised 01/10

Description

Records the date on which other treatment began at any facility.

Rationale

Collecting dates for each treatment modality allows for the sequencing of multiple treatments and aids in the evaluation of time intervals from diagnosis to treatment and from treatment to recurrence.

Instructions for Coding

- Record the date on which the care coded as *Other Treatment* [NAACCR Item #1420] was initiated.
- If other treatment is the first or only treatment administered to the patient, then the date other treatment started should be the same as the *Date of First Course of Treatment* (NAACCR Item #1270).
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date Other Treatment Started* is MMDDCCYY, with 99 indentifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date Other Treatment Started* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *RX Date–Other Flag* (NAACCR Item #1251) is used to explain why *Date Other Treatment Started* is not a known date. See *RX Date–Other Flag* for an illustration of the relationships among these items.

Examples

A patient with metastatic disease was started on an experimental therapy on March 16, 2010.	March 16, 2010
Alcohol was used as an embolizing agent for a patient on August 1, 2009	August 1, 2009
A polycythemia vera patient was given several phlebotomies, the first being on September 17, 2008	September 17, 2008

RX DATE–OTHER FLAG

Item Length: 2
 NAACCR Item #1251
 Valid Codes: 10-12, Blank
 New Item: 01/2010

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date Other Treatment Started* (NAACCR Item #1250).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Coding Instructions

- Leave this item blank if *Date Other Treatment Started* (NAACCR Item #1250) has a full or partial date recorded.
- Code 12 if the *Date Other Treatment Started* can not be determined, but the patient did receive first course other treatment.
- Code 10 if it is unknown whether any other treatment was given (*Other Treatment* [NAACCR Item #1420] is 9).
- Code 11 if no other treatment is planned or given (*Other Treatment* [NAACCR Item #1420] is 0, 7 or 8).
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

Code	Description
10	No information whatsoever can be inferred from this exceptional value (that is, unknown if any Other Treatment was given).
11	No proper value is applicable in this context (for example, no Other Treatment given).
12	A proper value is applicable but not known. This event occurred, but the date is unknown (that is, Other Treatment was given but the date is unknown).
(blank)	A valid date value is provided in item <i>Date Other Treatment Started</i> (NAACCR Item #1250).

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date Other Treatment Started* (NAACCR Item #1250) and *Rx Date–Other Flag* (NAACCR Item #1251). *In this table, the lower-case letter “b” is used to represent each blank space.*

Description	Traditional Date Other Treatment Started	Interoperable Date Other Treatment Started	Rx Date–Other Flag
	Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999	Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable.	
Full date known	MMDDCCYY (example: 02182007)	CCYYMMDD (example: 20070218)	bb
Month and year known	MM99CCYY (example: 02992007)	CCYYMMbb (example: 200702bb)	bb
Year only known	9999CCYY (example: 99992007)	CCYYbbbb (example: 2007bbbb)	bb
Unknown if other treatment given	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	10
No other treatment given	00000000 (example: 00000000)	bbbbbbbb (example: bbbbbbbb)	11
Date is unknown, other treatment given	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	12

OTHER TREATMENT

Item Length: 1
 Allowable Values: 0–3, 6–9
 NAACCR Item #1420
 Revised 06/05, 09/08, 01/10

Description

Identifies other treatment that cannot be defined as surgery, radiation, or systemic therapy according to the defined data items in this manual.

Rationale

Information on other therapy is used to describe and evaluate the quality of care and treatment practices.

Instructions for Coding

- The principal treatment for certain reportable hematopoietic diseases could be supportive care that does not meet the usual definition of treatment that “modifies, controls, removes, or destroys” proliferating cancer tissue. Supportive care may include phlebotomy, transfusion, or aspirin. In order to report the hematopoietic cases in which the patient received supportive care, SEER and the Commission on Cancer have agreed to record treatments such as phlebotomy, transfusion, or aspirin as “Other Treatment” (Code 1) for the hematopoietic diseases ONLY. (See instructions for coding in Section One).
- Code 1 for embolization using alcohol as an embolizing agent.
- Code 1 for embolization to a site other than the liver where the embolizing agent is unknown.
- Do not code presurgical embolization that given for a purpose to shrink the tumor.
- A complete description of the treatment plan should be recorded in the text field for “Other Treatment” on the abstract.
- If other treatment was provided to prolong a patient’s life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the other treatment administered in the item *Palliative Care* (NAACCR Item #3270).
- Code 8 if it is known that a physician recommended treatment coded as Other Treatment, and no further documentation is available yet to confirm its administration
- Code 8 to indicate referral to a specialist for Other Treatment and the registry should follow. If follow-up with the specialist or facility determines the patient was never there, code 0.

Code	Label	Definition
0	None	All cancer treatment was coded in other treatment fields (surgery, radiation, systemic therapy). Patient received no cancer treatment. Diagnosed at autopsy.
1	Other	Cancer treatment that cannot be appropriately assigned to specified treatment data items (surgery, radiation, systemic therapy).
2	Other–Experimental	This code is not defined. It may be used to record participation in institution-based clinical trials.
3	Other–Double Blind	A patient is involved in a double-blind clinical trial. Code the treatment actually administered when the double-blind trial code is broken.
6	Other–Unproven	Cancer treatments administered by nonmedical personnel.
7	Refusal	Other treatment was not administered. It was recommended by the patient’s physician, but this treatment (which would have been coded 1, 2, or 3) was refused by the patient, a patient’s family member, or the patient’s guardian. The refusal was noted in the patient record.
8	Recommended; unknown if administered	Other treatment was recommended, but it is unknown whether it was administered.
9	Unknown	It is unknown whether other treatment was recommended or administered, and there is no information in the medical record to confirm the recommendation or administration of other treatment. Death certificate only.

OTHER TREATMENT AT THIS FACILITY

Item Length: 1
 Allowable Values: 0–3, 6–9
 NAACCR Item #730
 Revised 01/04, 09/08, 01/10

Description

Identifies other treatment given at this facility that cannot be defined as surgery, radiation, or systemic therapy according to the defined data items in this manual.

Rationale

Information on other therapy is used to describe and evaluate the quality of care and treatment practices.

Instructions for Coding

- The principal treatment for certain reportable hematopoietic diseases could be supportive care that does not meet the usual definition of treatment that “modifies, controls, removes, or destroys’ proliferating cancer tissue. Supportive care may include phlebotomy, transfusion, or aspirin. In order to report the hematopoietic cases in which the patient received supportive care, SEER and the Commission on Cancer have agreed to record treatments such as phlebotomy, transfusion, or aspirin as “Other Treatment” (Code 1) for the hematopoietic diseases ONLY. (See instructions for coding in Section One).
- Code 1 for embolization using alcohol as an embolizing agent.
- Code 1 for embolization to a site other than the liver where the embolizing agent is unknown.
- Do not code presurgical embolization that given for a purpose to shrink the tumor.
- A complete description of the treatment plan should be recorded in the text field for “Other Treatment” on the abstract.
- If other treatment was provided to prolong a patient’s life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the other treatment administered in the item *Palliative Care* (NAACCR Item #3280).
- Code 8 if it is known that a physician recommended the patient receive treatment coded as Other Treatment, but no further documentation is available yet to confirm its administration.

Code	Label	Definition
0	None	All cancer treatment was coded in other treatment fields (surgery, radiation, systemic therapy). Patient received no cancer treatment. Diagnosed at autopsy.
1	Other	Cancer treatment that cannot be appropriately assigned to specified treatment data items (surgery, radiation, systemic therapy). Use this code for treatment unique to hematopoietic diseases .
2	Other–Experimental	This code is not defined. It may be used to record participation in institution-based clinical trials.
3	Other–Double Blind	A patient is involved in a double-blind clinical trial. Code the treatment actually administered when the double-blind trial code is broken.
6	Other–Unproven	Cancer treatments administered by nonmedical personnel.
7	Refusal	Other treatment was not administered. It was recommended by the patient’s physician, but this treatment (which would have been coded 1, 2, or 3) was refused by the patient, a patient’s family member, or the patient’s guardian. The refusal was noted in the patient record.
8	Recommended; unknown if administered	Other treatment was recommended, but it is unknown whether it was administered.
9	Unknown	It is unknown whether other treatment was recommended or administered, and there is no information in the medical record to confirm the recommendation or administration of other treatment. Death certificate only.

**PALLIATIVE CARE
(PALLIATIVE PROCEDURE)**

Item Length: 1
Allowable Values: 0–7, 9
NAACCR Item #3270
Revised 01/04, 01/10

Description

Identifies any care provided in an effort to palliate or alleviate symptoms. Palliative care is performed to relieve symptoms and may include surgery, radiation therapy, systemic therapy (chemotherapy, hormone therapy, or other systemic drugs), and/or other pain management therapy.

Rationale

This data item allows reporting facilities to track care that is considered palliative rather than diagnostic or curative in intent.

Instructions for Coding

- Record the type of palliative care provided.
- Surgical procedures, radiation therapy, or systemic therapy provided to prolong the patient's life by controlling symptoms, to alleviate pain, or to make the patient comfortable should be coded palliative care and as first course therapy if that procedure removes or modifies either primary or metastatic malignant tissue.
- Palliative care is not used to diagnose or stage the primary tumor.
- Do not code routine pain management following surgery or other treatment; do code first course pain management for persistent pain.

Code	Definition
0	No palliative care provided. Diagnosed at autopsy.
1	Surgery (which may involve a bypass procedure) to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
2	Radiation therapy to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
3	Chemotherapy, hormone therapy, or other systemic drugs to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
4	Patient received or was referred for pain management therapy with no other palliative care.
5	Any combination of codes 1, 2, and/or 3 without code 4.
6	Any combination of codes 1, 2, and/or 3 with code 4.
7	Palliative care was performed or referred, but no information on the type of procedure is available in the patient record. Palliative care was provided that does not fit the descriptions for codes 1–6.
9	It is unknown if palliative care was performed or referred; not stated in patient record.

Examples

Code	Reason
0	No palliative care was given.
1	A patient undergoes palliative surgical removal of brain metastasis. [Surgery recorded in <i>Surgical Procedure/Other Site</i> (NAACCR Item #1294)]
1	A patient with unresectable pancreatic carcinoma (no surgical procedure of the primary site is performed) receives bypass surgery to alleviate jaundice and pain.
2	A patient is diagnosed with Stage IV prostate cancer. His only symptoms are painful bony metastases in his right hip and lower spine. XRT is given to those areas. (Record all radiotherapy items also).
2	A patient with lung cancer with a primary tumor extending into the spine is treated with XRT to shrink tumor away from spine/nerves to provide pain relief. (Record all radiotherapy items also).
3	A patient is given palliative chemotherapy for Stage IIIB lung cancer. (Record all chemotherapy items also).
4	A 93-year old patient is diagnosed with multiple myeloma and enters a pain management clinic to treat symptoms. No other therapy is planned due to other medical problems.
5	A patient is diagnosed with widely disseminated small cell lung cancer. A palliative resection of a solitary brain metastasis is performed followed by XRT to the lower spine for painful bony metastasis. There is no known pain management. (Record all surgery and radiotherapy items also).
6	A patient diagnosed with colon cancer receives bypass surgery to alleviate symptoms and XRT to the liver for metastasis, and then enters a pain management clinic for treatment for unremitting abdominal pain. (Record all radiotherapy items also).
7	A patient enters the facility with a clinical diagnosis of unresectable carcinoma of the pancreas. A stent was inserted into the bile duct to relieve obstruction and improve the bile duct flow.

**PALLIATIVE CARE AT THIS FACILITY
(PALLIATIVE PROCEDURE AT THIS FACILITY)**

Item Length: 1
Allowable Values: 0–7, 9
NAACCR Item #3280
Revised 01/04, 01/10

Description

Identifies care provided at this facility in an effort to palliate or alleviate symptoms. Palliative care is performed to relieve symptoms and may include surgery, radiation therapy, systemic therapy (chemotherapy, hormone therapy, or other systemic drugs), and/or other pain management therapy.

Rationale

This data item allows reporting facilities to track care that is considered palliative rather than diagnostic or curative in intent.

Instructions for Coding

- Record only the type of palliative care at this facility.
- Surgical procedures, radiation therapy, or systemic therapy provided to prolong the patient's life by controlling symptoms, to alleviate pain, or to make the patient comfortable at this facility should be coded as palliative care and as first course therapy if that procedure removes or modifies either primary or secondary malignant tissue.
- Palliative care is not used to diagnose or stage the primary tumor.
- Do not code routine pain management following surgery or other treatment; do code first course pain management for persistent pain.

Code	Definition
0	No palliative care provided. Diagnosed at autopsy.
1	Surgery (which may involve a bypass procedure) to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
2	Radiation therapy to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
3	Chemotherapy, hormone therapy, or other systemic drugs to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
4	Patient received or was referred for pain management therapy with no other palliative care.
5	Any combination of codes 1, 2, and/or 3 without code 4.
6	Any combination of codes 1, 2, and/or 3 with code 4.
7	Palliative care was performed or referred, but no information on the type of procedure is available in the patient record. Palliative care was provided that does not fit the descriptions for codes 1–6.
9	It is unknown if palliative care was performed or referred; not stated in patient record.

Outcomes

DATE OF FIRST RECURRENCE

Item Length: 8
NAACCR Item #1860
Revised 06/05, 01/10

Description

Records the date of the first recurrence.

Rationale

This data item is used to measure the efficacy of the first course of treatment.

Instructions for Coding

- Record the date the physician diagnoses the first progression, metastasis, or recurrence of disease after a disease-free period.
- Reappearance of a tumor of the same histology in the same primary site during the time period defined by the SEER Multiple Primary and Histology Coding Rules does not constitute a recurrence.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date of First Recurrence* is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date of First Recurrence* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *Recurrence Date–1st Flag* (NAACCR Item #1861) is used to explain why *Date of First Recurrence* is not a known date. See *Recurrence Date–1st Flag* for an illustration of the relationships among these items.

RECURRENCE DATE–1st FLAG

Item Length: 2
 NAACCR Item #1861
 Valid Codes: 10-12, Blank
 New Item: 01/2010

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date of First Recurrence* (NAACCR Item #1860).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Instructions for Coding

- Leave this item blank if *Date of First Recurrence* (NAACCR Item #1860) has a full or partial date recorded.
- Code 12 if the *Date of First Recurrence* can not be determined, but the patient did have a recurrence following a disease-free period.
- Code 10 if it is unknown whether the patient had a recurrence.
- Code 11 if the patient was never disease free, became disease free but had no recurrence, or was initially diagnosed at autopsy.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

Code	Description
10	No information whatsoever can be inferred from this exceptional value (that is, unknown if the patient was ever disease-free or had a first recurrence)
11	No proper value is applicable in this context (that is, patient became disease-free after treatment and never had a recurrence; or patient was never disease-free; autopsy only case)
12	A proper value is applicable but not known (that is, there was a recurrence, but the date is unknown)
(blank)	A valid date value is provided in item <i>Date of First Recurrence</i> (NAACCR Item #1860).

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date of First Recurrence* (NAACCR Item #1860) and *Recurrence Date–1st Flag* (NAACCR Item #1861). *In this table, the lower-case letter “b” is used to represent each blank space.*

Description	Traditional Date of First Recurrence	Interoperable Date of First Recurrence	Recurrence Date–1st Flag
	Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999	Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable.	
Full date known	MMDDCCYY (example: 02182007)	CCYYMMDD (example: 20070218)	bb
Month and year known	MM99CCYY (example: 02992007)	CCYYMMbb (example: 200702bb)	bb
Year only known	9999CCYY (example: 99992007)	CCYYbbbb (example: 2007bbbb)	bb
Unknown if patient had a recurrence	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	10
No recurrence; never disease-free	00000000 (example: 00000000)	bbbbbbbb (example: bbbbbbbb)	11
Date is unknown, but patient had a recurrence	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	12

TYPE OF FIRST RECURRENCE

Item Length: 2

Allowable Values: 00, 04, 06, 10,

13–17, 20–22, 25–27, 30, 36, 40,

46, 51–59, 60, 62, 70, 88, 99

NAACCR Item #1880

Revised 06/05, 01/10

Description

Identifies the type of first recurrence after a period of documented disease-free intermission or remission.

Rationale

This item is used to evaluate treatment efficacy and as a long-term prognostic factor.

Instructions for Coding

- Code the type of first recurrence. First recurrence may occur well after completion of the first course of treatment or after subsequent treatment.
- Reappearance of a tumor of the same histology in the same primary site during the time period defined by the SEER Multiple Primary and Histology Coding Rules does not constitute a recurrence.
- If the patient has never been disease-free (code 70), continue to track for disease-free status. This may occur after subsequent treatment has been completed.
- If the patient is disease-free (code 00), continue to track until a recurrence occurs. First recurrence may occur well after completion of the first course of treatment.
- Once a recurrence has been recorded (code 04–62 or 88), subsequent recurrences are NOT to be recorded.
- Codes 00 through 70 are hierarchical. Record the highest-numbered applicable response.
- If the tumor was originally diagnosed as in situ, code recurrence to 06, 16, 17, 26, 27, 36, or 46 only. Do not use those codes for any other tumors. Codes 00, 88, or 99 may apply to any tumor.
- Codes 51–59 (organ or organ system of distant recurrence) apply only if all first occurrences were in a single category. There may be multiple metastases (or “seeding”) within the distant location.
- Code lymphomas or leukemias that are in remission 00. If the patient relapses, then code recurrence status as 59.
- If there is more than one primary tumor and the physician is unable to decide which has recurred, code the recurrent disease for each tumor. If, at a later date, the recurrent primary is identified, revise the codes as appropriate.

Code	Definition
00	Patient became disease-free after treatment and has not had a recurrence.
04	In situ recurrence of an invasive tumor.
06	In situ recurrence of an in situ tumor.
10	Local recurrence, and there is insufficient information available to code to 13–17. Local recurrence includes recurrence confined to the remnant of the organ of origin, to the organ of origin, to the anastomosis, or to scar tissue where the organ previously existed.
13	Local recurrence of an invasive tumor.
14	Trocar recurrence of an invasive tumor. Includes recurrence in the trocar path or entrance site following prior surgery.
15	Both local and trocar recurrence of an invasive tumor (both 13 and 14).
16	Local recurrence of an in situ tumor, NOS

Code	Definition
17	Both local and trocar recurrence of an in situ tumor.
20	Regional recurrence, and there is insufficient information available to code to 21–27.
21	Recurrence of an invasive tumor in adjacent tissue or organ(s) only.
22	Recurrence of an invasive tumor in regional lymph nodes only.
25	Recurrence of an invasive tumor in adjacent tissue or organ(s) and in regional lymph nodes (both 21 and 22) at the same time.
26	Regional recurrence of an in situ tumor, NOS.
27	Recurrence of an in situ tumor in adjacent tissue or organ(s) and in regional lymph nodes at the same time.
30	Both regional recurrence of an invasive tumor in adjacent tissue or organs(s) and/or regional lymph nodes (20–25) and local and/or trocar recurrence (10, 13, 14, or 15).
36	Both regional recurrence of an in situ tumor in adjacent tissue or organ(s) and/or regional lymph nodes (26 or 27) and local and/or trocar recurrence (16 or 17).
40	Distant recurrence, to a site not listed in 46–62 or there is insufficient information available to code to 46–62.
46	Distant recurrence of an in situ tumor.
51	Distant recurrence of an invasive tumor in the peritoneum only. Peritoneum includes peritoneal surfaces of all structures within the abdominal cavity and/or positive ascitic fluid.
52	Distant recurrence of an invasive tumor in the lung only. Lung includes the visceral pleura.
53	Distant recurrence of an invasive tumor in the pleura only. Pleura includes the pleural surface of all structures within the thoracic cavity and/or positive pleural fluid.
54	Distant recurrence of an invasive tumor in the liver only.
55	Distant recurrence of an invasive tumor in bone only. This includes bones other than the primary site.
56	Distant recurrence of an invasive tumor in the CNS only. This includes the brain and spinal cord, but not the external eye.
57	Distant recurrence of an invasive tumor in the skin only. This includes skin other than the primary site.
58	Distant recurrence of an invasive tumor in lymph node only. Refer to the staging scheme for a description of lymph nodes that are distant for a particular site.
59	Distant systemic recurrence of an invasive tumor only. This includes lymphoma, leukemia, bone marrow metastasis, carcinomatosis, generalized disease.
60	Distant recurrence of an invasive tumor in a single distant site (51–58) and local, trocar and/or regional recurrence (10–15, 20–25, or 30).
62	Distant recurrence of an invasive tumor in multiple sites (recurrences that can be coded to more than one category 51–59).
70	Since diagnosis, patient has never been disease-free. This includes cases with distant metastasis at diagnosis, systemic disease, unknown primary, or minimal disease that is not treated.
88	Disease has recurred, but the type of recurrence is unknown.
99	It is unknown whether the disease has recurred or if the patient was ever disease-free.

Examples

Code	Reason
52	Distant recurrence in the lung.
62	Recurrence in liver, lung and bone

DATE OF LAST CONTACT OR DEATH

Item Length: 8
NAACCR #1750
Revised 06/05, 01/10

Description

Records the date of last contact with the patient or the date of death.

Rationale

This information is used for patient follow-up and outcomes studies.

Instructions for Coding

- Record the last date on which the patient was known to be alive or the date of death.
- If a patient has multiple primaries, all records should have the same date of last contact.
- As of January 1, 2006, the CoC does not require *Class of Case* 00 cases to be followed.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date of Last Contact or Death* is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date of Last Contact or Death* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *Date of Last Contact Flag* (NAACCR Item #1751) is used to explain why *Date of Last Contact or Death* is not a known date. See *Date of Last Contact Flag* for an illustration of the relationships among these items.

DATE OF LAST CONTACT FLAG

Item Length: 2
 NAACCR #1751
 Valid Codes: 12, Blank
 New Item: 01/2010

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date of Last Contact or Death* (NAACCR Item #1750).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Instructions for Coding

- Leave this item blank if *Date of Last Contact or Death* (NAACCR Item #1750) has a full or partial date recorded.
- Code 12 if the *Date of Last Contact or Death* can not be determined
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

Code	Description
12	A proper value is applicable but not known. This event occurred, but the date is unknown (that is, the date of last contact is unknown).
(blank)	A valid date value is provided in item <i>Date of Last Contact or Death</i> (NAACCR Item #1750).

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date of Last Contact or Death* (NAACCR Item #1750) and *Date of Last Contact Flag* (NAACCR Item #1751). *In this table, the lower-case letter “b” is used to represent each blank space.*

Description	Traditional Date of Last Contact or Death	Interoperable Date of Last Contact or Death	Date of Last Contact Flag
	Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999	Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable.	
Full date known	MMDDCCYY (example: 02182007)	CCYYMMDD (example: 20070218)	bb
Month and year known	MM99CCYY (example: 02992007)	CCYYMMbb (example: 200702bb)	bb
Year only known	9999CCYY (example: 99992007)	CCYYbbbb (example: 2007bbbb)	bb
Date is unknown	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	12

VITAL STATUS

Item Length: 1
 Allowable Values: 0, 1
 NAACCR Item #1760

Description

Records the vital status of the patient as of the date entered in *Date of Last Contact or Death* (NAACCR Item #1750).

Rationale

This information is used for patient follow-up and outcomes studies.

Instructions for Coding

- This item is collected during the follow-up process with *Date of Last Contact or Death* (NAACCR Item #1750).
- If a patient has multiple primaries, all records should have the same vital status.

Code	Label
0	Dead
1	Alive

Example

Code	Reason
0	Death clearance information obtained from a state central registry confirms the death of the patient within the past year.
1	In response to a follow-up letter to a patient's following physician, it is learned the patient is alive.

CANCER STATUS

Item Length: 1
 Allowable Values: 1, 2, 9
 NAACCR Item #1770
 Revised 01/04

Description

Records the presence or absence of clinical evidence of the patient's malignant or non-malignant tumor as of the *Date of Last Contact or Death* (NAACCR Item #1750).

Rationale

This information is used for patient follow-up and outcomes studies.

Instructions for Coding

- Cancer status is based on information from the patient's physician or other official source such as a death certificate.
- The patient's cancer status should be changed **only** if new information is received from the patient's physician or other official source. If information is obtained from the patient, a family member, or other nonphysician, then cancer status is not updated.
- Cancer status changes if the patient has a recurrence or relapse.
- If a patient has multiple primaries, each primary could have a different cancer status.

Code	Label
1	No evidence of this tumor
2	Evidence of this tumor
9	Unknown, indeterminate whether this tumor is present; not stated in patient record

Example

Code	Reason
1	Patient with hematopoietic disease who is in remission.
1	A patient is seen by the physician on February 2, 2004 with no evidence of this tumor. The patient did not return to the physician. The patient was then called by the registry on August 29, 2005. The <i>Date of Last Contact or Death</i> (NAACCR Item #1750) is updated, but the cancer status is not.
2	A patient with prostate cancer is diagnosed with bone metastasis in April 2003. The registrar finds an obituary documenting the patient's death in a nursing home in June 2003.

FOLLOWING REGISTRY

Item Length: 10
 Right Justified, Zero-filled
 NAACCR Item #2440
 Revised 06/05, 09/08, 01/10

Description

Records the facility identification number of the registry responsible for following the patient.

Rationale

This data item is useful when the same patient is recorded in multiple registries.

Instructions for Coding

- For facilities with seven-digit FINs in the range of 6020009–6953290 that were assigned by the CoC before January 1, 2001, the coded FIN will consist of three leading zeros followed by the full seven-digit number.
- For facilities with eight-digit FINs greater than or equal to 10000000 that were assigned by the CoC after January 1, 2001, the coded FIN will consist of two leading zeros followed by the full eight-digit number.
- As of January 1, 2006, the CoC does not require *Class of Case* 00 cases to be followed.

Code	Definition
(fill spaces)	Ten-digit facility identification number.
009999999	If the following registry's identification number is unknown.

Note: A complete list of FINs is available on the American College of Surgeons Web site at <http://www.facs.org/cancer/coc/fin.html>.

Note: A written agreement may be drawn up between two registries noting which hospital will be responsible for follow-up.

NPI-FOLLOWING REGISTRY

Item Length: 10
 Allowable Value: Ten digits
 NAACCR Item #2445
 Revised 04/07, 09/08

Description

Records the registry responsible for following the patient.

Rationale

This data item is useful when the same patient is recorded in multiple registries.

NPI-Following Registry is the NPI equivalent of *Following Registry* (NAACCR Item #2440). Both are required during a period of transition.

Instructions for Coding

- Record the 10-digit NPI for the facility of the registry responsible for following the patient.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.
- Check with the registry, billing, or health information departments of the facility to determine its NPI, or search at <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>.

Code	Definition
(fill spaces)	10-digit NPI number for the facility.
(leave blank)	NPI for the facility of the following registry is unknown or not available.

FOLLOW-UP SOURCE

Item Length: 1
 Allowable Values: 0–5, 7–9
 NAACCR Item #1790

Description

Records the source from which the latest follow-up information was obtained.

Rationale

This data item is used by registries to identify the most recent follow-up source.

Instructions for Coding

Code	Label	Definition
0	Reported hospitalization	Hospitalization at another institution/hospital or first admission to the reporting facility.
1	Readmission	Hospitalization or outpatient visit at the reporting facility.
2	Physician	Information from a physician.
3	Patient	Direct contact with the patient.
4	Department of Motor Vehicles	The Department of Motor Vehicles confirmed the patient has a current license.
5	Medicare/Medicaid file	The Medicare or Medicaid office confirmed the patient is alive.
7	Death certificate	Information from the death certificate only.
8	Other	Friends, relatives, employers, other registries, or any sources not covered by other codes.
9	Unknown; not stated in patient record	The follow-up source is unknown or not stated in patient record.

**NEXT FOLLOW-UP SOURCE
(NEXT FOLLOW-UP METHOD)**

Item Length: 1
 Allowable Values: 0–5, 8, 9
 NAACCR Item #1800
 Revised 01/10

Description

Identifies the method planned for the next follow-up.

Rationale

This data item is used by registries to identify the method planned for the next follow-up.

Instructions for Coding

- Registries in CoC-accredited cancer programs are not required to follow foreign residents.
- As of January 1, 2006, the CoC does not require *Class of Case* 00 cases to be followed.

Code	Definition
0	Chart requisition
1	Physician letter
2	Contact letter
3	Phone call
4	Other hospital contact
5	Other, NOS
8	Foreign residents (not followed)
9	Not followed. Other cases for which follow-up is not required.

Case Administration

ABSTRACTED BY

Item Length: 3
Left Justified Alphanumeric
NAACCR Item #570

Description

Records the initials or assigned code of the individual abstracting the case.

Rationale

This item can be used for quality control and management in multistaffed registries.

Instructions for Coding

Code the initials of the abstractor.

Code	Definition
(fill spaces)	Initials or code of abstractor.

FACILITY IDENTIFICATION NUMBER (FIN)

Item Length: 10
 Right Justified, Zero-filled
 NAACCR Item #540
 Revised 09/08

Description

Identifies the facility reporting the case.

Rationale

Each facility's identification number (FIN) is unique. The number is essential to the National Cancer Data Base (NCDB) for monitoring data submissions, ensuring the accuracy of data, and for identifying areas for special studies.

Instructions for Coding

- *Facility Identification Number* is automatically coded by the software provider.
- For facilities with seven-digit FINs in the range of 6020009–6953290 that were assigned by the CoC before January 1, 2001, the coded FIN will consist of three leading zeros followed by the full seven-digit number.
- For facilities with eight-digit FINs greater than or equal to 10000000 that were assigned by the CoC after January 1, 2001, the coded FIN will consist of two leading zeros followed by the full eight-digit number.

Examples

Code	Reason
0006439999	6439999, General Hospital, Anytown, Illinois
0010000099	10000099, Anytown Medical Center, Anytown, Illinois

Note: A complete list of FINs is available on the American College of Surgeons Web site at <http://www.facs.org/cancer/coc/fin.html>.

NPI-REPORTING FACILITY

Item Length: 10
 Allowable Value: Ten digits
 NAACCR Item #545
 Revised 04/07, 09/08, 01/10

Description

Identifies the facility whose data are in the record.

Rationale

Each facility's NPI is unique. The number is essential to the National Cancer Data Base (NCDB) for monitoring data submissions, ensuring the accuracy of data, and for identifying areas for special studies.

NPI-Reporting Facility is the NPI equivalent of *Facility Identification Number* (NAACCR Item #540). Both are required during a period of transition.

Instructions for Coding

- *NPI-Reporting Facility* is automatically coded by the software provider.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- The facility's NPI can be obtained from the billing or accounting department, or searched at <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>.
- If the facility has more than one NPI number assigned, use the "umbrella" number that applies to the entire facility.
- NPI may be blank for cases diagnosed on or before December 31, 2006.

Code	Definitions
(fill spaces)	10-digit NPI number for the facility.
(leave blank)	NPI for the facility is unknown or not available.

ARCHIVE FIN

Item Length: 10
 Right Justified, Zero-filled
 NAACCR Item #3100
 Revised 01/10

Description

Identifies the facility that originally abstracted the case.

Rationale

It is essential for hospital registries to have the ability to distinguish cases originally accessioned by each registry of the merged unit. This enables the CoC to manage the receipt of historical data and to appropriately attribute these data.

Instructions for Coding

- *Archive FIN* is automatically coded by the software provider.
- This data item never changes and must be included as part of the patient record when data are submitted to the NCDB.
- For facilities that have not merged, the *Archive FIN* and *FIN* (NAACCR Item #540) will be the same.
- If facilities merged after January 1, 2003, a new FIN was assigned to represent the merged facility. This new FIN was assigned to all cases in the *merged* registry, but the *Archive FIN* for cases from each registry prior to the merger **does not** change.
- If a merged program continues to operate multiple campuses, the Archive FIN is the historic FIN for the respective facilities that are now separate campuses of the same hospital.
- For facilities with seven-digit FINs in the range of 6020009–6953290 that were assigned by the CoC before January 1, 2001, the coded FIN will consist of three leading zeros followed by the full seven-digit number. The Archive FIN must be recorded similarly.
- For facilities with eight-digit FINs greater than or equal to 10000000 that were assigned by the CoC after January 1, 2001, the coded FIN will consist of two leading zeros followed by the full eight-digit number. The Archive FIN must be recorded similarly.

Examples

Code	Reason
0006439999	General Hospital, Anytown, Illinois (FIN: 6439999). Original diagnosis was made at this facility; both the FIN and the Archive FIN are the same.
0006439999 or 0006430000	General Hospital (FIN: 6439999) and Anytown Medical Center (FIN: 6430000) in Anytown IL merged; the two cancer registries were combined and now report as Anytown Medical Center. The new FIN for this reporting facility is 10000099. All cases from the merged General Hospital and Anytown Medical Center registry have the new FIN (0010000099) assigned to them. In addition, either the General Hospital Archive FIN (0006439999) or the Anytown Medical Center Archive FIN (0006430000) is retained in each record depending on which registry originally accessioned the case.

NPI-ARCHIVE FIN

Item Length: 10
 Allowable Value: Ten digits
 NAACCR Item #3105
 Revised 01/10

Description

Identifies the facility that originally abstracted the case.

Rationale

It is essential for hospital registries to have the ability to distinguish cases originally accessioned by each registry of the merged unit. This enables the CoC to manage the receipt of historical data and to appropriately attribute these data.

NPI-Archive FIN is the NPI equivalent of *Archive FIN* (NAACCR Item #3100). Both are required during a period of transition.

Instructions for Coding

- *NPI-Archive FIN* is automatically coded by the software provider.
- This data item never changes and must be included as part of the patient record when data are submitted to the NCDB.
- For facilities that have not merged, the *NPI-Archive FIN* and the *NPI-Reporting Facility* (NAACCR Item #545) will be the same.
- If the facility has more than one NPI number assigned, use the “umbrella” number that applies to the entire facility.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.

Code	Definition
(fill spaces)	10-digit NPI number for the facility.
(leave blank)	NPI for the facility is unknown or not available.

DATE CASE COMPLETED – COC

Item Length: 8
 NAACCR Item #2092
 New Item: 1/1/2010

Description

This data item identifies the date that specified items are completed, based on the *Class of Case*, and those items pass the relevant edits. Follow-up information, including delayed treatment received elsewhere, may be coded after the *Date Case Completed–CoC*. This item should be autocoded by the registry software. The CoC specifications will not necessarily be the same as those used for *Date Case Completed* [NAACCR Item #2090], which CoC does not require.

Rationale

This item was created to measure abstracting timeliness of information that should be available when the facility's main involvement in the patient's first course care is completed, based on *Class of Case*. CoC Standard 3.3 requires that 90% of all cases be abstracted within 6 months of the patient's first contact with the facility in CoC accredited programs. It is assumed that for all except some unusual cases, all required items, not just those used to determine *Date Case Completed – CoC*, will have been completed for all analytic cases by the time the NCDB annual Call for Data begins.

Instructions

- This item may be left blank for cases diagnosed prior to 2010.
- Follow-up information, information about delayed treatment received elsewhere, and information about multiple tumors diagnosed later may be coded after the *Date Case Completed – CoC*.
- Corrections and updates may be made after the *Date Case Completed – CoC*.
- Appendix D provides a list of items in each broad completion category below.
- After all required items identified below for the patient's *Class of Case* have been abstracted, the registrar should run the standard NAACCR edit set "Hosp: vs 12 CoC Required - All" using the registry software. The registry software will record the *Date Case Completed – CoC* when those items are abstracted and the case passes all edits in that set.

Class of Case	Description	Items that Must Be Completed by Date Case Completed - CoC
00-22	All analytic cases	Identification, demographic, diagnostic
10-22	Patient received part or all first course treatment from facility	Staging, hospital-specific treatment
10, 12, 14, 20, 22	Patient received all first course treatment from facility, or unspecified whether all or part	Summary treatment (treatment at any facility)
00	Patient diagnosed at facility, received all treatment elsewhere	Facility referred to OR a treating physician
20-22	Patient diagnosed elsewhere, received part or all of treatment from facility	Facility referred from OR the managing physician

OVERRIDE ACSN/CLASS/SEQ

Item Length: 1
 Allowable Values: 1
 NAACCR Item #1985
 Revised 09/06, 09/08, 01/10

Description

Used with the EDITS software to override the edit *Accession Number, Class of Case, Seq Number (CoC)*.

Rationale

Some edits in the EDITS software package check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the override flag is used to skip the edit on future runs of the EDITS package.

EDITS Use

The edit, *Accession Number, Class of Case, Seq Number (CoC)*, checks the following:

- If the case is the only case or the first of multiple cases diagnosed at the facility (*Sequence Number–Hospital* = 00, 01, 60 or 61, and *Class of Case* = 00, 10, 12, 13, or 14), then the first 4 characters of the *Accession Number* (NAACCR Item #550) must equal the year of the *Date of First Contact* (NAACCR Item #580).
- If the case is first diagnosed at autopsy (*Class of Case* = 38), and the case is the only case or the first of multiple cases for a patient (*Sequence Number–Hospital* = 00, 01, 60, or 61), then the first 4 characters of the *Accession Number* must equal the year of the *Date of Last Contact or Death* (NAACCR Item #1750) AND must equal the year of the *Date of First Contact*.
- If the case is first diagnosed at autopsy (*Class of Case* = 38), and the case is the second or more case for a patient (*Sequence Number–Hospital* greater than 01 or greater than 61), then the year of the *Date of First Contact* must equal the year of *Date of Last Contact or Death*.

There are some exceptions to the above rules. *Override Acsn/Class/Seq* may be used to override the edit when the circumstances fit the following situation or one similar to it:

- The case may be the only or the first of multiple malignant cases for a patient (*Sequence Number–Hospital* = 00 or 01), but there is an earlier benign case (with an earlier year of the *Date of First Contact*) for which the *Accession Number* applies.

Instructions for Coding

- Leave blank if the EDITS program does not generate an error message for the edit *Accession Number, Class of Case, Sequence Number (CoC)*.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if a review of all items in the error or warning message confirms that all are correct.

Code	Definition
(leave blank)	Not reviewed; or reviewed and corrected.
1	Reviewed and confirmed as reported.

OVERRIDE HOSPSEQ/DXCONF

Item Length: 1
 Allowable Values: 1
 NAACCR Item #1986
 Revised 09/06, 09/08

Description

Used with the EDITS software to override the edit *Diagnostic Confirm, Seq Num–Hosp (CoC)*.

Rationale

Some edits in the EDITS software package check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the override flag is used to skip the edit on future runs of the EDITS package.

EDITS Use

The edit, *Diagnostic Confirm, Seq Num–Hosp (CoC)*, does the following:

- If any case is one of multiple primaries and is not microscopically confirmed or positive lab test/marker study, i.e., *Diagnostic Confirmation* > 5 and *Sequence Number–Hospital* > 00 (more than one primary), review is required.
- If *Primary Site* (NAACCR Item #400) specifies an ill-defined or unknown primary (C76.0–C76.8, C80.9), no further checking is done. If *Sequence Number–Hospital* is in the range of 60–88, this edit is skipped.

It is important to verify that the non-microscopically-confirmed case is indeed a separate primary from any others that may have been reported. This edit forces review of multiple primary cancers when one of the primaries is coded to a site other than ill-defined or unknown and is not microscopically confirmed or confirmed by a positive lab test/marker study.

- If this edit is failed and the suspect case is confirmed accurate as coded, and the number of primaries is correct, set the *Override HospSeq/DxConf* to 1. Do not set the override flag on the patient's other primary cancers.
- However, if it turns out that the non-microscopically-confirmed cancer is considered a manifestation of one of the patient's other cancers, delete the non-microscopically-confirmed case. Check the sequence numbers of remaining cases, correcting them if necessary. Also check for other data items on the remaining cases that may need to be changed as a result of the corrections, such as stage and treatment.

Instructions for Coding

- Leave blank if the EDITS program does not generate an error message for the edit *Diagnostic Confirm, Seq Num–Hosp (CoC)*.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if a review of all items in the error or warning message confirms that all are correct.

Code	Definition
(leave blank)	Not reviewed; or reviewed and corrected.
1	Reviewed and confirmed as reported.

OVERRIDE COC–SITE/TYPE

Item Length: 1
 Allowable Values: 1
 NAACCR Item #1987
 Revised 09/06, 09/08

Description

Used with the EDITS software to override the edits *Primary Site, Morphology-Type ICDO2 (CoC)*, *Primary Site, Morphology-Type ICDO3 (CoC)*, and/or *Primary Site, Morphology-Type, Behavior ICDO3 (CoC)*.

Rationale

Some edits in the EDITS software package check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the override flag is used to skip the edit on future runs of the EDITS package.

EDITS Use

There are multiple versions of edits of the type, *Primary Site, Morphology-Type*, which check for “usual” combinations of site and ICD-O-2 or ICD-O-3 histology. The SEER version of the edit is more restrictive than the CoC edit, and thus uses a different override flag. The CoC version of the edit will accept Override CoC-Site/Type or Override Site/Type as equivalent.

- The Site/Histology Validation List (available on the SEER Web site) contains those histologies commonly found in the specified primary site. Histologies that occur only rarely or never are not included. These edits require review of all combinations *not* listed.
- Since basal and squamous cell carcinomas of non-genital skin sites are not reportable to SEER, these site/histology combinations do not appear on the SEER validation list. For the CoC version of the edit, if *Primary Site* (NAACCR Item #400) is in the range C44.0-C44.9 (skin), and the ICD-O-3 histology is in the range 8000-8005 (neoplasms, malignant, NOS), 8010-8046 (epithelial carcinomas), 8050-8084 (papillary and squamous cell carcinomas), or 8090-8110 (basal cell carcinomas), no further editing is done. No override is necessary for these cases in the CoC version of the edit.

Review of these cases requires investigating whether the combination is biologically implausible or there are cancer registry coding conventions that would dictate different codes for the diagnosis (See *Cancer Identification* in Section I). Review of these rare combinations often results in changes to the primary site and/or morphology, rather than a decision that the combination is correct.

Instructions for Coding

- Leave blank if the EDITS program does not generate an error message for edits of the type *Primary Site, Morphology-Type*.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if a review of all items in the error or warning message confirms they are correct and coded in conformance with coding rules.

Code	Definition
(leave blank)	Not reviewed; or reviewed and corrected.
1	Reviewed and confirmed as reported.

OVERRIDE HOSPSEQ/SITE

Item Length: 1
 Allowable Values: 1
 NAACCR Item #1988
 Revised 09/06 09/08, 02/10

Description

Used with the EDITS software to override the edit *Seq Num–Hosp, Primary Site, Morph ICDO2 (CoC)* and/or the edit *Seq Num–Hosp, Primary Site, Morph ICDO3 (CoC)*.

Rationale

Some edits in the EDITS software package check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the override flag is used to skip the edit on future runs of the EDITS package.

EDITS Use

Edits of the type, *Seq Num–Hosp, Primary Site, Morph*, differ in use of ICD-O-2 or ICD-O-3 morphology. They force review of multiple primary cancers when one of the primaries is coded to a site-morphology combination that could indicate a metastatic site rather than a primary site. If *Sequence Number–Hospital* indicates the person has had more than one primary, then any case with one of the following site-histology combinations requires review:

- C76.0–C76.8 (Ill-defined sites) or C80.9 (unknown primary) and ICD-O-2 or ICD-O-3 histology < 9590. (Look for evidence that the unknown or ill-defined primary is a secondary site from one of the patient's other cancers. For example, a clinical discharge diagnosis of “abdominal carcinomatosis” may be attributable to the patient's primary ovarian cystadenocarcinoma already in the registry, and should not be entered as a second primary.)
- Lymph node primary sites (C77.0-C77.9) for histologies other than lymphomas, or hematopoietic primary sites for histologies not in range for hematopoietic diseases. (That combination is most likely a metastatic lesion. Check whether the lesion could be a manifestation of one of the patient's other cancers.)
- Any site and ICD-O-2 histology in the range 9720-9723, 9740-9741 or ICD-O-3 histology in the range 9740-9758. (Verify that these diagnoses are coded correctly and are indeed separate primaries from the others.)

If it turns out that the suspect tumor is a manifestation of one of the patient's other cancers, delete the metastatic or secondary case, re-sequence remaining cases, and correct the coding on the original case as necessary.

Instructions for Coding

- Leave blank if the EDITS program does not generate an error message for an edit of the type *Seq Num–Hosp, Primary Site, Morph*
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review of all items in the error or warning message confirms that all are correct.

Code	Definition
(leave blank)	Not reviewed; or reviewed and corrected.
1	Reviewed and confirmed as reported.

OVERRIDE SITE/TNM-STAGE GROUP

Item Length: 1
 Allowable Values: 1
 NAACCR Item #1989
 Revised 09/04, 09/08, 01/10

Description

Used with the EDITS software to override the edits of the type *Primary Site, AJCC Stage Group*, for AJCC staging editions 6 and later.

Rationale

This override flag allows identification of pediatric cancers that were staged according to a system other than the **AJCC** staging manual (which is predominantly directed toward adult staging) if they are not also **AJCC**-staged. In that situation an otherwise-stageable case may be coded 88 (not applicable) for all **AJCC** items.

EDITS Use

Edits of the type, *Primary Site, AJCC Stage Group*, check that the pathologic and clinical AJCC stage group codes are valid for the site and histology group according to the *AJCC Cancer Staging Manual, Sixth or Edition*, using the codes described for the items *Clinical Stage Group* (NAACCR Item #970) and *Pathologic Stage Group* (NAACCR Item #910). Combinations of site and histology not represented in any AJCC schema must be coded 88. Unknown codes must be coded 99. Blanks are not permitted.

Since pediatric cancers whose sites and histologies have an AJCC scheme may be coded according to a pediatric scheme instead, use *Override Site/TNM-Stage Group* to indicate the case was coded according to a pediatric staging system if it was not also coded according to the AJCC manual. Pediatric stage groups should *not* be recorded in the *Clinical Stage Group* or *Pathologic Stage Group* items. When neither clinical nor pathologic AJCC staging is used for pediatric cases, code all AJCC items 88. When any AJCC component is used to stage a pediatric case, follow the instructions for coding AJCC items and leave *Override Site/TNM-Stage Group* blank.

Instructions for Coding

- Leave blank if the EDITS program does not generate an error message for the edits of the type, *Primary Site, AJCC Stage Group*.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if the case is confirmed to be a pediatric case that was coded using a pediatric coding system.

Code	Definition
(leave blank)	Not reviewed; or reviewed and corrected.
1	Reviewed and confirmed as reported.

OVERRIDE AGE/SITE/MORPH

Item Length: 1
 Allowable Values: 1
 NAACCR Item #1990
 Revised 04/07, 09/08, 01/10

Description

Used with the EDITS software to override edits of the type *Age, Primary Site, Morphology*; *Age, Primary Site, Morph ICDO3–Adult*, and *Age, Primary Site, Morph ICDO3–Pediatric*.

Rationale

Some edits in the EDITS software package check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the override flag is used to skip the edit on future runs of the EDITS package.

EDITS Use

Edits of the type *Age, Primary Site, Morphology*; *Age, Primary Site, Morph ICDO3–Adult*; and *Age, Primary Site, Morph ICDO3–Pediatric* require review if a site-morphology combination occurs in an age group for which it is extremely rare or if the cancer was diagnosed in utero.

If the edit generates an error or warning message, check that the primary site and histologic type are coded correctly and that the age, date of birth, and date of diagnosis are correct.

Instructions for Coding

- Leave blank if the EDITS program does not generate an error message for the *Age, Primary Site, Morphology*; *Age, Primary Site, Morph ICDO3–Adult*, and *Age, Primary Site, Morph ICDO3–Pediatric* edits.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 for an unusual occurrence of a particular age/site/histology combination for a given age has been confirmed by review to be correct.
- Code 2 if the case was diagnosed in utero.
- Code 3 if both conditions apply.

Code	Definition
(leave blank)	Not reviewed; or reviewed and corrected.
1	Reviewed; age, site, and morphology combination confirmed as reported.
2	Reviewed; diagnosis in utero.
3	Reviewed; both conditions apply.

OVERRIDE SURG/DXCONF

Item Length: 1
 Allowable Values: 1
 NAACCR Item #2020
 Revised 09/06, 09/08

Description

Used with the EDITS software to override the edits *RX Summ–Surg Prim Site, Diag Conf (SEER IF76)*; *RX Summ–Surgery Type, Diag Conf (SEER IF46)*; and/or the edit *RX Summ–Surg Site 98-02, Diag Conf (SEER 106)*.

Rationale

Some edits in the EDITS software package check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the override flag is used to skip the edit on future runs of the EDITS package.

EDITS Use

Edits of the type, *RX Summ–Surg Prim Site, Diag Conf*, check that cases with a primary site surgical procedure coded 20-90 are histologically confirmed.

If the patient had a surgical procedure, most likely there was a microscopic examination of the cancer.

- Verify the surgery and diagnostic confirmation codes, and correct any errors.
- Sometimes there are valid reasons why no microscopic confirmation is achieved with the surgery, for example, the tissue removed may be inadequate for evaluation.

Instructions for Coding

- Leave blank if the EDITS program does not generate an error message for edits of the type, *RX Summ–Surg Prim Site, Diag Conf*.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review of all items in the error or warning message confirms that all are correct.

Code	Definition
(leave blank)	Not reviewed; or reviewed and corrected.
1	Reviewed, confirmed as reported.

OVERRIDE SITE/TYPE

Item Length: 1
 Allowable Values: 1
 NAACCR Item #2030
 Revised 09/06, 09/08, 01/10

Description

Used with the EDITS software to override edits of the type *Primary Site, Morphology-Type* and *Primary Site, Morphology-Type, Behavior ICDO3*.

Rationale

Some edits in the EDITS software package check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the override flag is used to skip the edit on future runs of the EDITS package.

EDITS Use

There are multiple versions of edits of the type, *Primary Site, Morphology-Type*, which check for “usual” combinations of site and ICD-O-2 or ICD-O-3 histology. The SEER version of the edit is more restrictive than the CoC edit, and thus uses a different override flag. The CoC version of the edit will accept *Override CoC-Site/Type* or *Override Site/Type* as equivalent.

- The Site/Histology Validation List (available on the SEER website) contains those histologies commonly found in the specified primary site. Histologies that occur only rarely or never are not included. These edits require review of all combinations *not* listed.
- Since basal and squamous cell carcinomas of non-genital skin sites are not reportable to SEER, these site/histology combinations do not appear on the SEER validation list. For the CoC version of the edit, if *Primary Site* (NAACCR Item #400) is in the range C440-C449 (skin), and the ICD-O-3 histology is in the range 8000-8005 (neoplasms, malignant, NOS), 8010-8046 (epithelial carcinomas), 8050-8084 (papillary and squamous cell carcinomas), or 8090-8110 (basal cell carcinomas), no further editing is done. No override is necessary for these cases in the CoC version of the edit.

Review of these cases requires investigating whether the combination is biologically implausible or there are cancer registry coding conventions that would dictate different codes for the diagnosis (See *Cancer Identification* in Section I). Review of these rare combinations often results in changes to the primary site and/or morphology, rather than a decision that the combination is correct.

Instructions for Coding

- Leave blank if the EDITS program does not generate an error message for edits of the type *Primary Site, Morphology-Type*.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review of all items in the error or warning message confirms that all are correct.

Code	Definition
(leave blank)	Not reviewed; or reviewed and corrected.
1	Reviewed, confirmed as reported.

OVERRIDE HISTOLOGY

Item Length: 1
Allowable Values: 1, 2, 3
NAACCR Item #2040
Revised 04/07, 09/08

Description

Used with the EDITS software to override any of five edits: *Diagnostic Confirmation, Behavior ICDO2 (SEER IF31)*; *Diagnostic Confirmation, Behavior ICDO3 (SEER IF31)*; *Morphology–Type/Behavior ICDO2 (SEER MORPH)*; *Morphology–Type/Behavior ICDO3 (SEER MORPH)*; and/or the edit *Morph (1973-91) ICD-O-1 (SEER MORPH)*.

Rationale

Some edits in the EDITS software package check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the override flag is used to skip the edit on future runs of the EDITS package.

EDITS Use

I. Edits of the type, *Diagnostic Confirmation, Behavior Code*, differ in the use of ICD-O-2 or ICD-O-3 and check that, for in situ cases (Behavior = 2), *Diagnostic Confirmation* specifies microscopic confirmation (1, 2 or 4). The distinction between in situ and invasive is very important to a registry, since prognosis is so different. Since the determination that a neoplasm has not invaded surrounding tissue, i.e. is in situ, is made microscopically, cases coded in situ in behavior should have a microscopic confirmation code. Very rarely, a physician will designate a case noninvasive or in situ without microscopic evidence.

If an edit of the type, *Diagnostic Confirmation, Behavior Code*, gives an error message or warning, check that *Behavior Code* (NAACCR Item #523) and *Diagnostic Confirmation* (NAACCR Item #490) have been coded correctly. Check carefully for any cytologic or histologic evidence that may have been missed in coding.

II. Edits of the type, *Morphology–Type/Behavior*, perform the following overrideable check:

- Codes listed in ICD-O-2 or ICD-O-3 with behavior codes of only 0 or 1 are considered valid, since use of the behavior matrix of ICD-O-2 and ICD-O-3 allows for the elevation of the behavior of such histologies when the tumor is in situ or malignant. This edit forces review of these rare cases to verify that they are indeed in situ or malignant.

If a *Morphology-Type/Behavior* edit produces an error or warning message and the case is one in which the 4-digit morphology code is one that appears in ICD-O-2 or ICD-O-3 only with behavior codes of 0 or 1, verify the coding of morphology and that the behavior should be coded malignant or in situ. The registrar may need to consult a pathologist or medical advisor in problem cases.

Exceptions to the above: If year of *Date of Diagnosis* > 2000, then a behavior code of 1 is valid for the following ICD-O-2 histologies and no override flag is needed: 8931, 9393, 9538, 9950, 9960-9962, 9980-9984, 9989. Similarly, the following ICD-O-3 histologies are valid with a behavior code of 1: 8442, 8451, 8462, 8472, and 8473.

Note: The *Morphology-Type/Behavior* edits are complex and perform several additional types of checks. No other aspects of their checks are subject to override.

Instructions for Coding

- Leave blank if the EDITS program does not generate an error message for the edits of the types *Diagnostic Confirmation* or *Morph* or *Morphology–Type/Behavior*.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.

- Code 1, 2 or 3 as indicated if review of all items in the error or warning message confirms that all are correct.

Code	Definition
(leave blank)	Not reviewed; or reviewed and corrected.
1	Reviewed, confirmed as reported for edits of the type <i>Morphology–Type/Behavior</i> .
2	Reviewed, confirmed as reported for edits of the type <i>Diagnostic Confirmation, Behavior Code</i> .
3	Reviewed: conditions 1 and 2 above both apply.

OVERRIDE LEUK, LYMPHOMA

Item Length: 1
 Allowable Values: 1
 NAACCR Item #2070
 Revised 09/06, 09/08, 01/10

Description

Used with the EDITS software to override edits of the type *Diagnostic Confirmation, Histology*.

Rationale

Some edits in the EDITS software package check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the override flag is used to skip the edit on future runs of the EDITS package.

EDITS Use

Edits of the type *Diagnostic Confirmation, Histology* differ in use of ICD-O-2 (NAACCR Item #420) or ICD-O-3 (NAACCR Item #522) and check the following:

- Since lymphoma and leukemia are almost exclusively microscopic diagnoses, this edit forces review of any cases of lymphoma that have diagnostic confirmation of direct visualization or clinical, and any leukemia with a diagnostic confirmation of direct visualization.
- For lymphomas, *Diagnostic Confirmation* (NAACCR Item #490) cannot be 6 (direct visualization) or 8 (clinical).
- For leukemia and other hematopoietic neoplasms, *Diagnostic Confirmation* cannot be 6 (direct visualization).

If an edit of the type, *Diagnostic Confirmation, Histology*, produces an error or warning message, check that the *Histology* and *Diagnostic Confirmation* items are correctly coded. Remember that positive hematologic findings and bone marrow specimens are included as histologic confirmation (code 1 in *Diagnostic Confirmation*) for leukemia.

Instructions for Coding

- Leave blank if the EDITS program does not generate an error message for the edits of the type *Diagnostic Confirmation, Histology*.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review of all items in the error or warning message confirms that all are correct.

Code	Definition
(leave blank)	Not reviewed; or reviewed and corrected.
1	Reviewed, confirmed as reported.

OVERRIDE SITE/BEHAVIOR

Item Length: 1
 Allowable Values: 1
 NAACCR Item #2071
 Revised 09/06, 09/08

Description

Used with the EDITS software to override the edits of the type *Primary Site, Behavior Code*.

Rationale

Some edits in the EDITS software package check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the override flag is used to skip the edit on future runs of the EDITS package.

EDITS Use

Edits of the type, *Primary Site, Behavior*, require review of the following primary sites with a behavior of in situ (ICD-O-2 or ICD-O-3 behavior = 2):

C26.9	Gastrointestinal tract, NOS
C39.9	Ill-defined sites within respiratory system
C55.9	Uterus, NOS
C57.9	Female genital tract, NOS
C63.9	Male genital organs, NOS
C68.9	Urinary system, NOS
C72.9	Nervous system, NOS
C75.9	Endocrine gland, NOS
C76.0-C76.8	Ill-defined sites
C80.9	Unknown primary site

Since the designation of in situ is very specific and almost always requires microscopic confirmation, ordinarily specific information should also be available regarding the primary site. Conversely, if inadequate information is available to determine a specific primary site, it is unlikely that information about a cancer being in situ is reliable.

- If a specific in situ diagnosis is provided, try to obtain a more specific primary site. A primary site within an organ system can sometimes be identified based on the diagnostic procedure or treatment given or on the histologic type. If a more specific site cannot be determined, it is usually preferable to code a behavior code of 3. In the exceedingly rare situation in which it is certain that the behavior is in situ and no more specific-site code is applicable, set *Override Site/Behavior* to 1.

Instructions for Coding

- Leave blank if the EDITS program does not generate an error message for *Primary Site, Behavior* edits.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review of all items in the error or warning message confirms that all are correct.

Code	Definition
(leave blank)	Not reviewed; or reviewed and corrected.
1	Reviewed, confirmed as reported.

OVERRIDE SITE/LAT/MORPH

Item Length: 1
 Allowable Values: 1
 NAACCR Item #2074
 Revised 09/06, 09/08

Description

Used with the EDITS software to override edit of the type *Laterality, Primary Site, Morph*.

Rationale

Some edits in the EDITS software package check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the override flag is used to skip the edit on future runs of the EDITS package.

EDITS Use

Edits of the type *Laterality, Primary Site, Morph* differ in whether they produce a warning or an error message and in use of ICD-O-2 or ICD-O-3 morphology and do the following:

- If the *Primary Site* (NAACCR Item #400) is a paired organ and *Behavior Code* (NAACCR Item #523) is in situ (2), then *Laterality* (NAACCR Item #410) must be 1, 2, 3 or 5.
- If diagnosis year is less than 1988 and *Histology* (NAACCR Item #522) is greater than or equal to 9590, then no further editing is performed. If diagnosis year is greater than 1987 and *Histology* equals 9140, 9700, 9701, 9590-9980, then no further editing is performed.

The intent of this edit is to force a review of in situ cases for which *Laterality* is coded 4 (bilateral) or 9 (unknown laterality) as to origin.

- In rare instances when the tumor is truly midline and the case was diagnosed prior to 2010 (when midline was coded 9), either change the *Laterality* code to 5 and leave the override blank, or enter code 1 for *Override Site/Lat/Morph*. For cases diagnosed in 2010 or later, *Laterality* must be coded 5 for midline tumors.
- If the rare combination is otherwise confirmed correct, enter code 1 for *Override Site/Lat/Morph*.

Instructions for Coding

- Leave blank if the EDITS program does not generate an error message for the *Laterality, Primary Site, Morphology* edits.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if a review of all items in the error or warning message confirms that all are correct.

Code	Definition
(leave blank)	Not reviewed; or reviewed and corrected.
1	Reviewed, confirmed as reported.

COC CODING SYSTEM–CURRENT

Item Length: 2

Allowable Values: 00–08, 99

NAACCR Item #2140

Revised 01/10

Description

Indicates the Commission on Cancer coding system currently used in the record.

Rationale

Knowledge of the coding system that describes the meaning of the codes currently stored for each case is necessary for interpretation of the coded data. It is also necessary for correct conversion of the record to a different coding system or to a different registry software system. This item differs from *CoC Coding System–Original* (NAACCR Item #2150) if the record has been converted to a more recent coding system.

Instructions for Coding

- All fields in a case record should be coded according to the same Commission on Cancer coding system following record conversion.
- This code does not apply to patient race, primary site, histology, TNM stage and its components, Collaborative Stage, comorbidities and complications, or cause of death. The original coding systems for these items are recorded in other fields.
- This item should be updated every time the record is converted to another coding system.

Code	Label	Definition
00	None	No CoC coding system used.
01	Pre-1988	Pre-1988 version (Cancer Program Manual Supplement)
02	1988	1988 <i>Data Acquisition Manual</i>
03	1989	1989 <i>Data Acquisition Manual</i>
04	1990	1990 <i>Data Acquisition Manual</i>
05	1994	1994 <i>Data Acquisition Manual</i>
06	1996	<i>Standards of the Commission on Cancer Volume II: Registry Operations and Data Standards (ROADS)</i>
07	1998	<i>Standards of the Commission on Cancer, Volume II: Registry Operations and Data Standards (ROADS)</i> 1998 Revisions
08	2003	<i>Facility Oncology Registry Data Standards (FORDS)</i>
99	Unknown	Unknown coding system.

Examples

Code	Reason
00	A case accessioned in 1980 was coded according to codes developed locally by the hospital before it became involved in the Commission on Cancer Approvals Program and no conversion of the record has occurred since its accession into the registry.
08	A case accessioned in 1980 was coded according to codes developed locally by the hospital before it became involved in the Commission on Cancer Approvals Program. In 1989, the registry records were converted to conform to the codes defined in the 1989 <i>Data Acquisition Manual</i> . The registry data were subsequently converted in 1996, 1998, and 2003 with the publication of each manual.

Code	Reason
08	A case accessioned in 1997 was coded according to 1996 <i>Standards of the Commission on Cancer, Volume II: Registry Operations and Data Standards (ROADS)</i> , and subsequently converted to correspond to the coding system expressed in <i>Facility Oncology Registry Data Standards (FORDS)</i> .
08	A new case was abstracted in 2010 using <i>Facility Oncology Registry Data Standards (FORDS) Revised for 2010</i> .
99	A case was accessioned in 1989, but it is unknown whether the 1988 or 1989 version of the <i>Data Acquisition Manual</i> was used to code the case. The conversion of this record to a more recent coding system is not possible due the uncertainty of its original coding system.

COC CODING SYSTEM–ORIGINAL

Item Length: 2
 Allowable Values: 00–08, 99
 NAACCR Item #2150
 Revised 01/10

Description

Indicates the Commission on Cancer coding system used to originally code the items.

Rationale

The coding system used when a case is originally coded limits the possible categories that could have been applied to code the case. Because code categories may change over time as new coding systems are developed, this item is used to assist interpretation when cases that may have been coded originally according to multiple coding systems are analyzed.

Instructions for Coding

- All fields in a case record should be coded according to the same Commission on Cancer coding system.
- This code does not apply to patient race, primary site, histology, TNM stage and its components, Collaborative Stage, comorbidities or complications, or cause of death. The original coding systems for these items are recorded in other fields.
- This item must not be changed when the record is converted to another coding system. That information is reflected in the data item *CoC Coding System–Current* (NAACCR Item #2140).
- Code 99 for cases coded prior to 2003 if the correct CoC coding system is not known, or if multiple coding systems were used to code a single case. Ordinarily, it will not be necessary to use code 99 for cases accessioned in 2003 or later.

Code	Label	Definition
00	None	No CoC coding system used.
01	Pre-1988	Pre-1988 version (Cancer Program Manual Supplement)
02	1988	1988 <i>Data Acquisition Manual</i>
03	1989	1989 <i>Data Acquisition Manual</i>
04	1990	1990 <i>Data Acquisition Manual</i>
05	1994	1994 <i>Data Acquisition Manual</i>
06	1996	<i>Standards of the Commission on Cancer, Volume II: Registry Operations and Data Standards (ROADS)</i>
07	1998	<i>Standards of the Commission on Cancer Volume II: Registry Operations and Data Standards (ROADS) 1998 Revisions</i>
08	2003	<i>Facility Oncology Registry Data Standards (FORDS)</i>
99	Unknown	Original CoC coding system used is not known.

Examples

Code	Reason
00	A case accessioned in 1980 was coded according to codes developed locally by the hospital before it became involved in the Commission on Cancer Approvals Program.
00	A case accessioned in 1980 was coded according to codes developed locally by the hospital before it became involved in the Commission on Cancer Approvals Program. In 1989, the registry records were converted to conform to the codes defined in the 1989 <i>Data Acquisition Manual</i> . The registry data were subsequently converted in 1996, 1998, and 2003 with the publication of each manual.
06	A case accessioned in 1997 was coded according to <i>1996 Standards of the Commission on Cancer, Volume II: Registry Operations and Data Standards (ROADS)</i> , and subsequently converted to correspond to the coding rules expressed in <i>Facility Oncology Registry Data Standards (FORDS)</i> .
99	A case was accessioned in 1989, but it is unknown whether the 1988 or 1989 version of the <i>Data Acquisition Manual</i> was used to code the case.

RACE CODING SYSTEM–CURRENT

Item Length: 1
 Allowable Values: 1–6, 9
 NAACCR Item #170
 Revised 01/04, 01/10

Description

Describes how race is currently coded. If converted, this field shows the system to which it was converted.

Rationale

Race codes (NAACCR Items #160–164) have changed over time. To accurately group and analyze data, it is necessary to record the system used to record the race codes.

Instructions for Coding

This item is autocoded by the software provider.

Code	Definition
1	4-value coding: 1 = White, 2 = Black, 3 = Other, 9 = Unknown
2	<1988 (1-digit)
3	1988 + (2-digit)
4	1991 + (added codes 20–97)
5	1994 + (added code 14)
6	2000 + (no new codes added, new items <i>Race #2–Race #5</i> added)
7	2010 + (added codes 15, 16, and 17; removed 09)
9	Other

RACE CODING SYSTEM—ORIGINAL

Item Length: 1
 Allowable Values: 1–6, 9
 NAACCR Item #180
 Revised 01/04, 01/10

Description

Describes how race was originally coded.

Rationale

Race #1–#5 codes (NAACCR Items #160–164) have changed over time. Identifying both the original and current coding systems used to code race promotes accurate data grouping and analysis.

Instructions for Coding

- This item is autocoded by the software provider.
- For cases diagnosed on or after January 1, 2010, this data item must be coded 7.

Code	Definition
1	4-value coding: 1 = White, 2 = Black, 3 = Other, 9 = Unknown
2	<1988 (1-digit)
3	1988 + (2-digit)
4	1991 + (added codes 20–97)
5	1994 + (added code 14)
6	2000 + (no new codes added, new items <i>Race #2–Race #5</i> added)
7	2010 + (added codes 15, 16, and 17; removed 09)
9	Other

SITE CODING SYSTEM–CURRENT

Item Length: 1
Allowable Values: 1–6, 9
NAACCR Item #450

Description

Describes how the primary site is currently coded. If converted, this field shows the system to which it was converted.

Rationale

This information is used for some data analysis and for further item conversions.

Instructions for Coding

This item is autocoded by the software provider.

Code	Definition
1	ICD-8 and Manual of Tumor Nomenclature and Coding (MOTNAC)
2	ICD-9
3	ICD-O, First Edition
4	ICD-O, Second Edition
5	ICD-O, Third Edition
6	ICD-10
9	Other

SITE CODING SYSTEM–ORIGINAL

Item Length: 1
Allowable Values: 1–6, 9
NAACCR Item #460

Description

Describes how the primary site was originally coded.

Rationale

This information is used for some data analysis. Converted codes have a slightly different distribution and meaning than codes entered directly. Cancer registries record case histories over many years, so not all cases will originally be assigned according to the same code version.

Instructions for Coding

This item is autocoded by the software provider.

Code	Definition
1	ICD-8 and Manual of Tumor Nomenclature and Coding (MOTNAC)
2	ICD-9
3	ICD-O, First Edition
4	ICD-O, Second Edition
5	ICD-O, Third Edition
6	ICD-10
9	Other

MORPHOLOGY CODING SYSTEM–CURRENT

Item Length: 1
 Allowable Values: 1–7, 9
 NAACCR Item #470
 Revised 01/10

Description

Describes how morphology is currently coded. If converted, this field shows the system to which it was converted.

Rationale

This information is used for some data analysis and for further item conversions. New versions of the codes used for recording histology and behavior reflect advances in medical and pathologic knowledge, and converted codes have a slightly different distribution and meaning than codes entered directly. Cancer registries record case histories over many years, so not all cases will originally be assigned according to the same code version.

Instructions for Coding

This item is autocoded by the software provider.

Code	Definition
1	ICD-O, First Edition
2	ICD-O, 1986 Field Trial
3	ICD-O, 1988 Field Trial
4	ICD-O, Second Edition
5	ICD-O, Second Edition, plus REAL lymphoma codes effective 1/1/95
6	ICD-O, Second Edition, plus FAB codes effective 1/1/98
7	ICD-O, Third Edition
8	ICD-O, Third Edition, plus 2008 WHO hematopoietic/lymphoid new terms effective 1/1/2010
9	Other

MORPHOLOGY CODING SYSTEM-ORIGINAL

Item Length: 1
 Allowable Values: 1-7, 9
 NAACCR Item #480
 Revised 01/04, 01/10

Description

Describes how morphology was originally coded. If later converted, this field shows the original codes used.

Rationale

This information is used for some data analysis and for further item conversions. New versions of the codes used for recording histology and behavior reflect advances in medical and pathologic knowledge, and converted codes have a slightly different distribution and meaning than codes entered directly. Cancer registries record case histories over many years, so not all cases will originally be assigned according to the same code version.

Instructions for Coding

- This item is autocoded by the software provider.
- For cases diagnosed on or after January 1, 2000, this data item must be coded 8.

Code	Definition
1	ICD-O, First Edition
2	ICD-O, 1986 Field Trial
3	ICD-O, 1988 Field Trial
4	ICD-O, Second Edition
5	ICD-O, Second Edition, plus REAL lymphoma codes effective 1/1/95
6	ICD-O, Second Edition, plus FAB codes effective 1/1/98
7	ICD-O, Third Edition
8	ICD-O, Third Edition, plus 2008 WHO hematopoietic/lymphoid new terms effective 1/1/2010
9	Other

ICD-O-2 CONVERSION FLAG

Item Length: 1
 Allowable Values: 0–4, blank
 NAACCR Item #1980
 Revised 01/04

Description

Specifies whether or how site and morphology codes were converted to ICD-O-2.

Rationale

This information is used for some data analysis and for further item conversions.

Instructions for Coding

- Codes 0, 1, and 2 are autocoded by the software provider.
- Codes 3 and 4 are manually entered following a review of the automated morphology conversion from ICD-O-1 or ICD-O-3 to ICD-O-2.

Code	Definition
(leave blank)	Not converted.
0	Primary site and morphology originally coded in ICD-O-2.
1	Primary site and morphology converted without review.
2	Primary site and morphology converted with review; morphology machine-converted without review.
3	Primary site machine-converted without review; morphology converted with review.
4	Primary site and morphology converted with review.
5	Morphology converted from ICD-O-3 without review.
6	Morphology converted from ICD-O-3 with review.

ICD-O-3 CONVERSION FLAG

Item Length: 1
 Allowable Values: 0, 1, 3, blank
 NAACCR Item #2116
 Revised 01/04

Description

Identifies how the conversion of morphology codes from ICD-O-2 to ICD-O-3 was accomplished.

Rationale

This information is used for some data analysis and for further item conversions. New versions of the codes used for recording histology and behavior reflect advances in medical and pathologic knowledge, and converted codes have a slightly different distribution and meaning than codes entered directly. Cancer registries record case histories over many years, so not all cases will originally be assigned according to the same code version.

Instructions for Coding

- Codes 0 and 1 are autocoded by the software provider.
- Code 3 is manually entered following review of the automated morphology conversion from ICD-O-2 to ICD-O-3.

Code	Definition
(leave blank)	Not converted.
0	Morphology (Morph–Type&Behav ICD-O-3, NAACCR Item #521) originally coded in ICD-O-3.
1	Morphology (Morph–Type&Behav ICD-O-3, NAACCR Item #521) converted from (Morph–Type&Behav ICD-O-2, NAACCR Item #419) without review.
3	Morphology (Morph–Type&Behav ICD-O-3, NAACCR Item #521) converted from (Morph–Type&Behav ICD-O-2, NAACCR Item #419) with review.

TNM EDITION NUMBER

Item Length: 2
 Allowable Values: 00–06, 88, 99
 NAACCR Item #1060
 Revised 01/04, 01/10

Description

Identifies the edition of the *AJCC Cancer Staging Manual* used to stage the case.

Rationale

AJCC stage and component T, N, and M codes and rules have changed over time. This item enables the analysis of cases grouped by edition number.

Instructions for Coding

This item is autocoded by the software provider.

Code	Label
00	Not staged (cases that have an AJCC staging scheme and staging was not done).
01	First Edition
02	Second Edition
03	Third Edition
04	Fourth Edition
05	Fifth Edition
06	Sixth Edition
07	Seventh Edition
88	Not applicable (cases that do not have an AJCC staging scheme).
99	Staged, but the edition is unknown.

**ICD REVISION COMORBIDITIES
AND COMPLICATIONS**

Item length: 1
Allowable values: 0, 1, 9
NAACCR Item #3165
Added 06/05

Description

This item indicates the coding system from which the *Comorbidities and Complications* (secondary diagnoses) codes are provided.

Rationale

Following the implementation of *FORDS*, it was determined that additional *Comorbidities and Complications* data items were needed.

Instructions for Coding

ICD Revision Comorbidities and Complications is to be recorded for patients diagnosed on or after January 1, 2006.

Code	Definition
0	No secondary diagnosis reported.
1	ICD-10
9	ICD-9

RX CODING SYSTEM–CURRENT

Item Length: 2

Allowable Values: 00–06, 99

NAACCR Item #1460

Description

Describes how treatment for this case is now coded.

Rationale

This information is used for some data analysis and for further item conversions.

Instructions for Coding

- This item is autocoded by the software provider.
- The *FORDS* manual **must** be used to record treatment for all cases diagnosed January 1, 2003, or later and this item **must** be coded 06.

Code	Definition
00	Treatment data not coded/transmitted, i.e., all treatment fields blank.
01	Treatment data coded using 1-digit surgery codes.
02	Treatment data coded according to 1983–1992 SEER manuals and CoC manuals 1983–1995.
03	Treatment data coded according to 1996 ROADS manual.
04	Treatment data coded according to 1998 ROADS supplement.
05	Treatment data coded according to 1998 SEER manual.
06	Treatment data coded according to FORDS.
07	Treatment data coded according to 2010 SEER manual.
99	Other coding, including partial or nonstandard coding.

DERIVED AJCC-FLAG

Item Length: 1
Allowable Values: 1, 2
NAACCR Item #3030
Added 01/04, 01/10

Description

Indicates the source data items used to derive AJCC Stage descriptors and Stage Group. It also indicates the target AJCC edition described by the derived AJCC Stage descriptors and Stage Group.

Rationale

AJCC Stage and component T, N, and M codes and rules change over time as does the method of deriving them. This item enables the analysis of cases grouped by coding and derivation version.

Instructions for Coding

Code	Description
(leave blank)	Not derived.
1	AJCC fields derived from Collaborative Stage.
2	AJCC fields derived from EOD (prior to 2004).

DERIVED SS1977-FLAG

Item Length: 1
Allowable Values: 1, 2
NAACCR Item #3040
Revised 01/10

Description

Indicates the source data items used to derive SEER Summary Stage 1997.

Rationale

The derivation of SS1977 varies over time with the coding rules and codes in use when the components were coded. This item enables the analysis of cases grouped by coding and derivation version.

Instructions for Coding

Code	Description
(leave blank)	Not derived.
1	SS1977 derived from Collaborative Stage.
2	SS1977 derived from EOD (prior to 2004).

DERIVED SS2000-FLAG

Item Length: 1
Allowable Values: 1, 2
NAACCR Item #3050
Added 01/04, 01/10

Description

Indicates the source data items used to derive SEER Summary Stage 2000.

Rationale

The derivation of SS2000 varies over time with the coding rules and codes in use when the components were coded. This item enables the analysis of cases grouped by coding and derivation version.

Instructions for Coding

Code	Description
(leave blank)	Not derived.
1	SS2000 derived from Collaborative Stage.
2	SS2000 derived from EOD (prior to 2004).

**CS VERSION INPUT ORIGINAL
(CS VERSION FIRST)**

Item Length: 6
Numeric
NAACCR Item #2935
Revised 01/10

Description

This item indicates the number of the version initially used to code Collaborative Staging (CS) fields. The CS version number is returned as part of the output of the CS algorithm.

Rationale

Over time, the input codes and instructions for CS items may change. This item identifies the correct interpretation of input CS items.

Instructions for Coding

This item is autocoded by the software provider.

Codes

CS Version Input Original is a 6-digit code. The first two digits represent the major version number; the second two digits represent minor version changes; and, the last two digits represent even less significant changes, such as corrections of typographical errors that do not affect coding or derivation of results (e.g., 010100).

CS VERSION INPUT CURRENT

Item Length: 6
Numeric
NAACCR Item #2937
New Item 01/2010

Description

This item indicates the version of CS input fields after they have been updated or recoded. This data item is recorded the first time the CS input fields are entered and should be updated each time the CS input fields are modified.

Rationale

Over time, the input codes and instructions for CS items may change. This item identifies the correct interpretation of input CS items.

Instructions for Coding

This item is autocoded by the software provider.

Codes

CS Version Input Current is a 6-digit code. The first two digits represent the major version number; the second two digits represent minor version changes; and, the last two digits represent even less significant changes, such as corrections of typographical errors that do not affect coding or derivation of results (e.g., 010100).

**CS VERSION DERIVED
(CS VERSION LATEST)**

Item Length: 6
Numeric
NAACCR Item #2936
Revised 01/10

Description

This data item is recorded the first time the CS output fields are derived and should be updated each time the CS Derived items are recomputed. The CS version number is returned as part of the output of the CS algorithm.

Rationale

The CS algorithm may be re-applied to compute the CS Derived items; for example, when the data are to be used for a special study, transmitted, or when an updated CS algorithm is produced. This item identifies the specific algorithm used to obtain the CS Derived values in the data record.

Instructions for Coding

This item is autocoded by the software provider.

Codes

CS Version Derived is a 6-digit code. The first two digits represent the major version number; the second two digits represent minor version changes; and, the last two digits represent even less significant changes, such as corrections of typographical errors that do not affect coding or derivation of results (e.g., 010100).

APPENDIX A

Use the table in this Appendix only for hematologic malignancies diagnosed prior to January 1, 2010. Beginning with diagnoses on that date, use *Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual* and the Hematopoietic and Lymphoid Neoplasms Database (Hematopoietic DB).

Appendix A: Definitions of Single and Subsequent Primaries for Hematologic Malignancies

Based on ICD-O-3 reportable malignancies, for use with diagnoses 01/01/2001 - 12/31/2009

Cancer registrars are often faced with multiple pathology reports in patients with hematologic malignancies, and the diagnoses reported may require different morphology codes. This is due in part to the fact that more intensive diagnostic study may yield a more specific diagnosis, and in part due to the natural histories of hematopoietic diseases, which may progress from one diagnosis into another.

The following chart, provided to aid the registrar in determining single versus subsequent primaries, employs the following guidelines:

1. “Lymphoma” is a general term for hematopoietic solid malignancies of the lymphoid series. “Leukemia” is a general term for liquid malignancies of either the lymphoid or the myeloid series. While it is recognized that some malignancies occur predominantly (or even exclusively) in liquid or solid form, because so many malignancies can potentially arise as either leukemias or lymphomas (or both), all hematopoietic malignancies are assumed to have this potential.
2. Malignancies of the lymphoid series are considered to be different from those of the myeloid series. Therefore, a lymphoid malignancy arising after diagnosis of a myeloid malignancy (or myelodysplastic or myeloproliferative disorder) would be considered a subsequent primary; however, a myeloid malignancy diagnosed after a previous myeloid malignancy would not count as a subsequent primary. Histiocytic malignancies are considered different from both lymphoid and myeloid malignancies.
3. Hodgkin lymphoma is considered to be different from non-Hodgkin lymphoma (NHL). Among the NHLs, B-cell malignancies are considered different from T-cell/NK cell malignancies. Therefore, a B-cell malignancy arising later in the course of a patient previously diagnosed with a T-cell malignancy would be considered a subsequent primary; however, a T-cell malignancy diagnosed later in the same patient would not be considered a subsequent primary.
4. The sequence of diagnoses affects whether a diagnosis represents a subsequent primary. In some cases, the order of occurrence of the two diagnoses being compared is a factor in the decision whether the second diagnosis is a new primary.

We gratefully acknowledge the assistance of Drs. Charles Lynch, Charles Platz, and Fred Dick of the University of Iowa. Dr. Tim Cote of the SEER Program, Jennifer Seiffert, MLIS, CTR, and Annette Hurlbut, RHIT, CTR for their assistance with this project.

To use the table, assign the ICD-O-3 code to the first diagnosis and find the row containing that code. Assign the ICD-O-3 code for the second diagnosis and find the column containing that code. In the cell at the intersection of the first diagnosis row and second diagnosis column, a “**S**” symbol indicates that the two diagnoses are most likely the **same** disease process (prepare/update a single abstract) and a “**D**” indicates that they are most likely **different** disease processes (prepare more than one abstract).

Note 1: If one of the two diagnoses is an NOS (not otherwise specified) term and the other is more specific and determined to be the same disease process, code the more specific diagnosis regardless of the sequence. For example, if a diagnosis of non-Hodgkin lymphoma, NOS is followed by a diagnosis of follicular lymphoma, assign the morphology code for the follicular lymphoma.

Note 2: The table “Single versus Subsequent Primaries of Lymphatic and Hematopoietic Diseases” (pages X-X) and the “Complete Diagnostic Terms for Table (based on ICD-O-3)” (page X) display only the ICD-O-3 primary (boldfaced) term associated with the code. Refer to the *International Classification of Disease, Third Edition* (ICD-O-3) for a complete list of related terms and synonyms.

Source: SEER Program, NCI E-mail: seerweb@ims.nci.nih.gov

SINGLE VERSUS SUBSEQUENT PRIMARIES OF LYMPHATIC AND HEMATOPOIETIC DISEASES

February 28, 2001 PAGE 1 SECOND DX ACROSS FIRST DX DOWN		1. 9590 Malignant lymphoma, NOS	2. 9591 NHL, NOS	3. 9596 Composite HD/NHL	4. 9650-9667 Hodgkin lymphoma	5. 9670-9671 ML, small B lymph	6. 9673 Mantle cell lymph	7. 9675-9684 ML, diff large B-cell	8. 9687 Burkitt lymphoma	9. 9689,9699 Marg zn, B-cl lym	10. 9690-9698 Follicular lymphoma
1. Malignant lymphoma, NOS	9590	S	S	S	S	S	S	S	S	S	S
2. NHL, NOS	9591	S	S	D	D	S	S	S	S	S	S
3. Composite HD/NHL	9596	S	S	S	S	S	S	S	S	S	S
4. Hodgkin lymphoma	9650-9667	S	D	D	S	D	D	D	D	D	D
5. ML, small B lymphocytic	9670-9671	S	S	D	D	S	D	S	D	D	D
6. Mantle cell lymphoma	9673	S	S	D	D	D	S	D	D	D	D
7. ML, diffuse, large B-cell	9675-9684	S	S	D	D	S	D	S	S	D	S
8. Burkitt lymphoma	9687	S	S	D	D	D	D	D	S	D	D
9. Marg zone, B-cell lymphoma	9689, 9699	S	S	D	D	D	D	D	D	S	D
10. Follicular lymphoma	9690-9698	S	S	D	D	D	D	S	D	D	S
11. Mycos fung, Sezary disease	9700-9701	S	S	D	D	D	D	D	D	D	D
12. T/NK-cell NHL	9702-9719	S	S	D	D	D	D	D	D	D	D
13. Precurs lym'blas lymph NOS	9727	S	S	D	D	D	D	D	D	D	D
14. Precurs lym'blas lymph B-cell	9728	S	S	D	D	D	D	D	D	D	D
15. Precurs lym'blas lymph T-cell	9729	S	S	D	D	D	D	D	D	D	D
16. Plasma cell tumors	9731-9734	D	D	D	D	D	D	D	D	D	D
17. Mast cell tumors	9740-9742	D	D	D	D	D	D	D	D	D	D
18. Histiocytos/Langerhans cell	9750-9756	D	D	D	D	D	D	D	D	D	D
19. Dendritic cell sarcoma	9757-9758	S	S	D	D	D	D	D	D	D	D
20. Immunoprolif disease, NOS	9760	S	S	D	D	S	D	S	D	D	D
21. Waldenstrom macroglob	9761	S	S	D	D	S	D	S	D	D	D
22. Heavy chain disease, NOS	9762	S	S	D	D	D	D	D	D	D	D
23. Immun sm intest disease	9764	S	S	D	D	D	D	D	D	D	D
24. Leuk/Acute leuk, NOS	9800-9801	S	S	D	D	D	D	D	S	D	D
25. Acute biphenotypic leukem	9805	S	S	D	D	S	S	S	S	S	S
26. Lymphocytic leukem, NOS	9820	S	S	D	D	D	D	D	S	D	S
27. BCLL/SLL	9823	S	S	D	D	S	D	S	D	D	D
28. Burkitt cell leukemia	9826	S	S	D	D	D	D	D	S	D	D
29. Adult T-cell leuk/lymph	9827	S	S	D	D	D	D	D	D	D	D
30. Polym'cyt leuk, NOS	9832	D	D	D	D	S	D	D	D	D	D
31. Polym'cyt leuk, B-cell	9833	D	D	D	D	S	D	D	D	D	D
32. Polym'cyt leuk, T-cell	9834	D	D	D	D	D	D	D	D	D	D
33. Precurs lym'cyt leuk, NOS	9835	S	S	D	D	D	D	D	D	D	D
34. Precurs B-cell leuk	9836	S	S	D	D	D	D	D	D	D	D
35. Precurs T-cell leuk	9837	S	S	D	D	D	D	D	D	D	D
36. Myeloid leukemias	9840-9910	D	D	D	D	D	D	D	D	D	D
37. Therapy related AML	9920	D	D	D	D	D	D	D	D	D	D
38. Myeloid sarcoma	9930	D	D	D	D	D	D	D	D	D	D
39. Acute panmyelosis	9931	D	D	D	D	D	D	D	D	D	D
40. Hairy cell leukemia	9940	D	D	D	D	D	D	D	D	D	D
41. Chron myelomonocyt leuk	9945	D	D	D	D	D	D	D	D	D	D
42. Juvenile myelomonocy leuk	9946	D	D	D	D	D	D	D	D	D	D
43. NK-cell leukemia	9948	S	S	D	D	D	D	D	D	D	D
44. Polycythemia vera	9950	D	D	D	D	D	D	D	D	D	D
45. Chron myeloprolif disease	9960	D	D	D	D	D	D	D	D	D	D
46. Myelosclerosis	9961	D	D	D	D	D	D	D	D	D	D
47. Essen thrombocythem	9962	D	D	D	D	D	D	D	D	D	D
48. Chron neutrophilic leukemia	9963	D	D	D	D	D	D	D	D	D	D
49. Hypereosinophilic syndrome	9964	D	D	D	D	D	D	D	D	D	D
50. Refractory anemias	9980-9986	D	D	D	D	D	D	D	D	D	D
51. Therapy related MDS	9987	D	D	D	D	D	D	D	D	D	D
52. Myelodysplastic syndr, NOS	9989	D	D	D	D	D	D	D	D	D	D

Codes: S--one primary only; D--presumably a subsequent primary

SEER Program, NCI. E-mail: seerweb@ims.nci.nih.gov

SINGLE VERSUS SUBSEQUENT PRIMARIES OF LYMPHATIC AND HEMATOPOIETIC DISEASES

February 28, 2001 PAGE 2 SECOND DX ACROSS FIRST DX DOWN		11. 9700-9701 MF, Sezary disease	12. 9702-9719 T/NK-cell lymphoma	13. 9727 Precurs lym'blas lymph NOS	14. 9728 Precurs lym'blas lymph B-cl	15. 9729 Precurs lym'blas lymph T-cl	16. 9731-9734 Plasma cell tumors	17. 9740-9742 Mast cell tumors	18. 9750-9756 Histiocytos; LCH	19. 9757-9758 Dendritic cell sarc	20. 9760 Immunoprolif dis
1. Malignant lymphoma, NOS	9590	S	S	S	S	S	S	S	S	S	S
2. NHL, NOS	9591	S	S	S	S	S	D	D	D	S	S
3. Composite HD/NHL	9596	S	S	S	S	S	D	D	D	D	S
4. Hodgkin lymphoma	9650-9667	D	D	D	D	D	D	D	D	D	D
5. ML, small B lymphocytic	9670-9671	D	D	D	D	D	D	D	D	D	D
6. Mantle cell lymphoma	9673	D	D	D	D	D	D	D	D	D	D
7. ML, diffuse, large B-cell	9675-9684	D	D	D	D	D	D	D	D	D	S
8. Burkitt lymphoma	9687	D	D	D	D	D	D	D	D	D	D
9. Marg zone, B-cell lymphoma	9689, 9699	D	D	D	D	D	D	D	D	D	D
10. Follicular lymphoma	9690-9698	D	D	D	D	D	D	D	D	D	D
11. Mycos fung, Sezary disease	9700-9701	S	D	D	D	D	D	D	D	D	D
12. T/NK-cell NHL	9702-9719	D	S	D	D	D	D	D	D	D	S
13. Precurs lym'blas lymph NOS	9727	D	D	S	S	S	D	D	D	D	D
14. Precurs lym'blas lymph B-cell	9728	D	D	S	S	D	D	D	D	D	D
15. Precurs lym'blas lymph T-cell	9729	D	D	S	D	S	D	D	D	D	D
16. Plasma cell tumors	9731-9734	D	D	D	D	D	S	D	D	D	D
17. Mast cell tumors	9740-9742	D	D	D	D	D	D	S	D	D	D
18. Histiocytos/Langerhans cell	9750-9756	D	D	D	D	D	D	D	S	D	D
19. Dendritic cell sarcoma	9757-9758	D	D	D	D	D	D	D	D	S	D
20. Immunoprolif disease, NOS	9760	D	D	D	D	D	S	D	D	D	S
21. Waldenstrom macroglob	9761	D	D	D	D	D	D	D	D	D	S
22. Heavy chain disease, NOS	9762	D	D	D	D	D	D	D	D	D	S
23. Immun sm intest disease	9764	D	D	D	D	D	S	D	D	D	S
24. Leuk/Acute leuk, NOS	9800-9801	D	S	S	S	S	D	D	D	D	D
25. Acute biphenotypic leukem	9805	S	S	S	S	S	D	D	D	D	D
26. Lymphocytic leukem, NOS	9820	S	S	S	S	S	D	D	D	D	S
27. BCLL/SLL	9823	D	D	D	D	D	D	D	D	D	S
28. Burkitt cell leukemia	9826	D	D	D	D	D	D	D	D	D	D
29. Adult T-cell leuk/lymph	9827	D	D	D	D	D	D	D	D	D	D
30. Prolym'cyt leuk, NOS	9832	D	D	D	D	D	D	D	D	D	D
31. Prolym'cyt leuk, B-cell	9833	D	D	D	D	D	D	D	D	D	D
32. Prolym'cyt leuk, T-cell	9834	D	D	D	D	D	D	D	D	D	D
33. Precurs lym'cyt leuk, NOS	9835	D	D	S	S	S	D	D	D	D	D
34. Precurs B-cell leuk	9836	D	D	S	S	D	D	D	D	D	D
35. Precurs T-cell leuk	9837	D	D	S	D	S	D	D	D	D	D
36. Myeloid leukemias	9840-9910	D	D	D	D	D	D	D	D	D	D
37. Therapy related AML	9920	D	D	D	D	D	D	D	D	D	D
38. Myeloid sarcoma	9930	D	D	D	D	D	D	D	D	D	D
39. Acute panmyelosis	9931	D	D	D	D	D	D	D	D	D	D
40. Hairy cell leukemia	9940	D	D	D	D	D	D	D	D	D	D
41. Chron myelomonocyt leuk	9945	D	D	D	D	D	D	D	D	D	D
42. Juvenile myelomonocy leuk	9946	D	D	D	D	D	D	D	D	D	D
43. NK-cell leukemia	9948	D	S	D	D	D	D	D	D	D	D
44. Polycythemia vera	9950	D	D	D	D	D	D	D	D	D	D
45. Chron myeloprolif disease	9960	D	D	D	D	D	D	D	D	D	D
46. Myelosclerosis	9961	D	D	D	D	D	D	D	D	D	D
47. Essen thrombocythem	9962	D	D	D	D	D	D	D	D	D	D
48. Chron neutrophilic leukemia	9963	D	D	D	D	D	D	D	D	D	D
49. Hypereosinophilic syndrome	9964	D	D	D	D	D	D	D	D	D	D
50. Refractory anemias	9980-9986	D	D	D	D	D	D	D	D	D	D
51. Therapy related MDS	9987	D	D	D	D	D	D	D	D	D	D
52. Myelodysplastic syndr, NOS	9989	D	D	D	D	D	D	D	D	D	D

Codes: S--one primary only; D--presumably a subsequent primary

SEER Program, NCI. E-mail: seerweb@ims.nci.nih.gov

SINGLE VERSUS SUBSEQUENT PRIMARIES OF LYMPHATIC AND HEMATOPOIETIC DISEASES

February 28, 2001 PAGE 3 SECOND DX ACROSS FIRST DX DOWN		21. 9761 Waldenstrom	22. 9762 Heavy chain dis	23. 9764 Imm sm intest dis	24. 9800-9801 Leuk/Acu leuk NOS	25. 9805 Acute biphenotypic leuk	26. 9820 Lym'cyt leuk, NOS	27. 9823 BCLL/SLL	28. 9826 Burkitt leukemia	29. 9827 Adult T-cell leuk/lym	30. 9832 Prolym leuk, NOS
1. Malignant lymphoma, NOS	9590	S	S	S	S	S	S	S	S	S	S
2. NHL, NOS	9591	S	S	S	S	S	S	S	S	S	D
3. Composite HD/NHL	9596	S	S	S	S	D	S	S	S	S	D
4. Hodgkin lymphoma	9650-9667	D	D	D	D	D	D	D	D	D	D
5. ML, small B lymphocytic	9670-9671	S	D	D	D	S	S	S	D	D	S
6. Mantle cell lymphoma	9673	D	D	D	D	S	D	D	D	D	D
7. ML, diffuse, large B-cell	9675-9684	S	S	S	D	S	S	S	D	D	S
8. Burkitt lymphoma	9687	D	D	D	S	S	S	D	S	D	D
9. Marg zone, B-cell lymphoma	9689, 9699	D	D	D	D	S	D	D	D	D	D
10. Follicular lymphoma	9690-9698	D	D	D	D	S	D	D	D	D	D
11. Mycos fung, Sezary disease	9700-9701	D	D	D	D	S	S	D	D	D	D
12. T/NK-cell NHL	9702-9719	D	D	D	D	S	S	D	D	D	D
13. Precurs lym'blas lymph NOS	9727	D	D	D	S	S	S	D	D	D	D
14. Precurs lym'blas lymph B-cell	9728	D	D	D	S	S	S	D	D	D	D
15. Precurs lym'blas lymph T-cell	9729	D	D	D	S	S	S	D	D	D	D
16. Plasma cell tumors	9731-9734	D	D	D	D	D	D	D	D	D	D
17. Mast cell tumors	9740-9742	D	D	D	D	D	D	D	D	D	D
18. Histiocytos/Langerhans cell	9750-9756	D	D	D	D	D	D	D	D	D	D
19. Dendritic cell sarcoma	9757-9758	D	D	D	D	D	D	D	D	D	D
20. Immunoprolif disease, NOS	9760	S	S	S	D	D	D	D	D	D	D
21. Waldenstrom macroglob	9761	S	D	D	D	D	S	S	D	D	D
22. Heavy chain disease, NOS	9762	D	S	S	D	D	S	S	D	D	D
23. Immun sm intest disease	9764	D	S	S	D	D	D	D	D	D	D
24. Leuk/Acute leuk, NOS	9800-9801	D	D	D	S	S	S	D	S	S	D
25. Acute biphenotypic leukem	9805	D	D	D	S	S	S	S	S	S	S
26. Lymphocytic leukem, NOS	9820	S	S	D	S	S	S	S	S	S	S
27. BCLL/SLL	9823	D	D	D	D	S	S	S	D	D	S
28. Burkitt cell leukemia	9826	D	D	D	S	S	S	D	S	D	D
29. Adult T-cell leuk/lymph	9827	D	D	D	D	S	S	D	D	S	D
30. Prolym'cyt leuk, NOS	9832	D	D	D	D	S	S	S	D	D	S
31. Prolym'cyt leuk, B-cell	9833	D	D	D	D	S	S	S	D	D	S
32. Prolym'cyt leuk, T-cell	9834	D	D	D	D	S	S	D	D	S	S
33. Precurs lym'cyt leuk, NOS	9835	D	D	D	S	S	S	D	D	D	D
34. Precurs B-cell leuk	9836	D	D	D	S	S	S	D	D	D	D
35. Precurs T-cell leuk	9837	D	D	D	S	S	S	D	D	D	D
36. Myeloid leukemias	9840-9910	D	D	D	S	S	D	D	D	D	D
37. Therapy related AML	9920	D	D	D	S	S	D	D	D	D	D
38. Myeloid sarcoma	9930	D	D	D	S	S	D	D	D	D	D
39. Acute panmyelosis	9931	D	D	D	S	S	D	D	D	D	D
40. Hairy cell leukemia	9940	D	D	D	S	S	D	D	D	D	D
41. Chron myelomonocyt leuk	9945	D	D	D	S	S	D	D	D	D	D
42. Juvenile myelomonocy leuk	9946	D	D	D	S	S	D	D	D	D	D
43. NK-cell leukemia	9948	D	D	D	S	S	S	D	D	D	D
44. Polycythemia vera	9950	D	D	D	S	D	D	D	D	D	D
45. Chron myeloprolif disease	9960	D	D	D	S	S	D	D	D	D	D
46. Myelosclerosis	9961	D	D	D	S	S	D	D	D	D	D
47. Essen thrombocythem	9962	D	D	D	S	D	D	D	D	D	D
48. Chron neutrophilic leukemia	9963	D	D	D	S	D	D	D	D	D	D
49. Hypereosinophilic syndrome	9964	D	D	D	S	D	D	D	D	D	D
50. Refractory anemias	9980-9986	D	D	D	S	S	D	D	D	D	D
51. Therapy related MDS	9987	D	D	D	S	S	D	D	D	D	D
52. Myelodysplastic syndr, NOS	9989	D	D	D	S	S	D	D	D	D	D

Codes: S--one primary only; D--presumably a subsequent primary

SEER Program, NCI. E-mail: seerweb@ims.nci.nih.gov

SINGLE VERSUS SUBSEQUENT PRIMARIES OF LYMPHATIC AND HEMATOPOIETIC DISEASES

February 28, 2001 PAGE 4 SECOND DX ACROSS FIRST DX DOWN		31. 9833 Prolym leuk, B-cell	32. 9834 Prolym leuk, T-cell	33. 9835 Precurs leuk, NOS	34. 9836 Precurs leuk, B-cell	35. 9837 Precurs leuk, T-cell	36. 9840-9910 Myeloid leukemias	37. 9920 Therapy rel AML	38. 9930 Myeloid sarcoma	39. 9931 Acute panmyelosis	40. 9940 Hairy cell leukemia	41. 9945 Chr myelomonocyt leu
1. Malignant lymphoma, NOS	9590	S	S	S	S	S	S	S	S	S	S	S
2. NHL, NOS	9591	D	D	S	S	S	D	D	D	D	D	D
3. Composite HD/NHL	9596	D	D	S	S	S	D	D	D	D	D	D
4. Hodgkin lymphoma	9650-9667	D	D	D	D	D	D	D	D	D	D	D
5. ML, small B lymphocytic	9670-9671	S	D	D	D	D	D	D	D	D	D	D
6. Mantle cell lymphoma	9673	D	D	D	D	D	D	D	D	D	D	D
7. ML, diffuse, large B-cell	9675-9684	S	D	D	D	D	D	D	D	D	D	D
8. Burkitt lymphoma	9687	D	D	D	D	D	D	D	D	D	D	D
9. Marg zone, B-cell lymphoma	9689, 9699	D	D	D	D	D	D	D	D	D	D	D
10. Follicular lymphoma	9690-9698	D	D	D	D	D	D	D	D	D	D	D
11. Mycos fung, Sezary disease	9700-9701	D	D	D	D	D	D	D	D	D	D	D
12. T/NK-cell NHL	9702-9719	D	D	D	D	D	D	D	D	D	D	D
13. Precurs lym'blas lymph NOS	9727	D	D	S	S	S	D	D	D	D	D	D
14. Precurs lym'blas lymph B-cell	9728	D	D	S	S	D	D	D	D	D	D	D
15. Precurs lym'blas lymph T-cell	9729	D	D	S	D	S	D	D	D	D	D	D
16. Plasma cell tumors	9731-9734	D	D	D	D	D	D	D	D	D	D	D
17. Mast cell tumors	9740-9742	D	D	D	D	D	D	D	D	D	D	D
18. Histiocytos/Langerhans cell	9750-9756	D	D	D	D	D	D	D	D	D	D	D
19. Dendritic cell sarcoma	9757-9758	D	D	D	D	D	D	D	D	D	D	D
20. Immunoprolif disease, NOS	9760	D	D	D	D	D	D	D	D	D	D	D
21. Waldenstrom macroglob	9761	D	D	D	D	D	D	D	D	D	D	D
22. Heavy chain disease, NOS	9762	D	D	D	D	D	D	D	D	D	D	D
23. Immun sm intest disease	9764	D	D	D	D	D	D	D	D	D	D	D
24. Leuk/Acute leuk, NOS	9800-9801	D	D	S	S	S	S	S	S	D	D	S
25. Acute biphenotypic leukem	9805	S	S	S	S	S	S	S	S	S	S	S
26. Lymphocytic leukem, NOS	9820	S	S	S	S	S	D	D	D	D	S	D
27. BCLL/SLL	9823	S	D	D	D	D	D	D	D	D	D	D
28. Burkitt cell leukemia	9826	D	D	D	D	D	D	D	D	D	D	D
29. Adult T-cell leuk/lymph	9827	D	D	D	D	D	D	D	D	D	D	D
30. Prolym'cyt leuk, NOS	9832	S	S	D	D	D	D	D	D	D	D	D
31. Prolym'cyt leuk, B-cell	9833	S	D	D	D	D	D	D	D	D	D	D
32. Prolym'cyt leuk, T-cell	9834	D	S	D	D	D	D	D	D	D	D	D
33. Precurs lym'cyt leuk, NOS	9835	D	D	S	S	S	D	D	D	D	D	D
34. Precurs B-cell leuk	9836	D	D	S	S	D	D	D	D	D	D	D
35. Precurs T-cell leuk	9837	D	D	S	D	S	D	D	D	D	D	D
36. Myeloid leukemias	9840-9910	D	D	D	D	D	S	S	S	S	D	S
37. Therapy related AML	9920	D	D	D	D	D	S	S	S	S	D	S
38. Myeloid sarcoma	9930	D	D	D	D	D	S	S	S	S	D	S
39. Acute panmyelosis	9931	D	D	D	D	D	S	S	S	S	D	S
40. Hairy cell leukemia	9940	D	D	D	D	D	D	D	D	D	S	D
41. Chron myelomonocyt leuk	9945	D	D	D	D	D	S	S	S	S	D	S
42. Juvenile myelomonocy leuk	9946	D	D	D	D	D	S	S	S	S	D	S
43. NK-cell leukemia	9948	D	D	D	D	D	D	D	D	D	D	D
44. Polycythemia vera	9950	D	D	D	D	D	D	D	D	D	D	D
45. Chron myeloprolif disease	9960	D	D	D	D	D	S	S	S	S	D	S
46. Myelosclerosis	9961	D	D	D	D	D	S	S	S	S	D	S
47. Essen thrombocythem	9962	D	D	D	D	D	S	S	S	S	D	S
48. Chron neutrophilic leukemia	9963	D	D	D	D	D	S	S	S	S	D	S
49. Hypereosinophilic syndrome	9964	D	D	D	D	D	S	S	S	S	D	S
50. Refractory anemias	9980-9986	D	D	D	D	D	S	S	S	S	D	S
51. Therapy related MDS	9987	D	D	D	D	D	S	S	S	S	D	S
52. Myelodysplastic syndr, NOS	9989	D	D	D	D	D	S	S	S	S	D	S

Codes: S--one primary only; D--presumably a subsequent primary

SEER Program, NCI. E-mail: seerweb@ims.nci.nih.gov

SINGLE VERSUS SUBSEQUENT PRIMARIES OF LYMPHATIC AND HEMATOPOIETIC DISEASES

February 28, 2001 PAGE 5 SECOND DX ACROSS FIRST DX DOWN		42. 9946 Juv myelomono leu	43. 9948 NK-cell leukemia	44. 9950 Polycythemia vera	45. 9960 Chr myeloprolif dis	46. 9961 Myelosclerosis	47. 9962 Ess thrombocythem	48. 9963 Chr neutrophil leu	49. 9964 Hypereosin syndr	50. 9980-9986 Refract anemias	51. 9987 Therapy rel MDS	52. 9989 Myelodys syn NOS
1. Malignant lymphoma, NOS	9590	S	S	D	D	D	D	D	D	D	D	D
2. NHL, NOS	9591	D	D	D	D	D	D	D	D	D	D	D
3. Composite HD/NHL	9596	D	D	D	D	D	D	D	D	D	D	D
4. Hodgkin lymphoma	9650-9667	D	D	D	D	D	D	D	D	D	D	D
5. ML, small B lymphocytic	9670-9671	D	D	D	D	D	D	D	D	D	D	D
6. Mantle cell lymphoma	9673	D	D	D	D	D	D	D	D	D	D	D
7. ML, diffuse, large B-cell	9675-9684	D	D	D	D	D	D	D	D	D	D	D
8. Burkitt lymphoma	9687	D	D	D	D	D	D	D	D	D	D	D
9. Marg zone, B-cell lymphoma	9689, 9699	D	D	D	D	D	D	D	D	D	D	D
10. Follicular lymphoma	9690-9698	D	D	D	D	D	D	D	D	D	D	D
11. Mycos fung, Sezary disease	9700-9701	D	D	D	D	D	D	D	D	D	D	D
12. T/NK-cell NHL	9702-9719	D	D	D	D	D	D	D	D	D	D	D
13. Precurs lym'blas lymph NOS	9727	D	D	D	D	D	D	D	D	D	D	D
14. Precurs lym'blas lymph B-cell	9728	D	D	D	D	D	D	D	D	D	D	D
15. Precurs lym'blas lymph T-cell	9729	D	D	D	D	D	D	D	D	D	D	D
16. Plasma cell tumors	9731-9734	D	D	D	D	D	D	D	D	D	D	D
17. Mast cell tumors	9740-9742	D	D	D	D	D	D	D	D	D	D	D
18. Histiocytos/Langerhans cell	9750-9756	D	D	D	D	D	D	D	D	D	D	D
19. Dendritic cell sarcoma	9757-9758	D	D	D	D	D	D	D	D	D	D	D
20. Immunoprolif disease, NOS	9760	D	D	D	D	D	D	D	D	D	D	D
21. Waldenstrom macroglob	9761	D	D	D	D	D	D	D	D	D	D	D
22. Heavy chain disease, NOS	9762	D	D	D	D	D	D	D	D	D	D	D
23. Immun sm intest disease	9764	D	D	D	D	D	D	D	D	D	D	D
24. Leuk/Acute leuk, NOS	9800-9801	S	D	D	S	S	D	S	S	D	S	S
25. Acute biphenotypic leukem	9805	S	S	D	S	S	D	D	D	S	S	S
26. Lymphocytic leukem, NOS	9820	D	S	D	D	D	D	D	D	D	D	D
27. BCLL/SLL	9823	D	D	D	D	D	D	D	D	D	D	D
28. Burkitt cell leukemia	9826	D	D	D	D	D	D	D	D	D	D	D
29. Adult T-cell leuk/lymph	9827	D	D	D	D	D	D	D	D	D	D	D
30. Prolym'cyt leuk, NOS	9832	D	D	D	D	D	D	D	D	D	D	D
31. Prolym'cyt leuk, B-cell	9833	D	D	D	D	D	D	D	D	D	D	D
32. Prolym'cyt leuk, T-cell	9834	D	D	D	D	D	D	D	D	D	D	D
33. Precurs lym'cyt leuk, NOS	9835	D	D	D	D	D	D	D	D	D	D	D
34. Precurs B-cell leuk	9836	D	D	D	D	D	D	D	D	D	D	D
35. Precurs T-cell leuk	9837	D	D	D	D	D	D	D	D	D	D	D
36. Myeloid leukemias	9840-9910	S	D	D	S	S	S	S	S	D	S	S
37. Therapy related AML	9920	S	D	D	D	S	D	D	D	D	S	S
38. Myeloid sarcoma	9930	S	D	D	S	S	S	S	D	D	S	S
39. Acute panmyelosis	9931	S	D	D	D	S	D	D	D	D	S	S
40. Hairy cell leukemia	9940	D	D	D	D	D	D	D	D	D	D	D
41. Chron myelomonocyt leuk	9945	S	D	D	S	S	D	S	D	D	S	S
42. Juvenile myelomonocy leuk	9946	S	D	D	D	S	D	D	D	D	S	S
43. NK-cell leukemia	9948	D	S	D	D	D	D	D	D	D	D	D
44. Polycythemia vera	9950	D	D	S	S	S	D	D	D	D	D	D
45. Chron myeloprolif disease	9960	D	D	D	S	S	S	S	D	D	D	D
46. Myelosclerosis	9961	S	D	D	S	S	S	S	D	D	S	S
47. Essen thrombocythem	9962	D	D	D	S	S	S	S	D	D	D	D
48. Chron neutrophilic leukemia	9963	D	D	D	S	S	S	S	D	D	D	D
49. Hypereosinophilic syndrome	9964	S	D	D	S	S	D	D	S	D	D	D
50. Refractory anemias	9980-9986	S	D	D	S	S	D	D	D	S	S	S
51. Therapy related MDS	9987	S	D	D	S	S	D	D	D	S	S	S
52. Myelodysplastic syndr, NOS	9989	S	D	D	S	S	D	D	D	S	S	S

Codes: S--one primary only; D--presumably a subsequent primary

SEER Program, NCI. E-mail: seerweb@ims.nci.nih.gov

COMPLETE DIAGNOSTIC TERMS FOR TABLE (BASED ON ICD-O-3)

1	9590 Malignant lymphoma, NOS
2	9591 Malignant lymphoma, non-Hodgkin, NOS
3	9596 Composite Hodgkin and non-Hodgkin lymphoma
4	9650-9667 Hodgkin lymphoma (all subtypes)
5	9670-9671 Malignant lymphoma, small B lymphocytic
6	9673 Mantle cell lymphoma
7	9675-9684 Malignant lymphoma, diffuse large B-cell
8	9687 Burkitt lymphoma
9	9689, 9699 Marginal zone B-cell lymphoma
10	9690-9698 Follicular lymphoma
11	9700-9701 Mycosis fungoides and Sezary syndrome
12	9702-9719 T/NK-cell non-Hodgkin lymphoma
13	9727 Precursor cell lymphoblastic lymphoma, NOS
14	9728 Precursor B-cell lymphoblastic lymphoma
15	9729 Precursor T-cell lymphoblastic lymphoma
16	9731-9734 Plasma cell tumors
17	9740-9742 Mast cell tumors
18	9750-9756 Histiocytosis/Langerhans cell histiocytosis
19	9757-9758 Dendritic cell sarcoma
20	9760 Immunoproliferative disease, NOS
21	9761 Waldenstrom macroglobulinemia
22	9762 Heavy chain disease, NOS
23	9764 Immunoproliferative small intestinal disease
24	9800-9801 Leukemia, NOS/Acute leukemia, NOS
25	9805 Acute biphenotypic leukemia
26	9820 Lymphoid leukemia, NOS
27	9823 B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma
28	9826 Burkitt cell leukemia
29	9827 Adult T-cell leukemia/lymphoma (HTLV-1 positive)
30	9832 Prolymphocytic leukemia, NOS
31	9833 Prolymphocytic leukemia, B-cell type
32	9834 Prolymphocytic leukemia, T-cell type
33	9835 Precursor cell lymphoblastic leukemia, NOS
34	9836 Precursor B-cell lymphoblastic leukemia
35	9837 Precursor T-cell lymphoblastic leukemia
36	9840-9910 Myeloid leukemias
37	9920 Therapy related acute myelogenous leukemia
38	9930 Myeloid sarcoma
39	9931 Acute panmyelosis with myelofibrosis
40	9940 Hairy cell leukemia
41	9945 Chronic myelomonocytic leukemia, NOS
42	9946 Juvenile myelomonocytic leukemia
43	9948 Aggressive NK-cell leukemia
44	9950 Polycythemia vera
45	9960 Chronic myeloproliferative disease, NOS
46	9961 Myelosclerosis with myeloid metaplasia
47	9962 Essential thrombocythemia
48	9963 Chronic neutrophilic leukemia
49	9964 Hypereosinophilic syndrome
50	9980-9986 Refractory anemias
51	9987 Therapy related myelodysplastic syndrome, NOS
52	9989 Myelodysplastic syndrome, NOS

Version 1.01. Codes corrected for terms in rows 7 and 9 on pages 2-5.

APPENDIX B: Site-Specific Surgery Codes

Note: The February 2010 updates changed the histologies that apply to these site-specific surgery codes. Those changes apply only to cases diagnosed in 2010 or later. Please consult *FORDS: Revised for 2009* for applicable histologies for cases diagnosed prior to that date.

ORAL CAVITY

**Lip C00.0–C00.9, Base of Tongue C01.9, Other Parts of Tongue C02.0–C02.9,
Gum C03.0–C03.9, Floor of Mouth C04.0–C04.9, Palate C05.0–C05.9,
Other Parts of Mouth C06.0–C06.9**

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

00 None; no surgery of primary site; autopsy ONLY

10 Local tumor destruction, NOS

11 Photodynamic therapy (PDT)

12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

13 Cryosurgery

14 Laser

No specimen sent to pathology from surgical events 10–14.

20 Local tumor excision, NOS

26 Polypectomy

27 Excisional biopsy

Any combination of 20 or 26–27 WITH

21 Photodynamic therapy (PDT)

22 Electrocautery

23 Cryosurgery

24 Laser ablation

25 Laser excision

30 Wide excision, NOS

Code 30 includes:

Hemiglossectomy

Partial glossectomy

40 Radical excision of tumor, NOS

41 Radical excision of tumor ONLY

42 Combination of 41 WITH resection in continuity with mandible (marginal, segmental, hemi-, or total resection)

43 Combination of 41 WITH resection in continuity with maxilla (partial, subtotal, or total resection)

Codes 40–43 include:

Total glossectomy

Radical glossectomy

Specimen sent to pathology from surgical events 20–43.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

PAROTID AND OTHER UNSPECIFIED GLANDS**Parotid Gland C07.9, Major Salivary Glands C08.0–C08.9**

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser

No specimen sent to pathology from surgical events 10–14.

- 20 Local tumor excision, NOS
 - 26 Polypectomy
 - 27 Excisional biopsy
 - Any combination of 20 or 26–27 WITH
 - 21 Photodynamic therapy (PDT)
 - 22 Electrocautery
 - 23 Cryosurgery
 - 24 Laser ablation
 - 25 Laser excision
- 30 Less than total parotidectomy, NOS; less than total removal of major salivary gland, NOS
 - 31 Facial nerve spared
 - 32 Facial nerve sacrificed
- 33 Superficial lobe ONLY
 - 34 Facial nerve spared
 - 35 Facial nerve sacrificed
- 36 Deep lobe (Total)
 - 37 Facial nerve spared
 - 38 Facial nerve sacrificed
- 40 Total parotidectomy, NOS; total removal of major salivary gland, NOS
 - 41 Facial nerve spared
 - 42 Facial nerve sacrificed
- 50 Radical parotidectomy, NOS; radical removal of major salivary gland, NOS
 - 51 WITHOUT removal of temporal bone
 - 52 WITH removal of temporal bone
 - 53 WITH removal of overlying skin (requires graft or flap coverage)
- 80 Parotidectomy, NOS

Specimen sent to pathology from surgical events 20–80.

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

(Revised 01/10, 02/10)

PHARYNX
**Tonsil C09.0–C09.9, Oropharynx C10.0–C10.9, Nasopharynx C11.0–C11.9
 Pyriform Sinus C12.9, Hypopharynx C13.0–C13.9, Pharynx C14.0**

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

00 None; no surgery of primary site; autopsy ONLY

10 Local tumor destruction, NOS

11 Photodynamic therapy (PDT)

12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

13 Cryosurgery

14 Laser

15 Stripping

No specimen sent to pathology from surgical events 10–15.

20 Local tumor excision, NOS

26 Polypectomy

27 Excisional biopsy

Any combination of 20 or 26–27 WITH

21 Photodynamic therapy (PDT)

22 Electrocautery

23 Cryosurgery

24 Laser ablation

25 Laser excision

28 Stripping

30 Pharyngectomy, NOS

31 Limited/partial pharyngectomy; tonsillectomy, bilateral tonsillectomy

32 Total pharyngectomy

40 Pharyngectomy WITH laryngectomy OR removal of contiguous bone tissue, NOS (does NOT include total mandibular resection)

41 WITH Laryngectomy (laryngopharyngectomy)

42 WITH bone

43 WITH both 41 and 42

50 Radical pharyngectomy (includes total mandibular resection), NOS

51 WITHOUT laryngectomy

52 WITH laryngectomy

Specimen sent to pathology from surgical events 20–52.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

ESOPHAGUS

C15.0–C15.9

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser

No specimen sent to pathology from surgical events 10–14.

- 20 Local tumor excision, NOS
 - 26 Polypectomy
 - 27 Excisional biopsy
 - Any combination of 20 or 26–27 WITH
 - 21 Photodynamic therapy (PDT)
 - 22 Electrocautery
 - 23 Cryosurgery
 - 24 Laser ablation
 - 25 Laser excision
- 30 Partial esophagectomy
- 40 Total esophagectomy, NOS
- 50 Esophagectomy, NOS WITH laryngectomy and/or gastrectomy, NOS
 - 51 WITH laryngectomy
 - 52 WITH gastrectomy, NOS
 - 53 Partial gastrectomy
 - 54 Total gastrectomy
 - 55 Combination of 51 WITH any of 52–54
- 80 Esophagectomy, NOS

Specimen sent to pathology from surgical events 20–80.

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

STOMACH**C16.0–C16.9**

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser

No specimen sent to pathology from surgical events 10–14.

- 20 Local tumor excision, NOS
 - 26 Polypectomy
 - 27 Excisional biopsy
 Any combination of 20 or 26–27 WITH
 - 21 Photodynamic therapy (PDT)
 - 22 Electrocautery
 - 23 Cryosurgery
 - 24 Laser ablation
- 25 Laser excision
- 30 Gastrectomy, NOS (partial, subtotal, hemi-)
 - 31 Antrectomy, lower (distal-less than 40% of stomach)***
 - 32 Lower (distal) gastrectomy (partial, subtotal, hemi-)
 - 33 Upper (proximal) gastrectomy (partial, subtotal, hemi-)

Code 30 includes:

Partial gastrectomy, including a sleeve resection of the stomach
 Billroth I: anastomosis to duodenum (duodenostomy)
 Billroth II: anastomosis to jejunum (jejunostomy)

- 40 Near-total or total gastrectomy, NOS
 - 41 Near-total gastrectomy
 - 42 Total gastrectomy**A total gastrectomy may follow a previous partial resection of the stomach.**

- 50 Gastrectomy, NOS WITH removal of a portion of esophagus
 - 51 Partial or subtotal gastrectomy
 - 52 Near total or total gastrectomy**Codes 50–52 are used for gastrectomy resection when only portions of esophagus are included in procedure.**

- 60 Gastrectomy with a resection in continuity with the resection of other organs, NOS***
 - 61 Partial or subtotal gastrectomy, in continuity with the resection of other organs***
 - 62 Near total or total gastrectomy, in continuity with the resection of other organs***
 - 63 Radical gastrectomy, in continuity with the resection of other organs*****Codes 60–63 are used for gastrectomy resections with organs other than esophagus. Portions of esophagus may or may not be included in the resection.**

80 Gastrectomy, NOS

Specimen sent to pathology from surgical events 20–80.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

*** Incidental splenectomy NOT included

COLON
C18.0–C18.9

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Code removal/surgical ablation of single or multiple liver metastases under the data item *Surgical Procedure/Other Site* (NAACCR Item #1294).

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser

No specimen sent to pathology from surgical events 10–14.

- 20 Local tumor excision, NOS
 - 27 Excisional biopsy
 - 26 Polypectomy, NOS
 - 28 Polypectomy-endoscopic
 - 29 Polypectomy-surgical excision
 - Any combination of 20 or 26–29 WITH
 - 21 Photodynamic therapy (PDT)
 - 22 Electrocautery
 - 23 Cryosurgery
 - 24 Laser ablation
 - 25 Laser excision
- 30 Partial colectomy, segmental resection
 - 32 Plus resection of contiguous organ; example: small bowel, bladder
- 40 Subtotal colectomy/hemicolectomy (total right or left colon and a portion of transverse colon)
 - 41 Plus resection of contiguous organ; example: small bowel, bladder
- 50 Total colectomy (removal of colon from cecum to the rectosigmoid junction; may include a portion of the rectum)
 - 51 Plus resection of contiguous organ; example: small bowel, bladder
- 60 Total proctocolectomy (removal of colon from cecum to the rectosigmoid junction, including the entire rectum)
 - 61 Plus resection of contiguous organ; example: small bowel, bladder
- 70 Colectomy or coloproctectomy with resection of contiguous organ(s), NOS (where there is not enough information to code 32, 41, 51, or 61)

Code 70 includes: Any colectomy (partial, hemicolectomy, or total) WITH a resection of any other organs in continuity with the primary site. Other organs may be partially or totally removed. Other organs may include, but are not limited to, oophorectomy, partial proctectomy, rectal mucosectomy, or pelvic exenteration.

- 80 Colectomy, NOS

Specimen sent to pathology from surgical events 20–80.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

RECTOSIGMOID**C19.9**

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Code removal/surgical ablation of single or multiple liver metastases under the data item *Surgical Procedure/Other Site* (NAACCR Item #1294).

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser ablation

No specimen sent to pathology from surgical events 10–14.

- 20 Local tumor excision, NOS
 - 26 Polypectomy
 - 27 Excisional biopsy
 Combination of 20 or 26–27 WITH
 - 21 Photodynamic therapy (PDT)
 - 22 Electrocautery
 - 23 Cryosurgery
 - 24 Laser ablation
- 25 Laser excision
- 30 Wedge or segmental resection; partial proctosigmoidectomy, NOS
 - 31 Plus resection of contiguous organs; example: small bowel, bladder

Procedures coded 30 include, but are not limited to:

- Anterior resection
- Hartmann operation
- Low anterior resection (LAR)
- Partial colectomy, NOS
- Rectosigmoidectomy, NOS
- Sigmoidectomy
- 40 Pull through WITH sphincter preservation (colo-anal anastomosis)
- 50 Total proctectomy
- 51 Total colectomy
- 55 Total colectomy WITH ileostomy, NOS
 - 56 Ileorectal reconstruction
 - 57 Total colectomy WITH other pouch; example: Koch pouch

60 Total proctocolectomy, NOS

65 Total proctocolectomy WITH ileostomy, NOS

66 Total proctocolectomy WITH ileostomy and pouch

Removal of the colon from cecum to the rectosigmoid or a portion of the rectum.

70 Colectomy or proctocolectomy resection in continuity with other organs; pelvic exenteration

80 Colectomy, NOS; Proctectomy, NOS

Specimen sent to pathology from surgical events 20–80.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

RECTUM**C20.9**

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Code removal/surgical ablation of single or multiple liver metastases under the data item *Surgical Procedure/Other Site* (NAACCR Item #1294).**Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser

No specimen sent to pathology from surgical events 10-14.

- 20 Local tumor excision, NOS
 - 27 Excisional biopsy
 - 26 Polypectomy
 - Any combination of 20 or 26–27 WITH
 - 21 Photodynamic therapy (PDT)
 - 22 Electrocautery
 - 23 Cryosurgery
 - 24 Laser ablation
 - 25 Laser excision
 - 28 Curette and fulguration

- 30 Wedge or segmental resection; partial proctectomy, NOS

Procedures coded 30 include, but are not limited to:

- Anterior resection
- Hartmann's operation
- Low anterior resection (LAR)
- Transsacral rectosigmoidectomy
- Total mesorectal excision (TME)

- 40 Pull through WITH sphincter preservation (coloanal anastomosis)

- 50 Total proctectomy

Procedure coded 50 includes, but is not limited to:

- Abdominoperineal resection (Miles Procedure)

- 60 Total proctocolectomy, NOS

- 70 Proctectomy or proctocolectomy with resection in continuity with other organs; pelvic exenteration

- 80 Proctectomy, NOS

Specimen sent to pathology from surgical events 20–80.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

ANUS

C21.0–C21.8

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser
 - 15 Thermal Ablation

No specimen sent to pathology from surgical events 10–15.

- 20 Local tumor excision, NOS
 - 26 Polypectomy
 - 27 Excisional biopsy
 Any combination of 20 or 26–27 WITH
 - 21 Photodynamic therapy (PDT)
 - 22 Electrocautery
 - 23 Cryosurgery
 - 24 Laser ablation
- 25 Laser excision
- 60 Abdominal perineal resection, NOS (APR; Miles procedure)
 - 61 APR and sentinel node excision
 - 62 APR and unilateral inguinal lymph node dissection
 - 63 APR and bilateral inguinal lymph node dissection

The lymph node dissection should also be coded under *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292) or *Scope of Regional Lymph Node Surgery at This Facility* (NAACCR Item #672).

Specimen sent to pathology from surgical events 20–63.

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

LIVER AND INTRAHEPATIC BILE DUCTS**C22.0–C22.1**

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser
 - 15 Alcohol (Percutaneous Ethanol Injection-PEI)
 - 16 Heat-Radio-frequency ablation (RFA)
 - 17 Other (ultrasound, acetic acid)

No specimen sent to pathology from surgical events 10–17.

- 20 Wedge or segmental resection, NOS
 - 21 Wedge resection
 - 22 Segmental resection, NOS
 - 23 One
 - 24 Two
 - 25 Three
 - 26 Segmental resection AND local tumor destruction
- 30 Lobectomy, NOS
 - 36 Right lobectomy
 - 37 Left lobectomy
 - 38 Lobectomy AND local tumor destruction
- 50 Extended lobectomy, NOS (extended: resection of a single lobe plus a segment of another lobe)
 - 51 Right lobectomy
 - 52 Left lobectomy
 - 59 Extended lobectomy AND local tumor destruction
- 60 Hepatectomy, NOS
 - 61 Total hepatectomy and transplant
- 65 Excision of a bile duct (for an intra-hepatic bile duct primary only)
 - 66 Excision of a bile duct PLUS partial hepatectomy
- 75 Bile duct and hepatectomy WITH transplant

Specimen sent to pathology from surgical events 20–75.

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

PANCREAS**C25.0–C25.9**

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 25 Local excision of tumor, NOS
- 30 Partial pancreatectomy, NOS; example: distal
- 35 Local or partial pancreatectomy and duodenectomy
 - 36 WITHOUT distal/partial gastrectomy
 - 37 WITH partial gastrectomy (Whipple)
- 40 Total pancreatectomy
- 60 Total pancreatectomy and subtotal gastrectomy or duodenectomy
- 70 Extended pancreatoduodenectomy
- 80 Pancreatectomy, NOS
- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

LARYNX
C32.0–C32.9

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser
 - 15 Stripping

No specimen sent to pathology from surgical events 10–15.

- 20 Local tumor excision, NOS
 - 26 Polypectomy
 - 27 Excisional biopsy
 - Any combination of 20 or 26–27 WITH
 - 21 Photodynamic therapy (PDT)
 - 22 Electrocautery
 - 23 Cryosurgery
 - 24 Laser ablation
 - 25 Laser excision
 - 28 Stripping
- 30 Partial excision of the primary site, NOS; subtotal/partial laryngectomy NOS; hemilaryngectomy NOS
 - 31 Vertical laryngectomy
 - 32 Anterior commissure laryngectomy
 - 33 Supraglottic laryngectomy
- 40 Total or radical laryngectomy, NOS
 - 41 Total laryngectomy ONLY
 - 42 Radical laryngectomy ONLY
- 50 Pharyngolaryngectomy
- 80 Laryngectomy, NOS

Specimen sent to pathology from surgical events 20–80.

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

(Revised 01/10, 02/10)

LUNG

C34.0–C34.9

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 19 Local tumor destruction or excision, NOS
Unknown whether a specimen was sent to pathology for surgical events coded 19 (principally for cases diagnosed prior to January 1, 2003).
- 15 Local tumor destruction, NOS
 12 Laser ablation or cryosurgery
 13 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
No specimen sent to pathology from surgical events 12–13 and 15.
- 20 Excision or resection of less than one lobe, NOS
 23 Excision, NOS
 24 Laser excision
 25 Bronchial sleeve resection ONLY
 21 Wedge resection
 22 Segmental resection, including lingulectomy
- 30 Resection of lobe or bilobectomy, but less than the whole lung (partial pneumonectomy, NOS)
 33 Lobectomy WITH mediastinal lymph node dissection
The lymph node dissection should also be coded under *Scope of Regional Lymph Node Surgery (NAACCR Item #1292)* or *Scope of Regional Lymph Node Surgery at This Facility (NAACCR Item #672)*.
- 45 Lobe or bilobectomy extended, NOS
 46 WITH chest wall
 47 WITH pericardium
 48 WITH diaphragm
- 55 Pneumonectomy, NOS
 56 WITH mediastinal lymph node dissection (radical pneumonectomy)
The lymph node dissection should also be coded under *Scope of Regional Lymph Node Surgery (NAACCR Item # 1292)* or *Scope of Regional Lymph Node Surgery at This Facility (NAACCR Item #672)*.
- 65 Extended pneumonectomy
 66 Extended pneumonectomy plus pleura or diaphragm
- 70 Extended radical pneumonectomy
The lymph node dissection should also be coded under *Scope of Regional Lymph Node Surgery (NAACCR Item # 1292)* or *Scope of Regional Lymph Node Surgery at This Facility (NAACCR Item #672)*.
- 80 Resection of lung, NOS
Specimen sent to pathology from surgical events 20–80.
- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY (Revised 01/04, 01/10, 02/10)

**HEMATOPOIETIC/RETICULOENDOTHELIAL/
IMMUNOPROLIFERATIVE/MYELOPROLIFERATIVE DISEASE
C42.0, C42.1, C42.3, C42.4 (with any histology)**

or

M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992 (with any site)

Code

- 98 All hematopoietic/reticuloendothelial/immunoproliferative/myeloproliferative disease sites and/or histologies, WITH or WITHOUT surgical treatment.

Surgical procedures for hematopoietic/reticuloendothelial/immunoproliferative/myeloproliferative primaries are to be recorded using the data item *Surgical Procedure/Other Site* (NAACCR Item #1294) or *Surgical Procedure/Other Site at This Facility* (NAACCR Item #674).

BONES, JOINTS, AND ARTICULAR CARTILAGE C40.0–C41.9
PERIPHERAL NERVES AND AUTONOMIC NERVOUS SYSTEM C47.0–C47.9
CONNECTIVE, SUBCUTANEOUS, AND OTHER SOFT TISSUES C49.0–C49.9

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

00 None; no surgery of primary site; autopsy ONLY

19 Local tumor destruction or excision, NOS

Unknown whether a specimen was sent to pathology for surgical events coded 19 (principally for cases diagnosed prior to January 1, 2003).

15 Local tumor destruction

No specimen sent to pathology from surgical event 15.

25 Local excision

26 Partial resection

30 Radical excision or resection of lesion WITH limb salvage

40 Amputation of limb

41 Partial amputation of limb

42 Total amputation of limb

50 Major amputation, NOS

51 Forequarter, including scapula

52 Hindquarter, including ilium/hip bone

53 Hemipelvectomy, NOS

54 Internal hemipelvectomy

Specimen sent to pathology from surgical events 25–54.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

SPLEEN

Spleen C42.2

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

00 None; no surgery of primary site; autopsy ONLY

19 Local tumor destruction or excision, NOS

Unknown whether a specimen was sent to pathology for surgical events coded 19 (principally for cases diagnosed prior to January 1, 2003).

21 Partial splenectomy

22 Total splenectomy

80 Splenectomy, NOS

Specimen sent to pathology for surgical events 21-80.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

SKIN
C44.0–C44.9

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser ablation

No specimen sent to pathology from surgical events 10–14.

- 20 Local tumor excision, NOS
 - 26 Polypectomy
 - 27 Excisional biopsy
 Any combination of 20 or 26–27 WITH
 - 21 Photodynamic therapy (PDT)
 - 22 Electrocautery
 - 23 Cryosurgery
 - 24 Laser ablation
- 25 Laser excision
- 30 Biopsy of primary tumor followed by a gross excision of the lesion (does not have to be done under the same anesthesia)
 - 31 Shave biopsy followed by a gross excision of the lesion
 - 32 Punch biopsy followed by a gross excision of the lesion
 - 33 Incisional biopsy followed by a gross excision of the lesion
 - 34 Mohs surgery, NOS
 - 35 Mohs with 1-cm margin or less
 - 36 Mohs with more than 1-cm margin
- 45 Wide excision or reexcision of lesion or minor (local) amputation with margins more than 1 cm, NOS. Margins MUST be microscopically negative.
 - 46 WITH margins more than 1 cm and less than or equal to 2 cm
 - 47 WITH margins greater than 2 cm

If the excision does not have microscopically negative margins greater than 1 cm, use the appropriate code, 20–36.
- 60 Major amputation

Specimen sent to pathology from surgical events 20–60.

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

BREAST**C50.0–C50.9**

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 19 Local tumor destruction, NOS

No specimen was sent to pathology for surgical events coded 19 (principally for cases diagnosed prior to January 1, 2003).

- 20 Partial mastectomy, NOS; less than total mastectomy, NOS
 - 21 Partial mastectomy WITH nipple resection
 - 22 Lumpectomy or excisional biopsy
 - 23 Reexcision of the biopsy site for gross or microscopic residual disease
 - 24 Segmental mastectomy (including wedge resection, quadrantectomy, tylectomy)

Procedures coded 20–24 remove the gross primary tumor and some of the breast tissue (breast-conserving or preserving). There may be microscopic residual tumor.

- 30 Subcutaneous mastectomy

A subcutaneous mastectomy, also called a nipple sparing mastectomy, is the removal of breast tissue without the nipple and areolar complex or overlying skin. It is performed to facilitate immediate breast reconstruction. Cases coded 30 may be considered to have undergone breast reconstruction.

- 40 Total (simple) mastectomy
 - 41 WITHOUT removal of uninvolved contralateral breast
 - 43 With reconstruction NOS
 - 44 Tissue
 - 45 Implant
 - 46 Combined (Tissue and Implant)
 - 42 WITH removal of uninvolved contralateral breast
 - 47 With reconstruction NOS
 - 48 Tissue
 - 49 Implant
 - 75 Combined (Tissue and Implant)

A total (simple) mastectomy removes all breast tissue, the nipple, and areolar complex. An axillary dissection is not done.

For single primaries only, code removal of involved contralateral breast under the data item *Surgical Procedure/Other Site* (NAACCR Item #1294) or *Surgical Procedure/Other Site at This Facility* (NAACCR Item #674).

If contralateral breast reveals a second primary, each breast is abstracted separately. The surgical procedure is coded 41 for the first primary. The surgical code for the contralateral breast is coded to the procedure performed on that site.

Reconstruction that is planned as part of first course treatment is coded 43-49 or 75, whether it is done at the time of mastectomy or later.

- 50 Modified radical mastectomy
 - 51 WITHOUT removal of uninvolved contralateral breast
 - 53 Reconstruction, NOS

-
- 54 Tissue
 - 55 Implant
 - 56 Combined (Tissue and Implant)
 - 52 WITH removal of uninvolved contralateral breast
 - 57 Reconstruction, NOS
 - 58 Tissue
 - 59 Implant
 - 63 Combined (Tissue and Implant)

Removal of all breast tissue, the nipple, the areolar complex, and variable amounts of breast skin in continuity with the axilla. The specimen may or may not include a portion of the pectoralis major muscle.

If contralateral breast reveals a second primary, it is abstracted separately. The surgical procedure is coded 51 for the first primary. The surgical code for the contralateral breast is coded to the procedure performed on that site.

For single primaries only, code removal of involved contralateral breast under the data item *Surgical Procedure/Other Site* (NAACCR Item #1294) or *Surgical Procedure/Other Site at This Facility* (NAACCR Item #674).

- 60 Radical mastectomy, NOS
 - 61 WITHOUT removal of uninvolved contralateral breast
 - 64 Reconstruction, NOS
 - 65 Tissue
 - 66 Implant
 - 67 Combined (Tissue and Implant)
 - 62 WITH removal of uninvolved contralateral breast
 - 68 Reconstruction, NOS
 - 69 Tissue
 - 73 Implant
 - 74 Combined (Tissue and Implant)
- 70 Extended radical mastectomy
 - 71 WITHOUT removal of uninvolved contralateral breast
 - 72 WITH removal of uninvolved contralateral breast

- 80 Mastectomy, NOS

Specimen sent to pathology for surgical events coded 20-80.

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

CERVIX UTERI**C53.0–C53.9**

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

For invasive cancers, dilation and curettage is coded as an incisional biopsy (02) under the data item *Surgical Diagnostic and Staging Procedure* (NAACCR Item #1350).

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser
 - 15 Loop Electrocautery Excision Procedure (LEEP)
 - 16 Laser ablation
 - 17 Thermal ablation

No specimen sent to pathology from surgical events 10–17.

- 20 Local tumor excision, NOS
 - 26 Excisional biopsy, NOS
 - 27 Cone biopsy
 - 24 Cone biopsy WITH gross excision of lesion
 - 29 Trachelectomy; removal of cervical stump; cervicectomy
 - Any combination of 20, 24, 26, 27 or 29 WITH
 - 21 Electrocautery
 - 22 Cryosurgery
 - 23 Laser ablation or excision
 - 25 Dilatation and curettage; endocervical curettage (for in situ only)
 - 28 Loop electrocautery excision procedure (LEEP)
- 30 Total hysterectomy (simple, pan-) WITHOUT removal of tubes and ovaries
Total hysterectomy removes both the corpus and cervix uteri and may also include a portion of vaginal cuff.
- 40 Total hysterectomy (simple, pan-) WITH removal of tubes and/or ovary
Total hysterectomy removes both the corpus and cervix uteri and may also include a portion of vaginal cuff.
- 50 Modified radical or extended hysterectomy; radical hysterectomy; extended radical hysterectomy
 - 51 Modified radical hysterectomy
 - 52 Extended hysterectomy
 - 53 Radical hysterectomy; Wertheim procedure
 - 54 Extended radical hysterectomy
- 60 Hysterectomy, NOS, WITH or WITHOUT removal of tubes and ovaries
 - 61 WITHOUT removal of tubes and ovaries
 - 62 WITH removal of tubes and ovaries

-
- 70 Pelvic exenteration
71 Anterior exenteration
Includes bladder, distal ureters, and genital organs WITH their ligamentous attachments and pelvic lymph nodes.
- 72 Posterior exenteration
Includes rectum and rectosigmoid WITH ligamentous attachments and pelvic lymph nodes.
- 73 Total exenteration
Includes removal of all pelvic contents and pelvic lymph nodes.
- 74 Extended exenteration
Includes pelvic blood vessels or bony pelvis.

Specimen sent to pathology from surgical events 20–74.

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

CORPUS UTERI**C54.0–C55.9**

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

For invasive cancers, dilation and curettage is coded as an incisional biopsy (02) under the data item *Surgical Diagnostic and Staging Procedure* (NAACCR Item #1350).

Codes

00 None; no surgery of primary site; autopsy ONLY

19 Local tumor destruction or excision, NOS

Unknown whether a specimen was sent to pathology for surgical events coded 19 (principally for cases diagnosed prior to January 1, 2003).

10 Local tumor destruction, NOS

11 Photodynamic therapy (PDT)

12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

13 Cryosurgery

14 Laser

15 Loop Electocautery Excision Procedure (LEEP)

16 Thermal ablation

No specimen sent to pathology from surgical events 10–16.

20 Local tumor excision, NOS; simple excision, NOS

24 Excisional biopsy

25 Polypectomy

26 Myomectomy

Any combination of 20 or 24–26 WITH

21 Electrocautery

22 Cryosurgery

23 Laser ablation or excision

30 Subtotal hysterectomy/supracervical hysterectomy/fundectomy WITH or WITHOUT removal of tube(s) and ovary(ies).

31 WITHOUT tube(s) and ovary(ies)

32 WITH tube(s) and ovary(ies)

40 Total hysterectomy (simple, pan-) WITHOUT removal of tube(s) and ovary(ies)

Removes both the corpus and cervix uteri. It may also include a portion of the vaginal cuff.

50 Total hysterectomy (simple, pan-) WITH removal of tube(s) and/or ovary(ies)

Removes both the corpus and cervix uteri. It may also include a portion of the vaginal cuff.

60 Modified radical or extended hysterectomy; radical hysterectomy; extended radical hysterectomy

61 Modified radical hysterectomy

62 Extended hysterectomy

63 Radical hysterectomy; Wertheim procedure

64 Extended radical hysterectomy

-
- 65 Hysterectomy, NOS, WITH or WITHOUT removal of tube(s) and ovary(ies)
66 WITHOUT removal of tube(s) and ovary(ies)
67 WITH removal of tube(s) and ovary(ies)
- 75 Pelvic exenteration
76 Anterior exenteration
Includes bladder, distal ureters, and genital organs WITH their ligamentous attachments and pelvic lymph nodes.
- 77 Posterior exenteration
Includes rectum and rectosigmoid WITH ligamentous attachments and pelvic lymph nodes.
- 78 Total exenteration
Includes removal of all pelvic contents and pelvic lymph nodes.
- 79 Extended exenteration
Includes pelvic blood vessels or bony pelvis.

Specimen sent to pathology from surgical events 20–79.

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

OVARY**C56.9**

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

00 None; no surgery of primary site; autopsy ONLY

17 Local tumor destruction, NOS

No specimen sent to pathology from surgical event 17.

25 Total removal of tumor or (single) ovary, NOS

26 Resection of ovary (wedge, subtotal, or partial) ONLY, NOS; unknown if hysterectomy done

27 WITHOUT hysterectomy

28 WITH hysterectomy

35 Unilateral (salpingo-)oophorectomy; unknown if hysterectomy done

36 WITHOUT hysterectomy

37 WITH hysterectomy

50 Bilateral (salpingo-)oophorectomy; unknown if hysterectomy done

51 WITHOUT hysterectomy

52 WITH hysterectomy

55 Unilateral or bilateral (salpingo-)oophorectomy WITH OMENTECTOMY, NOS; partial or total; unknown if hysterectomy done

56 WITHOUT hysterectomy

57 WITH hysterectomy

60 Debulking; cytoreductive surgery, NOS

61 WITH colon (including appendix) and/or small intestine resection (not incidental)

62 WITH partial resection of urinary tract (not incidental)

63 Combination of 61 and 62

Debulking is a partial or total removal of the tumor mass and can involve the removal of multiple organ sites. It may include removal of ovaries and/or the uterus (a hysterectomy). The pathology report may or may not identify ovarian tissue. A debulking is usually followed by another treatment modality such as chemotherapy.

70 Pelvic exenteration, NOS

71 Anterior exenteration

Includes bladder, distal ureters, and genital organs WITH their ligamentous attachments and pelvic lymph nodes.

72 Posterior exenteration

Includes rectum and rectosigmoid WITH ligamentous attachments and pelvic lymph nodes.

73 Total exenteration

Includes removal of all pelvic contents and pelvic lymph nodes.

74 Extended exenteration

Includes pelvic blood vessels or bony pelvis.

80 (Salpingo-)oophorectomy, NOS

Specimen sent to pathology from surgical events 25–80.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

(Revised 01/04, 01/10, 02/10)

PROSTATE**C61.9**

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Do not code an orchiectomy in this field. For prostate primaries, orchiectomies are coded in the data item *Hematologic Transplant and Endocrine Procedures* (NAACCR Item #3250).

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 18 Local tumor destruction or excision, NOS
- 19 Transurethral resection (TURP), NOS

Unknown whether a specimen was sent to pathology for surgical events coded 18 or 19 (principally for cases diagnosed prior to January 1, 2003).

- 10 Local tumor destruction, NOS
 - 14 Cryoprostatectomy
 - 15 Laser ablation
 - 16 Hyperthermia
 - 17 Other method of local tumor destruction

No specimen sent to pathology from surgical events 10–17.

- 20 Local tumor excision, NOS
 - 21 Transurethral resection (TURP), NOS
 - 22 TURP—cancer is incidental finding during surgery for benign disease
 - 23 TURP—patient has suspected/known cancerAny combination of 20–23 WITH
 - 24 Cryosurgery
 - 25 Laser
 - 26 Hyperthermia
- 30 Subtotal, segmental, or simple prostatectomy, which may leave all or part of the capsule intact
- 50 Radical prostatectomy, NOS; total prostatectomy, NOS
Excised prostate, prostatic capsule, ejaculatory ducts, seminal vesicle(s) and may include a narrow cuff of bladder neck.
- 70 Prostatectomy WITH resection in continuity with other organs; pelvic exenteration
Surgeries coded 70 are any prostatectomy WITH resection in continuity with any other organs. The other organs may be partially or totally removed. Procedures may include, but are not limited to, cystoprostatectomy, radical cystectomy, and prostatectomy.
- 80 Prostatectomy, NOS

Specimen sent to pathology from surgical events 20–80.

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

TESTIS**C62.0–C62.9**

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

00 None; no surgery of primary site; autopsy ONLY

12 Local tumor destruction, NOS

No specimen sent to pathology from surgical event 12.

20 Local or partial excision of testicle

30 Excision of testicle WITHOUT cord

40 Excision of testicle WITH cord or cord not mentioned (radical orchiectomy)

80 Orchiectomy, NOS (unspecified whether partial or total testicle removed)

Specimen sent to pathology from surgical events 20–80.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

KIDNEY, RENAL PELVIS, AND URETER**Kidney C64.9, Renal Pelvis C65.9, Ureter C66.9**

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-99922)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser
 - 15 Thermal ablation

No specimen sent to pathology from this surgical event 10–15.

- 20 Local tumor excision, NOS
 - 26 Polypectomy
 - 27 Excisional biopsy
 Any combination of 20 or 26–27 WITH
 - 21 Photodynamic therapy (PDT)
 - 22 Electrocautery
 - 23 Cryosurgery
 - 24 Laser ablation
- 25 Laser excision
- 30 Partial or subtotal nephrectomy (kidney or renal pelvis) or partial ureterectomy (ureter)

Procedures coded 30 include, but are not limited to:

 - Segmental resection
 - Wedge resection

- 40 Complete/total/simple nephrectomy—for kidney parenchyma
Nephroureterectomy

Includes bladder cuff for renal pelvis or ureter.

- 50 Radical nephrectomy

May include removal of a portion of vena cava, adrenal gland(s), Gerota's fascia, perinephric fat, or partial/total ureter.
- 70 Any nephrectomy (simple, subtotal, complete, partial, simple, total, radical) in continuity with the resection of other organ(s) (colon, bladder)

The other organs, such as colon or bladder, may be partially or totally removed.
- 80 Nephrectomy, NOS
Ureterectomy, NOS

Specimen sent to pathology from surgical events 20–80.

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

(Revised 01/10, 02/10)

BLADDER**C67.0–C67.9**

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser
 - 15 Intravesical therapy
 - 16 Bacillus Calmette-Guerin (BCG) or other immunotherapy

No specimen sent to pathology from surgical events 10–16.

- 20 Local tumor excision, NOS
 - 26 Polypectomy
 - 27 Excisional biopsy
 - Combination of 20 or 26–27 WITH
 - 21 Photodynamic therapy (PDT)
 - 22 Electrocautery
 - 23 Cryosurgery
 - 24 Laser ablation
 - 25 Laser excision
- 30 Partial cystectomy
- 50 Simple/total/complete cystectomy
- 60 Complete cystectomy with reconstruction
 - 61 Radical cystectomy PLUS ileal conduit
 - 62 Radical cystectomy PLUS continent reservoir or pouch, NOS
 - 63 Radical cystectomy PLUS abdominal pouch (cutaneous)
 - 64 Radical cystectomy PLUS in situ pouch (orthotopic)

When the procedure is described as a pelvic exenteration for males, but the prostate is not removed, the surgery should be coded as a cystectomy (code 60-64)
- 70 Pelvic exenteration, NOS
 - 71 Radical cystectomy including anterior exenteration

For females, includes removal of bladder, uterus, ovaries, entire vaginal wall, and entire urethra. For males, includes removal of the prostate. When a procedure is described as a pelvic exenteration for males, but the prostate is not removed, the surgery should be coded as a cystectomy (code 60-64).
 - 72 Posterior exenteration

For females, also includes removal of vagina, rectum and anus. For males, also includes prostate, rectum and anus.
 - 73 Total exenteration

Includes all tissue and organs removed for an anterior and posterior exenteration.
 - 74 Extended exenteration

Includes pelvic blood vessels or bony pelvis.

80 Cystectomy, NOS

Specimen sent to pathology from surgical events 20–80.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

BRAIN**Meninges C70.0–C70.9, Brain C71.0–C71.9,****Spinal Cord, Cranial Nerves and Other Parts of Central Nervous System C72.0–C72.9**

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Do not code laminectomies for spinal cord primaries.**Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Tumor destruction, NOS

No specimen sent to pathology from surgical event 10.**Do not record stereotactic radiosurgery (SRS), Gamma knife, Cyber knife, or Linac radiosurgery as surgical tumor destruction. All of these modalities are recorded in the radiation treatment fields.**

- 20 Local excision of tumor, lesion or mass; excisional biopsy
 - 21 Subtotal resection of tumor, lesion or mass in brain
 - 22 Resection of tumor of spinal cord or nerve
- 30 Radical, total, gross resection of tumor, lesion or mass in brain
- 40 Partial resection of lobe of brain, when the surgery can not be coded as 20-30.
- 55 Gross total resection of lobe of brain (lobectomy)

Codes 30 - 55 are not applicable for spinal cord or spinal nerve primary sites.**Specimen sent to pathology from surgical events 20–55.**

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

THYROID GLAND

C73.9

(Except for M9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

00 None; no surgery of primary site; autopsy ONLY

13 Local tumor destruction, NOS

No specimen sent to pathology from surgical event 13.

25 Removal of less than a lobe, NOS

26 Local surgical excision

27 Removal of a partial lobe ONLY

20 Lobectomy and/or isthmectomy

21 Lobectomy ONLY

22 Isthmectomy ONLY

23 Lobectomy WITH isthmus

30 Removal of a lobe and partial removal of the contralateral lobe

40 Subtotal or near total thyroidectomy

50 Total thyroidectomy

80 Thyroidectomy, NOS

Specimen sent to pathology from surgical events 25–80.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

LYMPH NODES**C77.0–C77.9**

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

00 None; no surgery of primary site; autopsy ONLY

19 Local tumor destruction or excision, NOS

Unknown whether a specimen was sent to pathology for surgical events coded to 19 (principally for cases diagnosed prior to January 1, 2003).

15 Local tumor destruction, NOS

No specimen sent to pathology from surgical event 15.

25 Local tumor excision, NOS

Less than a full chain, includes an excisional biopsy of a single lymph node.

30 Lymph node dissection, NOS

31 One chain

32 Two or more chains

40 Lymph node dissection, NOS PLUS splenectomy

41 One chain

42 Two or more chains

50 Lymph node dissection, NOS and partial/total removal of adjacent organ(s)

51 One chain

52 Two or more chains

60 Lymph node dissection, NOS and partial/total removal of adjacent organ(s) PLUS splenectomy
(Includes staging laparotomy for lymphoma.)

61 One chain

62 Two or more chains

Specimen sent to pathology for surgical events 25-62.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

ALL OTHER SITES

C14.2–C14.8, C17.0–C17.9, C23.9, C24.0–C24.9, C26.0–C26.9, C30.0–C 30.1, C31.0–C31.9, C33.9, C37.9, C38.0–C38.8, C39.0–C39.9, C48.0–C48.8, C51.0–C51.9, C52.9, C57.0–C57.9, C58.9, C60.0–C60.9, C63.0–C63.9, C68.0–C68.9, C69.0–C69.9, C74.0–C74.9, C75.0–C75.9

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser

No specimen sent to pathology from surgical events 10–14.

- 20 Local tumor excision, NOS
 - 26 Polypectomy
 - 27 Excisional biopsy
 - Any combination of 20 or 26–27 WITH
 - 21 Photodynamic therapy (PDT)
 - 22 Electrocautery
 - 23 Cryosurgery
 - 24 Laser ablation
 - 25 Laser excision
- 30 Simple/partial surgical removal of primary site
- 40 Total surgical removal of primary site; enucleation
 - 41 Total enucleation (for eye surgery only)
- 50 Surgery stated to be “debulking”
- 60 Radical surgery
Partial or total removal of the primary site WITH a resection in continuity (partial or total removal) with other organs.

Specimen sent to pathology from surgical events 20–60.

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

UNKNOWN AND ILL-DEFINED PRIMARY SITES**C76.0–C76.8, C80.9**

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Code

98 All unknown and ill-defined disease sites, WITH or WITHOUT surgical treatment.

Surgical procedures for unknown and ill-defined primaries are to be recorded using the data item *Surgical Procedure/Other Site* (NAACCR Item #1294) or *Surgical Procedure/Other Site at This Facility* (NAACCR Item #674).

APPENDIX C:
***FORDS* Page Revisions**

FORDS: An Evolving Data Manual

Following the initial release of *FORDS* in July 2002, the manual has undergone a series of modifications and revisions. All revisions have been made to the online edition of the manual and have been available to registries effective the date of revision.

This edition contains all the necessary additional documentation to support changes in case reporting to accommodate the standard data item changes to be implemented in 2010. The changes in the January 2010 release involved so much of this document that they are not itemized here. See *FORDS: Revised for 2009* for documentation of changes from 2003 through 2009 (see <http://www.facs.org/cancer/coc/fordsmanual.html> for a link). This appendix now contains changes introduced since the initial January 2010 release of *FORDS: Revised for 2010*.

Specific questions regarding these revisions may be directed to the editors of *FORDS: Revised for 2010*, Jerri Linn Phillips, MA, CTR (jphillips@facs.org), Andrew K. Stewart, MA (astewart@facs.org), or Anna Delev, CTR (adelev@facs.org). All other *FORDS*-related coding questions should be directed to the CoC's Inquiry and Response System (I&R) at <http://web.facs.org/coc/default.htm>.

CHANGES TO *FORDS* SECTION ONE

2010

CANCER IDENTIFICATION: Primary Site

02/01/2010

Instructions for assigning primary site and morphology codes to hematopoietic and lymphoid tumors now specify "and lymphoid" and designate the applicable histology range as M-9590-9992.

CANCER IDENTIFICATION: Morphology

02/01/2010

Instructions for assigning histology codes now specify they apply to "solid tumors".

CANCER IDENTIFICATION: Morphology - Grade/Differentiation

05/01/2010

Deleted breast, prostate and kidney from the 3-grade conversion instructions, because separate instructions exist for them.

FIRST COURSE OF TREATMENT: Surgery

02/01/2010

Second of duplicated "Reason for No Surgery of the Primary Site" deleted from list

CHANGES TO *FORDS* SECTION TWO: CANCER IDENTIFICATION

2010

Class of Case (NAACCR Item #610)

05/01/2010

Second sentence in description modified to read: “Analytic cases are grouped according to the location of diagnosis and first course of treatment.”

Added “or a decision not to treat” to description of code 22.

Date of Initial Diagnosis (NAACCR Item #390)

02/01/2010

Deleted two sentences from final paragraph: “The *Date of Diagnosis Flag* (NAACCR Item #391) is used to explain why *Date of Diagnosis* is not a known date. See *Date of Diagnosis Flag* for an illustration of the relationships among these items.”

Date of Diagnosis Flag (NAACCR Item #391)

02/01/2010

Item deleted. Because *Date of Initial Diagnosis* must always have a year estimated if the exact date is not known, this item will never be used.

Laterality (NAACCR Item #410)

Changed third bullet to read: “Where the right and left sides of paired sites are contiguous (come into contact) and the lesion is at the point of contact of the right and left sides, use code 5, midline. Note that ‘midline of the right breast’ is coded 1, right; midline in this usage indicates the primary site is C50.8 (overlapping sites).”

Histology (NAACCR Item #522)

03/10/2010

Deleted exception to sixth bullet for consistency with Multiple Primary and Histology rules.

Date Conclusive DX Flag (NAACCR Item #448)

05/01/2010

Corrected item name (from Date of Conclusive DX Flag).

CHANGES TO FORDS SECTION TWO: STAGE OF DISEASE AT DIAGNOSIS**2010****Clinical Stage (Prefix/Suffix) Descriptor** (NAACCR Item #980)

02/01/2010

Code 4 removed and the following instruction added: “Previous editions of FORDS included a code 4 for y-classification, and a note that it was not applicable for clinical stage. Code 4 has been removed from the list of valid codes”.

05/01/2010

Code 6 removed; it was a combination of code 4 (removed 02/10/2010) and another code.

Site-Specific Factor 1 (NAACCR Item #2880)

02/01/2010

BileDuctsIntrahepatic schema added to table.

Site C30.1 (middle ear) added to Head and Neck site codes in table footnote.

03/01/2010

Kaposi Sarcoma schema added to table.

Added “abstracted in CSV2” to SSF requirements in the table.

Site-Specific Factor 2 (NAACCR Item #2890)

02/01/2010

BileDuctsIntrahepatic schema added to table.

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 3 (NAACCR Item #2900)

02/01/2010

SkinEyelid SSF3 name changed to “Clinical Status of Lymph Nodes”.

Site C30.1 (middle ear) added to Head and Neck site codes in table footnote.

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 4 (NAACCR Item #2910)

02/01/2010

Added instruction: Prostate SSF4 (Prostate Apex Involvement) does not show on this table, because it is considered obsolete in 2010. However, it is required for cases diagnosed through 2009, as it was required in CSv1, even if it is abstracted in CSv2.

Site C30.1 (middle ear) added to Head and Neck site codes in table footnote.

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 5 (NAACCR Item #2920)

02/01/2010

MelanomaChoroid and MelanomaCiliaryBody schema added to table.

Site C30.1 (middle ear) added to Head and Neck site codes in table footnote.

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 6 (NAACCR Item #2930)

02/01/2010

SkinEyelid, MelanomaChoroid, and MelanomaCiliaryBody schema added to table.

Site C30.1 (middle ear) added to Head and Neck site codes in table footnote.

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 7 (NAACCR Item #2861)

02/01/2010

MelanomaChoroid and MelanomaCiliaryBody schema added to table.

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 8 (NAACCR Item #2862)

02/01/2010

SkinEyelid schema added to table.

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 9 (NAACCR Item #2863)

02/01/2010

SkinEyelid schema deleted from table.

MelanomaChoroid and MelanomaCiliaryBody schema added to table.

Site C30.1 (middle ear) added to Head and Neck site codes in table footnote.

03/01/2010

Added “abstracted in CSV2” to SSF requirements in the table.

Site-Specific Factor 10 (NAACCR Item #2864)

02/01/2010

TongueBase, PalateSoft, SkinEyelid, GISTPeritoneum, MelanomaChoroid, and MelanomaCiliaryBody schema added to table.

03/01/2010

Added “abstracted in CSV2” to SSF requirements in the table.

Site-Specific Factor 11 (NAACCR Item #2865)

02/01/2010

MelanomaChoroid, MelanomaCiliaryBody and MerkelCellVulva schema added to table. Site C03.1 (Gum, Lower) added to Head and Neck site codes in table footnote.

03/01/2010

Added “abstracted in CSV2” to SSF requirements in the table.

Site-Specific Factor 12 (NAACCR Item #2866)

02/01/2010

MelanomaChoroid and MelanomaCiliaryBody schema added to table.

03/01/2010

Added “abstracted in CSV2” to SSF requirements in the table.

Site-Specific Factor 13 (NAACCR Item #2867)

02/01/2010

MelanomaChoroid and MelanomaCiliaryBody schema added to table.

03/01/2010

Added “abstracted in CSV2” to SSF requirements in the table.

Site-Specific Factor 14 (NAACCR Item #2868)

02/01/2010

SkinEyelid schema deleted from table.

03/01/2010

Added “abstracted in CSV2” to SSF requirements in the table.

Site-Specific Factor 15 (NAACCR Item #2869)

03/01/2010

Added “abstracted in CSV2” to SSF requirements in the table.

Site-Specific Factor 16 (NAACCR Item #2870)

03/01/2010

Added “abstracted in CSV2” to SSF requirements in the table.

Site-Specific Factor 17 (NAACCR Item #2871)

03/01/2010

Added “abstracted in CSV2” to SSF requirements in the table.

Site-Specific Factor 18 (NAACCR Item #2872)

03/01/2010

Added “abstracted in CSV2” to SSF requirements in the table.

Site-Specific Factor 19 (NAACCR Item #2873)

03/01/2010

Added “abstracted in CSV2” to SSF requirements in the table.

Site-Specific Factor 20 (NAACCR Item #2874)

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 21 (NAACCR Item #2875)

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 22 (NAACCR Item #2876)

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 23 (NAACCR Item #2877)

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 24 (NAACCR Item #2878)

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 25 (NAACCR Item #2879)

02/01/2010

GISTPeritoneum schema deleted from table.

CHANGES TO *FORDS* SECTION TWO: FIRST COURSE OF TREATMENT

2010**Approach - Surgery of the Primary Site at This Facility** (NAACCR Item #668)

05/01/2010

Changed term “laparoscopic” to “endoscopic” in instructions and codes.

Added new bullet: “If both robotic and endoscopic surgery were used, code to robotic (codes 1 or 2).”

Surgical Margins of the Primary Site (NAACCR Item #1320)

02/01/2010

Changed list of lymphoma histologies to be coded 9 when sited to lymph nodes to “9590-9726, 9728-9732, 9734-9740, 9750-9762, 9811-9831, 9940, 9948 and 9971.”

Changed list of hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease histologies that are coded 9 to “9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992.”

Scope of Regional Lymph Node Surgery (NAACCR Item #1292)

02/01/2010

Changed list of lymphoma histologies to be coded 9 when sited to lymph nodes to “9590-9726, 9728-9732, 9734-9740, 9750-9762, 9811-9831, 9940, 9948 and 9971.”

Changed list of hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease histologies that are coded 9 to “9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992.”

Scope of Regional Lymph Node Surgery at This Facility (NAACCR Item #672)

02/01/2010

Changed list of lymphoma histologies to be coded 9 when sited to lymph nodes to “9590-9726, 9728-9732, 9734-9740, 9750-9762, 9811-9831, 9940, 9948 and 9971.”

Changed list of hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease histologies that are coded 9 to “9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992.”

Surgical Procedure/Other Site (NAACCR Item #1294)

02/01/2010

Changed list of hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease histologies that are coded 1 if treated surgically to “9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992.”

Surgical Procedure/Other Site at This Facility (NAACCR Item #674)

02/01/2010

Changed list of hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease histologies that are coded 1 if treated surgically to “9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992.”

Number of Treatments to this Volume (NAACCR Item #1520)

05/01/2010

Changed code range for number of treatments to 001-998 (from 091-998).

Changed examples to 3-digit codes (from 2).

Rx Date Rad Ended Flag (NAACCR Item #3221)

02/01/2010

Modified fourth bullet to read “Code 11 if no radiation is planned or given, or if it is not yet completed.”

Modified definition of code 11 to read “No proper value is applicable in this context (for example, radiation has not been completed).”

03/01/2010

Above changes were incorrect (NCDB apologizes).

Modified fourth bullet by removing “if it is not yet completed”

Modified definition of code 11 to read “No proper value is applicable in this context (for example, no radiation was administered).”

CHANGES TO FORDS SECTION TWO: CASE ADMINISTRATION**2010****Override Hospseq/Site** (NAACCR Item #1988)

02/01/2010

Changed the wording of the second bullet to read “Lymph node primary sites (C77.0-C77.9) for histologies other than lymphomas, or hematopoietic primary sites (C42.0-C42.4) for histologies not in range for hematopoietic diseases. (That combination is most likely a metastatic lesion. Check whether the lesion could be a manifestation of one of the patient's other cancers.)”

CHANGES TO *FORDS* SECTION TWO: APPENDIX B

2010**Section cover page**

02/01/2010

Added the following note: “The February 2010 updates changed the histologies that apply to these site-specific surgery codes. Those changes apply only to cases diagnosed in 2010 or later. Please consult *FORDS: Revised for 2009* for applicable histologies for cases diagnosed prior to that date”.

Rectum

05/01/2010

Corrected notation to indicate that codes 20-80 (rather than 20-28) send material to pathology.

Lung

02/01/2010

Corrected notation to indicate that codes 20-80 (rather than 20-25) send material to pathology.

Breast

05/01/2010

Changed explanatory note for code 30 to read: “A subcutaneous mastectomy, also called a nipple sparing mastectomy, is the removal of breast tissue without the nipple and areolar complex or overlying skin. It is performed to facilitate immediate breast reconstruction. Cases coded 30 may be considered to have undergone breast reconstruction.”

Corrected indentation of subcodes under codes 40, 50 and 60.

Hematopoietic/Reticuloendothelial/Immunoproliferative/Myeloproliferative Disease

02/01/2010

Changed list of included histologies to “9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992.”

Every site other than Hematopoietic/Reticuloendothelial/Immunoproliferative/Myeloproliferative Disease

02/01/2010

Changed list of excluded histologies to “9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992.”

APPENDIX D:

***FORDS* Items Required to Be Complete
to Enter *Date Case Completed* – *CoC* for
Cases Diagnosed in 2010**

See *Date Case Completed–CoC* (NAACCR Item # 2092) for instructions.

Category	FORDS Items	NAACCR Item #
Identification Class of Case 00-22	Addr at DX–City	70
	Addr at DX–State	80
	Addr at DX–Postal Code	100
	County at DX	90
	Date of 1 st Contact	580
	Date of 1 st Contact Flag	581
	Class of Case	610
	Primary Payer at DX	630
	NPI Archive FIN	3105
	Archive FIN	3100
	Accession Number	500
	Sequence Number	560
	Abstracted By	570
	ICD Revision Comorbidities and Complications	3165
	Comorbidities and Complications # 1	3110
	Comorbidities and Complications # 2	3120
	Comorbidities and Complications # 3	3130
	Comorbidities and Complications # 4	3140
	Comorbidities and Complications # 5	3150
	Comorbidities and Complications # 6	3160
	Comorbidities and Complications # 7	3161
	Comorbidities and Complications # 8	3162
	Comorbidities and Complications # 9	3163
	Comorbidities and Complications # 10	3164
	Override Acsn/Class/Seq	1985
	CoC Coding System - Current	2140
	CoC Coding System - Original	2150
	Vendor Name	2170
	ICD-O-3 Conversion Flag	2116
	Date of Last Contact or Death	1750
	Date of Last Contact Flag	1751
	City/Town – Current	1810
	State – Current	1820
	Postal Code – Current	1830
	Last Name	2230
	First Name	2240
	Middle Name	2250
	Medical Record Number	2300
	Military Record Number Suffix	2310
	Social Security Number	2320
	Patient Address (Number and Street) at Diagnosis	2330
Patient Address at Diagnosis – Supplemental	2335	
Patient Address (Number and Street) – Current	2350	
Patient Address–Current - Supplemental	2335	
Telephone	2360	
Demographic Class of Case 00-22	Race 1	160
	Race 2	161

	Race 3	162
	Race 4	163
	Race 5	164
	Spanish/Hispanic Origin	190
	Sex	220
	Age at Diagnosis	230
	Date of Birth	240
	Date of Birth Flag	241
	Birth Place	250
	Race Coding System – Current	170
	Race Coding System – Original	180
Diagnostic Class of Case 00-22	Date of Diagnosis	390
	Date of Diagnosis Flag	391
	Primary Site	400
	Laterality	410
	Histologic Type ICD-O-3	522
	Behavior Code ICD-O-3	523
	Grade	440
	Grade Path Value	441
	Grade Path System	449
	Diagnostic Confirmation	490
	Ambiguous Terminology DX	442
	Date of Conclusive DX	443
	Date Conclusive DX Flag	448
	Mult Tum Rpt as One Prim	444
	Date of Multiple Tumors	445
	Date of Mult Tumors Flag	439
	Multiplicity Counter	446
	Sequence Number - Hosp	560
	RX Hosp–DX/Stg Proc	740
	Regional Nodes Positive	820
	Regional Nodes Examined	830
	Site Coding System – Current	450
	Site Coding System – Original	460
	Morph Coding System – Current	470
	Morph Coding System – Original	480
	Override HospSeq/DxConf	1986
	Override CoC Site/Type	1987
	Override HospSeq/Site	1988
	Override Site/TNM-StgGrp	1989
	Override Age/Site/Morph	1990
	Override SeqNo/DxConf	2000
	Override Site/Lat/SeqNo	2010
	Override Surg/DxConf	2020
Override Site/Type	2030	
Override Histology	2040	
Override Leuk, Lymphoma	2070	
Override Site/Behavior	2071	
Override Site/Lat/Morph	2074	
Staging Class of Case 10-22	TNM Edition Number	1060
	TNM Path T	880
	TNM Path N	890
	TNM Path M	900

	TNM Path Stage Group	910
	TNM Path Descriptor	920
	TNM Path Staged By	930
	TNM Clin T	940
	TNM Clin N	950
	TNM Clin M	960
	TNM Clin Stage Group	970
	TNM Clin Descriptor	980
	TNM Clin Staged By	990
	Lymph-vascular Invasion	1182
	CS Tumor Size	2800
	CS Extension	2810
	CS Tumor Size/Ext Eval	2820
	CS Lymph Nodes	2830
	CS Lymph Nodes Eval	2840
	CS Mets at DX	2850
	CS Mets Eval	2860
	CS Mets at Dx-Bone	2851
	CS Mets at Dx-Brain	2852
	CS Mets at Dx-Liver	2853
	CS Mets at Dx-Lung	2854
	Site-Specific Factors 1-25 – if required for case	
	Derived SS1977	3010
	Derived SS2000	3020
	Derived AJCC–Flag	3030
	Derived SS1977–Flag	3040
	Derived SS2000–Flag	3050
	CS Version Input Current	2937
	CS Version Original	2935
	CS Version Derived	2936
	Derived AJCC 6 T	2940
	Derived AJCC 6 T Descript	2950
	Derived AJCC 6 N	2960
	Derived AJCC 6 N Descript	2970
	Derived AJCC 6 M	2980
	Derived AJCC 6 M Descript	2990
	Derived AJCC 6 Stage Grp	3000
	Derived AJCC 7 T	3400
	Derived AJCC 7 T Descript	3402
	Derived AJCC 7 N	3410
	Derived AJCC 7 N Descript	3412
	Derived AJCC 7 M	3420
	Derived AJCC 7 M Descript	3422
	Derived AJCC 7 Stage Grp	3430
Hospital-Specific Treatment Class of Case 10-22	RX Hosp–Surg App 2010	668
	Surgical Procedure of Primary Site at This Facility	670
	Scope of Regional Lymph Node Surgery at This Facility	672
	Surgical Procedure / Other Site at This Facility	674
	Chemotherapy at This Facility	700
	Hormone Therapy at This Facility	710
	Immunotherapy at This Facility	720
	Other Treatment at This Facility	730
	Palliative Care at This Facility	3280

	Date of First Course of Treatment	1270
	Date of 1 st Crs Flag	1271
	Date of First Surgical Procedure	1200
	RX Date–Surgery Flag	1201
	Date of the Most Definitive Resection of the Primary Site	3170
	RX Date–Mst Defin Srg Flag	3171
	Date of Surgical Discharge	3180
	RX Date–Surg Disch Flag	3181
	Date Radiation Started	1210
	RX Date–Radiation Flag	1211
	Date Radiation Ended	3220
	RX Date–Rad Ended Flag	3221
	Date Systemic Therapy Started	3230
	Date Chemotherapy Started	1220
	RX Date–Chemo Flag	1221
	Date Hormone Therapy Started	1230
	RX Date–Hormone Flag	1231
	Date Immunotherapy Started	1240
	RX Date–BRM Flag	1241
	Date Other Treatment Started	1250
	RX Date–Other Flag	1251
	RX Summ–Treatment Status	1285
	NPI- Managing Physician	2465
	NPI-Following Physician	2475
	NPI-Primary Surgeon	2485
	Primary Surgeon	2480
	NPI-Physician # 3	2495
	Physician # 3	2400
	NPI-Physician # 4	2505
	Physician # 4	2500
Summary Treatment	Surgical Procedure of Primary Site	1290
Class of Case 10, 12, 14, 20, 22	Scope of Regional Lymph Node Surgery	1292
	Surgical Procedure / Other Site	1294
	Surgical Margins of the Primary Site	1320
	Reason for No Surgery of Primary Site	1340
	Surgical Diagnostic and Staging Procedure	1350
	Palliative Care	3270
	Radiation / Surgery Sequence	1380
	Hematological Transplant and Endocrine Procedures	3250
	Chemotherapy	1390
	Hormone Therapy	1400
	Immunotherapy	1410
	Other Treatment	1420
	Reason for No Radiation	1430
	Rx Coding System–Current	1460
	Regional Dose: cGy	1510
	Number of Treatments to This Volume	1520
	Radiation Treatment Volume	1540
	Location of Radiation Treatment	1550
	Regional Treatment Modality	1570
	Boost Treatment Modality	3200
	Boost Dose: cGy	3210
	Systemic / Surgery Sequence	1639

Facility Referred To Class of Case 00	NPI-Inst Referred To	2425
	Facility Referred From	2420
Facility Referred From Class of Case 20-22	NPI-Inst Referred From	2415
	Facility Referred From	2410



AMERICAN COLLEGE OF SURGEONS
663 N. SAINT CLAIR ST.
CHICAGO, IL 60611-321